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ABSTRACT

STROMAL VASCULAR FRACTION RESTORES VASODILATORY FUNCTION BY REVERSING
MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS IN AGING-INDUCED
CORONARY MICROVASCULAR DISEASE

Evan Paul Tracy

April 19th, 2022

Background: Coronary Microvascular Disease (CMD) presents in aging post-menopausal women
with chronic angina due to microvascular hyperconstriction. The objective was to identify
mechanisms of adipose stromal vascular fraction’s (SVF) restorative effects on vasodilation. We
hypothesize aging-induced CMD is caused by a) abrogated flow-mediated dilation (FMD) due to
loss of nitric oxide signaling and b) ROS-dependent βADR desensitization & internalization,
reversible by ameliorating mitochondrial dysfunction and oxidative stress with SVF.
Methods: Coronary microvessels were isolated from female rats either young, old, or old with SVF
tail-vein injection (OSVF). Pressure myography, RNA-sequencing, immunofluorescence, Western
blotting, and morphological analysis were performed to compare between groups the density and
function of αADR and βADR and their downstream effectors, redox state, antioxidant and
prooxidant protein expression and function, mitochondrial dynamics, respiratory function, and
mitophagy. Contributors to FMD were determined by measuring FMD +/- scavengers/inhibitors of
FMD mediators. The contribution of ROS and nitrosylation to β1ADR desensitization and
internalization was determined by exogenous ROS or sodium nitroprusside (SNP) exposure prior
to concentration response to isoproterenol +/- inhibitors of desensitization and internalization.

v

Results: Aging is associated with faulty FMD and β1ADR-mediated dilation alongside
mitochondrial dysfunction. SVF attenuates baseline ROS and prooxidant expression in aging with
enhancement of mitochondrial membrane potential, oxygen consumption, ATP production,
antioxidant expression and glutathione, but not nitric oxide. Mitochondrial dynamics shifted away
from hyperfission in aging with recovery of fusion with SVF therapy. These effects culminated in
restored FMD and β1ADR-mediated dilation. The acute signaling mediator for FMD was nitric oxide
during youth, hydrogen peroxide in aging, shifting to peroxynitrite with SVF therapy. Vasorelaxation
to β1ADR-agonism was mechanistically linked to ROS and nitric oxide in an age-dependent
manner via their effects on desensitization and internalization.
Conclusions: SVF reverses chronic aging-associated oxidative stress and blunted FMD to young
control levels while utilizing acute peroxynitrite FMD signaling. We introduce a novel axis by which
ROS impacts β1ADR receptor trafficking, the ROS/RNS-β1ADR Desensitization and Internalization
Axis. ROS accumulation in aging leads to β1ADR desensitization and trafficking into endosomes,
whereas SVF reduces oxidative burden in this axis to restore functional β1ADR at the plasma
membrane.
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CHAPTER 1
INTRODUCTION PART 1
ADIPOSE STROMAL VASCULAR FRACTION FOR THE TREATMENT OF CORONARY
MICROVASCULAR DISEASE

Coronary microvascular disease (CMD) presents in a majority of post-menopausal, aging
women with chronic angina due to microvascular hyperconstriction, as opposed to atherosclerotic
blockage seen typically in men [1]. Clinically, CMD is defined as a coronary flow reserve (CFR) ≤
2.5, endothelial dysfunction with constriction to acetylcholine, and <20% coronary dilation to
nitroglycerin [1]. Coronary perfusion is compromised by ~43% in advanced age with a negative
correlation between advancing age and myocardial flow reserve, exacerbating CMD severity [2, 3].
Current treatments are known to be minimally effective. Beta blockers may be utilized to preserve
oxygen consumption by reducing the workload of the myocardium and lower renin release from
juxtaglomerular apparatus cells but may inhibit microvascular dilative beta-adrenergic receptor
(βADR) function [4, 5]. Conversely, beta agonists would lead to habituation over time and would
increase inotropic myocardial workload [4]. Although nitrates may provide acute relief of symptoms,
there is little evidence of reduced major adverse cardiac events (MACE) or mortality [6, 7]. Further,
nitrates cause rebound angina and increase oxidative stress, and are difficult to manage.
Therefore, designing a therapeutic strategy restoring vascular β1AR function in CMD presents a
paradoxical challenge. Ideal therapy for CMD will preferentially target the vasculature to increase
βADR function without habituation.
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In CMD, such a therapeutic strategy is of significant clinical interest considering up to 75% of
women and 15% of men with angina have no obstructive coronary pathology, representing 90,000
cases per year with greater chance of MACE than asymptomatic women (3-8.2% 5-year mortality
for normal to nonobstructive disease) [8]. CMD represents significant societal economic cost
burden, similar to that of obstructive disease (~$750,000 vs. $1,000,000 lifetime cost burden),
driven by repeat angiography, increased anti-ischemic therapy costs and increased hospitalization
showcasing the significance of this pathology and need for comprehensive management strategies
[9].
A novel strategy that can holistically treat each facet of CMD pathophysiology by mending the
pathologic microvessels themselves, rather than merely treating their symptomatic consequences,
is of significant clinical interest. Adipose-derived stromal vascular fraction (SVF) represents a
heterogenous population of cells, exosomes, proteins etc. with regenerative potential, including
mesenchymal and hematopoietic stem cells, microvascular endothelial cells, pericytes, fibroblasts,
B and T cells, natural killer cells, dendritic cells, and macrophages [10]. Our lab has previously
shown that injected SVF incorporates into carotid arteries and aorta, and to a lesser extent the
myocardium, lung, and brain [10, 11]. SVF therapy reverses aging-mediated reduction in CFR and
perfusion (a clinical determinant of CMD), improves maximal cardiac output one-week postinjection, and restores coronary flow reserve, reduces scar size, and improves ejection fraction
after myocardial infarction in rats [10-12]. One possible mechanism for the regenerative effects of
SVF could be due to its known antioxidant effects [13, 14].
A cornerstone aspect of vascular aging is increased oxidative stress [15]. There is a known
correlation between aging-associated oxidative stress and decline in functional vasodilation [1518], although uncertainty remains as to whether this relationship is purely correlational or if there is
a causal link. If there is causality, then targeting oxidative stress in age-related CMD may provide
new therapeutic avenues to restore vascular function. In this dissertation, the interplays of oxidative
stress in aging and two mechanisms for maintenance of microvascular patency are investigated:
flow- and β-adrenergic-mediated dilation.
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Increasing intraluminal flow causes shear stress that in youth activates endothelial nitric oxide
synthase (eNOS) to produce nitric oxide, leading to vasorelaxation [19]. During aging, this instead
leads to production of hydrogen peroxide resulting in hyperpolarization-mediated vasorelaxation
[20]. Overall, it is thought that the hyperpolarization-mediated pathways in aging are less efficient
than nitric oxide-mediated during youth. Indeed, reductions in FMD are correlated with advancing
age, which starts earlier in men but becomes more severe (steeper correlation) in postmenopausal
women [21]. Therefore, therapeutically restoring nitric oxide bioavailability in aging vessels may
restore effective FMD signaling.
Aging also leads to an overload of catecholamine production, with compensatory receptor
degradation. Therefore, it may be that aging-induced hyperconstriction is due in part to
downregulated adrenergic maintenance of patency. Upon catecholamine-receptor binding, Gprotein receptor kinase 2 (GRK2) causes desensitization by phosphorylation of βADR, reducing
dilation efficacy. Beta-arrestin associates with the phosphorylated receptor, which initiates
dynamin-mediated internalization of the βADR into endosomes for storage, eventual degradation,
or recycling back at the membrane. The protein expression of GRK2 and beta-arrestin are known
to increase in aging Fischer 344 rat aortas [22, 23].
Post-translational modification may also be in play, as S-nitrosylation sterically inhibits GRK2 to
block desensitization [24]. It is thought that thiol oxidation by ROS of the βADR facilitates
desensitization and/or internalization [25-27]. ROS activates phosphatidylinositol 3-kinase gamma
(PI3kγ) signaling, causing inhibition of protein phosphatase 2A (PP2A)-mediated recycling of the
βADR back to the plasma membrane [24]. Therefore, it may be possible to influence βADR function
by therapeutically modulating oxidative stress and nitrosative potential. Frame et al. found that
nitrosative exposure with sodium nitroprusside (SNP) can “uncover” β2ADR pools that increase
isoproterenol potency (albeit with reduced efficacy) through GRK2 nitrosylation/inhibition, leaving
functional β2ADR at the plasma membrane [28]. Mitochondrial antioxidant therapy with
mitoquinone mesylate (mitoQ) can improve endothelium-dependent dilation and FMD [29, 30]. The
role of mitochondrial redox dysfunction in aging coronary microvascular βADR- and flow-mediated
dilation with therapeutic potential of antioxidative strategies has yet to be elucidated.
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The hypothesis of this dissertation is that aging-induced CMD is caused by abrogated FMD
due to loss of nitric oxide signaling and ROS-dependent βADR Desensitization & Internalization
(Aim 1), reversible by therapeutically ameliorating mitochondrial oxidative stress and dysfunction
with SVF (Aim 2) (Figure 1). For Aim 1, the mitochondrial & ROS/RNS-dependent contributions to
FMD and βADR desensitization & internalization status was compared between young vs. aged
coronary microvessels. Specifically, the effects of aging on FMD and βADR dilative function was
determined, including which if any adrenergic receptors and/or their regulatory proteins were
up/downregulated with aging. Baseline microvascular mitochondrial function (ATP production,
oxygen consumption, mitochondrial membrane potential), redox status (ROS, RNS, antioxidant,
and prooxidant enzyme levels), and their relation to FMD and βADR dilative function was also
determined. For Aim 2, whether SVF reverses CMD by restoring mitochondrial function to restore
FMD and alter the ROS/RNS-βADR desensitization and internalization axis to preserve plasma
membrane βADR was determined. Specifically, whether SVF restores aged microvascular
mitochondrial function, redox status, FMD and βADR dilative function to young control levels.
Finally, the possibility of replicating the restorative effects of SVF on microvascular redox status,
FMD, and βADR dilative function with mitochondrial specific telomerase reverse transcriptase
(TERT) mediated antioxidant therapy (via cycloastragenol diet (CAG)) was studied. TERT
experiments show isolated effects of reducing mitochondrial ROS without off-target effects. SVF
mediates other potentially confounding effects (reducing inflammation) justifying TERT’s inclusion
[31, 32]. These studies are also novel for TERT’s therapeutic development for CMD, which may be
a simpler therapeutic considering its pharmacologic potential. Additionally, SVF preferentially
targets vasculature over myocardium, whereas TERT overexpression is global, an important
consideration since the goal is to enhance vascular, not myocardial βADR [10, 11].
The ability to therapeutically modulate vasodilative mechanisms through manipulating redox
dynamics as shown in this dissertation provide exciting new avenues for addressing management
of diseases such as CMD. It is predicted that microvascular aging is characterized by mitochondrial
dysfunction leading to elevated oxidative stress to cause dysfunctional flow- and βADR-mediated
dilation via reduced nitric oxide and enhanced receptor desensitization and internalization. FMD
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will be restored in aging with SVF via restored nitric oxide production (as well as reduced ROS that
siphons nitric oxide). Reduced ROS and enhanced nitrosative signaling will alleviate βADR
desensitization and internalization of the βADR receptor according to our conceptually novel
ROS/RNS βADR Desensitization & Internalization Axis. If the ROS/RNS-β1ADR desensitization &
internalization axis is therapeutically modifiable, this could represent a potential paradigm shift in
strategic management of certain adrenergic pathologies away from direct agonism, which leads to
receptor downregulation, towards targeting of the cause of dysfunction to restore adrenergic
homeostasis. For instance, such a translational innovation could be applicable to β2ADR
dysfunction in skeletal muscle wasting with age, or for β2ADR dysfunction in asthma/COPD, all of
which also have ROS components to the pathology [33-41].
Introductory Chapters 2-4 provide a contextual framework for this dissertation through
abridged first-author published review articles on how aging alters cardiovascular tissue remodeling
(Chapter 2 [42]), the physiological and clinical implications of a changing vascular redox state with
aging (Chapter 3 [43]), and the current state of the field of stem cell therapeutic strategies for
pathologies of the microvasculature (Chapter 4)[44]. In Chapter 5 experimental methodology is
provided. Then in Chapters 6-10, results of five separate studies classified as separate cohorts
are presented. Chapter 6 showcases evidence for abrogated βADR function corresponding with
diastolic dysfunction in aging, reversed by SVF [10]. Chapter 7 describes how β1ADR protein
expression is downregulated with aging, reversed by SVF, and we detail the expression and
function of key regulatory proteins of βADRs [45]. Chapter 8 provides evidence that mitochondrial
function is attenuated in aging, reversed by SVF and chapter 8 also shows effect of inhibiting
mitochondrial fission or fusion in ex vivo microvessels. Chapter 9 provides evidence that aging
increases oxidative stress, reversed by SVF and provides correlative and direct evidence that ROS
attenuate while RNS (nitric oxide) enhances βADR function via their effects on receptor trafficking
[46]. In addition, FMD is shown to be diminished with aging, restored by SVF through enhanced
peroxynitrite signaling [47]. In Chapter 10, a subset of these experiments were repeated to show
that mitochondrial antioxidation with TERT (CAG) also restores flow and βADR-mediated dilation
alongside reduction of oxidative stress, albeit not as robustly as SVF [48]. Finally, in Chapter 11,
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the culmination of these results is discussed in the context of current literature and provide future
direction for the advancement of SVF and TERT therapeutic strategies for the treatment of CMD.

Hypothesis: Aging-induced CMD is caused by a) abrogated FMD due to loss of nitric oxide
signaling and b) ROS-dependent βADR Desensitization & Internalization (Aim 1), reversible by
therapeutically ameliorating mitochondrial dysfunction with SVF (Aim 2).
Aim 1: Determine the Mitochondrial & ROS/RNS-dependent Contributions to FMD and
βADR Desensitization & Internalization Status in Young vs. Aged Coronary Microvessels.
Aim 2: Determine that SVF Reverses CMD by Restoring Mitochondrial Function to Restore
FMD and Alter the ROS/RNS-β1ADR Desensitization & Internalization Axis to Preserve
Plasma Membrane βADR.
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Figure 1: Graphical Illustration of Hypothesis. Coronary microvascular youth and aging + SVF
therapy will be associated with low ROS and high nitric oxide bioavailability that i) is generated in
response to flow to mediate FMD and ii) nitrosylates GRK2 to inhibit βADR desensitization. Aging
alone will enhanced ROS production that iii) facilitates βADR desensitization and internalization
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into endosomes with eventual degradation, iv) siphons nitric oxide to reduce GRK2 nitrosylation
and nitric oxide mediated FMD and v) generates hydrogen peroxide in response to flow to mediate
FMD. βAR beta-arrestin, CAT catalase; GP glutathione peroxidase, GRK2 G protein kinase 2, GSH
reduced glutathione, GSNO nitrosoglutathione, MnSOD manganese superoxide dismutase, NE
norepinephrine, S-NO S-nitrosylation, S-OH thiol oxidation. Image created using BioRender.com.
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CHAPTER 2
INTRODUCTION PART 2
CARDIAC TISSUE REMODELING IN HEALTHY AGING: THE ROAD TO PATHOLOGY1

This chapter aims to highlight the normal physiological remodeling that occurs in healthy aging
hearts, including changes that occur in contractility, conduction, valve function, large and small
coronary vessels and the extracellular matrix. These “normal” age-related changes serve as the
foundation that supports decreased plasticity and limited ability for tissue remodeling during
pathophysiological states, such as myocardial ischemia and heart failure.
Tissue remodeling is the active process of reorganization and rebuilding of an existing tissue,
but successful remodeling is dependent upon either physiological or pathophysiological conditions.
In the setting of advanced age, many factors have already initiated and pushed the tissue
environment into a pathophysiological outcome when a remodeling stimulus arises. This
introductory review chapter highlights the various age-related changes in cardiac tissue that directly
influence how tissue remodeling occurs following injury. These include cardiac hypertrophy,
vascular senescence, and modifications in conduction, valve function, coronary vascular structure
and function, angiogenesis and cardiomyocyte regeneration. Summarily, these alterations
contribute to the overall loss of plasticity, adaptation and regeneration in an aging heart, thereby
making the heart more susceptible to pathophysiological remodeling.

1

Chapter represents a publication with minor modifications from:
Tracy et al. Cardiac Tissue Remodeling in Healthy Aging: The Road to Pathology. Am J Physiol
Cell Physiol, 2020. https://doi.org/10.1152/ajpcell.00021.2020.
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2.01: Physiological versus Age-Related Remodeling
In the healthy heart, tissue is optimally structured to allow for maintenance of cardiac output
and flow to vital organs and peripheral tissues by optimizing stroke volume, maintaining ideal
sarcomere overlap (in accordance to the Frank-Starling Mechanism), limiting wall stress and
oxygen demand (in accordance to the Law of Laplace), and maintaining appropriate perfusion,
hemodynamics and conductive signaling [49]. In other words, wall stress is indirectly proportional
to wall thickness and directly proportional to chamber pressure and radius. Cardiac remodeling is
a process in which the heart adapts to changing conditions, with the ultimate goal of maintaining
ideal pump function primarily by altering the tissue, thereby modifying the above parameters. This
review will describe cardiac remodeling under “normal” conditions (physiologic remodeling) and
differentiate it from cardiac remodeling in advancing age (Figure 2) and in disease (pathological
remodeling, Figure 3).
Physiological remodeling occurs most often in the context of growth and development,
exercise, and pregnancy, whereas pathological remodeling arises in the context of advancing age
as well as in diseases such as myocardial infarction (MI), heart failure (HF), chronic kidney disease
and failure, and heritable diseases such as hypertrophic obstructive cardiomyopathy. In
physiological remodeling, the contractile function is normal or enhanced while general architecture
and organization of the heart is unaltered [50]. In pathological remodeling conditions, although
primary changes to the heart may be initially protective to preserve cardiac output and blood flow
to vital organs, eventually the system becomes unbalanced and cardiomyocyte death and fibrosis
can occur with reduced systolic and diastolic function, with HF as the typical chronic result.

2.02: Cardiac Hypertrophy
Most commonly, physiological cardiac remodeling results in cell size growth known as
cardiac hypertrophy [51]. Depending on the type of stress placed on the heart, the hypertrophy can
either be described as eccentric or concentric hypertrophy. When the ventricles of the heart are
exposed to volume overload, eccentric hypertrophy results in an increase in cardiac mass with
growth in chamber wall and septal thickness. Myocytes grow preferentially in length, with
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sarcomeres being aligned in series. Eccentric hypertrophy occurs in aerobic exercise and
pregnancy, but also in pathological conditions such as MI and dilated cardiomyopathy. Concentric
hypertrophy, which occurs in pressure overload, is defined as an increase in cardiac mass with
preferential cardiomyocyte thickening as opposed to lengthening, with sarcomeres aligned in
parallel. Concentric hypertrophy can occur in strength training such as weightlifting and wrestling,
which subject the heart to pressure overload, but mostly occurs in valvular diseases and in patients
with hypertension [50, 52]. In situations where the heart is under less-than-normal stress, such as
prolonged bedrest, in zero gravity, or during ventricular unloading with a ventricular assist device,
the heart will atrophy and cell size will physiologically shrink [53].
Exercise increases Akt levels two-fold through the mTOR pathway and leads to physiologic
cardiac hypertrophy [50]. However, prolonged stimulation (six weeks) in transgenic mice with
inducible Akt overexpression leads to cardiac dysfunction in the 15x range and is involved in
pathological remodeling and hypertrophy [50]. Akt signaling can be reduced by the activity of silent
information regulator 3 and 6 (SIRT3, SIRT6), which have been found to be reduced in aging [5456]. Physiologic and pathologic remodeling are associated with differences in thyroid hormone
receptor (TRα and TRβ) expression and associated gene expression [57]. TRβ1 is upregulated in
physiologic remodeling with increases in linked genes such as alpha myosin heavy chain (α-MyHC)
and sarcoplasmic reticulum Ca2+ - ATPase (SERCA) and reduction in β-MyHC. Pathologic
remodeling leads to downregulation of all thyroid receptors with decreases in α-MyHC and SERCA,
and with increases in β-MyHC. Since the concentration of thyroid hormone systemically is
unchanged, the physiologic and pathologic state can be said to be associated with hyperthyroid
and hypothyroid cell state, respectively. The aging heart reflects the pathologic hypothyroid cell
state, as TRβ1 expression is reduced by up to 60% with associated shift in MyHC gene expression
in rat models [58].
It is generally accepted that the age-related increase in left ventricular (LV) weight
(hypertrophy) is caused by elevation in afterload, or the pressure against which the heart must work
to eject blood [59]. This causes an increase in cardiac size is mainly due to cardiomyocyte
hypertrophy as aging progresses rather than an increase in number of cardiomyocytes (Figure 2f)
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[59] Afterload can be approximated by blood pressure or systemic vascular resistance and is
directly affected by the stiffness and plasticity of both the systemic and coronary vasculature. The
age-related increase in afterload can be measured by central aortic pulse wave velocity via MRI
[60]. As the prevalence of LV hypertrophy increases with age [61], this leads to a less compliant
ventricle, which can eventually result in diastolic dysfunction. Indeed, increased effective arterial
elastance (afterload) has been found to be related to reduced diastolic function in age [60]. Both
cardiac hypertrophy and diastolic dysfunction that occur with advancing age can be assessed
clinically by use of echocardiography.

2.03: Ultrasound Parameters of Age-Related Cardiac Remodeling
Echocardiography is a powerful non-invasive tool in the diagnosis of cardiac pathology. It
is a first line diagnostic and screening tool and is often utilized in research applications. Evidence
for

age-related

cardiovascular

remodeling

has

been

well-established

using

various

echocardiographic modalities. For example, 2D echocardiography studies have found decreased
LV dimensions and increased fractional shortening (FS), LV wall thickness, and LV mass
correlating with advanced age [61-65]. M-mode Doppler myocardial imaging studies of peak mean
velocity have determined that both diastolic filling and rapid ventricular filling decrease while atrial
contraction increases with age [66]. Each of the above are suggestive of diastolic dysfunction,
which also correlates with advancing age in both sexes occurring at a higher incidence in postmenopausal females (Figure 2d) [67].
Using color Doppler tissue imaging, Thomas et al. found evidence of augmented atrial
contractility and increased atrial contribution to diastolic filling, as evidenced by increased atrial
contraction velocity and ejection force in individuals over 50 years old [68]. Further, color flow
Doppler and pulsed Doppler studies have shown that there is an age-related increase in prevalence
of valvular regurgitation [69, 70].
2D/3D Speckle-Tracking imaging takes advantage of the unique interference patterns and
acoustic reflections of different regions of the myocardium referred to as a speckle pattern, which
can be tracked over time to gain quantitative information of wall motion and deformation. In the
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normal cardiac contraction, the LV rotates counterclockwise at the apex and clockwise at the base
in a twisting fashion [71]. During the isovolumic relaxation phase of diastole, the heart untwists. In
advancing age (>60), peak LV twist is quantitatively increased, with decreased and delayed
untwisting relative to younger and middle-aged participants [72]. Elderly adults also display
diminished LV global longitudinal strain, global radial strain, global circular strain, and global area
tracking compared to young and middle-aged groups [73]. These changes may be due to increased
myocardial stiffness caused by interstitial fibrosis related to diminishing of the elastic element
contribution to deformation [73]. Taken together, myocardial relaxation potential is diminished in
advanced age as evidenced by decreased diastolic untwisting and diminished strain with
concurrent increased systolic twist, likely factoring into diastolic dysfunction commonly seen in the
elderly.

2.04: Vascular Remodeling
During embryogenesis, vascular endothelial growth factor (VEGF) is the predominant
factor in the regulation of new blood vessel formation, stimulating new blood vessels to sprout from
existing vasculature via angiogenesis. Hypoxic regions of a given tissue generate VEGF gradients
to stimulate the differentiation of an endothelial cell into a tip cell which forms a stalk, ultimately
leading to the generation of a capillary [74]. Together, the process of angiogenesis and
vasculogenesis (single cells coming together to form a vessel) lead to a mature, perfused
microvessel network. With aging comes a decline in the ability to repair blood vessels and form
new ones, partly due to a decreased ability to generate VEGF (Figure 2a) [75]. Further, studies
have shown that endothelial cells from old mice exhibit a decreased capacity to proliferate and
migrate [76, 77]. Because of this vascular aging phenomenon, impaired angiogenesis and
endothelial migration lead to regions of reduced microvascular blood flow in the heart. This agerelated impairment in tissue remodeling presents in the coronary circulation as a decreased ability
to collateralize following an insult, such as MI [78].
Vascular aging is a process that is characterized primarily by endothelial senescence [79].
Senescence refers to the limited number of cell divisions one cell can undergo due to genetic and
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morphological changes. Age-related endothelial senescence is thought to be brought about by one
of two mechanisms. The first theory posits that telomeres at the ends of the chromosome are lost
with each cell division as aging progresses due to the imperfect nature of DNA polymerase at DNA
replication. This loss of telomeres decreases DNA stability and induces senescence [80]. Over two
decades ago Yang et al. showed that induction of telomerase into human endothelial cells staves
off senescence [81]. The second theory of age-related endothelial senescence relates to the
reduction in the bioavailability of nitric oxide (NO) and in the expression levels of endothelial nitric
oxide synthase (eNOS) as aging progresses [82]. The lowered levels of NO impair vasodilation in
the coronary vasculature but also increase endothelial sensitivity to apoptotic signals, leading to an
overall decline in endothelial function and angiogenic potential [83]. Part of the reason for the
reduction in NO bioavailability is due to an increase in reactive oxygen species (ROS). The radical,
unstable molecule superoxide rapidly combines with NO producing a reactive peroxynitrite [84].
These commonalities of age-related generators of endothelial dysfunction and the diminution of
angiogenic property listed above have been emerging as targets for therapeutics in the biomedical
field. Vascular dysfunction that occurs with normal aging at the level of the microcirculation
permeate upstream to the large conducting vessels that are detectable with diagnostic tests.
The large conducting arteries such as the aorta and carotid have multiple thick layers
consisting of vascular smooth muscle, elastin and collagen, all contributing to their distensibility
property. These components allow the large vessels to dampen the pulse pressure derived from
the LV, but also exhibit an age-dependent gradual stiffening which can be measured by ultrasound
and carotid-femoral pulse-wave velocity measurements (Figure 2e) [85]. With advancing age there
is an increase in availability and activity of angiotensin-converting enzyme (ACE-1) within
endothelial and vascular smooth muscle cells, increasing the conversion of angiotensin-I to -II [86].
Angiotensin-II

induces

a

signaling

cascade

that

leads

to

overexpression

of

matrix

metalloproteinase-2 (MMP-2) [87] and calpain-1, resulting in increased collagen I and II deposition
in the vascular wall [88]. Wang and colleagues studied this by infusing young rats with angiotensinII, which induced matrix remodeling on the carotid artery resulting in large arteries comparable to
old control rats [89]. Morphological changes in the human aorta (aged 50-80 yo) include a decrease
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in elastic fibers with an increase in fractured fibers [90] as well as an increase in collagen deposition
[91] compared to tissue obtained from children. With normal advancing age, a reduced plasticity of
vessels combined with the limited ability to remodel the coronary microcirculation in aging forces a
shift in hemodynamic functions and an increase in afterload.

2.05: Extracellular Matrix and Electrical Conduction
Electrical remodeling occurs typically around the seventh decade of life [92]. With
advancing age, there is increased incidence of dysfunction of the sinoatrial (SA) node with
decreased pacemaker cell density, atrioventricular dysfunction, and dysfunction of the his-purkinje
system with resultant bradycardia, palpitations, dizziness, syncope, fatigue, and confusion [93].
Echocardiogram measurements of elderly patients show increases in P-wave duration, P-R and QT interval, decreases in QRS and T-wave voltage, and a leftward shift of the QRS axis [93]. In
senescent mice, the QRS complex is significantly prolonged [94]. As a result, ectopic beat
frequency increases as does incidence of atrial fibrillation, other tachyarrythmias, and sick sinus
syndrome [92]. Factors that contribute to conduction system remodeling in age are important to
consider as they may lead to the eventual development of heart failure and will each be discussed
individually (Figure 2c) [95-98].
The status of extracellular matrix (ECM) accumulation in the heart is controlled by the
balance of degradation and synthesis. As such, deregulated ECM in aged hearts leads to cardiac
fibrosis, a phenomenon that has been observed in animal models including mice [99], rats [100],
dogs [101], and humans [102, 103]. Fibrosis is the process by which excess connective tissue
elements, including collagen and glycosaminoglycans, are deposited within the interstitium in a
regenerative process that can ultimately become pathologic. The ECM can become deranged
through many factors, and since a large component of the cardiac ECM is made up of collagen,
age-related changes in collagen content and cross-linking can be primary drivers of ECM
deregulation. The two types of collagen most abundant in the myocardium are: ~85% of the
“distensible” collagen I and ~11% of the “high tensile strength” collagen III. Even in healthy adults
without cardiovascular disease (CVD), collagen I is increased with advancing age (by up to 200%

14

[92, 104]) compared to LV samples obtained from young patients [102]. As a result, the ratio of
collagen I:III is altered with age and can impair cardiac biomechanics and conduction [105].
Collagen cross-linking by the enzyme lysyl oxidase increases collagen fibril thickness and stiffness,
and staves off breakdown from the collagenase MMP-1 [106]. However, advancing age increases
the incidence of collagen cross-linking and can lead to cardiac hypertrophy, hypertension, and
ventricular stiffness [107, 108]. Collagen cross-linkage with advancing age is driven by the
increased presence of advanced glycosylated end-products (AGEs) [107]. A decreased serum ratio
of CITP:MMP-1 can serve as a predictor of the degree of myogenic collagen cross-linkage [108].
While collagen deposition and cross-linking increase during aging, extracellular matrix
(ECM) degradation capacity also changes, primarily due to increased expression of matrix
metalloproteinases (MMPs) which can modulate the proteolytic activity of ECM. MMPs also
influence a variety of other cell signaling processes, such as cytokines, chemokines, growth factors,
hormones, angiogenic factor expression and activity. In cardiac aging, elevated MMP-9 is a major
mediator for increased LV stiffness in the aging heart [109] and has been reviewed elsewhere in
greater detail [110]. Age-related ventricular fibrosis is thought to occur in part through an imbalance
of MMPs and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). Bonnema et al.
illustrated that decreased ratios in aging human subjects of MMP-9:TIMP-1, MMP-9:TIMP-4, and
MMP-2:TIMP-4 [111] are associated with buildup of extracellular matrix, concentric remodeling,
and LV diastolic dysfunction. Clinical studies have found associations between MMP-9:TIMP-1 and
markers of collagen I and III synthesis (pro-collagen type-I carboxyterminal peptide (PICP) and procollagen type III aminoterminal peptide (PIIINP)) with tachyarrhythmia [92, 112]. Taken together,
these studies suggest that MMP:TIMP as well as PICP:PIIINP ratios could be used to elucidate the
homeostasis, or lack thereof, in myocardial collagen deposition as a predictor of tachyarrhythmia
risk. Furthermore, a better understanding of the complex interaction between MMPs and the ECM
in the context of aging may yield novel diagnostic indicators for the early detection of age-related
fibrosis [110].
Fibrosis is thought to be a major player in the development of age-related tachyarrhythmia
including atrial fibrillation. In age, reactive interstitial fibrosis is defined by enhanced interstitial
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space ECM without accompanying cardiomyocyte loss [113]. Interstitial fibrosis is often followed
by reactive fibrosis, which occurs to replace necrotic or apoptosed cardiomyocytes found in aging
potentially due to supply/demand mismatch [113]. Replacement by fibrosis is found throughout the
conduction system, including the SA node, atrioventricular node, His-bundle, and left bundle
branch. Specifically, the number of SA nodal cells decrease by 38.9% in tissue from individuals
50+ years old compared to adolescents and adults, indicating age-induced atrophy [114].
Reduction of SA node volume occurs mostly in the periphery, with replacement by fatty infiltration
and fibrosis. Indeed, fibrotic connective tissue volume was increased by 49.3% in elderly. It is
thought that the deposition of collagen by proliferating fibroblasts reduces conduction velocity and
alters electrical conductive properties of the tissue, thereby lowering the threshold for signaling
which results in inappropriate atrial firing [93, 115]. In general, fibrosis alters the typically uniform
anisotropic quality of cardiac tissue to non-uniform conduction [96, 115].
Another process by which inappropriate ECM accumulation occurs is through amyloid
deposition. Amyloidosis is the abnormal aggregation of protein into insoluble b-pleated linear
sheets that can cause cellular damage and apoptosis. In the heart, amyloid can cause restrictive
cardiomyopathy and arrhythmia. Deposition of the wild-type protein transthyretin into the ventricular
endomyocardium occurs naturally in advancing age and is characterized as systemic senile (agerelated) amyloidosis. A third of these patients develop electrophysiological pathologies including
atrioventricular and bundle-branch block and atrial fibrillation [93]. A mutant form of transthyretin
causes familial amyloid cardiomyopathy with more severe restrictive cardiomyopathy and
arrhythmia, presenting at a younger age. In isolated atrial amyloidosis, the culprit protein is atrial
natriuretic peptide, accumulation of which is normal in aging and can contribute to atrial fibrillation
risk. In a Finnish study, autopsy examination of persons >85 years of age revealed amyloid
deposition in the hearts of 25% of the population, with significant correlations between age and
degree of amyloid at time of death [116].
Aging has been shown to reduce the expression of the vitally important gap junction protein
connexin-43 by up to 50% [104]. Gap junctions are essential for transmission of signal between
cells along the conduction pathway and between myocytes to form the functional syncytium. The
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effect of lost functional syncytium pathways for conducting signal may be compounded by a loss of
cardiomyocytes themselves that occurs naturally in aging, with associated reactive fibrosis
replacement [113]. Interestingly, reduction in connexin-43 expression has been found to precede
interstitial remodeling and fibrosis [104] and could contribute to the initiation of fibroblast activation,
albeit through an unknown mechanism [92]. There is evidence that connexin-43 levels can be
restored in mouse models with age-associated hypertrophy and fibrosis by inhibiting the reninangiotensin-aldosterone system (RAAS), albeit with preserved fibrosis [117]. Long term
prophylactic RAAS treatment aimed at reducing fibrosis in aged mice preserves connexin-43
expression and reduces formation of arrhythmia [118, 119]. According to Jansen et al., both
connexin-43 downregulation and fibrotic changes are necessary for reduced conductive velocity
[120]. Connexin-43 also establishes communication between cardiomyocytes and fibroblasts, and
their communication influences cytokine production [121].
Ion currents (namely, potassium and calcium) undergo alterations in advanced age and
can alter action potential parameters in such a way that promotes inappropriate firing and atrial
fibrillation [96]. In aged canine right atrial cells, potassium currents are altered, with increased
transient outward (Ito) and sustained potassium current (Isus) [97]. Calcium/calmodulin dependent
protein kinase-2 upregulation is likely a modulating factor in greater Isus seen in advanced age,
leading to enhanced phosphorylation of potassium channels [96, 122]. According to Dun et al., Ltype calcium current was reduced by 47% in right atrial cells from aged canines compared to young
[97]. In addition, there is a reduction in the cardiac calcium channel pore-forming protein Cav1.2
expression in the SA node of aged guinea pig [123]. The authors of this study suggest that this
could be a major contributing factor in the well-known phenomenon of reduction of SA node function
and bradycardia in advanced age.
Regulation of intracellular calcium handling is modulated in part by phosphorylation events
of proteins such as phospholambin, and these events may be altered in advance age. In fact, the
sarcoplasmic/endoplasmic reticulum calcium ATPase pump itself has been suggested to be
reduced in age [96, 124, 125]. The ryanodine receptor has been shown to be hyperphosphorylated
in advanced age, leading to spontaneous diastolic calcium leak [98]. This abnormal calcium
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handling can lead to delayed after depolarizations (DADs) and early after depolarizations (EADs).
Both DADs and EADs can favor spontaneous ectopic impulses that form triggering events for
torsades de pointes, tachycardia, atrial fibrillation and other arrhythmias. Pulmonary vein, mitral
valve, and coronary sinus cells show the most triggered activity with enhanced DADs [96, 126,
127]. In canine, cardiac action potential curves in advanced age show longer plateau phase than
younger adults [96]. Additionally, in a study by Toda et al., action potentials at 90% repolarization
were found to be significantly prolonged in the aged rabbit compared to young [128]. In summary,
cardiac remodeling changes in aging including fibrosis, loss of cellular communication via connexin43, and changes in ion current and calcium handling impair conduction. These aging effects
ultimately prolong the cardiac action potential repolarization, increasing the risk of arrhythmia which
itself can increase risk of thromboembolism and further pathologic cardiac remodeling of the
aforementioned factors [129, 130].

2.06: Cardiac Valve Remodeling
The valves of the heart normally function in synchrony with the heart, although advancing
age can bring about morphological changes, such as stenosis or regurgitation, that lead to systemic
effects. During embryonic development, heart valves develop from progenitor cells that have
undergone an endothelial to mesenchymal transition which involves complex spatial and temporal
gene regulation [131]. After formation, stretch-driven homeostasis drives morphological changes
in valve leaflets during development [132]. However, the same age-related ECM changes
mentioned previously can also drive valvular remodeling, as shown by a longitudinal study looking
at aortic and pulmonary valves from human donors ranging in age from newborn to 53 years old
[133]. In this study, older valves exhibited an increased deposition of the main connective
component of cardiac valves, collagen type III, along with declining sulfated glycosaminoglycans
content leading to increased valvular stiffness. In addition, collagen cross-linking and fibrosis
increased with age, correlating with increased stiffness and decreased extensibility in the
circumferential direction. Calcium is another common deposition on valves in old age, leading to
valvular stiffness that can progress into aortic valve stenosis [134]. Although morphological
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changes occur to heart valves in advanced age, there is also limited proliferative potential when
compared to fetal valves, suggesting a more quiescent cell phenotype with age [135]; taken
together, these factors likely contribute to pathological remodeling in aging valves (Figure 2b).
It is interesting to note that despite having a generally reduced proliferative state in postfetal development, valves still successfully adapt to ensure proper valve closure throughout life
[133]. There are a few surgical procedures and drug therapies targeting the reversal of valve
fibrosis and calcification, with total valve replacement as a final option. In the last decade, the use
of angiotensin-II receptor type-1 blockers and ACE inhibitors have resulted in a slowing in valvular
remodeling [136] and calcium deposition [137]. A treatment for retaining the valve proliferation
capacity further into adulthood is still being explored; for now, statins, beta-blockers, and diuretics
are used to slow the progression of valve stenosis. In the field of biomedical regeneration, cadaver
valves are being decellularized and researchers have been harvesting stem cell sources from
patients to seed and rebuild valves for transplant [138].
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Figure 2: Cardiac Tissue Remodeling with Advancing Age. The effect of advancing age and
senescence on remodeling of the coronary vasculature (A and E), heart valves (B), conduction
system (C), cardiac mechanical properties as assessed via echocardiography (D), and
cardiomyocytes and extracellular matrix (F) are shown. ACE-1, angiotensin-converting enzyme-1;
ECM, extracellular matrix; HF, heart failure; HIF-1, hypoxia-inducing factor-1; Ito, transient outward
potassium channel; IVRT, isovolumic relaxation time; LTCC, L-type calcium channel; LV, left
ventricle; MMP-2, matrix metalloproteinase-2; NO, nitric oxide; PDGF, platelet-derived growth
factor; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor. Image created
with BioRender.com.

2.07: Acceleration of Age-Related Pathophysiological Tissue Remodeling
Certain populations may be more at risk for age-related cardiac and tissue remodeling, but
to understand this, one must have a grasp of the widely accepted geroscience hypothesis that
aging is a major modifiable risk factor for chronic disease [139]. There is a differentiation between
“chronological age” (someone born in 1990 is 30 in 2020) and “biological age”, or the notion that
one’s cellular and physiologic function could be “younger” or “older” than their chronological age.
The most famous influencers of aging are caloric restriction, cell senescence, and free radicals
[139]. Situations that modify these parameters can influence the so called “rate of aging”. It is
understood that major life illnesses and their treatments, such as cancer and chemotherapy,
diabetes mellitus and injectible insulin, or HIV/AIDS and anti-retrovirals leave individuals with
enhanced susceptibility to age-related pathological decline. This section will explore a nonexhaustive list of at-risk populations and drivers for increased “rate of age” and its effects on cardiac
remodeling, including pollution and smoking exposure, diabetes mellitus, and postmenopausal
state.
Measuring telomere length and telomerase activity may be the best approximation for
quantifying “rate of age”. Oxidative stress appears to be a primary influencer of telomerase activity
[139]. Therefore, decreased telomere length may represent an accumulation and lifetime burden
of oxidative stress. Telomerase dysfunction leads to mitochondrial dysfunction and can precede
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the onset of CVD [139]. Specifically, shorter telomere length has been associated with altered LV
longitudinal and cross-sectional mass, decreased ejection fractio (EF), aortic stenosis, and
atherosclerotic calcification. Telomerase knockout studies in mice have shown attenuated myocyte
division, increased apoptosis and hypertrophy, and cardiac remodeling reminiscent of dilated
cardiomyopathy [140]. Interestingly, there seems to be a discrepancy of about 8-12 years between
chronological age and biological age in individuals with CVD, in that patients with CVD have
telomeres that are the same length as healthy people 8-12 years older [140]. This phenomenon
may also reflect in part the decreased capacity for reparative cardiac remodeling during infarctrelated hypoxia, likely due to limited angiogenic potential and collateral growth in endothelial
senescence with telomere shortening in those with advanced age.
One mechanism for increased rate of telomere shortening and driver of aging is exposure
to ROS. This may be somewhat of a paradox, because it is also known that ROS accumulation
increases with age [141, 142]. Telomeres are prone to oxidative damage due to their high
percentage of guanine nucleotides. Loss of the UCP2 gene, involved in regulation of mitochondrial
ROS levels, leads to increased ROS production and shorter telomere length [143]. ROS not only
can damage DNA directly, but can also impair DNA repair mechanisms and damage telomerase
[144, 145]. Therefore, populations exposed to high levels of ROS-inducing pollution or cigarette
smoke may be at increased risk for telomere shortening and increased rate of aging. Vehicular
emissions and particulate matter have been shown to increase oxidative stress and are associated
with increases in CVD [140]. Specifically, exposure to particulate matter has been associated with
increases in blood pressure, provokes decompensated congestive HF, promotes angina pectoris
and MI, enhances inflammatory and atherosclerotic processes, and hyper-activates platelets
leading to increased thrombosis risk [141].
Interestingly, there appear to be molecular changes in aging that leaves senescent
individuals more susceptible to unfavorable cardiac remodeling in response to exposure to pollution
and/or smoking. Tankerskey et al. found evidence for uncoupling of nitric oxide synthase-3 (NOS3)
in 28-month-old mice exposed to carbon black relative to young controls and age-matched controls
breathing filtered air [141]. Furthermore, it was found that uncoupled NOS3 was paradoxically a
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supplier of ROS, contributing to cardiac dysfunction including increased right ventricular and
pulmonary vascular pressure, increased LV diameter at end-systole and end-diastole, and
decreased FS and EF. Remodeling and cardiac stress were evidenced with exposure to carbon
black by upregulation of natriuretic peptide (brain and atrial) and MMP-2 and MMP-9 transcription.
Cigarette smoke contains ROS, NO, peroxynitrite and organic compound free radicals as well as
pro-oxidant substances that encourage increased cellular proliferation of ROS [142]. Cigarette
smoke can also reduce NO availability, which normally acts as a vasodilator and is vasculo- and
cardioprotective. Vascular NAD(P)H oxidase activity is upregulated in aging, with a concomitant
downregulation of extracellular superoxide dismutase (SOD) [142]. Since aging is already
associated with an increase in oxidative-nitrosative stress and reduced bioavailability of NO, any
factor including pollution or cigarette smoke that causes further exposure to oxidative events
ultimately results in an acceleration of normal cardiovascular aging.

2.08: Populations at Risk of Pathophysiological Tissue Remodeling
Certain groups within the population are more prone to compounding repairs in tissue
regeneration, leading to more pathological events which can exacerbate a condition. One such
population at risk for aberrant cardiovascular remodeling are post-menopausal women. Normally
with advancing age, ovarian production of estrogen drops by 90%; the conversion of androgens in
adipose tissue then becomes the predominant source of estrogen after menopause [146]. Postmenopausal women are at higher risk for CVD compared to their age-matched male counterparts
[147], and more frequently present with HF with preserved EF (HFpEF) [148]. Regardless, HF
symptoms that appear in postmenopausal women are also common in oophorectomized young
women, suggesting that estrogen plays an important role in the vitality of blood vessel function
[149]. Vascular dysfunction in postmenopausal women is prominent in the resistance vessels of
the heart [150], lowering coronary flow reserve despite the absence of occlusive artery disease
[151]. In young female rodents and humans, estrogen protects vascular function via estrogenreceptor-2 G-protein coupled receptor 30 signaling [152], which inhibits ROS production, indirectly
increases NO bioavailability, and upregulates eNOS levels [153]. Along with vascular dysfunction

22

in aged women, angiogenesis is also impaired when circulating estrogen declines due to decreased
VEGF signaling from the estrogen receptor-2 [154]. Hormone replacement therapy has been
utilized to stave off the declining effects from a lack of estrogen. However, many clinical trials
showed little to no vascular benefit and even adverse effects of hormone replacement therapy in
aged females [155].

2.09: Pathologic Insult and Remodeling in the Aging Heart
Mortality due to coronary artery disease (CAD) and MI are increased exponentially with
advancing age even in the context of constant infarct size [156]. This lends credence to the idea
that there are age-related differences in how the aging heart remodels after pathologic insult
compared to a younger individual. Primarily, studies strongly support a limited functional plasticity
in older hearts that results from age-induced changes in the cardiac environment and around the
microvasculature (i.e. the stroma and myocardium). In 2003, Lakatta and Levy [157] described how
these age-associated alterations in cardiac structure and function pair with pathophysiological
disease mechanisms to determine the overall threshold, severity and outcome of CVD in the
geriatric population. In this section, tissue remodeling that occurs post-ischemia (Figure 3) during
dilatory cardiomyopathy and atherosclerosis will be used as a framework to explore the differences
between pathophysiological disease consequences in young vs old [156, 158]. Specifically, this will
be discussed in the context of age-related changes to inflammatory signaling (“inflammageing”),
cellular senescence, and the revascularization response to ischemia reperfusion (IR) injury.

2.10: Inflammageing
The term “inflammageing” refers to a pro-inflammatory state associated with aging, and is
defined by increased blood markers of inflammation without a triggering event, with simultaneous
reduction of capacity to launch an appropriate inflammatory response when a triggering event does
occur [158]. Specifically, with normal aging-related increases include: IL-1, IL-1RN, IL-6, IL-8, IL13, IL-15, IL-18, CRP, IFNα and IFNβ, TGF-β, TNF-α, PGE2, MCP-1, adiponectin and serum
amyloid-A, along with decreases in DHEAS and IL-2 (Figure 3b) [158-163]. Inflammageing is a
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dynamic process occurring with age as each individual cytokine increases at different ages and
with different slopes, and can vary greatly by individual [164]. At some unknown point in the aging
process, the increases of various cytokines/factors culminate in pathological effects, thereby setting
a pathological threshold, with morbidity defined as “unsuccessful aging”. This threshold is lowest
for individuals 60-80 years old, and risk factors that exacerbate inflammageing include: obesity,
genomic instability, cellular senescence, mitochondrial dysfunction, age-related gut microbiota
changes, NLRP3 inflammasome activation, chronic infection, and primary dysregulation of immune
cells. In turn, inflammageing is a known predictor of frailty, multimorbidity, decline of cognitive
function, and pertinent to this discussion, cardiovascular disease.
The inflammatory response seen in response to MI is important for clearance of dead cells
and initiation of the reparative process [165]. Disruption of this process can contribute to loss of
cardiac functionality and HF. In a healthy young heart subjected to MI, neutrophil infiltration peaks
at 1 day post-infarct, with macrophage appearance by post-infarct day 3 and lymphocytes (T and
B cells) at post-infarct day 7 [165]. Neutrophils and macrophages utilize excretion of ROS and the
tyrosine-protein kinase Mer for clearance of dead cells, respectively. There is a temporally related
dichotomy of pro-inflammatory N1 neutrophils and M1 macrophages occurring early in the infarcted
area, followed by an influx of reparative inflammatory-resolving N2 and M2 cells as time
progresses. A delicate balance of these pro- and anti-inflammatory cells are necessary for
successful infarct repair. Lastly, there is a robust response by fibroblasts to the cytokine TGF-β
involving the Smad2/3 pathway, resulting in appropriate fibrous tissue deposition.
Striking differences occur following a MI in the aged heart. Generally, there is a reduction
in the inflammatory response post-infarct with concomitant delay in dead cell clearance, potentially
via decreased phagocytic activity and attenuation of oxidative response by senescent
macrophages and neutrophils [156]. Additionally, there is an attenuation of the fibroblast response
to TGF-β and angiotensin-II to induce matrix synthesis, which can at least in part explain the fact
that infarcts in senescent hearts elicit reduced collagen and matricellular protein deposition,
culminating in loose and potentially unstable connective tissue scars (Figure 2) [156, 165]. The
reduced tensile strength of these infarcts has profound impacts on the mechanical properties of the
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heart, including systolic dysfunction and dilative remodeling more severe in advanced age relative
to young, even with constant infarct size [156]. It is thought that the lower inflammatory and fibrous
response in advanced age is due to enhanced baseline activation of these pathways that lead to a
lower reparative reserve in times of acute stress [156].

2.11: Cellular Senescence Drives Pathology
Cells that are classified as senescent are defined as having a loss of proliferative ability via
cell cycle arrest (as a means of natural cancer suppression), with cell enlargement, misshaped
nuclei, increased NF-κβ signaling, DNA damage, and resistance to apoptosis [158]. Senescent cell
density increases with aging in multiple organs, plays a fundamental role in inflammageing, and is
directly involved in cardiac remodeling in aging pathology [158]. Senescent cells exhibit increased
and inappropriate paracrine (with limited exocrine) secretion of molecules (collectively termed
senescence-associated secretory phenotype (SASP)) including: IL-1α, IL-1β, IL-6, IL-8, growth
regulated-a protein, fibroblast growth factor-2 and hepatocyte growth factor, MMP-1, MMP-3, and
collagenase-3 [158]. The detrimental effects of senescent cells has been demonstrated by showing
that clearance of p16INK4A cells (a marker of senescence) in mice increases lifespan and reduces
age-related decline of organ function [166] [167]. In addition, transplant of small numbers of
senescent adipose-derived stem cells diminishes physical function (treadmill speed, grip strength
etc.) and decreases survival by 5.2 fold in young mice [168].
Atherosclerosis is a prime example of how age-dependent cellular senescence can
contribute to significant pathogenesis. Initially, damaged endothelium allows for LDL particles to
enter the arterial wall and become oxidized and eventually taken up by migrating monocytes to
become foam macrophages, which release proinflammatory cytokines IL-1β and IL-18. In
advanced atherosclerotic lesions, markers of senescence and apoptosis accumulate in endothelial
and vascular smooth muscle cells [158]. These senescent cells secrete the SASP (including matrix
metalloproteinases) to further exacerbate inflammation and degradation of the extracellular matrix,
with eventual destabilization of the atherosclerotic plaque [158]. It is this degradation stage that
induces the proliferation and migration of smooth muscle cells into the intima where they form the

25

fibrous cap, and owing to the harsh inflammatory environment, themselves becomes senescent
[158]. Again, SASP matrix metalloproteinases can destabilize and thin the fibrous cap potentially
leading to rupture.
Heart failure characterized by dilatory cardiac remodeling is an end-stage pathological
consequence of myocardial aging. As discussed previously, myocardial aging decreases the
functional reserve of the heart, and age-related decreases in myocyte density lead to reduced
ability of the aged heart to compensate for acute changes in ventricular loading. Myocytes of
patients with age-related dilatory cardiomyopathy exhibit 48% senescence compared to just 16%
in healthy age matched controls and 15% in patients with idiopathic dilatory cardiomyopathy (non
age-related) [169]. Furthermore, in the pathologic dilative aged heart, there is an inadequate
proliferative compensation for the death of myocytes in spite of increased mitotic index, telomerase
activity, and cellular proliferation of myocytes, reflecting a heterogenic remodeling between
senescent and proliferative cells [169]. When the balance shifts towards accumulation of large,
improperly functioning senescent cells, this contributes to poor contraction and ventricular
dysfunction seen in eccentric dilative cardiomyopathy [170]. Senescence of fibroblasts also leads
to blunted response to fibrogenic growth factors post infarct, with similar decrease in scar tensile
strength and tendency for ventricular dilation [113].

2.12: Age-Impaired Revascularization Following Insult
The older population is more susceptible to injury and illness [171], while also taking up to
twice as long to heal as measured by time for re-epithelization of subcutaneous wounds [172].
Mentioned earlier, neutrophils regulate the clearing/inflammatory phase of ischemic injury, followed
by the proliferative phase which leads to a highly vascularized granulated tissue with a stabilized
ECM [173]. However, collateral vessel development after injury is significantly reduced in patients
>70 years old [174]. Proper collateral development is dependent upon upregulation of plateletderived growth factor (PDGF) on infiltrating cells [175] and endothelial function. PDGF stimulates
maturation of blood vessels by smooth muscle cell and pericyte recruitment [176]. Mature coated
vessels are protected from apoptotic signals, unlike immature vessels [173]. However, plasma
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samples from healthy individuals showed that there is a reduction in basal levels of PDGF after 25
years of age [177]. The decrease in basal PDGF combined with endothelial cell senescence,
described earlier, leads to collateral rarefaction (pruning of immature capillaries). Furthermore,
collateral blood vessels formed in aged animals and humans are more tortuous compared to their
young counterparts [178]. Perfused collateral coronary blood vessels are formed ~20 days after
the ischemic event [179]. Although increased collateral development does not improve LV dilation
one month post-ischemia, it does prevent further LV dilation as measured up to 2 years postischemia [180]. Clinicians can measure poor collateral development by the presence of fragmented
Q waves, defined as additional R waves or notching R-S waves in two contiguous leads [181].
Because of physiological changes that present with advancing age, the older population undergoes
diminished remodeling after injury that leads to pathological manifestations. In the case of MI,
decreased collagen deposition and poor reperfusion leads to enhanced ventricular dilation [182]
and perfusion mismatch in hypertrophied cardiomyoctyes [113] in elderly patients.

Figure 3. Age-dependent inflammatory and fibrotic response to myocardial infarction (MI)
as a consequence of tissue remodeling in aging. Inflammatory and fibrotic profiles of young
heart tissue at baseline and post-myocardial infarction (a) compared with aged heart tissue at
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baseline and post-MI (d). Cross section of heart, with healthy tissue in red; young hearts form a
stable scar (solid gray) (b), while aged hearts form a weak loose scar (nonsolid and thin) (e).
Histology of scar collagen network using Sirius Red-stained section of young (c) and senescent (f)
mouse infarct. CRP, C-reactive protein; DHEAS, dehydroepiandrosterone sulfate; MCP-1,
monocyte chemoattractant protein-1. Image created with BioRender.com.

2.13: Therapies to Address Age-Related Pathophysiological Remodeling
Advancing age will affect every individual and its impact on health deserves significant
attention. Currently, therapies for improving cardiac function after injury are targeted at improving
functional recovery and diminishing risk of further events. However, due to the intricate multifaceted
nature of the healing process, targeting a single component specific to improved healing is
challenging, especially in the context of advancing age. Discussion of emerging therapies that could
directly enhance cardiac tissue remodeling in advancing age including targeting of cardiac fibrosis,
inflammation, senescence and ROS can be found in the full review [183].
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CHAPTER 3
INTRODUCTION PART 3
AGING-INDUCED IMPAIRMENT OF VASCULAR FUNCTION: MITOCHONDRIAL REDOX
CONTRIBUTIONS AND PHYSIOLOGICAL/CLINICAL IMPLICATIONS2
The vasculature responds to the respiratory needs of tissue by modulating luminal diameter
through smooth muscle constriction or relaxation. Coronary perfusion, diastolic function, and
coronary flow reserve are drastically reduced with aging. This loss of blood flow contributes to and
exacerbates pathological processes such as angina pectoris, atherosclerosis, and coronary artery
and microvascular disease. Increased attention has recently been given to defining mechanisms
behind aging-mediated loss of vascular function and development of therapeutic strategies to
restore youthful vascular responsiveness. The ultimate goal is to provide new avenues for symptom
management, reversal of tissue damage, and preventing or delaying of aging-induced vascular
damage and dysfunction in the first place. The major objective of this chapter is to describe how
aging-associated mitochondrial dysfunction contributes to endothelial and smooth muscle
dysfunction via dysregulated ROS production, the clinical impact of this phenomenon, and to
discuss emerging therapeutic strategies. Pathological changes in regulation of mitochondrial
oxidative and nitrosative balance and mitochondrial dynamics of fission/fusion have widespread
effects on the mechanisms underlying the ability of the vasculature to relax, leading to
hyperconstriction with aging. We will focus on flow-mediated dilation, endothelial hyperpolarizing
factors, and adrenergic receptors. The clinical implications of these changes on major adverse
cardiac events and mortality are described.

2

Chapter represents a publication with minor modification from:
Tracy et al. Aging Induced Impairment of Vascular Function – Mitochondrial Contributions and
Physiological/Clinical Implications. Antioxidants & Redox Signaling (2021) 35 (12), 974-1015.
https://doi.org/10.1089/ars.2021.0031
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3.10: Historically Explored Mechanisms of Oxidative Changes in Aging
3.11: Causes of ROS Production in Aging
The free-radical theory of aging suggests that accumulated oxidative stress coincides and
contributes to the aging process. It is postulated that age-associated functional loss (such as
vascular function to maintain adequate perfusion) is the result of oxidative damage of proteins,
DNA (nuclear and mitochondrial), and lipids leading to cellular senescence. Cellular senescence is
characterized by the senescence-associated secretory phenotype (SASP), whereby cells exhibit
increased secretion of interleukins, chemokines, growth factors, matrix metalloproteinases,
insoluble proteins and extracellular matrix [158]. This leads to a proinflammatory state with
feedforward mechanisms that further increase harmful reactive oxygen and nitrogen species (ROS
and RNS), affecting many pathological processes linked to chronic diseases such as
cardiovascular disease, respiratory diseases, chronic kidney disease, cancer, neurodegenerative
diseases and muscular disorders [158]. Indeed, chronic inflammation may be induced in the elderly
population by genetic inflammasome involvement, leading to increased oxidative stress,
hypertension, and arterial stiffness [184]. In addition, increased apoptosis has been demonstrated
in senescent endothelial cells in humans, and vascular senescence can lead to irreversible
pulmonary arterial hypertension in both rats and humans [185]. The occurrence of SASP and
proinflammatory state is variable between individuals depending on genetic, environmental, and
behavioral influences, leading to the Geroscience hypothesis which proposes that the “rate of
aging” can be influenced by modifiable factors [158]. Specific to this chapter, we will focus on the
role and mechanisms by which oxidative stress hastens vascular aging resulting in endothelial
dysfunction.
The mitochondria are responsible for not only cellular energy production, but also the most
ROS generation [186, 187]. During oxidative phosphorylation, the electron transport chain (ETC)
utilizes the transfer of electrons between complexes to establish the proton gradient responsible
for powering ATP-synthase generating ATP [188]. The electrons traversing the ETC end up at
complex IV, where they are ultimately utilized in the production of water from oxygen and hydrogen.
One to three percent of these electrons do not make it to this step; instead, they leak to prematurely
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react with oxygen to form superoxide (O2•–)[189]. In senescent endothelial cells (via passaging),
the catalytic function of complex IV is reduced by up to 84% allowing for exacerbated electron
leakage with aging [190]. Superoxide generation occurs predominantly at complex I [191, 192]
during conditions of high proton motive force, NADH/NAD+ ratio, and CoQH2/CoQ ratio (sensor of
respiratory chain efficiency), the latter two occurring more frequently with aging [193-195]. A
significant amount of superoxide from complex I is generated during reverse electron transport,
where electrons are shunted back from CoQH2 back to complex I and reduce NAD+ to NADH. This
process is highly sensitive to membrane potential (protonmotive force) changes, with a 10 mV
decrease leading to 70% reduction in superoxide production within the mitochondrial matrix, albeit
not affecting cytosolic production [196]. Mitochondrial membrane potential decreases with aging,
which would theoretically lead to a decrease in superoxide production in aging. This is due to an
inherent increase in leakage of protons reducing the membrane potential with age, likely as a
probable adaptive mechanism to reduce oxidative stress in aging [197-199]. Despite this
adaptation, accumulation of ROS dominates aging-associated mitochondrial alterations.
There is an increase in pro-oxidation processes in the aging vasculature [200]. With aging,
there is a known increase in circulating angiotensin II (Ang II), angiotensin converting enzyme
(ACE), and angiotensin receptor 1 (AT1) expression [86, 201, 202]. Ang II induces endothelial
dysfunction through activation of inflammatory signaling (e.g. VCAM-1, NFkB), activation of COX2
producing vasoactive prostaglandins when bound to AT1 receptors, and activation of NADPH
oxidase (NOX) [201, 203-212]. These transmembrane proteins transfer electrons from NADPH to
molecular oxygen, leading to the generation of superoxide and hydrogen peroxide [211, 213-218].
NOX 1 and 2 contribute to superoxide production in endothelial cells and endothelial and smooth
muscle cells, respectively [213, 214, 219, 220]. Angiotensin receptor 1 and NOX activation also
lead to eNOS uncoupling, shifting from nitric oxide to superoxide production and attenuating
endothelium-dependent dilation (EDD)[221-224]. In aging, NOX subunits are overexpressed,
including the p67 subunit in mouse aorta [225, 226], p22phox subunit in rat mesenteric arteries [227],
and p47phox subunit in aging men [15]. Collectively these signaling cascades result in enhanced
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ROS generation and endothelial dysfunction, while inhibition of NOX improves overall EDD in
vessels from aging humans and rats [228-231].
Of the NOX isoforms, NOX4 is considered one of the primary vascular NOXs responsible for
endothelial hydrogen peroxide production. NOX4 is further upregulated by hypertrophic signaling
and β-arrestin mediated signaling, and along with the other NOXs are increased with age [215,
232-236]. There is current lack of clarity and consensus on the vascular effects of NOX4, with
studies showing both deleterious and protective roles [237]. The discrepancy in these studies, likely
stemming from differences in knockout/overexpression strategies, showcases the tight redox
balance required for homeostatic vascular function. Low chronic hydrogen peroxide accumulation
can be vasculoprotective, lowering blood pressure if produced acutely as an endotheliumdependent hyperpolarizing factor in response to shear stress. This is the case for juvenile rat
arteriolar dilation in contracting muscle via acute hydrogen peroxide production [160]. In NOX4
knockout mice, aortas develop increased inflammation, increased media hypertrophy, reduced
heme oxygenase-1 and nrf-2 gene expression, and endothelial dysfunction including reduced
eNOS function and nitric oxide [238, 239]. On the other hand, overabundance of hydrogen
peroxide chronically can induce autophagy, apoptosis, reduced vascular function, and is classically
known as a pathogenic mediator of atherosclerosis. In aging, NOX4 may err on the side of
promoting endothelial dysfunction, rather than protection [240, 241]. Potential positive effects of
NOX4 are likely mitigated due to eNOS uncoupling-mediated superoxide production, whereby any
effect of NOX4 to active eNOS through AKT signaling is potentially counterproductive. Evidence
suggests upregulated NOX4 and subsequent chronic hydrogen peroxide exposure in aging causes
eNOS uncoupling, reduced nitric oxide production and ACh-mediated vasodilation, endoplasmic
reticulum stress via IRE1α-oxidation, and mitochondrial dysfunction [240-243]. Further details on
the vascular protective and deleterious effects of NOX4 are reviewed by Gloria Salazar [244].
Xanthine oxidase has increased expression and activity with aging and is associated with
oxidative stress in several tissues, including the aorta, coronary, and mesenteric arteries [245-251]
and contributes to superoxide generation in response to increased pressure [252]. Although
inhibition of xanthine oxidase reverses endothelial dysfunction in hypoxia, hypercholesterolemia,
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hyperuricemia, and heart failure patients [253-256], inhibition seems unable to reverse agingmediated endothelial dysfunction in human, at least while evaluating peripheral vasculature [257].
The adaptor protein p66shc has been considered one of the master regulators of superoxide
production. Its expression, increased in advancing age, is mediated by Ang II signaling,
hypertrophy, and alpha-adrenergic receptor agonism (αADR) [188, 258-262]. Additionally, p66shc
is imported into the intermembrane space of the mitochondria where it steals an electron from
cytochrome c, facilitating its transfer to molecular oxygen to produce superoxide [263], while also
inhibiting the transcription of SOD2 through α1ADR/FOXO3A-mediated signaling [258]. Genetic
deletion of p66shc leads to a 30% increase in lifespan in p66shc -/- mice [264]. Genetic knockout of
p66shc in old murine aortic rings preserves, whereas overexpression reduces EDD to acetylcholine
(ACh) and nitric oxide bioavailability [259, 265-267].

3.12: Reduction of Anti-oxidative Processes in Aging
During youth and into healthy middle age (roughly ages < 55), antioxidants quench ROS to
maintain redox homeostasis. Superoxide is converted into hydrogen peroxide (H2O2) by
manganese superoxide dismutase (SOD2) in the mitochondrial matrix and copper/zinc superoxide
dismutase (SOD1) in the inner mitochondrial space and cytoplasm. Hydrogen peroxide can further
react via the Fenton reaction to form the hydroxyl ion. This is prevented by the conversion of
hydrogen peroxide to water and molecular oxygen by catalase and glutathione peroxidase
(predominant). Glutathione peroxidase oxidizes glutathione in concert with glutathione reductase
to reduce GSH, occurring in a cyclic manner [188, 268]. Superoxide can also react with nitric oxide
to form peroxynitrite, a potent oxidizing and nitrosylating agent. Vascular aging is associated with
a decrease in density and function of SOD1/2 [269-273], glutathione, glutathione reductase, and
glutathione peroxidase [274-282], which are associated with reduced EDD and aortic stiffening in
mice and rats. Positive correlations of aortic catalase concentration and activity with aging have
been observed as a potential compensatory mechanism (albeit insufficient) for increased hydrogen
peroxide concentration and vascular sensitivity to hydrogen peroxide [283, 284]. In contrast, in
aged pulmonary arteries and patients with untreated essential hypertension catalase concentration
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is decreased [285, 286]. Overexpression of catalase, glutathione peroxidase, or SOD in animal
models of aging are demonstrated to restore EDD and protect against vascular pathologies such
as aneurisms, atherosclerosis, with the added benefit of increased lifespan [287-293].
Additional antioxidative contributors to maintaining vascular redox homeostasis are sirtuin (Sirt)
deacetylases, which have been demonstrated to be decreased in aging mice and humans [294296]. Sustaining endothelial nitric oxide synthase (eNOS) deacetylation status preserves its ability
to produce nitric oxide and shifting to acetylated status with aging-mediated loss of Sirt1 contributes
to loss of nitric oxide bioavailability and increased superoxide [297-300]. This loss of nitric oxide is
associated with diminished capacity for endothelium- or shear stress-induced vasodilation in aorta,
femoral, and middle cerebral arteries subject to Sirt1 inhibition [296, 297, 301]. Conversely,
overexpression of endothelial Sirt1 mediates vasoprotection in aging through nitric oxideindependent effects via enhancing soluble guanylyl cyclase in smooth muscle and reducing AT1
receptor expression [302-305]. Sirt1 and mitochondrial Sirt3 regulate transcription factors for
antioxidant proteins including FOXO, the transcription factor for SOD2, to suppress the effects of
p66shc and reduce ROS [273, 306-308]. Childhood Sirt1 expression is a predictor of adulthood
microvascular function as reduced Sirt1 in young participants in a longitudinal cohort was
associated with premature cutaneous microvascular dysfunction in adulthood. This was assessed
via maximal response to local thermal hyperemia, post-occlusive reactive hyperemia, and
iontophoresis with ACh [309]. Many of the beneficial effects of caloric restriction on vascular
function are induced via sirtuins as they suppress senescence by delaying telomere attrition,
instigating DNA repair and genomic stability, and preservation of proteostasis by regulating heat
shock proteins [308, 310-313].

3.13 Effect of Estrogen Loss on Oxidative Stress During Aging
Aging-associated changes in hormones contribute to increased oxidative stress. Loss of
estrogen during the menopausal transition to post-menopause is associated with elevated risk for
cardiovascular disease. Post-menopausal females may exhibit coronary microvascular
dysfunction, defined by endothelial dysfunction, pathologic smooth muscle tone, and increased
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oxidative stress [1]. The loss of estrogen is one mediator of this disease due to the loss of its antioxidative properties. Estrogen modulates NOX to reduce superoxide production in rat in vivo
mesenteric microvessels [314, 315]. Loss of estrogen diminishes nitric oxide-mediated flowmediated dilation (FMD) in young ovariectomized rats while exhibiting elevated nitrotyrosine
(oxidative stress marker) and reduced SOD protein [316]. Ovariectomized rats given hormone
replacement therapy show restored SOD and nitric oxide-mediated FMD. Estrogen also activates
telomerase, limiting mitochondrial ROS production via the subunit telomerase reverse transcriptase
[317]. The activation of mitochondrial estrogen receptor-β leads to increased S-nitrosylation of
proteins, such as proteins that have a role in the homeostatic balance of β-adrenergic function.
The mitochondrial prooxidant effects on EDD in aging promote pathologic cardiovascular
remodeling and hypertension, while reduced perfusion and chronic ischemia have an impact on
morbidity and mortality. Therefore, understanding these intricate interactions is vital for
understanding proper therapeutic management and development. How these aging-dependent
vascular changes impact mechanisms for vasorelaxation including flow-mediated, potassium
channel-mediated, and βADR-mediated relaxation as well as parallel processes such as
mitochondrial fission and fusion are the focus of the remainder of this chapter.

3.20: Vascular Mitochondrial Fission/Fusion in Relation to Mitochondrial Redox
Homeostasis with Aging
3.21: Mitochondrial Dynamics and Dysfunction with Aging-induced Oxidative Stress and
Hyperglycemia
Mitochondria are dynamic organelles, changing shape and function as a direct result of the
surrounding molecular environment. Within other tissues and organs, the mitochondria are
traditionally known as energy hubs, producing ATP through oxidative phosphorylation. However,
within the vasculature, mitochondria act as a signaling hub rather than for energy as endothelial
cells are highly glycolytic [188, 318]. The mitochondria are integral in maintaining a balance
between production of ROS and signaling actions of nitric oxide, which can affect vasodilative
balance as alluded to in later sections of this chapter. In this capacity, the structure and function of
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mitochondria play an important role in vascular health and disease [188]. Mitochondrial dynamics
are delineated by biogenesis and mitophagy. On the one hand, biogenesis results in production of
new mitochondria characterized by a highly filamentous and networked structure that is viewed as
“fused”. Conversely, damaged mitochondria tend to exhibit a more diffuse, punctate structure,
caused by a process termed fission which is mediated by dynamin-related protein-1 (DRP-1) and
mitochondrial fission protein-1 (Fis-1). Damaged mitochondria either fuse with healthy mitochondria
- mediated by mitofusin 1 or 2 (Mfn-1 or 2) or optic atrophy 1 (Opa-1) - or are encapsulated and
degraded via mitophagy. Oxidative stress alters cultured endothelial mitochondrial structure,
transitioning from a more structured, tubular, networked state (e.g. fusion), to a more fragmented,
disrupted, or punctate state (e.g. fission). Aging-related changes to antioxidant vs. prooxidant
expression and function and their relation to mitochondrial dynamics, mitophagy, FMD, and
adrenergic-mediated dilation are illustrated in Figure 4.
Mitochondrial dynamics during health exist in a homeostatic balance between fission and fusion,
the disruption of which is implicated in cell senescence, quiescence, and aging processes [319].
Indeed, Jendrach, et. al. demonstrated in HUVECs serially cultured to induce senescence
(mimicking aging) that mitochondrial structure is altered in aging via reduced fusion and fission
events; aging was associated with mitochondrial DNA damage and loss of mitochondrial membrane
potential opening of the mitochondrial permeability transition pore, resulting in release of
cytochrome C and enhancing further enhancing oxidative stress [320]. Hyperfusion is a protective
response to boost mitochondrial respiration and counteract cell stress. A more connected (fused)
network of mitochondria allows for a more closely linked network of mitochondrial respiratory
complexes, maximizing energy production and signaling [321]. However, excessive hyperfusion
via Mfn-1 overactivation may be associated with induction of senescence, and DRP-1 repression
may induce ATR-mediated DNA damage response. Some level of fission appears necessary, as
senescent endothelial progenitor cells exhibit reduced Fis-1 with restoration of expression, thereby
reducing ROS and restoring youthful morphology, bioenergetics, and angiogenic potential [322].
Overly reduced DRP-1 function, while inducing hyperfusion, also reduces Mfn-1 and 2 and Opa-1
expression and processing [323]. On the other hand, disruption of this interconnected mitochondrial

36

network with hyperfission is linked to aberrant respiratory complexes and excessive ROS [324,
325].
In endothelial cell senescence, hyperfission dominates. In senescent rat aortic endothelial cells
(induced by Ang II), mitochondrial fission is upregulated alongside a pro-inflammatory phenotype
[326]. One mechanism for increased senescent endothelial fission is enhanced activity of DRP-1
due to loss of protein disulfide isomerase A1 (PDIA1). PDIA1 acts as a thiol reductase for DRP-1,
without which DRP-1 becomes sulfenylated at cysteine 644, leading to activation with increased
mitochondrial fragmentation and ROS production, further induction of senescence with reduced
angiogenesis, and reduced endothelium-dependent vasodilation to ACh [327]. DRP-1 may also be
redox regulated by S-nitrosylation-mediated activation, although this notion is controversial [328,
329]. DRP-1 is negatively regulated while Opa-1 is positively regulated by Sirt 3 deacetylation,
which is downregulated in aging [330, 331]. Reductions in rat aortic NO bioavailability (which occurs
in aging) also reduces the number of fused mitochondria, while increasing mitochondrial fission
[332]. These aging-induced balance shifts towards hyperfission has been observed in our lab with
RNA sequencing showing reduced Mfn-1 and enhanced DRP-1 in aging rat coronary microvessels
(more details in Chapter 8).
Changes in mitochondrial structure and function are impacted by their surrounding environment.
Exposure to ROS imparts damage to mitochondria DNA (mtDNA), with excessive oxidative stress
impairing oxidative phosphorylation and subsequently increasing the amount of ROS produced in
a feedforward manner [333]. As it relates to fission/fusion balance, these alterations have
consequences for dilative ability of the vasculature to maintain proper patency for oxygen and
metabolic and demand and for processes of aging-associated cardiovascular pathologies.
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Figure 4: Aging-related Changes in Mitochondrial Dynamics, Pro- and Antioxidant Enzymes,
and Effect of Subsequent ROS on Flow and Adrenergic-medicated Dilation: 1. During youth,
homeostatic redox balance occurs due to adequate antioxidant and limited prooxidant enzyme
expression, function, and/or signaling (up or down arrows) that is reversed with aging to increase
prooxidant and limit antioxidant enzyme expression, function, and signaling. Note for catalase,
expression is up or down regulated with aging depending on vascular location (up in aging in aorta
and coronary, down with aging in pulmonary arteries). Arrows between SIRT1 to SIRT3 to SOD2
refer to deacetylation that activates SOD2. 2. In youth, redox homeostasis allows for elongated and
networked mitochondrial morphology. When mitochondrial damage occurs in youth, fusion and
mitophagy are favored over fission with lower expression of fission proteins DRP1 and FIS1 in
youth relative to aging. Aging mitochondria are characterized morphologically as fragmented and
more likely to undergo fission than fusion or mitophagy. Note that beclin and parkin expression can
be increased or decreased with age depending on source. 3-5. Greater ROS generation in aging
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from dysfunctional mitochondria contributes to attenuation of effectiveness of flow- and βadrenergic mediated dilation. Figure created with BioRender.com.

3.22: What are the Functional Ramifications of Age-Associated Changes in Mitochondrial
Dynamics?
Reductions in vasodilation in aging have been attributed to excessive mtROS production as a
result of dysfunctional mitochondria including dynamics of fission/fusion balance. As described in
subsequent major sections of this chapter, aging is associated with skewed balance of ROS and
vasoprotective nitric oxide bioavailability [334-336], in part due to altered mitochondrial dynamics,
with reductions in vasodilation to shear stress (e.g. exercise or flow-mediated dilation) and
adrenergic agonism in older adults [268, 335, 337-340]. For now, we describe associations of
altered fission/fusion balance and their functional consequences on vasodilative capacity and
classic pathologies.
Evidence from animal models indicate that aging is associated with a general decrease in
mitochondria content within endothelial cells, coinciding with decreased mitochondrial respiration
and increased mitochondria superoxide generation and hydrogen peroxide [188]. These
maladaptive alterations with aging are associated with decreased mRNA expression of
mitochondrial biogenesis, and reductions in Mfn-1 and 2 [335, 341, 342]. Functionally, aginginduced increased DRP-1-induced mitochondrial fragmentation increases mitochondrial ROS
generation and reduces EDD to ACh [327, 343].
Exposure to high glucose, mimicking insulin resistance with aging (independent of
adiposity)[344, 345], is associated with increased ROS and altered mitochondria shape. Using a
photo-activatable mitochondrial reporter within the endothelium in mice both in vivo and ex vivo,
Durand, et. al. demonstrated that acute exposure to high glucose (via tail vein injection or cultured
primary cells) resulted in fragmented, disrupted mitochondrial networks relative to normal glucose
conditions [346]. Type 2 diabetes mellitus (T2DM) and manipulation of glucose concentrations
(mimicking aging-increased insulin resistance) induces mitochondrial fission and reduces
microvascular endothelial function [347-349]. Within the brachial artery and in resistance arterioles,
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presence of T2DM is associated with increased ROS, increased mitochondrial membrane potential
and increased protein markers of mitochondrial fission. These hyperfission changes in
mitochondrial dynamics are associated with reduced vasodilation to ACh within resistance
arterioles [327]. Interestingly, administration of mitochondrial-targeted antioxidants improved FMD
and ACh-induced vasodilation and decreased ROS [29, 30]. While T2DM and exposure to high
glucose induced mitochondrial fission, Tanner et. al. [347] demonstrated that exposure to low
glucose also is associated with increased mitochondrial fission in cultured endothelial cells, while
both pharmacological and genetic disruption of mitochondrial fission in low-glucose exposed
resistance arterioles improved microvascular endothelial function (ACh-induced vasodilation).
While the specific role for aging in-it-of-itself (vs. aging-associated hyperglycemic stress) within this
vasodilative context has yet to be fully elucidated, particularly within the microvasculature, it does
provide evidence of mitochondrial dynamics driving both conduit artery and microvascular
endothelial function. Therefore, further studies to directly link aging-mediated mitochondrial
dynamic dysfunction to vasodilative function are highly warranted.
Similar to endothelial cells, mitochondrial dynamics drastically impact vascular smooth muscle
function, reviewed elsewhere [350, 351]. Liu, et. al. demonstrated in rat mesenteric arteries and
thoracic aorta that administration of phenylephrine (α-adrenergic agonist) and potassium resulted
in mitochondrial fission within vascular smooth muscle cells, while inhibition of mitochondrial fission
reduced vasoconstrictor responses to phenylephrine and potassium [352]. Interestingly, aging
favors α-adrenergic constriction in coronary vessels as described in section 5 [41]. In a similar light,
Chen, et. al. [353] demonstrated that inhibition of mitochondrial fission reduced the vasoconstrictor
response of mesenteric arteries and thoracic aorta in rats to endothelin-1, which is also increased
in aging [354, 355].
There are implications for a role for mitochondrial hyperfission in aging-associated
cardiovascular pathologies. Wang, et. al. [356] demonstrated that reduction of mitochondrial fission
protein DRP-1 decreased vascular smooth muscle migration and reduced ROS, implicating a role
for mitochondrial hyperfission in atherosclerosis. Interestingly, Mfn-2 has been demonstrated to
inhibit vascular smooth muscle proliferation. Mfn-2 mediates apoptosis independent of its role
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within mitochondrial dynamics, and is critical for the apoptotic response to hydrogen peroxide in
vascular smooth muscle cells (hydrogen peroxide being an important pathologic mediator of
atherosclerosis)[342, 357]. However, Mfn-2 expression has been shown to be reduced in mouse
and rat atherosclerosis and hypertension [358]. Cardiac ischemia-reperfusion injury is associated
with downregulation of Opa-1 in a DRP-1 hyperfission-dependent manner [359, 360], and Opa-1
and Mfn-1 and 2 have been shown to be protective against the development of heart failure from
pressure overload [361, 362].

3.23: Vascular Mitochondrial Mitophagy
Over the past decade, the role of mitophagy in vascular structure and function in health and
disease has become a popular area of research. The most well characterized mitophagy signaling
cascade is the PTEN-induced kinase 1 (PINK1)-Parkin-mediated pathway. Emerging evidence has
demonstrated that mitophagy may be activated independent of Parkin-mediated mitophagy. More
recent work has shown these distinct signaling pathways are unique to the environmental stressors
mitochondria are exposed to, as well as distinct to the tissue studied [363].

3.24: Receptor-Mediated Mitophagy
The outer mitochondrial membrane expresses receptors specific for mitophagy, described as
containing LC3-interacting regions, which function to dock with LC3 for canonical autophagy
degradation. Currently, three receptors have been described as such: NIX, BNIP3
(BCL2/adenovirus e1B 19 kDa interacting protein 3), and FUNDC1 (FUN14 domain-containing
protein 1). De-phosphorylation of threonine and serine residues allows for FUNDC1 to link with
LC3B and undergo canonical autophagy [364, 365]. Hypoxia appears to be the primary driving
factor that activates FUNDC1-mediated mitophagy, and this mitophagy pathway may be
particularly important within the vascular responses to hypoxia (e.g. ischemia-reperfusion). Zhang,
et. al. demonstrated that hypoxia elicits FUNDC1-mediated mitophagy, evidenced by elevated
mitochondrial proteins and the reciprocal marker of autophagy, p62, in FUNDC1 knockout mice,
and no change in LC3-I expression [366]. Furthermore, platelets (which are exposed to varying
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levels of oxygen throughout the vasculature) from FUNDC1 KO mice do not demonstrate formation
of autophagosomes containing mitochondria. These responses are autophagy-dependent, as
deletion of Atg5 resulted in no mitophagy activation in response to hypoxia in platelets. Functionally,
exposure to coronary ischemia-reperfusion increased mitophagy in wild-type (Cre negative) but not
FUNDC1 platelet specific KO [366]. While the specific role of FUNDC1-mediated mitophagy has
been described in other organs and tissues, the specific role within the vasculature and whether
this is altered with aging is unclear, representing a ripe area for future investigation. Fundamental
questions regarding the role of FUNDC1 need to be addressed. Specifically, is FUNDC1-mediated
mitophagy altered with disease or aging? In vascular-specific diseases such as peripheral arterial
disease (PAD), the primary culprit of symptoms is a mismatching of oxygen delivery to oxygen
demand, rendering tissues hypoxic. Do aberrant deviations in FUNDC1 and mitochondrial function
play a role in development and progression of PAD?
The aforementioned mitophagy-related receptors BNIP3 and NIX are also oxygen sensitive.
Both BNIP3 and NIX express LC3 interacting region and interact with LC3 via phosphorylation of
various serine sites to degrade mitochondria via canonical autophagy. In old mouse aortas (aged
27-28 months), no BNIP3 protein expression differences were found relative to young mice [367];
however, protein expression of NIX was increased in older mice (18-19 months) basally and in
response to serum starvation relative to young mice [368]. Interestingly, administration of trehalose
(2% in drinking water) increased protein expression of BNIP3 [367]. Within these studies,
mitochondrial morphology of the older mice aortas was not examined. From a cell perspective,
BNIP3-mediated mitophagy is important for maintenance of homeostasis in response to
experimental hyperglycemia in the cerebral vasculature [369]. Together, these findings indicate
that receptor-mediated-mitophagy within the vasculature may be impaired with advancing age and
in the presence of cardiovascular risk factors. Future investigations into the specific roles of
receptor-mediated mitophagy are warranted.

3.25 Non-Receptor Mediated Mitophagy
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The most widely described mitophagy pathway is PINK1-Parkin mitophagy. Broadly, under nonstressed conditions, PINK1 is shuttled into the mitochondria where it is subsequently degraded.
PINK1 and Parkin act in concert with mitochondrial fission to encapsulate and degrade damaged
mitochondria. Upon mitochondrial outer membrane depolarization, PINK1 accumulates on the
outer membrane and recruits the E3 ubiquitin ligase Parkin. Parkin ubiquinates the damaged,
depolarized mitochondria, which are then encapsulated by an autophagosome which fuses with an
autolysosome containing acidic hydrolases, thereby degrading the mitochondria. Loss of Parkin
function or aberrant actions of regulated (S-nitrosylated) Parkin result in the inadequate clearance
of damaged mitochondria and may trigger further mitochondrial fission or fragmentation [370-372].
Parkin plays a crucial role in mitochondrial dynamics. The role of mitophagy within premature
hypertension and vascular aging has recently been succinctly reviewed elsewhere [373]. In relation
to vascular aging, LaRocca, et. al. [367] demonstrated that within the aorta of old mice, protein
expression of Parkin is reduced relative to young mice. The reduction in Parkin was paralleled with
an increase in superoxide production and increase in aortic stiffness (aortic pulse-wave velocity).
Interestingly, Tyrell, et. al. [368] demonstrated that aged mice demonstrated increased levels of
Parkin within the aorta, coinciding with reduced mitochondrial function and increased mitophagy.
The differences in Parkin expression in these two studies may be due to the selected age range,
as LaRocca et al. [367] studied mice that can be considered very old (27-28 months) whereas Tyrell
et al. [368] were interested in mice transitioning from middle age to old (18-19 months). Activation
of autophagy with trehalose (2% drinking water) normalized Parkin expression, while spermidine
did not influence levels of Pink-1 or Parkin in older mice fed a low-fat diet. Interestingly however,
when mice were administered a western style diet (high fat, high sugar), spermidine offset the
hypercholesteremic-induced increases in Parkin, and preserved mitochondrial respiration within
the aorta [368].

Future investigations should examine the association between changes in

mitochondrial proteins such as PINK1, Parkin, BNIP3, FUNDC1 and NIX and alterations in
mitochondrial structure as they relate to functional outcomes.

3.30: ROS/RNS-Direct Vasodilation in Relation to Mitochondria and Aging
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3.31: Age-Related Decline in Nitric Oxide with increased Mitochondrial Hydrogen Peroxide
Signaling
In healthy adult individuals, nitric oxide plays a pivotal role in endothelium-dependent regulation
of coronary vasodilation and blood flow [316]. In the aging population, the endothelium has
diminished control over vascular tone [374]. This loss of endothelial function is induced by a
reduction in nitric oxide availability via diminished flow-induced endothelial nitric oxide production
[316, 375, 376] and/or amplified nitric oxide scavenging due to oxidative stress [375, 377, 378].
Additionally, nitric oxide generated in response to local hypoxia from red blood cell nitric oxide
synthase (RBC-NOS) and RBC ATP-purinergic receptor agonist signaling induced nitric oxide are
reduced with aging due to reduced red blood cell deformability and oxidative stress [379-382].
Indeed, oxidative stress is a primary player in declining endothelial function in aging; excessive
production of superoxide in the aged vasculature leads to an increase in nitric oxide scavenging as
superoxide and nitric oxide combine to produce the cytotoxic free radical peroxynitrite in mice [383],
rats [384-386], and humans [228]. Combination of superoxide and nitric oxide to produce
peroxynitrite involves a diffusion-limited reaction that occurs approximately three times faster than
the dismutation of superoxide to hydrogen peroxide by SOD [387, 388].
Flow-induced hydrogen peroxide generation is not diminished in advanced age [316], but rather
is excessively enhanced in an aging rat model [389]. Beyer et al. utilized a series of
inhibitors/scavengers of vasodilative precursors (indomethacin for COX mediated prostacyclin
synthesis, L-NAME for eNOS, and PEG-Catalase for hydrogen peroxide) and evaluated
vasodilative function in human coronary and adipose microvessels across the human lifespan [20].
The mechanism of FMD evolves throughout life. In children (0-18 years old) and young adults (1955 years old), prostacyclin PGI2 and nitric oxide are the main vasodilative mediators, respectively.
With onset of coronary artery disease (CAD) in older adults (>55 years old), the FMD mediator
switches to hydrogen peroxide independent of age, and total vasodilative effect is diminished
irrespective of aging, effects also seen in rodents [316]. Supplementation of exogenous low-dose
DETANONOate (nitric oxide donor, mimicking youth) in CAD vessels reduces the mitochondrial
ROS and hydrogen peroxide-FMD response, whereas eNOS blockade in young vessels (mimicking
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age/CAD) induces compensatory hydrogen peroxide-FMD [20]. Collectively, this evidence
demonstrates a plasticity in vasodilator mechanisms that changes throughout the human lifespan.
Hydrogen peroxide (as well as superoxide and peroxynitrite) can serve as an endotheliumderived hyperpolarizing factor that act through calcium-activated potassium channels to elicit FMD
[268, 377, 390-392]. It is thought that eNOS-generated superoxide may be a primary contributor to
hydrogen peroxide generated for FMD [393]. Against the dogma that ROS are intrinsically harmful,
it appears they function as a compensatory mechanism in aging (and CAD), at least initially, leading
to reduced nitric oxide bioavailability albeit with less efficacious vasodilation [268]. Hydrogen
peroxide may be the least damaging of the ROS, as it cannot quench nitric oxide and may confer
some benefit. In some cases, hydrogen peroxide has been shown to improve nitric oxide
production, upregulate eNOS expression and function, and enhance nitric oxide-FMD by stabilizing
sGCβ1 mRNA to increase cGMF production [394-398]. Peroxynitrite may have a beneficial
function, as it is a nitric oxide donor, acting as a reserve pool for nitric oxide [268]. However, these
potential beneficial effects are limited or reversed when concentrations exceed buffering capacity
due to antioxidant protein dysfunction and pro-oxidant signaling, as discussed in the first section,
as well as by enhanced toxic hydroxyl radical formation. In some cases, hydrogen peroxide can
exhibit vasoconstriction [268]. Overall, these lessons in the complexity of redox balance for
vasodilative function and perfusion capacity teach us that the aim for future therapeutics should be
to restore youthful nitric oxide-mediated FMD as opposed to merely inhibiting ROS, as ROS serve
as a beneficial compensatory mechanism (albeit insufficient).

3.32: Acetylcholine and Sodium Nitroprusside-Mediated Vasodilation Reduced in Age
Impairment of EDD in aging is further evidenced by reduced relaxation to the eNOS agonist
ACh in mice [399-402], rats [374, 375, 386, 403], pigs [404] and humans [405-407]. Proper dosedependent dilation to ACh indicates intact, healthy endothelium, whereas vasoconstriction to ACh
may point to endothelial dysfunction [408]. In contrast, endothelium-independent relaxation to
sodium nitroprusside (SNP) is not commonly compromised [386, 405, 406, 409], which suggests
that smooth muscle cell-mediated dilation to nitric oxide is preserved in advancing age. Oxidative
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stress appears to trigger this age-related loss in endothelial function as well, as the simultaneous
decreasing nitric oxide and increasing superoxide levels result in deteriorating nitric oxide-mediated
signaling. Scavenging of superoxide via SOD transiently reestablished normal endothelial function
in a transgenic mouse model of aging [402].

3.33: mtROS Uncouple eNOS in Age, Shift to Superoxide Instead of Nitric Oxide Production
The mitochondria play an incredibly important role in vascular stasis, regulating ROS levels via
a complex interplay of enzymes as well as non-enzymatic antioxidants [410]. When this
mitochondrial regulatory network is imbalanced, vascular deficits follow. For example, the
uncoupling of eNOS by mtROS plays a pivotal role in the shift from nitric oxide to superoxide in
advancing age [411]. In addition to direct mitochondrial ROS release and NOX, uncoupled eNOS
is one of the primary sources of endothelium-derived superoxide [376, 385]. Tetrahydrobiopterin
(or BH4), an essential cofactor in the catalysis of nitric oxide from L-arginine, superoxide, and
NAPDH, is oxidized by high concentrations of peroxynitrite, high levels of which have been
associated with atherosclerosis, hypertension, inflammation, cancer, and other deleterious effects
of aging [412-414]. Then, in the absence of BH4, eNOS becomes uncoupled and leads to the
production of superoxide as well as additional peroxynitrite in a detrimental positive feedback loop
[415-417]. Peroxynitrite nitrosylates and further uncouples eNOS, and also nitrosylates and
inactivates SOD2, allowing further superoxide accumulation [386]. These are example of ROSinduced ROS release (RIRR), which can also trigger dysfunctional mitochondria and/or NOX to
produce additional superoxide [418-420]. In RIRR events, a slow accumulation of ROS serves as
the trigger for the ensuing burst of ROS released upon depolarization of the mitochondrial
membrane potential [420, 421] and opening of mitochondrial permeability transition pores (mPTP)
[422]. This phenomenon can be adaptive, as in instances of culling injurious organelles or cells, or
maladaptive, leading to the death of otherwise healthy mitochondria and cells [420]. Opening of
mPTP can also directly stimulate the release of superoxide from the mitochondrial matrix; this efflux
of superoxide from a subset of dysfunctional and/or activated mitochondria can prompt nearby
mitochondria to do the same, leading to even higher levels of circulating ROS [419].
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Uncoupled eNOS can also lead to endothelial dysfunction in both coronary and peripheral
vessels [418]. SOD2 plays a vital role in the dismutation of superoxide to hydrogen peroxide and
the regulation of cellular redox homeostasis [423]. In a transgenic mouse model of aging involving
SOD2, amplified levels of mitochondrial ROS and mitochondrial DNA damage were found in
SOD2+/- mice compared to wild-type littermates; the resulting eNOS uncoupling in these mice was
evidenced by severely impaired vasorelaxation [271]. Transgenic SOD2-/- mice only survive roughly
10 days to three weeks after birth due to a number of physiological ailments, including extensive
mitochondrial injury within cardiomyocytes [424, 425]. Similar studies have shown that endothelial
dysfunction associated with eNOS uncoupling by mitochondrial ROS can be prevented by the
mitochondrial-targeted antioxidant mitoTEMPO [426]. In addition, SOD2-overexpressing mice were
moderately spared from eNOS uncoupling-induced vascular dysfunction [427].

3.34: Flow-Mediated Dilation by Nitric Oxide or Hydrogen Peroxide Influenced by Mitochondria
Signaling (ROS)-Dependent Exocytosis of Endothelium-Derived Extracellular Vesicles
Mitochondrial generation of superoxide [377] and hydrogen peroxide [428] both contribute
directly to flow-induced vasodilation and are upregulated in response to shear stress. In human
coronary and other resistance arterioles, mitochondrial-derived superoxide and hydrogen peroxide
are required for the formation of endothelium-derived extracellular vesicles (eEV), after which the
eEVs bind with the cell membrane and release their contents into the circulation [429]. These eEV
can be beneficial, assisting with protein, lipid, and microRNA transport. However, the presence of
high levels of eEV in blood serum has been linked to endothelial dysfunction [430], likely through
the contents contained within the eEV, including ceramide and plasminogen activator inhibitor 1,
which can cause arterioles to shift from nitric oxide to hydrogen peroxide production, inducing
further endothelial dysfunction [429]. Indeed, the addition of exogenous introduction of ceramide
to healthy human arterioles induces mitochondrial ROS production leading to a diseased
phenotype [431].
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3.35: Mitochondrial Respiratory Dysfunction Correlates to Endothelium-Dependent (ACh) but not
Independent (SNP) Vasodilation in Aging, Likely Through Free Radical-Linked Mechanism
Mitochondrial respiration also plays a role in vasodilatory responses. In experiments involving
whole human skeletal muscle feed arteries (endothelial plus VSMC), vasodilation via endotheliumdependent agonist ACh is drastically reduced in vessels from older patients and directly correlated
via linear regression to reduced mitochondrial respiratory function within the vessels in an agedependent fashion [432]. Vascular mitochondrial oxidative respiratory capacity, as measured by
state 3 mitochondrial respiratory complex I as well as complex I + II, is significantly higher in vessels
from young when compared to elderly subjects [432, 433]. Similar to the EDD deficits, this
mitochondrial respiratory dysfunction in older patients is significantly correlated with endotheliumdependent (ACh) but not endothelium-independent (SNP) vasodilation, again suggesting
maintained smooth muscle control of dilation to nitric oxide even in the elderly population.
Concomitantly, mitochondrial levels of superoxide are highest in the older patients.

3.36: Flow-Mediated Dilation Attenuation in Aging Correlates with Increased S-nitrotyrosine
The attenuation of flow-mediated dilation observed in advanced aging is correlated with
increased nitrotyrosine, an oxidatively modified amino acid and marker of oxidative stress usually
linked to peroxynitrite. In humans, excessive levels of nitrotyrosine were found in brachial artery
endothelial cells of older men; deficits in flow-mediated vasodilation were strongly correlated with
increased levels of nitrotyrosine [15]. Similar age-linked increases in nitrotyrosine have been
described in rat arteries [386, 434, 435]. In aortas isolated from aged rats, decreased nitric oxide,
increased eNOS activity, superoxide overproduction and subsequent peroxynitrite formation all
combined to increase nitrosylation of tyrosine within mitochondrial SOD2 in a dynamic example of
the complex interplay of ROS within the aging vasculature [386]. Additionally, overexpression of
nitrotyrosine and flow-induced deficits have also been linked to estrogen levels, as ovariectomized
rats show similar levels of peroxynitrite-induced nitrosylation when compared to aged rats [316].
Scavenging of peroxynitrite via FeTMPyP, a synthetic porphyrin complexed with iron, significantly
improved endothelium-dependent relaxation in aging rats [435]. Antibiotic treatment for four weeks
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has also shown beneficial antioxidant effects in aortic oxidative stress of old mice, as shown by
decreased pro-inflammatory cytokines, decreased nitrotyrosine, and lower levels of superoxide
[436].

3.40: Alterations to Endothelium-Dependent Hyperpolarization in Relation to Mitochondrial
Redox Balance with Aging
3.41: Description of Normal Vasodilative Endothelium-Dependent Hyperpolarization
Various factors mediate endothelium-dependent hyperpolarization (EDH), starting in the
endothelial membrane and conducting through to the vascular smooth muscle cells (VSM) cells to
facilitate vasodilation. When endothelial intracellular [Ca2+] is increased due to shear stress
activation of mechanosensitive transient receptor potential vanilloid type 4 channel (TRPV4),
calcium-dependent potassium channels (SKCa and IKCa) cause hyperpolarization and K+ efflux,
thereby stimulating VSM Na+, K+-ATPase and inward rectifying K channels (KIR) [19]. The calcium
increase to initiate this pathway also activates eNOS to produce nitric oxide, however this is
diminished with aging. Instead, with aging the calcium preferentially triggers mitochondrial ROS
production such as hydrogen peroxide, which then activate the endothelial KCa channels [437].
Hyperpolarization and calcium signaling are propagated through connexin gap junctions to the
VSM, that together with hyperpolarization from other VSM potassium channels (Kv, KATP, and BKCa)
lead to closing of voltage-gated calcium channels (VGCCs), reducing intracellular calcium leading
to vasodilation [19, 438-440]. ACh- and FMD-mediated vasodilation can be blocked in part by
inhibiting endothelial potassium channels with apamin (SKCa) and charybdotoxin (IKCa and BKCa),
highlighting the critical role of potassium channels in the signaling of vasodilation. These pathways
are of unique importance as they allow axial conductive signaling for coordinated modulation of
tone and blood flow of a large area of vascular network. Therefore, alterations due to pathology
may be especially consequential. More details on EDH mechanisms can be read in the
comprehensive reviews by Feletou and Garland et al. and depicted along with influences of aging
and oxidative stress in Figure 5 and accompanying Table 1 [19, 441].
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Figure 5: Flow Mediated Dilation Pathway with Mitochondrial Contributions and Effects of
Aging and ROS/RNS: (2.1) Flow induced shear stress activates mechanosensitive endothelial
TRPV4 channels allowing for calcium entry, which activates basal membrane calcium sensitive
small and intermediate conductance potassium channels (SKCa & IKCa) causing potassium efflux
and hyperpolarization that along with calcium can spread to the vascular smooth muscle (VSM)
cell via connexin 40 gap junctions. Potassium in the intercellular space activates the Na+/K+ATPase and inward rectifying potassium channel (KIR), causing smooth muscle hyperpolarization.
Hyperpolarization is amplified by contributions from calcium dependent large conductance
potassium channels (BKCa), voltage-gated potassium channels (KV), and ATP sensitive potassium
channels (KATP). Taken together, the hyperpolarization signal inhibits the voltage gated calcium
channel (VGCC) from transporting calcium into the cell, reducing intracellular calcium and inducing
vasodilation. In youth, the initial calcium signal activates eNOS to produce nitric oxide, which
causes VSM cell relaxation via production of cGMP, activation of potassium channels, and
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stimulation of cGMP-dependent protein kinases that activate myosin light chain kinase
phosphatase. In aging, eNOS is downregulated and dysfunctional and instead shear stress induces
production of hydrogen peroxide that activates potassium channels to induce hyperpolarization
mediated vasodilation. (2.2) Red blood cells (RBCs) contribute to hypoxic vasodilatory response
by production of nitric oxide from red blood cell nitric oxide synthase (RBC-NOS) and ATP traversal
through pannexin 1 to activate endothelial purinergic (P2y) receptors, increasing intracellular
calcium and activation of eNOS to produce nitric oxide. In aging, reduced deformability of RBCs
leads to reduced contribution of this pathway towards vasodilation. (2.3) Mitochondrial
depolarization caused by activation of mitochondrial KATP channels induces ROS mediated
alterations of ryanodine receptors on nearby endoplasmic reticulum, which leads to release of
calcium sparks. Calcium sparks activate the BKCa channel causing hyperpolarization, inhibition of
VGCC, reduced intracellular calcium and vasodilation. Overall, sedentary aging and oxidative
stress reduce FMD efficacy. Figure created with BioRender.com
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Table 1: The Effects of Aging on the Various Channel Expression and/or Function in the
FMD Pathways. Green represents activating whereas red represents inhibitory effects of
ROS/RNS/Adrenergic Signaling. Note: references for this table can be found in text and in the
original publication (https://doi.org/10.1089/ars.2021.0031). Image created with BioRender.com.

3.42: Effect of ROS/RNS on Endothelium-Dependent Hyperpolarization
Mitochondrial superoxide, hydrogen peroxide, and peroxynitrite demonstrate vasodilator actions
through activation of hyperpolarization pathways, and therefore there is an increased reliance on
this in aging as nitric oxide mechanisms decline. This effect is partly mediated by TRPV4, which
can be activated by hydrogen peroxide but is inhibited by peroxynitrite [428, 442-444]. Superoxide
generated through xanthine oxidase and peroxynitrite has been shown to inhibit Kv channel activity,
which can be restored by SOD whereas hydrogen peroxide is able to activate Kv channels [445-
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447]. In rat cerebral arterioles, peroxynitrite inhibits BKCa channels [448, 449]. In porcine coronary
arteries and rat renal microvessels, nitric oxide and hydrogen peroxide were shown to activate BKCa
[231, 450, 451]. On the contrary, hydrogen peroxide has also been shown to close BKCa channels
in porcine renal artery patch clamp experiments [452]. This discrepancy likely indicates a direct
inactivating and indirect activating effect of hydrogen peroxide on BKCa channels. Superoxide
decreases whereas hydrogen peroxide, peroxynitrite, and nitric oxide enhance KATP function in
renal, cerebral, mesenteric and coronary vasculature [390, 453]. The KIR channel is activated by
superoxide in rat mesenteric artery [454]. These complex effects are likely due to thiol modification
of key cysteines including glutathionylation [455]. Further details on how oxidative stress affects
potassium channel function are available in various reviews [447, 456-458].

3.43 Mitochondrial Depolarization-Mediated Vasodilation
Mitochondrial depolarization induced by ROS generates calcium sparks that have vascular
effects [459]. In a study by Katakam et al., ROS-dependent (diazoxide) and -independent (BMS191095) activators of KATP-dependent mitochondrial depolarization were utilized in wild-type, lean,
and insulin resistant obese rats to elucidate a pathway for mitochondrial depolarization-mediated
vasodilation in cerebral artery VSM [460]. In mitochondrial microdomains adjacent to the
sarcoplasmic reticulum, ryanodine-sensitive calcium channels become activated, releasing calcium
sparks that activate plasma membrane BKCa channels, leading to K+ efflux and hyperpolarization
to close VGCCs to decrease overall intracellular [Ca2+] and facilitate vasodilation [460]. Activation
of the ryanodine receptor occurs due to ROS-mediated post-translational modification (hydrogen
peroxide-, superoxide-, or peroxynitrite-mediated) [460-462]. However, since BMS-191905 also
activated this pathway, the authors conclude that there is a secondary ROS-independent
mechanism for mitochondrial depolarization-mediated vasodilation. In obese insulin resistant rats,
there is impairment of calcium spark release due to endoplasmic reticulum (ER) stress, impaired
activation of BKCa, and plasma membrane ATP-sensitive K+ channels. In aging, the functional
release of calcium sparks from ryanodine receptor activation with caffeine is reduced, owing to
reduced coupling of the ryanodine receptor with the T-type calcium channel CaV3.2 in mouse
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mesenteric arteries [463]. It is unknown how aging affects mitochondrial KATP function, although
there are indications of dysfunction since the potassium cycle is impaired with decreased
intramitochondrial potassium in aging rats [464].

3.44: Effect of Aging on Endothelium-Dependent Hyperpolarization
During certain phases of pathology or aging with active lifestyle (i.e. “healthy aging”),
hyperpolarization-mediated vasodilative mechanisms can increase in function to partially
compensate for lack of nitric oxide-mediated signaling [465-468]. However, in diabetes and studies
of sedentary aging, it appears that elevated oxidative stress including increased superoxide,
hydrogen peroxide, and peroxynitrite culminates in reduced EDH function [441, 445, 469-471]. For
instance, in aged rats, EDH-mediated relaxation from ACh or TRPV4 activator GSK1016790A was
reduced compared to young; the response in young rats is reduced to old levels by inhibiting TRPV4
and SKCa [472]. In old age, Feher et al. found that although local responses to bradykinin remain
intact with age, the conductive axial response (spread hyperpolarization and dilation at distant sites)
was diminished in coronary arteries of humans, and local conductive responses were due to
enhanced SKCa and IKCa activity, with similar findings observed in mouse models [469, 473].
Similarly, inward rectifying potassium channels (KIR) function is increased with aging, with no
change in KIR mRNA [474].
On the other hand, endothelial TRPV4 expression and calcium signaling, an initiator of the
hyperpolarization vasodilation response, are reduced in aging but can be restored by lentiviral
induced overexpression in aging rat mesenteric arteries [475]. Expression and function of the BKCa
channel is diminished in aging mesenteric, skeletal muscle, and coronary (but not cerebral)
vasculature leading to inhibited vasorelaxation [476-478]. However, KV1.5 channel protein
expression does not change with age, although inhibition leads to increased myogenic tone in aging
vs. youth, indicating increased KV1.5 function with aging in skeletal muscle arterioles [478]. Direct
inhibition of VSM cell Na+/K+ ATPase leads to constriction in young, but not old rats, indicating
potentially reduced contribution for the Na/K ATPase in EDH-mediated vasodilation in aging [479].
It is known that ROS-mediated glutathionylation of the β1 subunit inhibits Na+/K+ ATPase function
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and is reversible by nitric oxide [480]. In addition, KATP channels are dysfunctional during aging, as
the necessary subunits Kir6.1 and SUR2B are downregulated and PKA-mediated activation is
attenuated (albeit, activation with KATP activator and nitric oxide donor nicorandil as well as direct
PKA activation leads to no age-related differences) [464]. The Cav3.2 T-type voltage-gated calcium
channel, involved in the ryanodine receptor/BKCa-mediated hyperpolarization and dilation
response, is also downregulated in aging including in coronary arteries and can be inhibited by
hydrogen peroxide and ROS [481, 482]. Alternatively, the L-Type Cav1.2 channel expression and
function in aging varies greatly from study to study, being either over- or under-expressed
depending on the arterial bed being studied. In coronary artery VSM cells, Cav1.2 expression and
current is not affected by aging in rats but is decreased in posterior and middle cerebral arteries
and increased in mesenteric arteries in mice [482]. The Cav1.2 channel can be glutathionylated
and activated by hydrogen peroxide and oxidized glutathione [483].
Considering ROS are important factors in EDH, yet excessive oxidative stress tends to have
inhibitory effects on EDH, this implies that a fine homeostatic balance is required for ideal
vasodilative performance. EDH is also a minor contributor to relaxation during β-adrenergicmediated vasodilation through simultaneous activation of Kv and KATP channels [440, 447, 484] and
α-adrenergic agonism can close Kv channels [440]. Furthermore, βADR activation leads to transient
increase of ROS, which can activate L-type calcium channels and induce alterations in calcium
signaling [485, 486]. Therefore, EDH dysfunction in aging may also contribute to βADR dysfunction.
Additionally, the fine redox balance necessary for functional EDH extends to intrinsic βADR
function. In all, mitochondrial dysfunction plays a critical role in the signaling of vasodilation, and
alterations of mitochondrial function with aging has significant implications for vasodilative function.

3.50: Adrenergic Alterations in Relation to Mitochondrial Redox Homeostasis with Aging
3.51 Description of Adrenergic Receptor Homeostatic Shift with Aging
The expression and function of adrenergic receptors varies with tissue location and branching
order and are influenced by redox status of endothelial cells causing adrenergic dysfunction in
aging. The major role of these receptors on vascular tissue, specifically, is to mediate
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vasorelaxation or vasoconstriction via agonism typically in response to circulating catecholamines.
The β-adrenergic receptors β1, β2, and β3 activate G-stimulatory (Gs) protein to activate adenylate
cyclase which in turn converts ATP into cyclic AMP (cAMP), leading to activation of protein kinase
A (PKA) to phosphorylate the myosin light chain kinase, resulting in inactivation of the myosin light
chain, and finally resulting in vasodilation [24, 487]. On the other hand, α1ADR activates Gq alpha
subunit and phospholipase C to hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) into
diacylglycerol (DAG) and inositol triphosphate (IP3), which in turn activates its receptor in the
endoplasmic reticulum to release calcium and induce vasoconstriction. The α2 receptors induce
vasoconstriction via activation of G inhibitory (Gi) protein, thereby inhibiting adenylate cyclase.
In the coronary vasculature, endothelial cells express predominantly β1 adrenergic while the
smooth muscle cells (SMCs) express predominantly β1 and α1 adrenergic receptors [41]. Moving
down the vascular tree towards the capillaries, relative expression of β1ADR and α1ADR
decreases whereas β2ADR, β3ADR and α2ADR increase. In healthy vessels, the balance favors
β vasodilation to adrenergic agonism, however, with aging or disease, this balance shifts to favor
αADR mediated vasoconstriction [10, 41]. This is in part due to the decline in function and
expression of βADRs with age in many tissues including the aortic [488], mesenteric [471, 489],
and coronary [10] vasculature, but increased in aging cerebral vasculature [18, 490, 491]. Coronary
and aortic α1ADR, on the other hand, do not display changes in expression with age promoting a
propensity for hyperconstriction [41, 492, 493], whereas α1ADR expression or function with aging
decreases in skeletal muscle and renal artery, albeit skeletal muscle is paradoxically
hyperconstricted with aging [494-497]. The changes in vascular adrenergic function with age are
irrespective of alterations of downstream signaling. βADR dysfunction with age leads to insufficient
cAMP synthesis, while exogenous stimulation of elements downstream from the receptor stimulate
normal cAMP production [498-502]. Age-related βADR function is not due to G-protein switching
from stimulatory to inhibitory [499, 500, 503], suggesting dysfunction of the βADR itself or with
coupling, rather than downstream signaling messengers.
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3.52: Effect of Aging on Adrenergic Receptor Regulation through Desensitization, Internalization,
and Recycling
Current consensus is that functional adrenergic changes in aging are mediated by regulatory
proteins and post-translational modifications at the level of the βADR, which can be influenced by
aging-induced redox changes. Upon agonism in young vessels, a protein complex including either
G-protein receptor kinase (GRK) or β-Adrenergic Receptor Kinase, and β-arrestin associates with
the βADR to cause desensitization, blunting the ability of agonists to increase cAMP. This
regulatory system is upregulated in aging, alongside increased circulating catecholamines [504,
505]. Interestingly, GRK2 (the most commonly implicated GRK) increases 3.6- and 1.5-fold in the
cytosolic and membrane fraction, respectively, with β-arrestin increasing 1.6-fold in aged (24
months old) Fischer 344 rat aortas [22, 23]. Upon receptor-agonist binding, GRKs associate with
the β receptor, leading to receptor phosphorylation thereby sterically hindering the G protein
coupling and causing G stimulatory protein dissociation [506]. The β receptor can also be
phosphorylated independent of agonist (or at very low agonist concentration) binding by PKA and
PKC. Both of these mechanisms are negative feedback regulators since their activation is cAMPdependent [507]. In addition, GRK-mediated phosphorylation recruits β-arrestin to the receptorGRK complex, further causing steric hindrance and desensitization [507]. β-arrestin primes the βreceptor for dynamin-mediated internalization into clathrin-coated endosomes for storage,
trafficking to lysosomes for degradation, or eventual recycling to the plasma membrane [508-511].
These pro-desensitization and internalization processes exist in a homeostatic balance with the
process of resensitization, where βADR receptors are dephosphorylated at the plasma membrane
or predominantly at the endosome, then trafficked back to the plasma membrane ready to receive
agonistic signals and induce vasodilation [24, 512-515]. Resensitization is mediated by
phosphatases, namely protein phosphatase 2A (PP2A)[516]. This homeostatic balance between
desensitization/internalization and resensitization favors the former in aging, not only because of
increased GRK2 and β-arrestin expression, but also due to inhibition of resensitization. The
dephosphorylation action by PP2A is inhibited by the endogenous inhibitor of PP2A, I2PP2A.
I2PP2A is activated by PI3Kγ-mediated phosphorylation [24, 517]. The Ang II activation of the AT1
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receptor activates PI3Kγ-mediated pathways and increases with aging [518-521]. Oxidative stress
has been shown to activate PI3Kγ signaling in diabetic rat cardiomyocyte model (high glucose coculture)[522]. Together, aging-induced Ang II and ROS signaling could in part explain the eschewed
balance towards βADR phosphorylation, desensitization, and ultimately hyperconstriction with
diminished agonist-relaxation. Inhibiting PI3Kγ in peripheral vessels rescues endotheliumindependent vasodilation through induced L-type calcium channel dysfunction and also preserves
β-adrenergic receptor function in cardiomyocytes from heart failure rats, although the ability to
preserve βADR function in the endothelium by PI3Kγ inhibition still needs confirmation [523-531].

3.53 Effect of Redox Status on Adrenergic Receptor Regulation
The above processes can be influenced by redox status to affect βADR function and location.
The βADR and its regulatory proteins can be oxidized/nitrosylated by ROS/RNS. A major known
regulator of desensitization/internalization is S-nitrosylation (SNO) post-translational modification
[24, 532]; SNO of β-arrestin and dynamin favor desensitization/internalization and inhibit αADR
mediated

vasoconstriction

desensitization/internalization

[533-537].
and

is

In
the

contrast,
major

SNO

of

post-translational

GRK2
regulator

prevents
against

desensitization/internalization [538, 539]. Studies utilizing exogenous SNO agents find βADR
localization to the plasma membrane, with decreased β-arrestin localization, and enhanced
vasodilation suggesting SNO of GRK2 supersedes pro-desensitization/internalization SNO
processes [539]. In addition, PKA is constitutively activated by SNO and facilitates cross-talk by
increasing cAMP to induce vasodilation in “β-adrenergic-like” signaling [540]. Of equal importance
is the process for denitrosylation of these proteins by nitrosoglutathione reductase. Knockout of
nitrosoglutathione reductase reduces vascular tone, while inhibition improves β-adrenergic
function, suggesting a fine balance of SNO is necessary for ideal βADR function [541-543]. These
proteins are nitrosylated in part via nitric oxide produced by eNOS, which is dysfunctional in aging
[399]. Therefore, it is possible that aging-mediated reduction of eNOS function, increased
superoxide (which siphons nitric oxide to form peroxynitrite), and reduced nitric oxide bioavailability
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reduce the ability to maintain the nitrosylated status of these proteins, causing a shift favoringadrenergic receptor desensitization/internalization.
While it’s been known that oxidative stress negatively impacts functional vasodilation, its role in
βADR physiology has only recently being investigated. The β1-3ADRs contain cysteine residues
susceptible to oxidation whereas only β1-2ADRs have extracellular tyrosine residues susceptible
to nitration [27]. Data from our lab in female Fischer-344 rats suggests that percent vasorelaxation
to β1 agonist norepinephrine directly and positively correlates with nitric oxide concentration and
inversely correlates with superoxide and hydrogen peroxide, but not peroxynitrite concentration, in
an aging-dependent manner (see Chapter 9 for more details). Exogenous superoxide/hydrogen
peroxide incubation in young rat vessels completely abrogates β1ADR receptor agonist
(dobutamine and norepinephrine) mediated vasodilation [42]. Exogenous peroxynitrite also blunts
vasodilation to S-nitrosocysteine (nitrosylating agent) by oxidizing cysteine or nitrosylating tyrosine
recognition sites [26]. Peroxynitrite forms S-nitrosoglutathione with glutathione presence, providing
a potential pathway for SNO of GRK2 and inhibition of desensitization/internalization (or dynamin/βarrestin promoting desensitization/internalization). This pathway is likely reduced with aging as is
GSH [286]. Of interest, S-nitrosoglutathione also inhibits NOX and could therefore also reduce
oxidative stress [286]. Phosphorylated STAT3 is a positive transcriptional regulator of
cardiomyocyte β1ADR that also mediates transcription of antioxidant (SOD2), proangiogenic
(VEGF), and antiapoptotic proteins, and exerts noncanonical actions to reduce ROS production,
regulate mitochondrial complex 1 function and mitochondrial permeability transition pore opening
[544, 545]. In addition, STAT3 can become activated upon agonism of the β1ADR [545]. This
provides another regulatory link between β1ADR and ROS, and of interest STAT3 is known to be
reduced with aging and therefore contributing to endothelial dysfunction, albeit many of these listed
actions of STAT3 need to be confirmed in the vasculature [544].
While oxidation tends to attenuate βADR vasodilatory function, nitrosylation has a protective
effect. Exogenous S-nitrosoglutathione (a nitrosylating agent) is able to mediate nitrosylation of
GRK2, inhibiting phosphorylation and subsequent desensitization and internalization of the β2ADR
even during isoproterenol agonism, with subsequent cAMP production [538]. Frame et al. showed
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that pre-incubation with SNP (a nitrosylating agent and nitric oxide donor) improves β2ADR function
to vasodilate in vivo arcade and terminal arteries of the hamster cheek pouch tissue [28].
Specifically, SNP pre-incubation “uncovers” distinct pools of βADR receptors to allow for increased
potency at the picomolar range (albeit with reduced efficacy at the micromolar range). Additionally,
in the study by Frame et al., a culture system and fluorescence imaging (FRET analysis) were used
to show the influence of nitrosative and oxidative stress on internalization of the β2-adrenergic
receptor.

Exogenous

superoxide

production

increased

internalization

of

the

β2ADR.

Desensitization/internalization was blocked with SNP and dynasore (dynamin inhibitor of
endocytosis) incubation; GRK2 was seemingly nitrosylated by nitric oxide, while dynamin-mediated
endosome formation was blocked by dynasore. The concentration response and fluorescence data
suggest that with this treatment, some of the β2ADR were protected from internalization (i.e. not
internalized) and remain functional at the plasma membrane. It was hypothesized that preventing
desensitization and endosome formation would improve βADR function in the classic dose ranges
(10-9-10-4 M). Instead, SNP/dynasore pretreatment altered the pharmacodynamics by improving
isoproterenol potency but reducing efficacy. The explanation is that increased cellular RNS state
also facilitates dynamin and β-arrestin nitrosylation, which are pro-internalization processes. The
balance between GRK2 nitrosylation/dynamin inhibition and dynamin/β-arrestin nitrosative
activation leads to the functional changes seen. It is speculated that SNP shortens the time for
β2ADR dephosphorylation with increased cycling of phosphorylation state, uncovering dilation
potential at lower doses (10-14-10-11M).
To summarize, βADR density and function are reduced in aging vasculature, leading to
diminished vasodilatory capacity and hyperconstricted tone. Adrenergic regulatory proteins are
subject to regulation by ROS/RNS. Therefore, aging-mediated alterations of redox balance may
influence the homeostatic balance of desensitization/internalization and resensitization. This is
supported since changes in ROS/RNS with age correlate with β1ADR function and the results of
Frame et al. show that exogenously supplying ROS (mimicking aging) or RNS (mimicking youth)
influences desensitization/internalization of the β2-adrenergic receptors (albeit in HeLa cells, not
endothelial cells) [28]. These complex interactions are illustrated in Figure 6, including pathways
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for how ROS/RNS may influence βADR function in what we name for the first time the ROS/RNSβADR Desensitization & Internalization Axis. Further experimentation in young vs. aged
endothelium, mimicking studies such as by Frame et al, are needed to establish the validity of this
axis, which could represent several novel opportunities for therapeutic targeting for diseases with
adrenergic pathologies [28].

Figure 6: Effect of Aging on Vascular Adrenergic Signaling Homeostatic Balance: These
effects culminate in reduced vascular βADR with aging, albeit αADR functional expression is
unchanged, favoring hyperconstriction. βADR (β-adrenergic receptor), αADR (α-adrenergic
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receptor), GRK2 (G-protein receptor kinase 2), eNOS (nitric oxide synthase). Figure created with
BioRender.com.
3.60: Aging-mediated Mitochondrial/Endothelial Dysfunction - Effect on Major Adverse
Cardiac Events and Current Therapies
Mitochondrial DNA4977 (mtDNA) deletion, also referred to as the “common deletion,” is
responsible for key subunits of mitochondria respiratory complexes that, if damaged, result in
impaired respiration and production of ROS [546]. mtDNA damage is associated with the presence
and progression of atherosclerosis resulting in impaired mitochondrial structure and function to
ultimately produce excess ROS, which if left unchecked further produces ROS (ROS-induced ROS
release, RIRR) [547, 548]. The relation of mtDNA damage and atherosclerosis has been recently
reviewed elsewhere [549, 550], and higher mtDNA damage is associated with impaired vascular
function in peripheral blood mononuclear cells [551]. In relation to aging, accumulation of
mtDNA4977 deletions within cardiac tissue (e.g. left ventricle) over time can result in pathological
cardiovascular consequences [551-554]. In patients with CAD, increased levels of mtDNA4977
deletion in peripheral blood are associated with MACEs and all-cause mortality, suggesting that
accumulation rather than presence the common deletion alone is a crucial factor in predicting
adverse outcomes [555-557]. Furthermore, mtDNA copy number may also decrease with
pathologies. Indeed, for every one standard deviation reduction in mtDNA copy number, Wang, et.
al. [558] demonstrated that the risk of CAD increases 1.14-fold in peripheral blood leukocytes.
Furthermore, Koller, et. al. demonstrated that lower mtDNA copy number in peripheral blood
leukocytes was associated with an almost two-fold increase in risk for peripheral artery disease
and all-cause mortality [559]. This evidence suggests that mtDNA copy number is an independent
risk factor for future CAD [558], vascular dysfunction, and all-cause mortality.
On the contrary, Vecoli, et. al. [557] demonstrated that changes in mtDNA copy number in
peripheral blood alone did not predict MACE or all-cause mortality; rather, changes in mtDNA copy
number coupled with increased mtDNA4977 deletion increases risk for MACE. In further support of
this notion, data from the VA Normative Aging Study demonstrated that peripheral blood mtDNA
copy number is associated with increased mtDNA damage, independent of chronological age [560].
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The link between mitochondrial dysfunction and MACE is further propagated by the finding that in
patients with mitochondrial diseases, there is a 2.4-fold greater risk for MACE, and 14-fold
increased risk of all-cause mortality [561]. Taken together, mtDNA damage accumulation and
decreased mtDNA copy number significantly increase the risk for future MACEs. Emerging
therapies to ameliorate oxidative stress and mitochondrial dysfunction in aging are summarized in
Table 2.

Table 2: Emerging Therapies for Reducing Vascular Oxidative Stress in Aging. Note:
references

for

this

table

can

be

(https://doi.org/10.1089/ars.2021.0031).

63

found

in

the

original

publication

CHAPTER 4
INTRODUCTION PART 4
STATE OF THE FIELD: CELLULAR AND EXOSOMAL THERAPY APPROACHES IN
VASCULAR REGENERATION3
Pathologies of the vasculature are often complex in nature, leading to loss of physiological
homeostatic regulation of patency and adequate perfusion to match tissue metabolic demands.
Microvascular dysfunction is a key underlying element in the majority of pathologies of failing
organs and tissues. Contributing pathological factors to this dysfunction include oxidative stress,
mitochondrial dysfunction, endoplasmic reticular (ER) stress, endothelial dysfunction, loss of
angiogenic potential and vascular density, and greater senescence and apoptosis. In many clinical
settings, current pharmacologic strategies utilize a single or narrow targeted approach to address
symptoms of pathology rather than a comprehensive and multifaceted approach to address their
root cause. To address this, efforts have been heavily focused on cellular therapies and cell-free
therapies (e.g. exosomes) that can tackle the multifaceted etiology of vascular and microvascular
dysfunction. In this chapter, we discuss 1) the state of the field in terms of common therapeutic cell
population isolation techniques, their unique characteristics and their advantages and
disadvantages, 2) common molecular mechanisms of cell therapies to restore vascularization
and/or vascular function, 3) arguments for and against allogeneic vs. autologous applications of
cell therapies, 4) emerging strategies to optimize and enhance cell therapies through priming and
preconditioning, and finally, 5) emerging strategies to bolster therapeutic effect through alternative
administrative and dosing.

3

Chapter represents a publication with minor modification from:
Tracy et al. State of the Field: Cellular and Exosomal Therapy Approaches in Vascular
Regeneration. AJP Heart & Circulatory Physiology. (2022) 322 (5), H702-H724.
https://doi.org/10.1152/ajpheart.00021.2022
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4.10: Stem Cell Sources, Unique Characteristics, Advantages and Disadvantages:
Stem cells are defined by their ability to self-renew and differentiate. However, their potential to
carry out those abilities is variable throughout development and through the lifespan [562]. Since
their discovery in the early 1960’s [563], there has been a race for discovering sources of stem
cells that can be used therapeutically, including for microvascular repair. In this section, we briefly
detail each of the major sources of stem cells and provide a summary of their methods of isolation
(also described in Figure 7) as well as the unique characteristics, advantages, and disadvantages
of each stem cell type (Table 3).

4.11: Bone Marrow Derived Stem Cells
One of the first methods of isolation entails aspirating the bone marrow from the superior iliac
crest under mild anesthesia (conscious sedation followed by local anesthetic) [564, 565]. However,
a more recent, less invasive method involves mobilizing the BM-MSCs pharmacologically with
granulocyte colony-stimulating factor, then harvesting by a peripheral blood draw and isolation with
fibrin microbead binding [566]. Direct comparison of the concentration of mesenchymal stem cells
(MSCc) between the two methods showed that bone aspirate yielded ~5.25 million cells/mL versus
a yield of ~2.7 million cells/mL using the blood draw method [567]. Additionally, studies have shown
both methods are similar in terms of cell survival, development of graft versus host disease, and
differentiation capacity in vitro, however the peripheral blood draw method is favored for cell
therapy/microvascular repair therapies due to a greater ease of harvest and less patient discomfort
[568, 569].

4.12: Adipose Stromal Vascular Fraction
Adipose stromal vascular fraction (SVF) contains a mixture of cells that work together via
directed differentiation and paracrine signaling pathways capable of enhancing revascularization
via angiogenesis and is capable of anti-inflammatory effects [570, 571]. The heterogenous
population of SVF is composed of MSCs (CD90), endothelial cells (CD31), pericytes (CD146),
hematopoietic stem cells (CD45), macrophages (CD11b), B (CD19) and T (CD4) cells, dendritic
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cells (CD14), and endothelial progenitor cells (EPCs). SVF can be further refined to produce more
homogenous cell populations such as adipose derived stem cells (ADSCs or ASCs) or adiposederived mesenchymal stem cells (AMSCs) [572, 573]. Overall, SVF has been shown to contain a
higher stromal elements than bone marrow [574]. Additionally, the benefit of having multiple
locations for harvesting and yielding more cell populations gives adipose tissue a greater
autologous benefit [575].
Primary benefits of SVF relate to the ease in harvesting adipose tissue, usually via lipoaspiration, a higher cell yield due to the presence of more stem cells in the fat than bone marrow,
and less patient discomfort [576] [577]. Enzymatic-based isolation methods to isolate the SVF
utilizes collagenase, centrifugation, and filtration, giving a much higher cell yield than mechanical
disruption alone. This has led to the development of medical equipment that performs this
automated process in the operating suite [578].

4.13: Embryonic and induced Pluripotent Stem Cells
Embryonic stem cells (ESCs) are derived from the inner mass of the blastocyst resulting in
embryo destruction or from single blastomeres as an embryo-preserving technique which is similar
to pre-implantation genetic testing routinely used during assisted reproduction. Clinical grade
human ESCs are typically derived from donated excess in vitro fertilization cryopreserved embryos
and then stored long-term as cell lines. The use of ESCs has been a historically inflammatory
subject, particularly in the United States where laws around ESC research vary widely by state.
Since the therapeutic use of ESC may not be viable due to ethical concerns, use of cell sources
with similar properties to ESCs should be considered. Indeed, with the development of induced
pluripotent stem cells (iPSCs), enthusiasm for ESC research has somewhat faded [579]. iPSCs are
adult somatic cells that have been induced to pluripotency using the Yamanaka transcription
factors. Both ESCs and iPSCs are capable of self-renewal without differentiation or with
differentiation into many different cell lineages and/or types [580, 581]. Published protocols have
demonstrated that iPSCs and ESCs can be coaxed into different lineages, including vascular
endothelial cells [582], smooth muscle cells [583] and cardiomyocytes [584, 585].
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One example of a protocol to differentiate iPSCs into endothelial cells (iPSC-ECs) was
demonstrated by Ikuno et al. in 2017 using VEGF and cyclic adenosine monophosphate (cAMP)
after the iPSCs were directed down a mesodermal germ lineage [586]. iPSC-ECs have been shown
to be capable of forming microvascular structures in an in vitro 3D culture [580] and in vivo [587].
iPSC-ECs and human umbilical vein endothelial cells (HUVECs) were compared for angiogenic
potential in 3D culture and in vitro (mice) to determine the regenerative potential of iPSC-ECs in
their current state of therapeutic development [580]. At 2 weeks in 3D culture, capillary sprouting
was much more abundant in the HUVEC samples while the iPSC-ECs had significantly decreased
total network length, fewer vessel branch points and fewer segments formed compared to the
HUVEC samples. Inferior angiogenic potential of iPSC vs. HUVEC was attributed to lower matrix
metalloproteinase-9 (MMP-9) expression and activity, highlighting the necessity for standardization
of iPSC production [580]. In vitro, both iPSC-EC and HUVEC implants formed vessels containing
lumens and were perfused by the host following implantation, as measured by presence of
erythrocytes, at days 7 and 14 [587]. By day 7 both groups demonstrated comparable perfusion of
the matrices and by day 14 vessel densities were comparable between the groups. The iPSC-ECs
had significantly less a-smooth muscle actin from fibroblast-derived pericyte coated vessels than
HUVECs, indicating lower vascular maturity. Further research is needed to overcome the barriers
to iPSC-EC translation potential such as improving the maturity of these vessel-like structures as
well as investigating whether modifying iPSC-EC MMP-9 expression or activity can boost
angiogenic efficiency of iPSCs similar to HUVECs.
A more robust differentiation protocol has been developed by Wang et al. in 2020. Delivery of
modified messenger RNA (mRNA) for the erythroblast transformation specific variant transcription
factor 2 during the intermediate mesodermal stage of differentiation allowed vigorous and
reproducible differentiation of 13 human iPSC lines into iPSC-ECs with high efficiency, forming
perfused vascular networks in vivo that were lined primarily with the human iPSC-ECs. Six week
old NOD-SCID mice were subdermally implanted with 1x106 iPSC-ECs in a collagen 1, fibrin,
fibroblast growth factor (FGF), and erythropoietin matrix. After 7 days, the grafts were perfused and
were phenotypically, transcriptionally, and functionally comparable to host endothelial cells [588].
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Effectiveness of iPSC-EC may be further enhanced by methods to facilitate maturation of cell
function, as has been done in iPSC-derived cardiomyocytes by optimizing culture conditions such
as extracellular matrix or 3D culture conditions mimicking host environment. Indeed, growth of
iPSC-ECs co-cultured with iPSC-derived spinal motor neurons in spinal cord organoid chips lead
to increased maturation and transcription of vascular interaction pathways over growth in 96-well
plates. Additional studies are necessary in order to determine appropriate maturation conditions.
Overall, the continued development of iPSC-ECs is warranted, as it allows for opportunities to tailor
treatment to individual patient-specific conditions, such as iPSC-EC microvascular grafts that
produce factor VIII for hemophilia A [589].

4.14: Umbilical, Amniotic, and Placental Derived Stem Cells
While inducing pluripotency poses a time and cost barrier and use of embryological stem cells
is controversial, extra-fetal tissues present a multipotent-ready source of stem cells. These include
tissues from the layers of the placental membrane after birth, amniotic fluid at different time points
in utero, and the umbilical cord, making extra-fetal tissues relatively free of risks and ethical issues
[590]. From the umbilical cord, there are several MSC populations (UCB-MSCs) that can be
isolated from the cord, cord lining, subamnion, or Whartons Jelly [591]. Amniotic MSCs can be
procured at any time during pregnancy, usually during diagnostic amniocentesis, or in some cases,
therapeutic amnioreduction with the fluid undergoing centrifugation and culture [592]. Placental
MSCs are procured from whole organ during delivery or from diagnostic chorionic villus sampling
specimens through digestion, centrifugation, and culture and have been shown to enhance
angiogenesis in wound healing models after therapeutic delivery [592-594]. The use of extra-fetal
stem cells may be especially poignant for fetal interventions given their relation; however, their use
is also applicable in the adult population considering some of their inherent advantages over adult
stem cells [595].

4.15: Unique Regenerative Mechanisms, Advantages, and Disadvantages of Various Stem Cells
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While the proposed mechanisms of effect are similar across cell sources, there are a few
nuances that distinguish the various stem cell sources. Bone marrow aspiration is an invasive
procedure and it leads to a relatively lower cell yield in comparison to adipose. However, since BMMSCs were one of the first cell therapy sources discovered they have been more heavily
researched [596]. On the contrary, ADSC yield is inconsistent among donors but provide a
heterogeneous source of supporting cells and MSCs [597, 598]. Despite inconsistencies in fat
depot volumes and ADSC yields, MSCs from adipose tissue are approximately 500 times more
(~5,000 cells/1g fat) abundant than in BM-MSCs [575, 599]. Further, ADSCs enter senescence
later than BM-MSCs, possess a greater proliferative capacity, and have superior protein secretion
(FGF and insulin-like growth factor) and immunomodulatory effects [600]. On the other hand, BMMSCs show a preferential benefit in differentiating into osteogenic and chondrogenic lineages as
well as benefits in proteins secreted (stromal cell derived factor-1 (SDF-1) and hepatocyte growth
factor (HGF)) [601]. This reveals the importance of selecting the appropriate source for a given
clinical application.
To get a better understanding of the genomic landscape of adipose vs. bone marrow MSCs,
single-cell RNA sequencing data revealed these main differences: ADSCs showed higher
immunosuppression capacity, lower transcriptomic heterogeneity, and lower immunogenicity than
BM-MSCs, while BM-MSCs showed higher levels of metabolic activity, respiration, and oxygen
consumption, [602]. Whether these differences impact effectiveness of microvascular regeneration
should be investigated.
Despite the limited number of cells retrieved at the time of harvest, stem cells from bone marrow
or adipose tissue can be expanded in culture but often undergo differentiation or enter senescence
following 8 weeks in culture [603]. However, MSCs taken from birth-derived tissues, such as
umbilical, placental, and Wharton’s Jelly-derived MSCs have a high proliferative capacity in culture
and do not undergo senescence after prolonged passaging [599]. Their collection is also
noninvasive. One thing to note, though, is the health status of the fetus may not be known;
therefore, genomic and chromosomal tests may need to be done to ensure no donor cell
abnormalities [591].

69

Induced pluripotent stem cells have been shown to have similar plasticity to embryonic sources
in terms of karyotype, phenotype, telomerase activity, and capacity for differentiation [604].
However, they have also been shown to harbor epigenetic changes that can alter their
differentiation capacity away from embryonic like cell types towards somatic cell types [605].
Additionally, iPSCs take a long time to expand and direct their differentiation, and thus are
associated with a higher cost [606]. Furthermore, iPSCs possess the ability to mobilize and engraft
as well, but not along the same homing SDF-1/C-X-C motif chemokine receptor 4 (CXCR4) axis as
BM- or AD-MSCs. iPSCs ability to engraft is mediated by integrin-β1 adhesion and requires lineage
direction for targeting tissue in vascular therapeutics [607].
Angiogenic mechanisms have been shown to be different between cell sources and should be
considered when choosing a source for cellular therapy. In fibrin-angiogenesis models, AD-MSCs
utilize plasminogen activator-plasmin axis by endothelial cells for vessel invasion and elongation,
with MMPs serving to regulate capillary diameter. Further, they exhibit upregulation of angiogenic
factors urokinase plasminogen activator, HGF, and tumor necrosis factor-alpha (TNFα) [608]. This
aspect of AD-MSC angiogenesis is more akin to fibroblast-mediated angiogenesis than BM-MSC
mediated angiogenesis. BM-MSCs execute angiogenesis in part through MMPs without
involvement of the plasminogen activator-plasmin axis [609].
Paracrine angiogenic mechanisms between cell sources is also known to vary and has been
elegantly reviewed by Maacha et al. [610]. To briefly summarize, MSC exosomes have been shown
to carry proangiogenic miRNAs and differ between sources. MicroRNAs are small-size non-coding
RNAs that negatively affect protein expression post-transcription and have recently garnered a lot
of attention. Some proangiogenic miRNAs of AD-MSC exosomes include miRNA 148, 532-5p, 378,
let-7f, 125a, 31, and 181b, with the latter three repressing antiangiogenic delta like canonical notch
ligand 4, hypoxia inducing factor 1 (HIF-1), and transient receptor potential cation channel
subfamily M member 7 expression [610]. BM-MSC exosomes carry proangiogenic miRNAs 132,
494, 19a, 21a-5p, 210-3p, and 210 with the latter repressing antiangiogenic Efna3 expression in
endothelial cells [610, 611]. Finally, endometrial MSC exosomes have been shown to carry
proangiogenic miRNA-21-5p. In terms of soluble factors, the total angiogenic potential is
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characterized as highest in Wharton’s Jelly, BM, and placental MSCs vs. lower potential in AD- and
UCB-MSCs [610]. The AD-MSC secretome was shown to be high in VEGF/VEGF-D, insulin-like
growth factor 1, intelukin (IL) -8, MMP-3, MMP-9 and and relatively lower in transforming growth
factor-beta (TGFβ-1), VEGF-A, HGF, bFGF, and angiopoietin-1. BM-MSCs were characterized as
high in VEGF-D and lower relatively in VEGF, macrophage colony stimulating factor, IL-1ra, SDF1α, MCP-1, IGF-1, IL-8, MMP-3, and MMP-9. Amniotic MSC secretome was characterized as high
in VEGF, TGFβ-1, VEGF-A, HGF, bFGF, and angiopoietin-1 [610]. These differences may have
functional impact for various therapeutic applications. When choosing sources of stem cells,
attention should be paid to specific mechanisms of action pertinent to each cell type for the
hypothesis in question, as well as the advantages and disadvantages of each cell type.
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Figure 7: Cell Sources and Isolation Strategies. Locational sources and strategies for isolation
and differentiation of stem cells including bone marrow derived mesenchymal cells, adipose derived
cells and microvascular fragments, stem cells from birth derived tissues, and embryonic stem cells.
Image created with BioRender.com
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Table 3: Advantageous and Disadvantageous Qualities of Cell Sources

Bone Marrow

Adipose

Cardiac
Human
Umbilical
Embryonic
Amniotic

Placental

Induced
Pluripotent
Microvascular
Fragments

Advantage
Enhanced engraftment and
retention of other stem cells
Greater transcriptomic
heterogeneity (vs. AMSC)
Ease of isolation
Higher cell yield (vs. BM-MSC)
Autologous potential
Low immunogenicity (vs. BM-MSC)
Higher immunosuppression
capacity (vs. BM-MSC)
Heterogenous cell population
May be more applicable to cardiac
pathophysiology than other sources
High concentration of cells
No senescence during passaging
High plasticity
Low immunogenicity
High plasticity
High concentration of cells
Chorionic Villi MSC:
Available first trimester
Ideal for fetal therapeutic
applications
Limited senescence during
passaging
High plasticity
Higher immunosuppression
Multiple locations for
harvest/minimally invasive
Quicker revascularization of target
tissue
Supplement to other stem cell
sources

Disadvantage
Higher immunogenicity (vs. ADSC)
Invasive harvesting procedure
Lower cell yield (vs. ADSC)
Lower transcriptomic heterogeneity
(vs. BM-MSC)
Poor survival/engraftment
Inconsistency among
donors/samples
Difficult to harvest (invasive)
Have not been definitively shown to
generate mature cardiomyocytes
Genomic/chromosomal tests may
be needed to rule out abnormalities
Ethical concerns
Risk of teratoma formation
Only available starting second
trimester limiting autologous use.
Chorionic Villi MSC:
Relatively poor
engraftment/retention

hiPSC-CM: poor
retention/engraftment
high cost
long time to procure
Lower cell fraction than SVF
(macrophages, stem cells, etc.)

4.20: Mechanisms of Action for Stem Cell Regeneration of Vascular Function
Around the early 2000’s, the use of stem cells as a cellular therapy for stimulating microvascular
growth garnered excitement based on observations of apparent cell adoption of a vascular cell
phenotype and mapping to vascular fate. Based on these initial findings, it was thought that stem
cells mediated their therapeutic abilities through direct differentiation replacing the injured cells of
the host tissue [612]. While direct cell interactions including differentiation is indeed supported
[613], the relatively low rate of vascular integration and evidence of little to no incorporation [614]
suggested that paracrine mechanism might play a more dominant role. Thus, the prevailing theory
today is the paracrine hypothesis, which states that stem cells exert their regenerative effects
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through secretion of factors that enhance or regulate physiological and molecular processes.
Evidence of this notion comes from the ability to utilize stem cell conditioned media and yielding
the same or similar therapeutic effects. This section explores the specific mechanisms, both direct
and indirect (paracrine) of stem cell mediated microvascular regeneration. Stem cell effects on
angiogenesis and immunomodulatory effects will be described in each subsection as relevant and
all information is summarized in Figure 8. Effects of each stem cell source on microvascular
regenerative parameters specifically are summarized in Table 4. In further support of expanded
impacts, additional examples of stem cell effects on functional dilation, atherosclerosis,
mitochondrial function, ER stress, DNA and lipid oxidation, and vascular aging are also provided.
In these sections, the focus shifts to the specific stem cell types (e.g. mesenchymal) that dominate
the literature. The lack of parallel studies across stem cell sources emphasizes the need for
systematic comparisons of stem cell effects for optimizing therapy translation.
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Figure 8: Mechanisms of Stem Cell Mediated Vascular Regeneration. MSC therapies improve
vascular health through direct (1) or paracrine (2) mechanisms to rejuvenate vasodilatory function
(3), angiogenesis and vascular/capillary density (4-5), reduce calcification, smooth muscle
proliferation, and thrombosis (6), reduce lipid peroxidation (7), attenuate oxidative stress and
restore mitochondrial function (8), abrogate ER stress (9), DNA oxidation and fibrosis (10),
apoptosis, and senescence (11). Image created with BioRender.com.

Table 4: Microvascular Regenerative Effects of Cell Therapies. Note: references for this table
can be found in text and in the original publication (https://doi.org/10.1152/ajpheart.00021.2022).
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Table 4: Continued

4.21: Direct Cell Interactions
There is evidence that MSCs are capable of direct differentiation into pericyte and endotheliallike cells [615, 616]. Differentiation into the latter has been shown through mechanotransducive
stimulation such as shear stress and MSC-endothelial extracellular matrix (ECM) protein
interactions [613, 617-620]. Differentiation also occurs in the presence of VEGF via Rho/ROCK

76

and myocardin-related transcription factor A signaling and CYR61/CNN-1 gene upregulation [621].
Nitric oxide released from nearby endothelial cells and S-nitrosoglutathione reductase also mediate
differentiation into endothelial-like cells [622, 623]. These differentiated cells are considered “like”
endothelial cells in that they express a milieu of endothelial cell markers including VEGF receptors
1 and 2 and Von Willebrand Factor. Notably, differentiation is not complete. For example, as MSCderived endothelial networks lack other endothelial markers such as platelet endothelial cell
adhesion molecule 1 [624]. It should also be noted that many of these studies are in vitro, so
whether these conditions can cause endothelial-like differentiation in vivo should be determined.
Endothelial-like cells exhibit behavior akin to resident endothelial cells, namely, that they have
angiogenic and vasculogenic potential to create new patent cell networks [620, 625, 626]. Growth
determination factor 11 and TGFβ receptor/ERK/EIF4E pathway further enhance endothelial-like
differentiation and angiogenic potential [627]. Autologous BM-MSC derived endothelial-like cells
have been used in 3D bioprinting for the fabrication of carotid and femoral grafts that maintain
patency with minimal inflammation when implanted in dogs [628].
These MSC differentiated endothelial-like cells can mediate recovery in the setting of vascular
disorders [629-631]. However, direct differentiation and engraftment does not always lead to
recovery of organ function. For instance, amnion-derived MSCs differentiated to cardiomyocyte
and endothelial-like cells in a rat model of heart failure, but this came without recovery of cardiac
function or reduction in fibrosis [632]. To note, functional vascular recovery is often achieved
despite very low cell therapy engraftment and differentiation [633], leading to the era of the current
paracrine hypothesis.
Stem cells can also associate directly with endothelial cells to mediate recovery through
juxtacrine interactions [619, 634]. Through gap junctions, such as connexin 43, miRNA, glucose,
protein, and even mitochondria can be transferred between MSC and endothelial cells [635]. In a
mouse stroke model, the flux of glucose from endothelial cells to MSC allows for reduced VEGF
uptake, angiogenic signaling, permeability and inflammatory response as a protective recovery
mechanism. This mechanism can be blocked by gap junction inhibition [636, 637]. Following an
ischemia/reperfusion-like injury in HUVECs, mitochondria from MSCs can be directly transferred
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from tunneling nanotubes rescuing oxygen consumption rate [638]. Transfer of the aforementioned
organelles is initiated upon MSC recognition of phosphatidylserines present on apoptotic induced
cultured endothelial cells. Other than direct transfer, stem cells can also release factors and
mitochondria in a paracrine manner.

4.22: Indirect (Paracrine) Cell Interactions
The “paracrine hypothesis” suggests stem cells exert much of their beneficial effect on damaged
tissue through the paracrine action of their secretome (i.e. exocytosed contents or vesicles) rather
than engraftment of stem cells into damaged tissue [639]. Using cell culture systems that prevent
direct contact while allowing exchange of factors in the shared media, stem cells can exert
regenerative, differentiation induction and proangiogenic effects via paracrine mechanisms [640,
641]. Much of the focus of the field has been on the potential of exosomes as a key therapeutic
mechanism as well as an opportunity as a cell-free therapeutic alternative. To reflect this emphasis
in the field, exosomes will be the focus in this section as well as highlighting non-exosome (e.g.
conditioned media) paracrine effects when appropriate.
Exosomes are membrane-bound vesicles ranging from 30-150 nm released from cells that
function in a paracrine manner transporting proteins, lipids, RNAs, microRNAs (miRNA),
mitochondria and more between cells [639, 642, 643]. Exosomes are formed through invaginations
of the late endosome, where cytoplasmic contents are encapsulated in multivesicular bodies.
Proteins from the ER and golgi complex can be sorted into multivesicular bodies then released to
the extracellular environment through fusion and exocytosis where exosomes often circulate to
target cells via chemoattraction [644]. Cellular recognition of exosomes occurs through either
opsonized free-floating exosomes, through adhesion, or via antigen recognition [645]. Exosomes
mediate their effects via intracellular signaling pathways that can be initiated after exosome soluble
signaling or juxtacrine signaling. Genetic or protein content transfer can occur via fusion,
macropinocytosis, or receptor/raft mediated endocytosis, albeit the latter two may also result in
lysosomal degeneration as is the case with phagocytosis [644].
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The utilization of MSC-derived exosomes circumvents the limited cell numbers as exosomes can
be continuously harvested from media of cell cultures and have been shown to have efficacy as a
vascular therapeutic. Antioxidant proteins can be released to have a direct restorative effect or
miRNAs can indirectly influence host cell function through regulation of genetic expression [646].
For example, in Yang et al.’s 2018 study, exosomal miRNA-181b-5p (181b-Exos) increased protein
expression of factors that promoted angiogenesis in brain microvascular endothelial cells after
oxygen deprivation. Endothelial progenitor cells and AD-MSCs exosomes carry other
proangiogenic miRNAs, such as miRNA-126, 296, 278, and 210 [647].
Exosomal therapy shows regenerative potential in vascular settings. Secrotomes isolated from
human adipose mesenchymal stem cells increased vascularized granulation tissue and endothelial
cell density of the dermis of in vivo mouse wounds compared to controls. Promisingly, injury sites
in the group treated with secretomes expressed significantly higher levels of CD31 (a marker of
vascular endothelial cells) [648]. In vitro treatment with induced vascular progenitor cell (iVPC)
exosomes resulted in increased vessel length and area of endothelial cells. In vivo, iVPC-Exo
therapy significantly increased perfusion of an ischemic hindlimb model. The results suggest a
similar angiogenic effect whether iVPCs or iVPC-Exo are administered, and that the effects of
iVPCs are likely due to exosome secretion [639]. A comparative study examined the effect of
exosomes isolated from BM-MSCs, AD-MSCs, and UCB-MSCs for the treatment of MI in rats. All
three types limited damage from induced MIs, stimulated angiogenesis via increased VEGF, bFGF,
and HGF, and increased microvascular density, with AD-MSCs having the most significant effect
[649]. Signaling cascades initiated by the stem cell secretome increased the ability of fibroblasts,
keratinocytes, and vascular endothelial cells to migrate. MSC exosomes also have applications for
attenuating pathologies associated with vascular barrier dysfunction [650, 651].
Stem cell exosome-based therapy has many advantages compared to cellular therapy. Studies
have shown that administration of stem cell derived exosomes leads to similar outcomes compared
to administration of the stem cells themselves [639]. In some studies, exosomes even outperform
their parent cells for microvascular regeneration [652]. Without the stem cell, there is no evidence
of tumorigenesis [639] and risk of immunogenicity [653] and cell emboli are greatly reduced. There
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are also practical advantages to non-cell therapy including avoiding complex FDA guidance of cell
therapy, simplified large scale pharmaceutical production and ease of storage compared to cells.
Exosomes may also be utilized synthetically as drug/gene therapy delivery vehicles, enhancing
bioavailability due to their size and have potential for homing to site of interest through targeting
peptides on their membranes [654]. The major disadvantages to exosomal therapy from a
pharmaceutical standpoint is low yield of exosomal release from mammalian cells, cumbersome
methodology for isolation, and ensuring batch to batch consistency in exosomal contents [654].
Alternative methods that are potentially more amenable to large scale exosome production are
currently being investigated and need to be verified for clinical use in variety of stem cell sources
and pathologies [655]. Other methods such as changing culturing conditions are described by Phan
et al. [642]. Evaluation of surface markers is currently done for ensuring batch consistency [656],
but this still does not fully ensure inside contents are uniform throughout.

4.23: Stem Cell Remediation of ER Stress
The ER is an important site for protein, lipid and sterol synthesis, protein trafficking and folding,
and calcium storage and release. ER stress occurs when the capacity of the ER to fold proteins is
outpaced by synthesis of proteins, due to physiologic or pathologic strain [657]. In a pig study of
renal artery stenosis and in porcine kidney tubular cell culture with induced ER stress (via
thapsigargin treatment), AD-MSCs and EPCs were able to both restore renal blood flow and
glomerular filtration rate (albeit AD-MSC were more effective) as well as similarly improve
microvascular density in the inner and middle cortex [658]. EPCs reduced oxidative stress (NADPH
oxidase p67and p47 subunits) while AD-MSCs reduced inflammation (decreased TNFα and IL-1β,
increased IL-10), caspase-3 mediated apoptosis, and ER stress via reduced CHOP, GRP94, and
Derlin-3. EPCs were also able to increase VEGF while both EPCs and AD-MSC reduced p67 and
p47 and both decreased fibrosis. Interestingly, this mechanism for MSC repair seems to be contact
dependent via a direct cell effect, as culturing with an insert plate to only allow exchange of culture
media alone did not replicate these regenerative effects. MSCs can also reduce ER stress via
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blocking palmitic acid-mediated HUVEC endothelial-to-mesenchymal transition dependent on MSC
secretion of stanniocalcin-1 [659].

4.24: Stem Cell Rejuvenation of Mitochondrial Function
One major element of stem cell mediated vascular rejuvenation is antioxidation of host tissue
[660]. MSCs are highly resistant to oxidative stress since they constitutively express catalase,
superoxide dismutase 1-3 (SOD1-3), glutathione peroxidase (GPx), SIRT 1, 3, and 6, and
thioredoxin, heme oxygenase-1, as well as having abundant antioxidant molecule glutathione
(GSH) and redox sensitive forkhead box O3 signaling [660-665]. These antioxidative elements
have been shown to mediate recovery from vascular injury and disease in part by reducing
oxidative stress and its markers (nitrotyrosine, and 8-OHdG) and increasing host endothelial
cell/vascular smooth muscle cell (VSMC) antioxidative protein content and/or activity [666-668].
For example, BM-MSCs upregulate aortic HO-1 and catalase to reduce oxidative stress in mouse
radiation-induced aortic injury, accompanied by reduced fibrosis, aortic thickening, apoptosis, and
inflammation (TNFα and intercellular adhesion molecule 1) [669].
Some of these antioxidative factors have been shown to be secreted or trafficked in exosomes
to vascular targets, including catalase, SOD1-3, GPx1-7, GSH, SIRT1-6, peroxiredoxin 1-6, and
thioredoxin 1-2 [660, 666, 668, 670]. Under hypoxic conditions of pulmonary arterial hypertension,
MSC exosomes reduced reactive oxygen species (ROS) by increasing GSH/GSSH balance and
also positively affected the citric acid cycle by increasing pyruvate dehydrogenase and glutamate
dehydrogenase 1, restoring energy balance and oxygen consumption rate in VSMC [671]. Further,
miRNA-132-3p delivered by MSC exosomes to endothelial cells reduces ROS by downregulating
Ras p21 protein activator 1 and increasing Ras and PI3K expression [672]. MSC exosomalmediated reduction in ROS can also be accompanied by increasing endothelial- but reducing
inducible-nitric oxide synthase, thus restoring nitric oxide bioavailability [673]. Reduced cellular
oxidative stress from antioxidative MSCs ameliorates endothelial lipid peroxidation and DNA
oxidative damage and maintains mitochondrial DNA replication and stability [674-677]. More details
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about the emerging understanding of the antioxidative role of stem cells is summarized by Stavely
et al. [660].
Healthy mitochondria exist in a balance between fission, fusion, biogenesis and mitophagy,
deviation from these leads to increased oxidative stress, reduced respiration and vascular function
[43]. Stem cell therapies have also been shown to mediate shifts in the mitochondrial bioenergetics,
dynamics, and respiration. Zhu et al. found that in HUVECs and rat aortas, high glucose insult led
to excessive dynamin related protein-1 mediated mitochondrial fragmentation, ROS production,
reduced membrane potential and ATP production, blunted mitophagy leading to increased
caspase-3 and Bax mediated apoptosis [678]. All these observations were reversed when cocultured or infused with BM-MSCs, including a return in mitochondrial morphology to a filamentous
fused network. Notably, the authors found an increase in mitophagy mediators Pink1 and Parkin
with MSC therapy, small inhibiting RNA (siRNA) inhibition of which ameliorated the restorative
effects MSCs. In another study, diabetic endothelial dysfunction was treated with MSC conditioned
media [679]. MSC-conditioned media reduced ROS, prevented apoptosis (increased Bcl-2,
decreased Bax), increased migration and tubulogenesis in HUVECs subjected to high glucose and
and improved vasodilation in thoracic aorta. These effects were mediated by increased expression
of SIRT1 and mitochondrial biogenesis activator peroxisome proliferator-activated receptor gamma
coactivator 1 (PGC-1a), specifically through the phosphoinositide 3-kinase/protein kinase-B
(Akt)/SIRT1 and SIRT1/AMP-activated protein kinase/PGC-1a axes.
Mitochondrial functional recovery from MSC therapy can also occur via the direct and paracrine
mechanisms through donation of whole mitochondria, mitochondrial membrane fragments, or
mitochondrial DNA through tunneling nanotubes, connexin 43 gap junctions, cell fusion, and
exosomes/extracellular vesicles (EVs) [638, 677, 680-682]. Apoptotic endothelial cells (HUVECs)
exposed to oxygen/glucose deprivation and reoxygenation express phosphatidylserines that serve
as a stem cell recognition site for the formation of nanotubules and nearly unidirectional transfer of
mitochondria from stem cell to injured endothelial cell [638]. In a rat model of stroke (middle cerebral
artery occlusion/reperfusion), BM-MSCs were found to increase angiogenesis, motor function,
microvascular basal and maximal oxygen consumption rate and extracullaular acidification rate and
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reduce infarct size and lactic acid production [681]. Interestingly, vessel density in the peri-infarct
area correlated with host cells that have received BM-MSC mitochondria. Restorative effects were
not seen with nanotube inhibition with annexin V or latrunculin-A. Since these inhibitors do not
reduce paracrine signaling, the BM-MSCs direct therapeutic mechanism was postulated to be
through engraftment and subsequent direct mitochondrial transfer.
In coronary artery VSMCs, MSCs nanotube-mediated mitochondrial trafficking is bidirectional
and a signal for MSC proliferation [683]. With hydrogen peroxide (H2O2) exposure, HUVECs
transfer their mitochondria to MSCs where they are degraded via autophagy [684]. This induces
heme oxygenase-1 production and subsequent mitochondrial biogenesis (PGC-1a and
mitochondrial transcription factor A) and mitochondrial donation from MSCs to HUVECs. HUVECs
then exhibit increased mitofusion 1-2 and reduced apoptosis. The restorative response was
dependent on mitochondria being “damaged” (high superoxide) and intact fission and fusion
mechanisms. In lipopolysaccharide induced lung injury model (pulmonary microvascular
endothelial cells and in vivo), there is increased ROS with reduced mitochondrial membrane
potential, basal and maximal oxygen consumption rate and ATP turnover, and diminished vascular
barrier function. This was reversed by MSC-exosomes but not exosomes devoid of mitochondria
[677].

4.25: Stem Cell Effect on Vascular Dilative Function, Aging, Atherosclerosis, and Hypertension
These antioxidative effects on mitochondrial biogenesis/dynamics/mitophagy confer functional
benefits in terms of vasodilative function including that of microvessels. Indeed, it has been shown
that mitochondrial state 3 and 4 respiratory function correlates with both acetylcholine and flowmediated (but not nitric oxide mediated) vasodilation [432]. Intravenous SVF delivery reversed
aging-associated loss of b-adrenergic agonist (norepinephrine) dilation and improved dobutamineinduced coronary flow reserve, an indicator of coronary microvascular function in a rodent model
[10]. Myogenic responsiveness to intraluminal pressure changes is improved in mesenteric arteries
via an H2S-mediated mechanism after treatment with UCB-MSCs in mice with endothelial nitric
oxide synthase (eNOS) knockout [685]. There is improved endothelial-dependent (acetylcholine),
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but not -independent (nitric oxide) dilation with MSC therapy in rat thoracic aorta (high glucose
model) and during rabbit limb blood flow analysis (limb ischemia model) with improved perfusion
[633]. Interestingly, both acetylcholine and flow mediated dilation operate via activation of eNOS
and nitric oxide. In a rat model of brain death and ischemia reperfusion, BM-MSC conditioned
media mediates a restoration of aortic vasodilatory sensitivity to acetylcholine, no change in
maximal endothelium-independent response and is less sensitive to constrictive phenylephrine
[686]. Further, these aortas treated with conditioned media exhibited less neutrophilic infiltration
and reduced caspase-3, 8, 9, 12, vascular cell adhesion molecule-1, and intercellular adhesion
molecule-1 (CD54) expression, and nitrotyrosine [686]. Interestingly, the regenerative effect of BMMSCs on vasodilatory function to flow may be gender specific, as flow-mediated dilation was
significantly restored in male but not female patients in the POSEIDEN-DCM study of dilated nonischemic cardiomyopathy [687].
Reduction of endothelium-dependent dilation in aging is associated with oxidative stressinduced senescence and short telomeres, reversed by antioxidant therapy [688]. In HUVECs and
in aged mice, gingival-derived MSC exosomes attenuate oxidative stress-induced senescence by
reducing senescence associated gene expression of B-galactosidase, p21, p53, phosphorylated
gH2AX, and mTOR/pS6 signaling [689]. Human iPSC exosomes reverse the effects of senescence
(via high glucose insult) on HUVECs. Specifically, they reduce the proportion of senescent cells
(senescence-associated B-galactosidase) to increase cell viability, and restore ability to form
capillary-like structures [690]. MSC exosomes reduce DNA damage, inflammation, fibrosis and
senescence associated phenotype via ataxia telangiectasia mutated/p53/p21 signaling in radiation
induced lung endothelial injury via miRNA-214-3p [691].
Aging-associated atherosclerosis and calcification represents another avenue in which stem cell
therapy offers regenerative potential. In mouse aortic VSMCs with induced calcification by bglycerophosphate, MSC-conditioned media reduces alkaline phosphatase activity, reduces
intracellular calcium content, mRNA expression of Msx2, Runx2, osteocalcin, bone morphogenic
protein-2, protein expression of bone morphogenic protein-2 and Runx2, reduced TNFa, IL-1b, IL6, caspase-3, and increased Bcl-2/Bax ratio [692]. In rat aortic VSMCs exposed to advanced
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glycation end products with induced calcification, BM-MSC exosomes calcification and ROS
production via enhanced miRNA-146a targeting of thioredoxin-interacting protein [693]. In a rat
model of hyperlipidemia, a synthetic vascular graft embedded with small EVs from human placentaderived MSCs reduced calcification, thrombosis, and improved graft patency with M1-M2
macrophage phenotypic switch [694]. These EVs contained VEGF, miRNA-126 and miRNA-145
[694]. Rat aortic neointimal hyperplasia and vascular smooth muscle proliferation is inhibited by
BM-MSC exosomal miRNA-125-b, which represses myo1e expression [695]. These effects of stem
cells on atherosclerosis and calcification are likely important for microvascular function as well, as
coronary artery disease severity is correlated with microvascular disfunction [696, 697], albeit
microvascular disease may precede coronary artery disease [698].
MSC therapy can also mediate microvascular regeneration in the setting of increased
hypertension and peripheral resistance. MSC therapy leads to a reduction in both circulating reninangiotensin-aldosterone as well as the angiotensin type 1 receptor and increased angiotensin type
2 receptor expression in a chronic renal artery stenosis rat model [699]. The reduction in
sympathoexcitation reduces systolic blood pressure, albeit it does not lower systolic blood pressure
to pre-stenotic levels. Most importantly, MSC therapy lead to recovery of the microvascular tree in
the stenotic kidney [699] allowing for improved glomerular filtration rate and renal plasma flow [700].
Human amniotic MSCs reduce portal pressure in portal hypertension alongside recovered
microvascular function [701]. Further, there was reduced oxidative stress and inflammation and
enhanced nitric oxide together culminating in enhanced liver function tests.

4.30: Autologous vs. Allogeneic (Self vs. Shelf)
There is current discussion about whether autologous or allogeneic sourcing is most appropriate
for stem cell therapy and often referred to as “self or shelf”. Allogeneic cells can be more readily
obtained however autologous cells better match host biologic and immunologic dynamics. If one
were to imagine the “ideal stem cell donor candidate”, its’ properties would include a young person
with no prior disease history, healthy lifestyle habits whose stem cells would be at no risk for
causing rejection/immune response, maximum potential for engraftment, survival, proliferation,
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maximal and consistent secretion of therapeutic factors. Likewise, the ideal stem cell recipient for
most successful therapeutic benefit would be someone with minimal disease progression
(preventative care) with limited co-morbidities and healthy lifestyle habits. In reality, patients often
have multiple co-morbidities and progressive disease presentation. Similarly, donor stem cells,
even from an ideal stem cell donor candidate, can still potentially elicit immune responses [702].
How would one choose the universal stem cell donor that these allogeneic cellular therapeutics are
based on? What would be the criteria? The dynamics of autologous vs. allogeneic strategies are
described below and compared in Figure 9.
Potentially, allogeneic stem cells could be produced in enormous quantities and readily
available on a large pharmaceutical scale for clinical use, i.e., “off the shelf.” Issues of collection,
aging, and disease states can be avoided with use of an ideal donor, who may be a young individual
without chronic disease history and a healthy lifestyle [703]. The challenges of allogeneic stem cell
sources include immune reactions to the HLA antigens on donor cells and infection transmission
from donor to patient [703]. On the other hand, MSCs are relatively hypo-immunogenic [704] and
approximately half of international clinical trials from 2004-2018 use allogeneic MSCs as their
source [705, 706]. The mechanism behind why MSCs exhibit a hypo-immunogenic property is due
to their capacity to be conditional antigen presenting cells in the early phase of an immune response
[707, 708] then immunomodulate through secretion of soluble factors [709, 710]. A newer area of
research involves CRISPR-Cas9 gene editing to increase immune compatibility of allogeneic stem
cells used for therapy [711, 712].
An additional consideration for allogeneic stem cells is sex as a biological variable [713, 714].
SVF from male vs. female mice exhibit slightly different cellular composition [715]. Under oxidative
stress conditions, SVF from male donors showcase some differences, including increased IL-33
(inflammatory) and FGF in SVF-HUVEC co-cultures, whereas female SVF exhibited increased proangiogenic secretion of platelet-derived growth factor a and b and decreased IL-1b [716]. Albeit,
SVF antioxidant and VEGF gene and protein expression was similar between the sexes. These
differences need to be further explored for any potential differences in therapeutic efficacy, in terms
of cell efficacy as well as male to female or female to male stem cell delivery.
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Pivoting to autologous stem cells, their use dismisses the immunological concerns of non-selftissue. However, autologous stem cell use can be complicated by age and disease states that
cause cellular dysfunction. Most logically, patients with gene-linked diseases may not receive as
much benefit via therapy with autologous cells. Additionally, the vast number of cells necessary to
isolate and expand ex vivo makes collection from autologous donors challenging, especially in
states of disease or aging [703].
In a 2018 study by Redondo J. et al., BM-MSCs derived from patients with progressive multiple
sclerosis (MS) were compared to MSCs from controls with the goal of determining whether the
inflammatory conditions of MS compromise MSC function. The data showed that the MS-derived
MSCs had decreased potential for expansion that was inversely related to the duration of
progressive MS. Additionally, the MS-derived MSC cells produced markers of early aging in vitro,
including accelerated telomere shortening and senescence compared to control [717]. In a 2021
study, MSCs obtained from the adipose of pigs with atherosclerotic renal artery stenosis displayed
decreased levels of VEGF and capacity for angiogenesis, and increased rates of cellular
senescence compared to control cells [718]. Hyperglycemia can also influence MSC kinetics.
MSCs isolated from abdominal fat of human diabetic donors between the age of 40 to 72 years
showed significantly fewer colony forming units, lower proliferation rates, and a lower number of
cells displaying CD105+ (an angiogenic biomarker) compared to cells from non-diabetic agematched controls [719]. The results of these studies suggest that in patients with chronic disease
states, autologous stem cells may not be the best option.
Age can also factor in, as adipose-derived SVF from old Fischer-344 rats (24 months) has been
compared to that of young rats (4 months). In vivo, subcutaneous implants of age-dependent SVFladen collagen constructs showed that old SVF resulted in decreased total and perfused vessels,
and smaller, less mature vessels than those embedded with young SVF after 4 weeks of
implantation. They also found increased expression of thrombospondin-1, a protein correlated with
decreased angiogenesis and migration in old SVF samples. Neutralization of thrombospondin-1
with antibodies prior to implantation ameliorated this effect [720]. Another study revealed a negative
correlation in yield of human SVF cells with age (19-71 years old) in female donors [721].
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Other donor characteristics that should be considered are lifestyle and modifiable factors. For
example, viable SVF yield has a significant negative correlation to smoking level of the donor [722].
ADSCs from smokers has exhibited reduced vasculogenic potential via increased angiostatic
activin A expression, reduced ADSC migration and differentiation, reduced platlet derived growth
factor a and b, ANGPT1, ANGPT2, HGF, SDF-1, and increased Notch2, Notch3, and plasminogen
activator inhibitor-1 [723]. Increased physical activity of patients has also been associated with
significantly lower viability of SVF without affecting the initial cell yield [722]. Lastly, ADSCs isolated
from patients of a range of body mass index (BMI) have been compared. As BMI increases, there
is an inverse correlation to differentiation potential, proliferation, and colony forming potential [713,
724]. Further studies need to be done to ascertain more lifestyle, genetic, or naturally mitigating
factors that can nullify a stem cell therapies beneficial affects to a vascular bed.

Figure 9: Allogenic vs. Autologous Stem Cell Therapeutic Strategies in Differing Patient
Populations. The advantages and disadvantages of allogenic (shelf) stem cell therapies are shown
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with attention paid to donor sex differences (a). For the autologous (self) strategy, effectiveness of
stem cell therapies are shown in “ideal” recipients as well as various patient populations such as
obesity, smoking, atherosclerosis, diabetes, and aging (b). Image created with BioRender.com

4.40: Strategies to Improve Stem Cell Engraftment and Function
Stem cell therapies have been historically limited in their effectiveness by low engraftment and
retention, and autologous potential is plagued by imperfections in stem cell function described
previously. These described shortcomings of cell sources and therapies, either from autologous or
allogeneic sources, give rise to the important discussion of whether these cells can be modified in
ways to improve or exceed their initial potential. These limitations can potentially be ameliorated
by priming or preconditioning the cells prior to therapeutic use with the goal exposing exogenous
cells with factors mimicking the potentially harsh environment in which they will be administered,
this improving cell engraftment and therapeutic robustness. Common strategies include hypoxic or
ROS preconditioning, pharmacologic priming, gene editing, extracellular supportive methods, and
co-therapies with microvascular fragments, all of which will be discussed in the following section
and illustrated in Figure 10.

4.41: Preconditioning with Hydrogen Peroxide
Repeated replication of stem cells causes senescence and damage via oxidative stress, similar
to the aging of in vivo somatic cells. Reactive oxygen species, and reactive nitrogen species (RNS),
are produced during cell expansion primarily via mitochondrial complexes, peroxisomes, and other
cell processes. Although low acute levels of ROS are important for normal cellular functions, high
chronic levels are capable of causing cellular harm and dysfunction [725]. Additionally, oxidative
stress in the host environment can decrease stem cell engraftment [726].
For these reasons, methods to enhance stem cell resistance to oxidative stress, or conditioning
them to be “accustomed” to oxidative stress has been an exciting area of research. One priming
technique is preconditioning of stem cells with H2O2. For example, H2O2-preconditioned ADSC
exosomes yielded improved microvascular density in rat skin flap model of ischemia reperfusion

89

with reduced inflammation and apoptosis, increased flap survival, tube length, and blood perfusion
units compared to unconditioned ADSC exosomes [727]. Another study found that H2O2preconditioning improved survival, migration, proliferation, tissue engraftment, wound closure and
microvascular density in mice with full thickness excisional wounds compared to unconditioned
MSCs [728]. The mechanism for this was upregulation of cyclin D1, SDF-1, and CXCR4/7 receptors
as well as decreased Bax/Bcl-2 ratio, cleaved caspase 3/9, and inhibited p16 and glycogen
synthase kinase 3b expression [728]. Preconditioning also enhanced oxidative stress resistance,
as preconditioned MSCs were able to resist increases in superoxide fluorescence and
mitochondrial membrane depolarization during oxidative challenge compared to unconditioned
cells [728].

4.42: Hypoxic Preconditioning
Hypoxic preconditioning is a common method to induce stem cell resistance to oxidative stress
in preparation for therapeutic utilization in ischemic tissue. Hao et al. found that chorionic villiderived MSCs subjected to hypoxic conditioning exhibited better survival and angiogenic capacity,
including reduced caspase-3, activation of Akt signaling, increased VEGFA, HGF, and culminating
in increased endothelial cell proliferation, migration, and tube formation [729, 730]. Mouse
peripheral blood mononuclear cells subjected to hypoxic preconditioning show increased
(compared to non-preconditioned cells) antioxidant gene expression, lower ROS levels, higher
survivability in oxidative stress conditions and in ischemic hindlimb muscle tissue. This
corresponded with greatly improved microvascular density and perfusion 28 days after therapy
[731]. Antioxidant and cytoprotective genes upregulated included heme oxygenase-1, autocrine
motility factor, hexokinase-2, IL-1b, VEGF, and induced nitric oxide synthase [731]. Hypoxia
preconditioning of MSCs also can upregulate proteins supportive of the angiogenic process,
fibronectin 1, E-cadherin, N-cadherin, and many integrins [732, 733]. Hypoxia can also upregulate
pro-angiogenic and cytoprotective miRNA expression, such as miRNA-675 (decrease HIF-1a
negative regulators to increase VEGF) [734]. Hypoxia preconditioned adipose MSCs have also
been shown to reverse rat erectile dysfunction by upregulating VEGF and its receptor, angiotensin
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1, basic FGF, brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, SDF-1 and
CXCR4, and neuronal nitric oxide synthase, culminating in increased angiogenesis [735]. Further,
hypoxia preconditioned BM-MSCs release more VEGFA and SDF-1a than normoxic, becoming
“endothelial-like” cells with angiogenic potential [736]. VEGF is also produced more by hypoxia
preconditioning of MSCs, enhancing angiogenesis when injected into rabbit molar pulp cavities
[737].
Mechanisms behind hypoxia preconditioning increasing VEGF and angiogenic capacity could
be wnt-dependent through protein kinase A signaling and HIF-1a-GRP78-Akt axis [738-740] or
through PrPC-dependent JAK2/STAT3 activation and inactivation of caspase-3 [741]. One reason
for increased survival after hypoxia preconditioning may be due to enhanced autophagy. In EPCs
engrafted in ischemic limb, which exhibited greater microtubule-associated protein 1A/1B light
chain 3 stained autophagic structures, restoration of blood perfusion, and enhanced arteriogenesis
and angiogenesis after EPC transplant in rat ischemic abdominal wall muscle [742].
Cell-free therapeutic strategies also benefit from hypoxia preconditioning [733, 743]. Human
AD-MSCs derived EVs cultivated under hypoxic conditions demonstrated improved tube formation
of targeted HUVECs compared to normoxic cultivation or supernatant [744]. In human UCB-MSC
exosomes, angiogenesis, proliferation, and migration are further enhanced by hypoxic
preconditioning than non-hypoxic preconditioning in HUVEC cell culture and mouse femur fracture
models [745]. Meta-analysis has been done comparing hypoxic to normoxic preconditioned
exosomes for cardiac repair after MI, but the same analysis has not been done for vascular
parameters and would be useful to the field [746].
Finally, hypoxia preconditioning has benefits for tissue engineering. In 3D bioprinted SVFvascularized bone grafts, short-term hypoxic preconditioning facilitates microvascular growth with
increased VEGFA and HIF-1a expression in vitro and in vivo and inosculation with host (mouse)
vasculature [747]. Hypoxic preconditioning of primary rat myoblasts caused downregulation of
miRNA-1, miRNA-206, and angiopoietin-1 with upregulation of VEGFA with greater percentage
volume of blood vessels in a Matrigel construct [748].

91

4.43: Priming with Growth Factors and Cytokines
Use of growth factors and cytokines can also have therapeutic benefit for regenerative stem cell
therapy. Dental pulp MSCs secretion of VEGF and HGF as well as vasculogenic ability is enhanced
by preconditioning with FGF [737]. Priming ADSCs with TNFa has shown a multitude of changes:
improved proliferation, cell motility and migration, increased adhesion to monocytes (albeit
decreased adhesion to endothelial cells), increased mRNA of VEGF, IL-8, monocyte
chemoattractant-1, intercellular adhesion molecule-1, increased ROS generation, and increased
positive regulators of angiogenesis (Akt, small GTPase Rac1, ERK1/2, p38 MAPK) [749]. In mouse
hind limb ischemia, TNFa-primed ADSCs increased blood flow recovery, arteriole density, and
reduced necrosis [749]. The angiogenic properties of human lung mesenchymal stromal cells in
wound healing and tube formation assays are enhanced by stimulation with IL-1b through NF-kB
dependent-miRNA-433 targeting of Dickkopf Wnt signaling pathway inhibitor 1 and subsequent bcatenin upregulation [750].

4.44: Genetically Modified Stem Cells
The capacity for induction of angiogenesis by stem cells can be greatly enhanced by genetic
modification. For instance, BM-MSCs overexpressing VEGF-A165 leads to higher amounts of VEGF
released, homing to hypoxic sites, enhanced angiogenesis and perfusion over non-expressed
MSCs in limb ischemia models [751-753]. Sometimes, a mixed strategy of preconditioning (i.e.
hypoxic) and genetic overexpression is developed. Fierro et al. explain in their MSC-VEGF
formulation that their cells are thawed 48 hours before injection in order to be preconditioned by
hypoxia, allowing for 10% of cells to be retained one month after injection, as opposed to 1% without
the hypoxic preconditioning [754].
Telomerase reverse transcriptase (TERT) and/or myocardin overexpressing adipose and bonemarrow MSCs not only increases viability and proliferation with reduced apoptosis, but also
increases blood flow and arteriogenesis in mouse ischemic hind limb [755]. Although the driving
concept for TERT overexpression is to enhance stem cell function, TERT can be enhanced in
recipient cells via exosomal mechanisms [756-758], and TERT itself is known to reduce oxidative
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stress and recover vascular function [48, 759]. Therefore, whether stem cells are able to mediate
vascular recovery via TERT donation or upregulation is warranted future inquiry.
Overexpression of HIF-1a via lentivirus in rat BM-MSCs lead to exosomes that transferred HIF1a to hypoxic-injured HUVECs and improved their tube formation, increased VEGF, plateletderived growth factor, and angiotensin 1 expression, preserved migration, and enhanced
proliferation, all more efficiently than non-overexpressed control exosomes [760]. HIF-1a
overexpression also leads to increased Jagged1 notch ligand and exosomal production carrying
pro-angiogenic miRNA-15, miRNA-16, miRNA-17, miRNA-31, miRNA-126, miRNA-145, miRNA320a, miRNA-424, with greater in vivo angiogenesis in mouse subcutaneous Matrigel plug than
control non-overexpressed exosomes [761].
Stem cells can also be made to overexpress miRNA in order to negatively regulate harmful
processes that can overall enhance stem cell regenerative properties. Overexpressing miRNA-1263p in human UCB-MSCs along with co-culture with HUVECs (as well as exosomal treatment)
resulted in increased tube formation, migration, and proliferation [762]. In a rat tail vein
arterialization model, human UCB-MSCs overexpressing miRNA-126-3p exhibited higher and
accelerated re-endothelization and reduced inflammation (TNFa) and intimal hyperplasia, all
showcasing the ability of miRNA overexpression for treatment of vein graft disease [762]. As
described in the study, microRNA-126-3p targeted HUVEC SPRED-1 and PIK3R2, negative
regulators of VEGF, and then lowered their mRNA and protein concentration, alongside increased
Akt and ERK1/2 phosphorylation, explaining their pro-angiogenic capabilities. On the contrary,
some deleterious miRNAs could be targeted in stem cells to improve their function. For example,
miRNA-142 is upregulated in aged mouse bone marrow MSC and increases ROS by disrupting
pexophagy (autophagy of peroxisomes) via Epas1 [763].
Small interfering RNA can also be utilized for priming of stem cells. For instance, siRNA against
caspase-3 in BM-MSCs allows for greater survival against H2O2-mediated apoptosis, showcasing
the promise for such a strategy in ischemic and oxidative environments [764]. In diabetic mice, BMMSCs with siRNA targeted against NADPH oxidase 4 showed reduced oxidant levels, decreased
adipogenic differentiation, decreased PPARg, enhanced endothelial differentiation, greater tubular
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formation, and greater phosphorylated eNOS and nitric oxide bioavailability [765]. Transplanted
NADPH oxidase 4 siRNA diabetic MSCs into wild type hind-limb ischemia showed blood flow
recovery as well as increased collateral artery diameters and capillary density compared to nonsiRNA diabetic MSCs [765].
Manipulation of stem cell EVs, exosomal content, or synthesis of simple synthetic EVs inspired
by stem cell contents may be an advantageous strategy for the field, as major hurdles include
heterogenous composition of EVs with potentially deleterious miRNAs such as MSC derived miR130b-3p, which has been shown to promote lung cancer cell proliferation, migration, and invasion
[766]. Found naturally in dental pulp MSCs, microRNA-4732-3p has in vitro and in vivo antioxidant
and angiogenic properties (i.e. improved tube formation, migration, and enhanced areal percentage
of CD31). MicroRNA-4732-3p incorporated into synthetic liposomes via electroporation and was
delivered intramyocardially to infarcted rats, resulting in preserved cardiac function and reduced
scar tissue [766]. Therefore, a strategy where miRNAs are first studied and identified in natural
exosomal therapeutics and then “mimicked” in synthetic liposomes has the advantages of
homogeneity and upscaled copy number, potentially increasing dosage per delivery. Indeed, the
synthetic miRNA-4732-3p liposomes outperformed control MSC EVs [766].
Genetically enhanced stem cells can exhibit antioxidative, antisenescent and anti-inflammatory
properties. PGC-1a overexpression enhances angiogenesis in diabetic conditions by protecting
against oxidative conditions [767]. Embryonic stem cells genetically edited to express active
FOXO3 were derived into endothelial cells that led to vascular regeneration in a mouse ischemic
injury [768]. An intriguing strategy to increase stem cell therapeutic effectiveness relies not only on
reducing donor stem cell ROS, but also ROS microenvironment of the host. Zhu et al. utilized
mouse

BM-MSCs

triple

overexpressing

SOD1+glutathione

peroxidase

(intracellular

antioxidants)+SOD3 (extracellular antioxidant), then transplanted into control, diabetic, or diabetic
+ N-acetylcysteine antioxidant treatment models of critical limb ischemia [769]. Bone marrow MSC
survival, proliferation, and migration was significantly enhanced by this treatment strategy, as was
release of VEGF, FGF-2, HGF, and placenta growth factor-2, and these effects were mediated in
part by loss of ROS (superoxide and hydrogen peroxide) induced advanced glycation end products
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[769]. Survival of BM-MSCs was over 50% after 1-3 weeks after injection vs. 30-35% with either
overexpression or N-acetylcysteine alone vs. 10% without overexpression/N-acetylcysteine
treatment. This is significant as survival is typically around 1% for systemic injections and 10% for
targeted injection (intracoronary or intramyocardial) [769]. Additionally, laser Doppler determined
that this particular stem cell strategy enhanced blood flow recovery, increased capillary density,
and reduced inflammatory infiltration in the ischemic limb [769]. This study suggests that perhaps
priming/preconditioning of the host themselves would be of benefit for stem cell therapeutic
effectiveness.

4.45: Pharmacologic Preconditioning
Pharmacologic strategies can also be employed to improve the effectiveness of stem cell
treatment, often in combination with hypoxia/H2O2 preconditioning or with extracellular support.
SIRT1 activation is often used in aging conditions due to its ability to enhance survival and respond
to stress and inflammatory responses via targeting p53, FOXOs, and NF-kB. Liu et al. used
SRT1720 SIRT1 activation combined with hypoxic and H2O2 strategy in aged rat and human BMMSCs for therapeutic application in rat MI. Angiogenesis was greatly increased by this strategy as
well as reduced stem cell apoptosis, fibrosis, scar size and improved cardiac performance. The
improved survival was due to upregulated Fas apoptosis inhibitory molecule, of which siRNA
targeting ameliorated anti-apoptosis [770]. SIRT1 also has a role in diabetes, as diabetic rat BM
early outgrowth cells exhibit reduced SIRT1 mRNA and reduced tube formation in vitro and
neovascularization in vivo. There was also reduced secretion of pro-angiogenic ELR+ CXC
chemokines CXCL1, CXCL3, and CXCL5 [771]. SRT170 reversed these findings to improve
angiogenesis in vitro [771].
ADSCs from aged equines with concomitant metabolic syndrome showcase enhanced ROS,
senescence, ER stress and mitochondrial dysfunction. Preconditioning with resveratrol (SIRT1
activator) and 5-azacytydine (inhibits DNA methylation) reduced ROS, enhanced SOD activity,
promoted mitochondrial fusion over fission, restored mitochondrial membrane potential, restored
elongated (vs. punctate) morphology, and restored mitophagy (increased PINK). Resveratrol and
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5-azacytydine also reduced ER stress (reduced PERK), were anti-inflammatory (reduced TNFa,
IL-6, increased regulatory T-cells), decreased apoptosis and increased proliferation of ADSCs, and
microvesicles from these cells enhance vascularization in horses with suspensory ligament injury
[772-774].
Other drugs to improve stem cell mediated angiogenesis include 5-aza-dc, 2,4-dinitrophenol,
and dimethyloxalylglycine [775]. 5-aza-2’-deoxycytidine increased transdifferentiation and
endothelial marker expression and angiogenesis on Matrigel of BM stem cells [776]. In BM-MSC,
2,4-dinitrophenol (electron transport chain blocker) and dimethyloxalylglycine (prolyl hydrolase
inhibitor) increased atrial natriuretic peptide and VEGF, as well as HIF-1a, respectively promoting
angiogenesis in rat MI models [777].
Pharmacologic preconditioning is also commonly used for antioxidative or anti-ischemic
purposes. Trimetazine (anti-ischemic) lowers tissue demand for oxygen by lowering fatty acid
oxidation and reducing ATP demand, making the host microenvironment more amenable for stem
cell integration and therapeutic effect. Trimetazine preconditioned BM-MSCs were protected
against ROS and had higher survival than non-preconditioned, and exert enhanced
neovascularization, capillary density and cardiac function in ischemia reperfusion injury in part
through enhanced HIF-1a and Bcl-2 [778, 779].
In an in vitro setting, BM-MSCs from diabetic rats preconditioned with antioxidant Nacetylcysteine

showed

reduced

peroxisome

proliferator-activated

receptor

g,

dichlorodihydrofluorescein and nitrotyrosine (reduced ROS), greater adiponectin, greater
endothelial cell differentiation (percent CD31+), increased tubules, eNOS and phosphorylated
eNOS, and NO concentration compared to diabetic rat MSCs without preconditioning [765]. Iron
chelator deferoxamine improved survival and total antioxidant capacity of human ADSCs
secretome and increased VEGF receptor-a and angiopoietin 1 mRNA [780, 781]. Mitotempol is a
mitochondrial ROS scavenger that was used to precondition dysfunctional diabetic mouse ADSCs,
which increased their survival, differentiation potential, migration, and proangiogenic qualities in
diabetic mice with critical limb ischemia similar to control (nondiabetic) ADSCs [782].
Preconditioning with antioxidant celastrol, in combination with an injectable hydrogel scaffold, led
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to increased rat and human BM-MSC survival, VEGFA and SDF-1a expression, and neovascular
density post-implant into a scratched HUVEC wound closure culture model [783]. This
demonstrates the potential for a combination strategy with pharmacologic or other preconditioning
strategies with extracellular support systems. For more pharmacologic strategies, refer to detailed
reviews by Noronha and Miceli et al. [733, 775].

4.46: Extracellular Support
It is known that the ability of endothelial cells to adapt to varied tissue environments and
vascularize in an organotypic manner is lost after 2D culture [784]. One strategy to increase
engraftment is to administer the stem cells within an extracellular matrix designed to support the
cells. For example, hydrogels are physiochemical mimics of the 3D microenvironment that stem
cells naturally inhabit, and therefore may be more encouraging of their natural development and
therapeutic milieu. There are many types of hydrogel (natural; alginate, fibrin, collagen, chitosan,
hyaluronic acid, etc. and synthetic; polyethylene glycol, methylcellulose etc.), each with advantages
and limitations [785]. Rat BM-MSCs encapsulated in n-isopropylacrylamide thermosensitive
hydrogel further promotes angiogenesis and wound healing in diabetic foot ulcer [786]. In a
biomimetic pullulan-collagen hydrogel, murine BM-MSCs were seeded and produced greater
angiogenic cytokines (VEGF) than in standard culture and showed enhanced viability, engraftment,
and angiogenesis with accelerated healing faster than standard culture in murine excisional wound
healing model [787]. In rat critical limb ischemia, hydrogel with BM-MSCs greatly increased
capillary density, number of blood vessels, and capillary to muscle fiber ratio compared to cell
therapy or cell-free hydrogel alone [788]. A detailed review of hydrogel applications, including
advantages and disadvantages of hydrogel and cargo types for critical limb ischemia are provided
by Xing et al. [785].
Exosomes can also be loaded into hydrogels. For example, Zhang et al. used UCB-MSC
exosomes in hyaluronic acid hydrogel with nanohydroxyapatite poly-ε-caprolactone scaffolding to
repair cranial bone defects in rat in part through enhanced vascular recovery. In vitro the exosome
hydrogel contributed to enhanced proliferation, migration, and angiogeneic differentiation of
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endothelial progenitor cells, potentially via miRNA-21 upregulation of the NOTCH1/DLL4 pathway
[789]. Hydrogel microenvironments can also influence stem cell characteristics. A newly designed
poly ethylene glycol maleate citrate and β-tricalcium phosphate hydrogel (with rat BM-MSCs)
showed enhanced osteogenic and angiogenic properties in spinal fusion surgery, and the
enhanced angiogenic properties were due to effects of the biomaterial in inducing MSC-exosomal
angiogenic function [790]. One advantage of utilizing an exosome-laden hydrogel is the stable
release of exosomes over time. Injectable chitosan-graft-analine tetramer with exosomes were able
to promote angiogenesis with greater tube formation, migration and proliferation and accelerated
diabetic wound healing while also promoting M2 macrophage phenotype [791].
In a 2018 study by Jeong et al., an injectable decellularized matrix (IDM) was combined with
human ADSCs. They found that the addition of IDM reduced rates of anoikis (cell death due to loss
of extracellular matrix) and upregulated mRNA expression of angiogenic factors in vitro.
Conversely, mouse hindlimb ischemic tissue was used to compare IDM + human ADSCs treatment
to ADSCs alone and found that engraftment was enhanced in the IDM + ADSCs group. Angiogenic
paracrine expression and microvessel density were increased in the IDM + ADSCs group as well
[792]. A more recent study in 2021 found that gelatin microspheres were embedded with thymosin
b4 (Tb4), an actin-sequestering protein known to support cardiac cells and promote vasculogenesis
and cell engraftment. Tb4 has also been shown to promote cell survival in hypoxic conditions.
Treatment with human iPSC-CMs + Tb4 into induced MIs in porcine increased stem cell
engraftment and induced vasculogenesis compared to either treatment alone [793].
Spheroids are another strategy to generate a 3D environment that encourages aggregation and
cell-cell interaction that may better mimic natural conditions and self-assembling. The most
common method is the hanging drop method, where MSC are contained in droplets of determined
volume on lids carefully placed on culture plates containing media that prevents drop evaporation.
MSC in spheroids exhibit further enhanced antioxidative, anti-inflammatory, and antiapoptotic
properties such as reduced cleaved caspase-3, TNFa and enhanced catalase, HIF-1a, and
superoxide dismutase, compared to 2D monolayer culture [794]. Metanalysis of 28 studies of MSC
in spheroids shows enhanced angiogenic potential from bone marrow, adipose, and UCB-MSC
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sources across 9 of those studies (7 in vitro and 4 in vivo) to April 2019. In vitro, MSC spheroids
lead to higher expression of VEGFA, VEGFB, HGF, fibronectin, laminin, fibrinogen, tissue inhibitor
of MMP-1, MMP-2, TGFb1, FGFb, SDF-1a, HIF-1a, platelet-derived growth factor a and b, among
others [794]. However, in vivo models of wound healing (mice, AD-MSC), ischemic flap (mice, ADMSC), renal ischemia-reperfusion (rat, AD-MSC), and hindlimb ischemia (mouse, UCB-MSC)
demonstrate that MSC spheroids were associated with higher regenerative capacity for wound
closure, cell engraftment, survival, differentiation into endothelial cells, secretion of VEGF, FGF2,
intercellular adhesion molecule, vascular adhesion molecule, neuron-glial antigen 2, and HGF
along with higher angiogenesis and vascularization vs. 2D culture [794]. MSC spheroids can also
be preconditioned with hypoxia or drugs such as DMOG, which further enhance oxidative
resistance, survival, adhesion, CXC-chemokine receptor 4-homing to injury, and angiogenic
potential [795]. More comprehensive details on the role for extracellular support and biomaterials
for enhanced stem cell contribution to angiogenesis are provided by Lee and Noronha et al. [775,
796].
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Figure 10: Priming, Preconditioning, Dosing, & Administrative Strategies to Enhance Stem
Cell Potency and Effectiveness. Optimal therapeutic performance by stem cells can be elicited
via hypoxic/ROS preconditioning and preconditioning with growth factors and cytokines (1), with
genetic modification (2), with pharmacologic intervention (3), extracellular support such as
hydrogels (4), or by utilization of novel dosing (5) or administration (6) strategies. Image created
with BioRender.com

4.47: Microvessel Fragments and Heterogenous Cell Populations
Initial stem cell therapy studies used heterotypic cell populations versus homogenous cell types.
For example, experiments commonly used whole bone marrow versus specific MSC populations.
Seemingly motivated by the cell therapy potential and a reductionist approach, the studies then
detailed/focused on isolation and characterization of stem cell sub-types. The question remains
whether a heterogenous cell mixture is beneficial. The importance of this question is most
provocatively highlighted by recent use of adipose derived microvascular fragments and SVF. Both
cell populations are derived from adipose tissue and SVF can be viewed as a more digested form
of the same cell mixture. Importantly, both cell populations contain endothelial cells, smooth muscle
cells, pericytes, immune cells, stem cells and other stromal cells.
When it comes to improving engraftment to restore tissue and vascular function, one promising
line of study is co-delivery of the cells of interest with native microvessel fragments (arterioles,
venules, capillaries) harvested from fat tissue. Transplanted microvessels have potential to improve
engraftment and maturation of co-transplanted cells (e.g. human iPSC-cardiomyocytes (iPSC-CM))
by several mechanisms, including improved angiogenesis and secretion of pro-angiogenic factors,
anastomoses with host vasculature, immunomodulation (promoting M1-M2 shift in macrophage
phenotype [797]), and ability to adapt to varied host tissue environments. Of particular importance
for microvessel fragments may be the “perivascular niche”, the idea that vasculature is made up of
endothelial and smooth muscle cells, but also contains a microenvironment made of pericytes,
immune cells, and regenerative cells [798, 799]. These extravascular cells are necessary for native
microvascular function, for example, pericytes secrete hepatocyte growth factor to promote vessel
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sprouting [800]. This means that microvessels not only support co-transplanted stem cells; they
may in fact contain their own regenerative milieu of cells that encourage angiogenesis and
anastomoses, thereby increasing vascular density and perfusion. The emerging dynamics of
microvascular fragment therapy is described in greater detail by Laschke et al. and in Figure 11
[801].
Stem and immune cells that are physically associated in the vascular wall or perivascular area
of microvascular fragments such as endothelial progenitor cells and mesenchymal stromal cells
are included when delivering microvascular fragments [801-803]. Since these stem cells are
delivered in their native microenvironment with microvascular fragments, they have higher
proliferation rate and differentiation potential [804]. Microvascular fragments are most easily
isolated from adipose tissue via liposuction and limited enzymatic digestion (similar to adipose SVF
albeit with a shorter digestion time).
Separately, stromal vascular fractions and microvascular fragments have historically been used
for tissue engineered grafts. In a rat MI model, SVF on an implanted vicryl graft preserved
microvascular perfusion and heart function due to SVF engraftment into coronary microvessels
[12]. Nunes et al. found that SVF cells have angiogenic potential, incorporate into neovascular
sites, and form perfused microvascular networks that anastomose with host microvascular
fragments [805]. These SVF-derived vascular networks also form a functional interface with
parenchymal cells i.e. hepatocytes in their liver tissue mimic model. However, as mentioned above,
isolation of SVF cells eliminates donor microvascular fragments and there is argument that
utilization of microvascular fragments as a vascularization unit is more appropriate and efficacious.
Spater et al. compared adipose SVF and microvascular fragments seeded on collagenglycosaminoglycan scaffolds implanted into full thickness skin defect mouse dorsal skinfold
chambers [806]. Cellular composition (endothelial, perivascular, adipocytes, stem cells) was
comparable between SVF and microvascular fragments, albeit viability was higher in the latter with
higher microvascular density, collagen count, and better incorporation into host tissue.
Microvascular fragments/networks grafts themselves have been used in the setting of MI in mice
to improve vascularization via inosculation and improved perfusion. These transplanted
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microvascular networks inosculate with host around day 7, complete with arterioles, venules, and
capillaries containing erythrocytes culminating in reduced left ventricular infarct size and function
[807]. Considering the advantages of microvascular fragments, it is curious whether their
supplementation of cell-based therapies would be of additive benefit.
There is emerging evidence that stem cell therapy can be enhanced by co-delivery with
microvessel fragments that promote anastomosis with host vasculature, reducing ischemic
conditions when administered alongside stem cell therapy [808]. Whole microvessel inclusion is
important because it allows quicker perfusion than waiting for them to assemble and mature. In a
2020 study by Sun et al., infarcts in rats were treated with microvessels plus human iPSC-CMs,
iPSC-CMs alone, or iPSC-CMs co-transplanted with a suspension of dissociated endothelial cells
via direct injection into the heart muscle. Compared to the iPSC-CMs only group, the microvessel
plus iPSC-CMs group had significantly increased engraftment and stem cell survival as well as
increased graft vascularity. The transplanted microvessels anastomosed with host vasculature and
increased graft perfusion in the first week compared to iPSC-CM only group. The microvessels
have been shown to secrete proangiogenic paracrine factors that may be the cause of earlier and
more robust blood perfusion [808]. In addition, cardiac function was improved only in the animals
that received microvessels. Moreover, ready-made microvessel fragments allowed a 6-fold
increase in iPSC-CM survival, reduced scar size, reversed fractional shortening and ejection
fraction loss, and 2-fold increase in vascular area and graft perfusion 5-days post-transplant [809].
In the context of stem cell transplantations in type 1 diabetes, Hiscox et al. found that a
engineered mouse islets with microvessel fragments increased islet stability [810]. Very recent
research by Aghazadeh et al., 2021, used microvessels co-transplanted with pancreatic progenitor
cells into the subcutaneous space of the diabetic mice and results showed that a functional
connection formed quickly (within 1 week) leading to a significant decrease in pancreatic progenitor
cell death. The progenitor cells developed into beta cells and successfully reduced blood glucose
levels ~8 weeks after transplantation into the subcutaneous space. This study also demonstrated
that the implanted microvessels were better at connecting to host vasculature than single
endothelial cells [811].
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As adipose-derived microvessel fragments have been found to be rich in resident proangiogenic stromal and MSCs, a study more than a decade ago posed the intriguing question
whether fragments from other tissue types would display similar angiogenesis and network
formation [812]. The investigators chose the microvessel fragments of a unique and highly
differentiated tissue, brain cortex microvascular fragments (BMFs), to compare to rodent
epididymal fat microvessel fragments (FMFs). They found that the BMFs, like the FMFs, could
generate new microcirculation, indicating that the potential of microvessel fragments is not limited
to FMFs and is probably independent of the tissue source. Notably, the BMFs formed vessel
networks with higher vascular density sooner and with lower permeability [812].
These studies support that microvascular fragments provide an exciting new avenue for
regenerative medicine. This is coupled with the ease of isolation and preservation advantages (can
be cryopreserved without loss of function [813]). Microvascular fragments themselves can also be
primed, for example with erythropoietin or insulin like growth factor 1 to increase angiogenic
potential [814-816], or with other factors based on specific patient needs, such as hepatocyte
growth factor for diabetic recipients [800]. Just like stem cells, priming of microvascular fragments
from autologous aged patients may be necessary, as vascularization function wanes with aging
[817]. More focus is necessary in the field on consistent microvascular fragment isolation protocols,
specific cellular/fragment balance, advantages/disadvantages of autologous vs. allogeneic
microvascular fragment inclusion, priming conditions for microvascular fragment and stem cell cotherapy, and which combinations and in what proportions/doses are most efficient and
complimentary with various stem cell therapies.
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Figure 11: Microvascular Fragment Co-Therapeutic Strategies to Enhance Stem Cell
Potency and Effectiveness. The “perivascular niche” of microvascular fragments allows for
effective therapeutic applications in myocardial infarction to reduce scar size, induce angiogenesis,
inosculation, and perfusion, with improved cardiac performance. Furthermore, microvascular
fragments optimize stem cell therapy when delivered as a co-therapeutic [801, 807]. Image created
with BioRender.com

4.50: Dosing and Administration Strategies
4.51: What is the Ideal Dose?
Initially used to treat leukemia in the 1950’s, there are currently 4,400 active clinical trials utilizing
cell-based therapeutics [818] with 900 focused on treating cardiovascular diseases (according to a
search on February 2022 on grants.gov). One question being continually studied is the dosing
strategy for cell-based therapies due to a deficit in the regulation and standardization of cell therapy
doses. A few preclinical studies have begun testing varying doses of cells with studies ranging from
administering 1 million to 450 million MSCs to improve cardiac function in a cardiovascular disease
state in pigs and sheep [819]. Three preclinical studies using a MI model in large animals treated
with similar doses of mesenchymal cell therapies reported varying cardiac function results upon

104

follow up. Hamamoto and colleagues reported that 25 million allogeneic mesenchymal precursor
cells directly injected into the epicardium during time of infarct reduced scar size, improved end
diastolic, end systolic, and ejection fraction measures in sheep [820]. However, Hashemi et al.
administered 24 million allogeneic MSCs via catheter to infarcted region 3 days post MI in pigs
which improved only scar size [821]. Both aforementioned results are inconsistent with a study
done by Schuleri and colleagues that showed administering 20 million autologous MSCs directly
into the infarct resulted in no improvement in scar formation in a pig MI model [822]. While two of
the studies demonstrated MSCs efficacy in improving cardiac function following MI at set end
points, the therapeutic mechanism was not explored. A time-course [823] and 4-week endpoint
[824] in a rat MI model with intravenously (i.v.) injected 5x106 allogeneic BM-MSCs to examine the
mechanistic effects of MSCs in the heart. Both studies showed that i.v. administered MSCs home
to the infarcted area and increase capillary density via angiogenesis which correlated to improved
heart function [823, 824]. The varying results of favorable cardiac outcomes could be due to the
degree of dose and method of injection, as well as the source of the cells being used [819].
Unlike pharmaceuticals which can be repeatedly administered as well as at varying
concentrations; the use of cell-based therapies in clinical trials is primarily and historically been a
one-time administration, therefore the long term therapeutic potential of cell therapies needs to be
examined. A clinical trial using a one-time administration of autologous bone marrow mononuclear
cells to treat peripheral artery disease showed significant improvement in the ankle-branchial index
and increased skin ulcer healing by 6 months [825]. To further examine long-term efficacy on the
vasculature, a clinical trial utilized autologous BM-MSCs in improving coronary artery disease [826].
At a 3-year follow-up, patients receiving the cell therapy reported reduced angina and reduced
need for revascularization interventions [826]. This data suggests that cell-based therapies are not
only safe to use in patients long-term but can promote healing in tissue through angiogenesis.
However, it is naive to think that one administration of cells is enough to provide life-long therapeutic
remedy. Despite clinical trials reporting improvements long-term, there is little evidence that a
majority of administered cells persist past a few months [827]. Hong and collegues examined this
phenomenon in mice after administration of 100,000 cardiac progenitor cells into the coronaries or
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the myocardium [828]. At 35 days post administration there were approximately 1,000 cells left in
the entirety of the heart [828]. To mitigate this precipitous decline in cell retention, recent preclinical
studies have been examining the efficacy of repeated dosing strategies for cell-based therapies.
Guo and colleagues administered 0, 1, 2, or 3 intraventricular doses, 14 days apart, of 1 million
cardiac mesenchymal cells to 3-week-old MI regions in mice [829]. Mice receiving the three doses
of MSCs had improved left ventricular ejection fraction following each administration [829].
However, what if a higher dose was administered? It is important to remember that the continual
administration of autologous stem-cell therapies is restricted by the quantity available for harvest
from a patient as well as if the patient donating or receiving the cell therapy has any
pathologies/conditions that would affect the cellular therapeutic. Another important consideration is
the patients current medication intake, and how these can affect stem cell therapeutic potency and
whether dosing or administration strategies should be altered based on patient medication [830].
Finally, there is considerable variation in how proper dosing should be defined for exosome-based
therapies, such as numbers of exosomes vs. total exosomal protein or RNA content [611]. It is
crucial that accuracy and reproducibly be the driving force alongside intended therapeutic effect in
how dosing of cell and cell-based therapies are determined.

4.52 – How Should Cells Be Administered?
While the initial consensus that stem cell therapies are safe and several studies mentioned in
this review demonstrate therapeutic gains, the results can be variable, possibly due to the utilization
of different routes of administration. The most common routes are topical, intravenous, intraarterial,
intramuscular, and intralesional [704]. Intravenous administration is the most broadly studied due
to the low risk of adverse events, repeated dosing if necessary, and is easier on the patient [827].
An early study utilizing a coronary ligation MI model in mice found that i.v. administration of isogenic
MSCs 3 hours post-ischemia resulted in a reduced infarct size, improved left ventricular function,
and increased capillary density 4 weeks later [824]. These results were corroborated in a 12 weekend-point [831]. Together, these studies demonstrate that i.v. administration of a cell therapy results
in increased angiogenesis and functional improvement to an ischemic injury in as little as 28 days

106

that is sustained 12 weeks post-administration. To investigate this repeated dosing via i.v.
administration route, Hong and colleagues used a large animal MI model given a single 150 million
dose or repeated (50 million/day for 3 days) doses of human ADSCs 28 days following the ischemic
injury. Both treatment groups had improved ejection fraction, coronary flow reserve, and
angiogenesis in the peri-infarct area. However, the single dose resulted in a significant decrease
in the area of the perfusion defect [832]. Shortly after studies demonstrating that i.v. administration
of MSCs improved cardiac parameters after injury, in 2007 it was reported that the MSCs homed
to the infarcted region of the myocardium [833]. In a time-course study using a rat model of chronic
MI, it was shown that 24 hours following i.v. administration of 5x106 MSCs approximately 52% of
injected cells were retained in the lungs while less than 1% were in the heart [834]. However, no
MSCs were detected in the lungs or heart at 30 days post-injection [834]. Interestingly, despite the
same method of administration, varying degrees of cell engraftment and biodistribution have been
reported. For example, in an aged rat model, a tail vein injection of 6 million SVF cells resulted in
approximately 5% of SVF cells engrafting into the myocardium, with the largest portion being
retained in the carotid artery (approximately 50% of total nucleated cells), approximately 40 % in
the aorta, and approximately 18% in the lung 28 days post administration [11]. Importantly, with the
ever-growing evidence that intravenous administration of a cell therapy results in a majority of the
cells getting trapped in the lungs, the possibility of adverse events need to be examined. However,
it’s important to note that extensive pre-clinical and clinical trials have shown the safety of stem cell
therapies utilizing varying sources (cell type and allogeneic vs. autologous), doses, and route of
administration.
As discussed previously, the prevailing hypothesis for the therapeutic mechanism is the
paracrine or secretory hypothesis due to repeated studies reporting low engraftment with a steady
decline following administration. The biodistribution and the effect MSCs have on other organs
leading to improvements in heart function and angiogenesis have been investigated. Luger and
colleagues examined i.v. delivery of human MSCs in immunocompetent mice with acute or chronic
MI receiving the cell therapy 24 hours or 4 weeks post injury respectively [835]. In the acute MI and
chronic MI models, MSC retention in the heart was markedly low despite being measured shorty
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after administration. However, both groups showed improved left ventricular function as early as 1
week following administration of the cell therapeutic. Interestingly, the acute MI model showed a
reduction in the number of splenic natural killer cells. Normally following an MI, the natural killer
cells residing in the spleen migrate to the site of injury producing a robust pro-inflammatory
response with deleterious effects on healing and repair [836], but the supplementation of MSCs
resulted in low splenic and cardiac natural killer cell numbers over the course of the study (10
weeks) [835]. MSCs also reduced the number of splenic and cardiac neutrophils [835] which can
orchestrate a macrophage switch to a healing phenotype [837]. This phenomenon was
demonstrated by Dayan and collogues when left ventricular function was improved at 2 and 4
weeks following an administration of human UC-MSCs 48 hours after coronary artery ligation in
MOD/SCID mice, which equated to a reduced number of macrophages in the myocardium with the
remaining macrophages expressed as a pro-reparative and anti-inflammatory phenotype (M1 to
M2) [838]. The following data has been corroborated using AD-MSCs [839]. Mounting evidence
suggests that despite a wide biodistribution from intravenous cell injection, there is a beneficial
effect on organs with low engraftment (such as the heart), possibly due to cell therapy regulating
the host’s immune cells via homing in lymphoid organs such as the spleen [827].
Many studies have been developing methods in conjunction with intravenous administration to
increase cell engraftment/homing to the area of interest. A technique termed, “ultrasound targeted
microbubble destruction” (UTMD), was developed in the early 2000s and utilizes a bioactive
substance incorporated into microbubbles which can then be injected into a patient’s blood stream.
Following injection, an ultrasound wand is placed over the area of interest where the sound waves
burst the bubbles, thus promoting accumulation as a targeted therapeutic [840]. Bone marrow
mononuclear cells combined with UTMD in a rat model of ischemic hind-limb resulted in the
mononuclear cells attaching to the endothelium and increased collateral vessel development [841].
These results were mirrored in a rabbit MI model where UTMBD with BM-MSCs improved cardiac
function in the infarcted heart, specifically ejection fraction and increased the collateral circulation
[842]. In more recent years, a modified version of UTMD has arisen using superparamagnetic
nanoparticles (SPIONs) and external magnetic fields. The SPIONs have been added to AD-MSCs
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and i.v. injected to Wistar rats subjected to stroke [843]. A strong magnet was placed next to the
ischemic area for 30 minutes yielding a high initial recruitment of AD-MSCs to the brain, but
researchers reported the engrafted cells showed signs of death after 1 day [843]. Contrary to these
results, a study in a Wistar rat model of sciatic nerve damage demonstrated that i.v. injected ADMSCs with SPIONs home to the injured nerve following a 24-hour exposure to a magnetic field
[844]. At 7 days post-injection, 3.3% of administered cells still remained because cell viability and
cell differentiation ability were unaffected by the SPIONs [844]. The utilization of microbubbles or
SPIONs represent a promising advancement in the application of cell therapies to increase homing
whilst circumventing the need for direct injection/delivery. Albeit the intravenous administration of
cell therapies has been widely discussed and utilized, in recent years researchers have been
exploring other ways to deliver stem cells to patients.
The newest forms of cell administration, specifically for stromal cells isolated from adipose
tissue, have been reported in solid, liquid, and gas phases. The solid phase of administration
combines platelet poor plasma with adipose derived stromal cells to form gelatin seeded matrix
that could be advantageous in dermal applications [845]. As previously mentioned, both adiposederived stem cells and adipose-derived stromal vascular fraction cells have been combined with
collagen matrices and either injected [792] or implanted sub-dermally [806]. In both cases, the
utilization of a sold/semi-solid phase in conjunction with a cell therapy greatly increased the
angiogenic potential, microvascular density, and cellular engraftment into the host tissue [792, 806].
The stromal cells, typically in the liquid phase for most applications discussed and utilized in the
clinic, are often injected into a vein or organ. More recently, stromal cells were used in combination
with a micro-dermal roller aimed at increasing treatment penetration for improved restoration
through the layers of the skin [845]. In an animal model with a distal dermal flap developing
necrosing, microneedeling with a dermal roller significantly increased the number of new vessels
in the flap, improving viability [846]. On human patients, microneedeling was combined with
conditioned medium from human ESC cultures and resulted in improved skin pigmentation and
decreased the look of wrinkles compared to microneedeling alone; however, the sub-dermal
vascular effects of this therapy regime were not examined [847].
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Lastly, stromal cells in the liquid form have been combined with a nebulizer to deliver the
therapeutic as an aerosolized treatment. The short and long-term safety/efficacy of intranasal
administration of MSCs was examined with human MSCs administered in repeating doses to
juvenile immunodeficient mice, with no adverse events nor tumor formation reported. One hour
post intranasal administration resulted in a majority of the cells accumulating in the lungs compared
to the majority of the cells found in the stomach 1 day post-administration. Following up, cells could
not be detected in the brain, lungs, liver, heart, spleen, kidney, or stomach one week postadministration [848]. The intranasal route of administration has the added benefit of bypassing the
blood brain barrier non-invasively, and for that reason it has been utilized to administer neural stem
cells to the brain as a treatment for Parkinson’s disease [849, 850] and Alzheimer’s disease [851].
The pace of scientific community in exploring the therapeutic mechanism behind cell and cell-based
therapies combined with the novel developments in delivery and dosing strategies (Figure 4) bring
the use of stem cells, autologous or allogeneic, ever closer to a therapeutic for a wide range of
disease and pathologic states.
4.60: Future Perspectives
In consideration of designing an appropriate approach for the mediation of vascular and
microvascular regeneration, this review highlighted critical questions necessary to move the field
forward. What is the optimal therapeutic dose? How should cells be administered? What cells
should be used? How should cells be conditioned, if at all? Is there an advantage to the use of
homogenous or heterogeneous cell populations? Should cellular components (e.g. exosomes or
secreted factors) be used in lieu of cells? How do various clinical situations and presentations effect
how we answer these questions? These questions, while still completely unanswered, framed our
exploration of the field’s current state and identification of future research directions. In order to
provide quality evidence-based solutions to these questions, the field must embrace emerging
trends in scientific rigor, reproducibility, and ethics. For instance, quality control standards are only
beginning to be suggested in the field, and should be undertaken [852]. This is especially true for
cell-free studies utilizing exosomes, as standardization is needed in terms of how we define dosage
(based off of exosomal count vs. total protein content). Further comparative studies and discussion
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are needed to determine whether the advantages of exosomal therapy over stem cell therapies
warrants such a refined approach [853]. What potentially unique positive effects are we missing by
removing the cellular component? Indeed, there is emerging discussion on the benefits of
heterogeneity of using cell fractions or combined cell therapies vs. one therapy with one isolated
cell type, perhaps similar discussion is needed in the debate for cellular vs. cell-free therapies [854856]. Lastly, ensuring studies are representive of all facets of our population, including the inclusion
of proper consideration of sex and gender as a biological variable [714] are necessary so that the
answers we determine for these questions are translatable and equitable for all.
Cellular therapies represent a quickly evolving movement with exciting promise to overcome
many limitations of current clinical standards. At the same time, the field is still young and concepts
of optimal standardization in terms of which cells to use and in what situations, isolation practices,
conditions for culture and expansion, ideal donor characteristics, dosing, and administration are
not yet established. This chapter highlights the most recent trends in these areas as it relates to
vascular regeneration in an effort to take stock of the current state of the field, in hopes that future
approaches become more standardized. Although the majority of the field has moved to accept the
paracrine hypothesis as the prevailing theory for the majority of stem cell mediated vascular
regeneration, there is still relevance for the direct mechanism, such as differentiation and direct
transfer of cellular contents which should not be wholly discounted. These mechanisms can
improve vasodilative function, angiogenesis, vascular density, mitochondrial function while
reducing calcification and smooth muscle proliferation, reduce lipid and DNA oxidation, ER stress
fibrosis, senescence. There has been much debate about the merits of autologous vs. allogeneic
strategies. The most feasible answer to the debate currently is that the use of autologous or
allogeneic stem cells will likely depend on individual clinical characteristics and needs with each
strategy having appropriate clinical situations. These situations should balance ease of utilizing
reproducible large-scale manufactured cell therapies vs. cell therapies that can be more tailored to
individual patient needs, all while keeping patient health status and goals of treatment in mind. The
potential disadvantages of autologous therapy may be mitigated by advances in cell priming and
preconditioning as well as alternative dosing and administration. In all, cellular therapeutics
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rejuvenate vascular dynamics in acute and chronic pathologies in animal and human models with
wide opportunities for further optimization for individual pathologic states as well as donor and
recipient health status.
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CHAPTER 5
MATERIALS AND METHODS

5.01: Animal Model, Groups, and Endpoint Procedures
Surgeries for all animals were carried out in accordance with approved protocols from the
University of Louisville Institutional Animal Care and Use Committee and the NIH Guide for the
Care and Use of Laboratory Animals [857]. Female Fisher 344 young control (YC, 3–6-month-old,
Harlan Laboratories, Indianapolis, IN, USA) and aged (23-24-month-old, National Institute on
Aging, Bethesda, MA, USA) rats were housed in pairs and allowed free access to food and water.
Rats were accustomed to a regular 12-hour light/dark cycle and acclimated to facility environment
for at least one week prior to endpoint procedures. Aged rats were randomly divided into separate
groups, old control (OC, 24 months), old treated with bone marrow stem cells (OBM), old injected
with SVF (OSVF), or old given oral cycloastragenol (OCAG). Diet and SVF/BM-MSC injection
began/occurred at 23 months of age, with sacrifice at 24 months of age. Euthanasia was achieved
by removal of the heart under deep anesthesia (lack of tactile toe reflex and lower respiratory rate)
consisting of 5% inhaled isoflurane with 1.5-2.0 L/min O2 flow in an induction chamber.

5.02 Urine Collection and Catecholamine Analysis
Prior to endpoint procedures, a subset of YC, OC, and OSVF animals (n=6 per group) in one
cohort and OC and OCAG (n=5 and 7) in a separate cohort were individually placed in metabolic
cages with free access to food and water for overnight collection of urine (18.5 hours). Frozen
samples were sent to the University of Louisville Bioanalytical Core for mass spectrometry analysis
of excreted catecholamine levels as previously described [858]. Urine volume and catecholamine
levels were acquired at baseline and following 4-weeks (post therapy).
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5.03: Rat Bone Marrow Cell Isolation and Culture
BM-MSC were isolated from femur and tibia bones of young female and male Fischer-344 GFP+
rats (colony maintained in house) using a protocol modified from Barbash et al. [859] and Lennon
et al. [860]. Briefly, 3-4 donor animals were anesthetized deeply with 5% inhaled isoflurane
balanced with 1 L/min O2 and then euthanized via removal of the heart. Using sterile technique,
femur and tibia bones were exposed and disarticulated at the associated joints, and extraneous
muscle and tissue removed leaving only the bones of interest. Care was taken to obtain whole
intact bones from each animal. After removal of muscle and connective tissue, bones were stored
in DMEM + Penicillin/Streptomycin on ice. Bone cutters were used to remove the proximal and
distal end from each bone just below the marrow cavity. Whole bone marrow was then flushed with
10mL sterile Complete Medium (DMEM + 15% fetal bovine serum + Glutamine +
Penicillin/Streptomycin) per bone using a 10 mL syringe and 27g needle; bone marrow was
collected into a sterile 70 µm filter screen fitted onto a sterile 50 mL conical tube. After filtration,
cells were centrifuged at 1400 rpm for 8 min at room temperature and counted with a
hemocytometer. Freshly isolated BM-MSC were cultured with an initial seeding density of 7.5x107
cells per T75 culture flask in 10 mL Complete Medium; flasks were placed in a 37°C incubator with
5% CO2 for 3 days, after which medium was changed every 2-3 days until 95% confluence. Cells
were then treated with 0.25% trypsin at 37°C for 2 minutes and passaged into T75 culture flasks
(1.5x106 cells/flask). Media was changed every 2-3 days and flasks passaged at 95% confluence;
this method was repeated until cells were harvested at P3 or P4 for infusion into O+BM rats (16
O+BM rats total).

5.04: SVF Isolation and Injection
Young (3-6 mo) rats from a green-fluorescent positive (GFP+) Fischer-344 colony (original
breeders obtained from University of Missouri RRRC, strain #307, colony maintained in house)
were utilized to obtain SVF cells as described before [10-12]. In short, a 1:1 mixture of male
epididymal and female ovarian fat pads was isolated. The fat was harvested, washed, and finely
minced with subsequent digestion in 0.75 mg/mL Type 1 collagenase solution (Vitacyte,
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Indianapolis, IN, 011-1030) and 1 mg/mL DNAse (Sigma, Burlington, MA 9003-96-9) in 0.1% BSAPBS. Two centrifugation cycles at 400 rpm for 4 minutes were performed to separate and then
remove buoyant adipocytes. The SVF cell pellet was resuspended in 0.1% BSA-PBS followed by
a second centrifugation cycle for 5 minutes and removal of remaining supernatant. The cell pellet
was resuspended in 0.1% BSA-PBS once more, followed by gravity filtration through 20 µm mesh.
The final SVF solution was collected, and cells counted by hemocytometer, followed by a final
centrifugation, removal of supernatant, and resuspension in normal saline to allow for 1 mL
injections with 10 million SVF cells. The SVF-saline solution was warmed to 37°C and injected in
the tail vein of rats under isoflurane anesthesia.

5.05: Echocardiography
LV systolic and diastolic function were evaluated by transthoracic echocardiography using a
Vevo 3100 with MS250D transducer with a frequency of 13-24 MHz as previously described [11]
(FUJIFILM VisualSonics Inc., Toronto, Ontario, Canada). Briefly, rats were anesthetized and
maintained with isoflurane (induction chamber at 5% with 1.5–2.0 L/min O2 flow followed by 1.5%
with 1.5 L/min O2 flow). Rats were then placed in a supine position and the thorax was shaved.
Body temperature was maintained at 37–38°C, and heart rate was monitored using Vevo Imaging
Station. Variables that represent diastolic function - IVRT, E/A and E/e’ ratios - were obtained during
resting condition utilizing an apical four chamber view with conventional pulsed wave Doppler and
tissue Doppler. E/A ratio was calculated from the peak velocity flow in early diastole (the E wave)
to peak velocity flow in late diastole caused by atrial contraction (the A wave) during resting
conditions [11]. Results from five cardiac cycles during expiration were averaged together and used
for between-group and within-group comparisons.
In addition to the standard echocardiographic imaging of cardiac function, coronary flow reserve
measurements were obtained from modified parasternal short-axis projection was used for Doppler
recording of the LAD during rest while animals were anesthetized with 1.5% inhaled isoflurane, and
again during two cardiac stress states induced via dobutamine (20 µg/kg/min) and adenosine (140
µg/kg/min) in a random order. The tail vein was cannulated with a 27-gauge butterfly needle for
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drug administration. Dobutamine and adenosine were infused for a maximum of 5 minutes using
an automated perfusion pump (KD Scientific, Holliston, MA), with a recovery period between drugs
to allow the heart to return to baseline LAD velocity and heart rate. LAD BF velocity pre-stress and
during the stress challenge were averaged from three consecutive cardiac cycles and CFR was
calculated as the ratio of the mean peak LAD BF velocity values during each stress condition and
rest [861].

5.06: Hemodynamic Measurements
Rats were anesthetized with an intraperitoneal injection of ketamine (50 mg/kg) / xylazine
(12.5 mg/kg) / acepromazine (2.0 mg/kg) mix. Conductance readings were made for ~35–60 min
prior to harvesting heart tissue. Briefly, the rat was placed in a supine position on a 37 °C pad,
tracheotomized and connected to a ventilator to control breathing. The right carotid artery was
isolated using silk sutures. The cranial aspect of the carotid artery was ligated and a microsurgical
clip was placed on the proximal carotid artery for hemostasis. The chest cavity was opened
between the right 5th and 6th intercostal area and retracted to expose the inferior vena cava (IVC)
near the diaphragm; saline-soaked silk suture was placed under the IVC and left for later use during
occlusion measurements. An arteriotomy was performed with microsurgical scissors, and a 1.9 F
PV 6.00mm conductance catheter (Transonic, London, ON, Canada) calibrated to current
atmospheric pressure was introduced into the carotid artery. The catheter was then secured into
the carotid artery with sutures and advanced retrograde across the aortic valve into the LV;
continuous hemodynamic monitoring insured proper catheter placement in the LV. PV loops were
recorded in the steady state with the ventilator off for 8-10 seconds to reduce loop variability. The
ventilator was turned on immediately following baseline recording. After 2-3 minutes of recovery,
the ventilator was again turned off and the silk suture under the IVC was gently lifted to induce
occlusion of the IVC. Immediately following occlusion recording, catheter was removed and the
animal was humanely euthanized via vital organ removal. Data recording and analyses of both
baseline and occluded PV loops were performed using LabChart Pro software (ADInstruments,
Colorado Springs, CO). Blood pressure alone was acquired for OCAG and a subset of OC rats in
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a similar aspect, except with anesthesia from isoflurane 5% inhaled isoflurane with 1.5-2.0 L/min
O2 flow.

5.07: Heart and Subepicardial Arteriole Isolation
Hearts were isolated from each euthanized rat and coronary arterioles were dissected and
transferred to a vessel chamber pressure myography system. Each end of the vessel was attached
to a glass pipette and subjected to physiologic temperature (37°C) and pressure (45 mmHg) as
shown in Figure 12a-e. Vessels were allowed to achieve spontaneous tone of >20% constriction
from initial diameter [10-12]. Whole heart, left ventricle, total body weight, initial tone achieved, and
maximum dilation were acquired for each animal for each separate cohort.

Figure 12: Outline of Pressure Myography Methodology. Female Fisher-344 rats in five
experimental groups including young control (3-6 months old), old control (24 months old), old +
SVF or BM (OSVF or OBM, 24 months old) with SVF/BM-MSC tail vain injection (10 million cells)
one month prior to sacrifice, and old + daily CAG diet (OCAG) one month prior to sacrifice (a). At
time of sacrifice, hearts are removed and microvessels (100-200 μm) dissected and attached to
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glass pipettes of a pressure myography rig allowing flow through the vessel via a flow pump at 025 μL/minute at 37°C and 45 mmHg (physiologic pressure) (b). Vessel fluorescence or intraluminal
diameter can be tracked in real time with examples at tone (c), dilation (d) and constriction (e).

5.08: Pressure Myography with Concentration or Flow Response
The following experiments were randomized to each vessel in five separate cohort studies. For
the first cohort, concentration-response curves to isoproterenol (non-specific β-AR agonist, SigmaAldrich I6504), dobutamine (primarily a β1-receptor agonist with lower β2 activity, Sigma-Aldrich
D0676), norepinephrine (NE) (α1-, α2-, β1-, and β2-AR agonist, Sigma-Aldrich A9512), and
salbutamol (β2-AR agonist, Sigma-Aldrich S8260). Following the agonist responses, some vessels
were incubated in the β1-receptor antagonist CPG20712A (Sigma-Aldrich C231) prior to a second
concentration-response curve of isoproterenol or NE. Other vessels were incubated in the β2receptor antagonist ICI118551 (Sigma-Aldrich I127) prior to a second concentration-response
curve of isoproterenol. A third subset of vessels received both CPG20712A and ICI118551
simultaneously prior to an additional concentration-response curve of isoproterenol. A final subset
of vessels were given the beta-1 blocker atenolol (10 µM, 20 minutes) after an initial NE response
and prior to obtaining a second NE concentration response.
For the second cohort, vessels were subjected to BRL-37344 (β3-AR agonist, Sigma B169),
norepinephrine, and NE following 30 min incubation with Paroxetine HCl (NE+Parox)(GRKselective antagonist, VWR 89160-896), Sodium Fluoride (NaF)(Gs activator, Sigma-Aldrich
S6776). NE concentration response was also assessed following 20 min incubation with
CPG20712A (NE+CPG), Forskolin (AC activator, VWR 89156-986), or ICI118551. Finally,
concentration responses were obtained with dobutamine alone, dobutamine following 20 min
incubation with ICI118551 (Dob+ICI), and 8-bromo-cAMP (cAMP-dependent protein kinase
activator, VWR 89157-000).
For the third cohort, FMD and concentration responses to NE were obtained for YC, OC, and
OSVF while inhibiting either DRP-1 mediated mitochondrial fission with MDIVI (10 µM 30 min,
Tocris Bioscience 338967-87-6) or inhibiting OPA-1 mediated mitochondrial fusion with MYLS22
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(50 µM, 1 hour, Fisher Scientific 50-203-0440). Percent dilation responses for norepinephrine and
flow were plotted against mean fluorescence intensity (MFI) values for hydrogen peroxide,
peroxynitrite, superoxide, nitric oxide, glutathione, as well as mitochondrial membrane potential,
ATP, and oxygen content (described further later).
For the fourth cohort, baseline concentration-response curves were generated for each group
for dobutamine at 10-10-10-5 [M] (primary β1ADR agonist, partial β2ADR agonist, Sigma-Aldrich,
Burlington, MA D0676), isoproterenol 10-14-10-4 [M] (non-specific βADR, Sigma-Aldrich, Burlington,
MA I6504), and norepinephrine at 10-9-10-4 [M] (primary β1ADR, β2ADR, α1ADR, and α2ADR
agonist, Sigma-Aldrich, Burlington, MA A9512). Vessels were monitored for two minutes at each
concentration and diameter recorded manually using video calipers. Percent dilation was
calculated as ([intraluminal diameter at specific concentration – diameter at baseline]/[maximal
diameter – diameter at baseline]) x 100. Maximal percent dilation responses for norepinephrine
were plotted against mean fluorescence intensity (MFI) values for hydrogen peroxide, peroxynitrite,
superoxide, nitric oxide, glutathione. Once experiments were concluded, vessels were washed with
calcium-free physiologic salt solution twice for fifteen minutes each time, followed by sodium
nitroprusside (SNP, 10-4 [M] Sigma-Aldrich 13451, 2 minutes) to achieve maximum dilation. Tone
was calculated as 1-(initial diameter/maximum diameter) x 100.
Isoproterenol concentration-response curves were also generated for vessels from YC and
OSVF vessels pre-incubated for 1 hour with exogenous hydrogen peroxide (10-4 [M] Sigma-Aldrich,
Burlington, MA, 7722841) plus menadione (superoxide donor, 10-5 [M], Sigma-Aldrich, Burlington,
MA, 130-37-0) plus or minus dynasore (inhibits dynamin-mediated internalization, 1.6 µM Abcam,
120192, 1 hour) and paroxetine (GRK2 antagonist, 5 µM, VWR 89160-896, 1 hour). Additional
isoproterenol concentration-response curves were generated for OC vessels with either incubation
of dynasore, paroxetine, or SNP pre-treatment. Vessels were incubated with SNP (10-4 [M]) for one
minute, followed by a fifteen-minute wash without SNP, followed by isoproterenol concentrationresponse generation plus low-dose SNP (10-9 [M]).
Vessels from each group were incubated with inhibitors of β1ADR recycling including okadaic
acid (PP2A inhibitor, 10-9 [M], APeX Bio A4540) and BEZ235 (PI3Kγ inhibitor, 10-6 [M]
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MedChemExpress, Monmoth Junction, NJ, HY-50673), and concentration curves for isoproterenol
were generated. In separate YC and OSVF vessels, concentration curves for isoproterenol were
generated with exogenous hydrogen peroxide and menadione plus or minus BEZ235 coincubation.
Percent dilation to varied flow rates (0, 5, 10, 15, 20, 25 µL/min, 2 minutes each) were assessed
in separate vessels from each group. Following baseline FMD, flow rates were re-assessed with
addition of uric acid (peroxynitrite scavenger, 1 mM Sigma-Aldrich, Burlington, MA, 69-93-2 for 20
min), catalase (hydrogen peroxide scavenger, 500 U/ mL, Sigma-Aldrich, Burlington, MA, C4963,
1 hour), and L-NAME (eNOS inhibitor, 10-5 [M] Sigma-Aldrich, Burlington, MA, N5751 for 20 min),
separately.
For the fifth cohort, concentration responses to dobutamine (10-10-10-5 [M]) NE (10-9-10-4 [M])
and acetylcholine (10-10-10-5 [M]) were obtained for YC and OC +/- peptides that shunt telomerase
reverse transcriptase (TERT) towards the mitochondria (nucXTERT), shunt TERT towards the
nucleus (mitoXTERT), or activate TERT transcription (AGS499). The isolated vessels were
preincubated with these peptides for 12 hours in the pressure myography setup prior to
concentration response acquisition. Separately, OC Fisher-344 rats were given unrestricted access
to a diet of cycloastragenol (CAG, mixed in their normal chow), a TERT activator and expression
inducer. YC, OC, and OCAG isolated vessels were evaluated for dobutamine, norepinephrine, and
acetylcholine as above as well as flow 0-25 μL/min +/- preincubation with L-NAME, uric acid, or
PEG-catalase. Peptides were generously gifted by Dr. Andreas Beyer from the Medical College of
Wisconsin.

5.09: Pressure Myography with Fluorescence Imaging
Isolated coronary arterioles from YC, OC, OSVF, OCAG were infused with fluorescent dyes for
superoxide (Mitosox, 0.1 µM, 30 min, Invitrogen, m36008), peroxynitrite (Biotracker 515, 20 µM, 30
min, Sigma-Aldrich SCT035), hydrogen peroxide (Mitopy1, 10-5 [M], 1 hour, Tocris 1041634-69-8),
nitric oxide (2,3-diaminonapthalene (DAN), 10-4 [M], 10 minutes Alfa Aesar, 771-97-1), and
glutathione (SEMKUR-IM, 250 µM, 1 hour, ProteinMods). Mitosox, mytopy1, and DAN MFI were
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also analyzed in response to phenylephrine (10-4 [M]), isoproterenol (10-4 [M]), norepinephrine (104

[M]), salbutamol (10-4 [M]), dobutamine (10-5 [M],), and BRL (10-3 [M]). Mitosox MFI was also

analyzed in YC vs. OC in response to paroxetine (5 µM, 1 hour) and 17-DMAG (250 nM, APExBIO
A2213, 1 hour) inhibition of GRK2 and heat shock protein 90, respectively. For YC, OC, and OSVF,
additional dyes were used to assess mitochondrial function such as mitochondrial membrane
potential dye JC-1 (2 μM, 1 hour, ThermoFisher Scientific T3168), Biotracker ATP (5 uM, 1 hour,
Sigma Aldrich SCT045), and oxygen sensing dye Biotracker 520 (10 μM, 1 hour, Sigma Aldrich
SCT033). Experiments were carried out in physiologic salt solution without albumin. Flow (10 and
25 µm/min) was applied to infused vessels plus or minus either Diethyldithiocarbamic acid (DETC,
1 mM, Fisher, Hampton, NH 140-61-7, 1 hour) or 3-amino-1,2,4-triazole (AMT, 100 µM, SigmaAldrich A8506, 1 hour) with images taken after 2 minutes at each flow rate. Mean fluorescence
intensity (MFI) for each image was calculated from the average of two regions of interest (ROI) of
consistent size (20 x 100 µm) applied over the left and right vessel walls using NIS Elements AR
Analysis software (Nikon Instruments, Melville, NY, USA). For Mitosox, cobalt chloride (generates
superoxide through hypoxia-inducible factor 1, 0.5 mM, Sigma-Aldrich 15862, 1 hour) represented
positive control whereas Tiron (superoxide scavenger, 10 mM, Acros Organics 174140250, 1 hour)
represented a negative control. For Biotracker 515, menadione (10-5 [M], Sigma-Aldrich 130-37-0)
+ SNP (10-4 [M]) for 1 hour represented positive control, whereas Tiron (10 mM) + catalase (10
mM, 500 U/mL) for 1 hour represented a negative control. For Mytopy1, exogenous hydrogen
peroxide (10-4 [M], 20 minutes) represented positive control whereas catalase (500 U/mL, 1 hour)
represented a negative control. For DAN, exogenous SNP (10-4 [M], 2 minutes) represented
positive control whereas CPTiO flow (1 mM, Sigma-Aldrich, Burlington, MA, C221, 20 minutes)
represented a negative control. For JC-1, carbonyl cyanide 3-chlorophenylhydrazone (CCCP, 50
μM, 5 minutes, Sigma-Aldrich C2759) represents a negative control. For Biotracker ATP,
oligomycin (10 μM, 1 hour, Sigma-Aldrich 75351) represents the positive control whereas
camptothecin (10 μM, 1 hr, Sigma-Aldrich C9911) represents the negative control. For Biotracker
520, CoCl2 represents the positive control. Simplified illustration of ROS and the fluorescent labels,
enzyme activator/donors, and inhibitors/scavengers are summarized in Figure 13.
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Figure 13: Map Illustrating Fluorescent Labels (Blue), Activators/Donors/Positive Controls
(Green) and Inhibitors/Scavengers/Negative Controls (Red).

5.10: Immunofluorescence Staining and Western Blotting
Coronary arterioles measuring 750-1000 µm in length and <250 µm in diameter were isolated
and fixed in 2% paraformaldehyde for one hour. After fixation, vessels were washed 2 x 15 minutes
in DCF-PBS followed by 20 minutes in 0.5% Triton-X/DCF-PBS, all at room temperature with mild
rotation. Next, vessels were placed in blocking solution containing 5% donkey serum, 0.5% BSA,
and 0.5% triton X/DCF-PBS for one hour followed by incubation with primary antibodies including
β1AR (1:100 Abcam ab3442), β2AR (1:100 Abcam ab182136), β3AR (1:200 Abcam ab59685),
a1AR (1:100 Invitrogen PA1-30159), a2AR (1:100 Abcam ab3462), manganese superoxide
dismutase (MnSOD, 1:100, Novus Biologicals, NB100-1992SS), catalase (1:100 dilution, Bioss
980693W), NOX4 (1:100 Novus NB110), heat shock protein 70 (1:100 Abcam 2787), glutathione
synthetase (1:100 Novus Biologicals NBP2-75513), S-nitrosocysteine (1:100 Abcam 268288),
PP2A (1:100 Abcam 81G5), I2PP2A (1:100 Santa Cruz Biotechnologiessc-133138), and PI3ky
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(1:100 Arigo Biolaboratories ARG43246). Additionally, DRP1 (1:100 Cell Signaling Technology
D6C7), TOM20 (1:100 Abcam ab56783), MFN1 (1:100 Novus Biologicals 11E9-1H12) and MFN2
(1:100 Novus Biologicals AF7884-SP) were used in YC, OC, OSVF, and OCAG. Vessels were left
rotating at 4°C overnight. Normal rabbit serum replaced primary antibody for negative control
vessels. The following day, the vessels were washed x3 times in DCF-PBS, followed by one-hour
incubation in donkey anti-rabbit IgG Alexa Fluor 594 (1:300 Invitrogen A21207), goat anti-mouse
IgG Alexa Fluor 488 (1:300 Abcam 150113), or donkey anti-sheep Alexa Fluor 647 (1:300 Abcam,
ab150179) as appropriate in blocking solution. Nuclei were stained with DAPI (Life Technologies
R37606). Vessels were placed on slides with mounting media and coverslip, then imaged with
Olympus FV1000 confocal microscope system (Olympus America, Center Valley, PA, USA) with a
405 and 562 nm laser. The pixel density set for image capture was 1024x1024 with 2 µm Z-step
with 20X magnification, with 12 slices stacked together post-image capture. a-ARs were captured
at 40x and adrenergic receptor image slice number varied from 6-18, therefore, MFI was
normalized to the total number of slices for these images. Immunofluorescence intensity for each
antibody were quantified using the Nikon NIS Elements AR Analysis software using 20 µm x 100
µm area. ROI boxes were placed on the right and left vascular walls (endothelial + smooth muscle)
excluding cardiomyocytes with MFI averaged.
For imaging of β1AR localization, coronary microvessels were stained with RAB5 endosomal
marker (1:100, LSBio LS-B12415-300), and β1AR (1:100 Abcam ab3442). For secondary staining,
donkey anti-rabbit IgG Alexa Fluor 594 (1:300 Invitrogen A21207) and goat anti-mouse IgG Alexa
Fluor 488 (1:300 Abcam 150113) were used. Staining steps were the same as above, except with
the use of 0.1% triton X instead of 0.5% triton X. After this initial staining with antibodies,
microvessels were stained with red CellBright plasma dye (1:125, Biotium 30023) for 20 minutes
followed by three washes in PBS and mounting with PBS.
Following subepicardial arteriole isolation, hearts and aortas were flash frozen and stored for
protein isolation. Protein was isolated from 3-mm sections of hearts of the LV regions of the heart
near the apical LAD by tissue homogenization in RIPA lysis buffer, 1X protease inhibitor (Sigma
P8340), and phosphatase inhibitor solution containing 1 mM sodium orthovanadate (Sigma S6508)
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and 7.5 mM sodium fluoride (Sigma S6776). The homogenate solution incubated at 4°C with gentle
rocking for 30 min before being sonicated on ice at 40% power 3 x10 sec each. Homogenate was
then centrifuged at 4°C and 12,000 rpm for 20 min. The supernatant was transferred to new tubes
for protein concentration using BioRad DC protein assay (5000111) and a Biotek Synergy 4
spectrophotometer (Biotek Instruments, Highland Park, VT, USA). Protein stocks were sampled
and diluted 1:50 (heart) or 1:10 (aorta) prior to concentration assay. BSA (Sigma A6003) from
0.1875 to 1.5 mg/mL in RIPA was used to generate a standard curve. Loading samples were made
at 30 µg of protein in 4X Laemmli (BioRad 161-0747) and RIPA buffers then boiled at 95°C for 5
min. Samples were run on 4-20% gradient precast gels (BioRad, 4561095) at 200V for 30 min.
Gels were placed in a wet tank transfer cassette with a nitrocellulose membrane (BioRad, 1620112)
for transfer at 100V for 1 hour 20 min surrounded in ice with stir bar set to 300 rpm to ensure
uniform temperature in tank. Membranes where then blocked in a 5% BSA/1X TBS-T solution for
1 hour at RT with gentle rocking. The following primary antibodies were diluted in a 2% BSA/1X
TBS-T solution and incubated with gentle rocking at 4°C overnight to probe for: Pink1 (1:500,
Abcam #ab23707), Parkin (1:1000, Cell Signaling #2132S). Secondary anti-rabbit (Cell Signaling
7074S) HRP-conjugated antibodies were diluted in 2% BSA/1X TBS-T solution at 1:5000 for all the
blots and incubated at RT for 1 hour with gentle rocking. Chemiluminescence was performed using
BioRad’s ECL clarity max solutions (1705062) and imaged using a Chemidoc MP (BioRad,
Hercules CA, USA). Intensity of the bands was measured using ROI boxes in ImageJ (NIH). The
band intensity of the protein of interest was normalized to its GAPDH band intensity, then the mean
of this ratio was calculated by group.

5.11: RNA Sequencing
Additional coronary arterioles were allocated for RNA sequencing via flash freezing; samples
were stored at -80°C until samples from all groups were collected as done previously [862]. Six
isolated vessels were pooled from two animals in the same group for n=3 biological
replicates/group. RNA was harvested with RNAqueous Micro kit (Invitrogen, Waltham, MA,
AM1931) and quantified on a NanoDrop (ThermoFisher, Waltham MA, USA). Samples were sent
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to the University of Louisville Genomics Core for quality control analysis using the Agilent
Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA) and quantified using a Qubit
fluorometric assay (Thermo Fisher Scientific, Waltham, MA) as previously described [863]. Poly-A
enrichments, barcoding, and Illumina Next-Gen sequencing for library preparation were performed
as previously described [863, 864]. Gene transcripts were analyzed by the University of Louisville
Bioinformatics Core for differential expression analysis between group comparisons as previously
described [865].

5.12: Mitochondrial Morphometric and Colocalization Analysis
Morphometric analysis was accomplished using ImageJ and the MiNA Image-J tool utilizing
protocols modified from Durand et al, Merrill et al, Valente et al [346, 866, 867]. 60x confocal images
(with 3x optcal zoom) of microvessels stained with antibodies against mitochondrial TOM20
(described above) were analyzed in two separate cohorts. The first being YC, OC, and OCAG and
the second being YC, OC, and OSVF. In the OSVF cohort, but not the OCAG cohort, there was an
additional step in the vessel staining with Vector TrueView Autofluorescence Quenching Kit (Vector
Laboratories, SP-8400-15) before DAPI counterstaining and the denoise function was used to
reduce background noise, enhancing image quality. In the MiNA Analyze Morphology window,
radius was set to 3 under median filter, radius (sigma) and mask weight were set to 5 and .9 under
unsharp mask, and blocksize, histogram bins, and mask slope were set to 127, 256, and 3
respectively under Enhance Local Contrast. Aspect ratio and form factor (inverse of circularity)
were obtained by analyze à analyze particles setting size from .1-infinity and circularity from 0-1
and selecting “display results” and “summarize”. Mitochondrial mass was determined by analyze
à

histogram

à

list.

Mitochondrial

fission

factor

was

calculated

as

(number

of

particles/mitochondrial mass). Finally, colocalization of mitochondria (TOM20) with DRP-1 and
MFN-1 in these same images was determined using the EzColocalization protocol [868].

5.13: Statistical Analysis
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SigmaPlot 14 (Systat) was utilized for statistical analyses, with significance level set at p ≤ 0.05
for all analysis. Concentration- and flow-response curves as well as MFI evaluations were analyzed
with Two-Way Repeated Measures ANOVA with Bonferroni, Holm-Sidak, Dunn’s post hoc testing
as appropriate. RNA sequences were analyzed using Cufflinks-Cuffdiff2 with an absolute |log2FC|
≥ 1 to determine differential expression as previously described [865]. Tone acquired pre- and postinhibition were analyzed using a paired t-test for within group difference while between group
difference were analyzed using one-way ANOVA. Data are presented as means plus or minus
standard error of the means as indicated. For pressure myographic fluorescence analysis, 20% of
the data was re-analyzed by blinded inter- and intraobservers. Linear regression and Bland-Altman
Plots were generated to assess for bias in interpretation of data. For confocal images, the images
were coded and analyzed in a blind fashion with the code being broken only after all MFI
quantifications were acquired.
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CHAPTER 6
RESULTS PART 1
ENHANCED BETA-1 ADRENERGIC RECEPTOR RESPONSIVENESS IN CORONARY
ARTERIOLES FOLLOWING INTRAVENOUS STROMAL VASCULAR FRACTION THERAPY IN
AGED RATS4

6.01: Animal Characteristics and Circulating Catecholamines
To determine if systemic i.v delivery of SVF or BM-MSC affected fundamental animal
characteristics and circulating plasma catecholamine levels, gross anatomical measurements and
sampled right ventricular blood; were collected in Table 5. All aged groups (OC, O+SVF, and
O+BM) exhibited increased body weight (BW), total ventricular weight, and LV weight compared to
YC (Table 5). Although it is not significant, there are higher circulating plasma levels of
norepinephrine (NE) and epinephrine (EPI) in OC rats than in YC and O+SVF (Table 5). The O+BM
group has significantly lower NE (0.2±0.03, n=6) and EPI (0.05±0.01, n=6) levels compared to OC
(NE 3.32±0.96; EPI 2.12±0.5, n=15) (Table 5). There was no difference in plasma levels of
serotonin (5HT) between the groups. The OC (0.12±0.02, n=15) showed significantly higher
dopamine (DA) levels compared to YC (0.04±0.01, n=10) (Table 5).

4

Chapter represents a publication with minor modification from:
Rowe G; Kelm N; Beare J; Tracy E; Yaun F; LeBlanc A. Enhanced Beta-1 Adrenergic Receptor
Responsiveness in Coronary Arterioles following Intravenous Stromal Vascular Fraction Therapy
in Aged Rats. Aging. 2019 11(13) 4561-4578. doi: 10.18632/aging.102069
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Table 5: Animal Characteristics and Plasma Catecholamine Levels. Gross anatomical
measurements and catecholamine levels were measured and averaged. p < 0.05 vs YC (*), vs OC
(#), and vs OSVF ($); data are presented as means ± SEM (n) and analyzed with one-way ANOVA
followed by Bonferroni post hoc testing.

6.02: Echocardiography and Hemodynamic Measurements
To determine whether a cell therapy (SVF or BM-MSC) had any effect on cardiac parameters
in aged animals compared to control, echocardiography was performed during rest and
summarized in Table 6. OC rats exhibited a slight increase in stroke volume (SV) due to increased
LV end systolic and diastolic volumes (LVVs/d) and dimensions (LVDs/d), but ejection fraction (EF)
and CO were preserved (Table 6). The O+SVF (2.58±0.44, n=10) and O+BM (3.32±0.47, n=6)
treated groups showed a significant increase in LVDs when compared to OC (2.17±0.33, n=9,
P≤0.05) but only the SVF treated group had a significant increase in LV mass (500.49±46.39, n=10)
when compared to YC (418.92±46.44, n=10) (Table 6). Both cell treated (O+SVF and O+BM)
groups demonstrated a statistical difference when compared to YC in the following parameters:
LVDs, LVDd, LVVs, and LVVd (Table 6). The O+BM group had a significant decrease in EF and
fractional shortening (FS) when compared to YC (Table 6). Additionally, the O+BM group had
significantly reduced SV, EF, and FS compared to OC and O+SVF (Table 6).
To determine whether a cell therapy (SVF or BM-MSC) had any effect on hemodynamic
variables in aged animals compared to control, PV loop experiments were performed and
summarized in Table 6. There were no significant differences regarding a majority of the PV loop
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measurements. This is likely due to the differential anesthetic effects of ketamine used for the PV
loop measurements (ketamine is a known cardiac depressor [869]) vs. isoflurane used during
echocardiography. During periods of vena cava occlusion, preload recruitable stroke work (PRSW)
was measured as an index of myocardial contractility. The O+BM (569.06±149.59, n=6) group
showed a significant loss in PRSW when compared to YC (-2127.74±865.62, n=13) (Table 6).
Notably, there were no differences in PRSW between the O+SVF (-1111.31±305.77, n =12) treated
group and YC (-2127.74±865.62, n=13).
In order to evaluate the ability of the heart to respond to a stressor, Doppler recordings of peak
left anterior descending (LAD) artery BF velocity were measured during a dobutamine or an
adenosine infusion i.e., the Coronary Flow Reserve (CFR) (Figure 14A and 1B). The OC
(1.77±0.4, n=9) group had diminished dobutamine-induced CFR compared to YC (2.31±0.36,
n=10) (Figure 14A). Treatment with SVF therapy (O+SVF) significantly improved dobutamine(2.7±0.68, n=10) and adenosine- (2.6±0.41, n=10) induced CFR when compared to OC
(dobutamine 1.77±0.4; adenosine 1.61±0.26, n=9), achieving levels similar to YC (dobutamine
2.31±0.36; adenosine 2.08±0.55, n=10) (Figure 14A and 1B). Adenosine-induced CFR was
significantly lower in the O+BM (2.27±0.27, n=6) group when compared to O+SVF treated, but was
still significantly higher than OC (Figure 14B).
Echocardiographic measures of diastolic function are displayed in Figure 15, including
isovolumic relaxation time (IVRT), E/A ratio – representing the ratio of peak velocity of blood flow
from gravity in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial
contraction (the A wave) – and E/e’ – representing the ratio of mitral peak velocity of early filling (E)
to early diastolic mitral annular velocity (e'). All measures showed an age-related deterioration in
diastolic function when compared to YC (Figure 15A-D). The O+SVF treated rats showed a
statistically significant improvement in E/A and E/e’ ratios when compared to OC (Figure 15B and
2C). The O+BM group was similar to OC in that it had significantly decreased E/A and E/e’ ratios
as compared to YC, and E/A when compared to O+SVF (Figure 15B and 2C). There is a significant
increase in the time constant of left ventricular relaxation measured by PV relationship (tau) when
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comparing OC (19.16±0.83, n=16) and O+BM (19.01±0.74, n=6) to YC (15.61±0.48, n=13) (Figure
15D).

Table 6: Summary of Cardiac Functional Parameters. Data are presented as means ± SEM,
analyzed with one-way ANOVA followed by post hoc test where appropriate. ≤ 0.05 vs Young
Control (*), vs Old Control (#), and vs Old + SVF ($)
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Figure 14: Coronary Flow Reserve Using Doppler Echocardiography in Rats. Stress test was
performed on experimental groups using dobutamine (A) or adenosine (B) and CFR was
calculated. O+SVF group exhibited increased CFR vs. OC in both adenosine and dobutamine
conditions. P≤0.05 vs Young Control (*), vs Old Control (#), and vs Old+ SVF ($); Data are
presented as means ± SD, analyzed with one-way ANOVA followed by post-hoc Dunn’s (A) or
Holm-Sidak (B) test.
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Figure 15: Diastolic function assessment using echocardiography and pressure- volume
loop (PV-loop). Compared to YC rats, there was an age-related deterioration in diastolic function
as measured via echocardiography by IVRT (A), E/A ratio (B), E/e’ ratio (C), and hemodynamically
by Tau (D). Old rats treated with SVF significantly reversed this dysfunction in measures of E/A
ratio (B) and E/e’ ratio (C) compared to OC and normalized diastolic function to YC levels in IVRT
(A) and Tau (D). P≤0.05 vs Young Control (*), vs Old Control (#), and vs Old+SVF ($); Data are
presented as means±SD, analyzed with one-way ANOVA followed by post-hoc Holm-Sidak (B, D)
or Dunn’s (A,C) test.

6.03: Subepicardial Arteriole Isolation Experiments
Arterioles under 150 µm in luminal diameter from the LAD distribution were dissected and
isolated to assess whether cell therapy or adrenergic inhibition altered basic vessel characteristics
such as spontaneous tone. Neither age (OC) nor a cell therapy (O+SVF and O+BM) significantly
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altered the maximum dimeter or average spontaneous tone reached (Table 7). Average tone after
incubation with ICI118551, CPG20712A, or both ICI118551+CPG20712A was not significantly
different between the groups or when compared to pre-inhibition (Table 7). β-AR agonists and
antagonists were used to assess if cell therapy altered microvascular reactivity to adrenergic
stimuli.
Dobutamine (β1-AR) and salbutamol (β2-AR) were used to examine if cell therapy alters β1(dobutamine) or β2-AR (salbutamol) responsiveness; data is represented in Figures 16 A and B.
At the highest concentrations (1e-6 and 1e-5 [M]), vasorelaxation to dobutamine is significantly lower
with age (OC) and in the O+BM group when compared to YC. At concentration 1e-6 [M], O+SVF
(26.96±4.7,n=11) vasorelaxation is significantly higher when compared to O+BM (6.98±2.74, n=6)
(Figure 16 A). There is no difference between the groups at any dose of salbutamol; however, it is
worth noting that the O+SVF group had a larger relaxation response at every dose compared to
the other groups (Figure 16B).
Isoproterenol (non-selective β-AR agonist) alone or combined with a β1- or β2-AR antagonist
(or both) was used to examine whether receptor activity pre- and post-inhibition is altered with age,
and if receptor activity is restored with cell treatment; this data is summarized in Figures 17 A-D.
The complete concentration response of isoproterenol-induced relaxation in O+BM is significantly
lower when compared to O+SVF (P≤0.005) (Figure 17A). Pre-incubation with ICI118551 (a β2-AR
antagonist) revealed no difference between the groups. There is a statistically significant reduction
in isoproterenol relaxation after inhibition with ICI118551 when compared to the uninhibited
isoproterenol dose response for the YC, O+SVF, and O+BM groups at various doses (^) (Figure
17B). Preincubation with CPG20712A (β1-AR antagonist) revealed no difference between the
groups (Figure 17C), but there was a significant attenuation of the 1e-8 [M] response in YC and
O+SVF compared to their isoproterenol response (^). For concentrations 1e-7 through 1e-4 [M], all
four groups showed a significant attenuation in relaxation when compared to their corresponding
pre-inhibitor isoproterenol concentration response (^) (Figure 17C). Figure 17D used both
ICI118551 and CPG20712A to show potential β3-AR activity. There was no difference between the
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groups, and every group showed a significant attenuation in relaxation when compared to the
corresponding isoproterenol concentration response (^) (Figure 17D).
Norepinephrine (β1-, β2-, a1-, a2-AR agonist) and the β1-AR antagonist CPG20712A were
used to show vasoreactivity to a circulating catecholamine; data is represented in Figures 18 A
and B. NE-induced relaxation is significantly decreased in the OC group compared to YC and
O+SVF (Figure 18A). It is notable that there is no difference between YC and the O+SVF groups.
When CPG20712A was used to attenuate NE-induced relaxation, there was a significant reduction
in relaxation post-inhibition at concentrations 3e-7 through 1e-4 [M] for YC and O+BM (^) (Figure
18B). Atenolol, a clinically indicated beta-1 blocker for CMD, significantly attenuated NE-induced
relaxation in YC from 3x10-7 through 10-4 [M] (p = .017 for 3x10-7, < .001 remaining doses), with no
significant reduction in OC, and significantly attenuated NE-induced relaxation in OSVF from 3x106

through 10-4 [M] (p = .006, <.01, <.01, <.01, .05, .012)(Figure 19a-c).

Table 7: Isolated Vessel Characteristics. Luminal diameters were measured. Tone was
calculated as a percent of the maximum diameter for pre- and post-incubation with an inhibitor. P ≤
0.05 vs Young Control (*), vs Old Control (#), and vs Old + SVF ($); data are presented as means
± SEM (n) and analyzed with paired t-tests for within group difference while between group
difference were analyzed using one-way ANOVA
Isolated Vessel
Characteristics
Maximum Diameter
Average % Tone
Average % Tone after
Incubation with
ICI118551 (n)
Average % Tone after
Incubation with
CPG207212A (n)
Average % Tone after
Incubation with
ICI118551 +
CPG207212A (n)

YC (n=31)

OC (n=38)

O+SVF (n=32)

O+BM (n=16)

141.1±5.99
28.77±5.51
25.43±1.2
(5)

144.97±4.61
29.59±1.19
31.05±2.94
(7)

144.56±4.62
30.1±1.73
27.04±2.69
(8)

151.19±11.4
25.87±1.83
29.45±15.57 (4)

26.94±2.26
(9)

29.52±1.97
(14)

34.25±3.59
(9)

38.42±4.05
(6)

27.86±1.7
(9)

27.24±2.22
(9)

32.78±4.47
(6)

30.78±11.68 (5)
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Figure 16: Isolated Coronary Arteriolar Vasoreactivity to b1AR and b2AR Agonists.
Dobutamine, primarily a b1-AR agonist, induced vasorelaxation in all groups (A). Coronary
arterioles from YC animals exhibited a significantly greater dilation compared to OC and O+BM at
concentrations 1e-6 and 1e-5 [M] (*) (A). Salbutamol, a b2-AR agonist, induced mild vasorelaxation
that was similar between all the groups (B). P≤0.05 vs Young Control (*), vs Old Control (#), and
vs Old + SVF ($); data are presented as means ± SEM and analyzed with two-way repeated
measures ANOVA followed by post-hoc Bonferroni test.
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Figure 17: Contribution of b1AR and b2AR to Isoproterenol-induced Vasodilation from
Isolated Coronary Arterioles. Vasorelaxation to isoproterenol, primarily a non-selective b1-, b2-,
and b3-AR agonist, was significantly impaired in the O+BM group compared to O+SVF ($) (A).
Isoproterenol with ICI118551, a b2-AR antagonist, eliminated differences between the groups.
Compared to pre-incubation, all groups except OC (YC, O+SVF, and O+BM) had significant
attenuation in the inhibited dose response (^) at several concentrations (B). Isoproterenol with
CPG20712A, a b1-AR antagonist, also eliminated differences between the groups, and all groups
exhibited significant attenuation in the response compared to pre-inhibition (^) (C). No group
differences to isoproterenol were noted following inhibition with both ICI118551 and CPG20712A,
and all groups exhibited significant attenuation in the response compared to pre-inhibition (^) at
every concentration (D). P ≤ 0.05 vs Young Control (*), vs Old Control (#), vs Old+SVF, and prevs post-inhibition (^); data are presented as means±SEM and analyzed with two-way repeated
measures ANOVA, paired for inhibitor analysis, followed by post-hoc Bonferroni test.
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Figure 18: Contribution of b2AR to Norepinephrine-Induced Vasoreactivity in Isolated
Coronary Arterioles. Relaxation to NE was significantly impaired in OC animals compared to YC
and O+SVF groups at all concentrations (A). NE with CPG20712A, a b1-AR antagonist, attenuated
(^) the majority of the vasodilation response (3e-7 – 1e-4 [M]) in YC and O+BM treated groups (B).
P≤0.05 vs Young Control (*), vs Old Control (#), vs Old + SVF ($), and pre- vs post-inhibition (^);
data are presented as means ± SEM and analyzed with two-way repeated measures ANOVA,
paired for inhibitor analysis, followed by post-hoc Bonferroni test.
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Figure 19: Effect of b1-Blocker Atenolol on Dilation to Norepinephrine. Beta-blockers such
as atenolol (beta 1 blocker) is clinically indicated first-line pharmacotherapy for CMD. Atenolol (10
μM) significantly reduces YC (a) but not OC (b) dilation to norepinephrine, with significant reduction
in OSVF (c). Significance as p < .05 with Student’s t-test at each dose.
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CHAPTER 7
RESULTS PART 2
CELL THERAPY RESCUES AGING-INDUCED BETA-1 ADRENERGIC RECEPTOR AND GRK2
DYSFUNCTION IN THE CORONARY MICROCIRCULATION5
7.01: Animal Characteristics and Catecholamine Metabolism
To determine if systemic i.v. delivery of SVF altered animal characteristics and/or excreted
catecholamines in the urine, we collected gross anatomical characteristics and sampled urine from
overnight collection chambers; these data are presented in Table 8. All aged groups exhibited
increased body weight (BW), total ventricular weight, and left ventricular (LV) weight when
compared to YC animals (Table 8). With aging (OC, 138.31±10.09 ng/mg creatinine, n=6),
significantly higher levels of NE excreted in the urine were observed when compared to young
animals (YC, 76.53±7.84 ng/mg creatinine, n=6); this was not reversed by SVF treatment
(O+SVF,151.02±14.96 ng/mg creatinine, n=6) (Table 8). In contrast, there were no age-related or
group differences in urine levels of epinephrine (Epi), serotonin (5HT), dopamine (DA), or a
metabolite of serotonin (5-HIAA) between the groups (Table 8).

Table 8: Animal Characteristics and Urine Catecholamine Levels. Gross anatomical
measurements and catecholamines levels in the urine from overnight collection were measured
and one-way ANOVAs followed by Bonferroni post hoc testing. Urine catecholamine levels were
normalized to mg creatinine. Data are presented as means±SEM (n), p < .05 vs. YC (*).

5

Chapter represents a publication with minor modification from:
Rowe G, Tracy E, Beare J, LeBlanc A. Cell Therapy Rescues Aging-Induced Beta-1 Adrenergic
Receptor and GRK2 Dysfunction in the Coronary Microcirculation. Geroscience.
https://doi.org/10.1007/s11357-021-00455-6
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7.02: Microvascular Expression and Function of Adrenergic Receptors
To assess changes to the populations of all the adrenergic receptors (β1-3 ADRs and a12 ADRs) within coronary microvessels with advancing age or following SVF administration,
immunofluorescence was performed on a subset of microvessels isolated from explanted hearts.
Images from each group were used to analyze the fluorescence intensity measured on the
endothelial/smooth muscle cell layer of each microvessel (Figure 19a-b), and quantification of β13 ADRs or a1-2 ADRs fluorescence is shown in Figure 19c. There was a significant decrease in
the β1ADR with age, but the β1ADR receptor expression is restored to young levels following SVF
cell therapy (p£.05, n=9/group, Figure 19c). No other group differences were observed in β2-3
ADRs or a1-2 ADRs.
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Figure

19:

Immunofluorescent

Detection

of

Adrenergic

Receptors

in

Coronary

Microvessels. In coronary microvessels, the β1ADR is significantly reduced in aging and reversed
to youthful levels by SVF therapy as measured by Mean Fluorescence Intensity (arbitrary units)
while β2-3 ADRs and α1-2 ADRs remain unchanged (a-c). AMIRA 3D reconstruction of
microvessels shown in (b) for β1-2. Data is presented as means±SEM, n values in parentheses for
each corresponding bar from left to right, and significance determined by One-Way ANOVA with
Bonferroni post hoc testing, p£.05 vs. YC (*) and vs. OC (#). ROI boxes are 10x100 µm. Scale bar
equals 100 µm for the βADR panels and 50 µm α-AR panels.

7.03: Isolated Subepicardial Vessel Characteristics and β1-3-AR Mediated Vasodilation
Arterioles under 150 μm in luminal diameter from the LAD distribution were dissected and
isolated to assess whether cell therapy or adrenergic inhibition altered basic vessel characteristics
such as spontaneous tone. Aged groups (OC, 16.50 ±0.73 µm, n=50 and O+SVF, 15.67±0.96 µm,
n=27) had increased wall thickness compared to microvessels isolated from young animals (YC,
12.02±0.56 µm, n=40) (Table 9). Maximum diameter (Dmax) achieved was significantly higher in
OC vessels (154.35±3.61 µm, n=55) when compared to YC (137.6±3.51 µm, n=42) and O+SVF
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cell therapy (140±4.3 µm, n=31) (Table 9). Spontaneous tone at the beginning of the experiment,
post-GRK2 inhibition with Paroxetine HCl, post-β1ADR inhibition with CPG20712A, and postβ2ADR inhibition with ICI118551 exhibited no significant differences among the groups (Table 9).
The adrenergic agonist NE and β1ADR antagonist CPG20712A were used to show β1ADR
contribution to vasoreactivity via pressure myography; data is represented in Figures 20a-c.
Following CPG20712A incubation, there was a significant attenuation of NE-induced relaxation
when compared to pre-inhibition at doses 1e-6 - 1e-4 [M] for all groups (Figure 20a-c). Similarly, NE
or dobutamine alongside β2ADR antagonist ICI118551 shows non-significantly attenuated dilation
except for dobutamine + ICI118551 at 10-5-10-4 [M] (Figure 21a-c and Figure 22a-c). There was
a slight but non-significant decrease in dilation to β3ADR agonist BRL-37344 in OC and OSVF
compared to YC (Figure 23).

Table 9: Isolated Vessel Characteristics. Luminal diameters were measured. Tone was
calculated as a percent of the maximum diameter for pre- and post-incubation with an inhibitor.
Data are presented as means ± SEM (n) and significance determined by One-Way ANOVA
followed by post hoc tests where appropriate. p < .05 vs. YC (*) and vs. OC (#).
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Figure 20: Contribution of b1ADR to NE-Induced Vasorelaxation in Isolated Coronary
Microvessels. NE-mediated vasorelaxation is significantly attenuated by β1ADR inhibition with
CPG20712A at 1e-6 to 1e-4 [M] doses in YC (a), OC (b), and O+SVF (c). Data are matched pre- to
post-inhibition and presented as means±SEM. Significance determined by Two-Way Repeated
Measures ANOVA with Bonferroni post hoc analysis. p < .05 when pre- vs. post-inhibition (*).

143

Figure 21: Contribution of the β2ADR to NE-mediated Vasodilation. Using pressure
myography, isolated coronary microvessels from YC, OC, and O+SVF animals were subjected to
βADR agonism with NE with and without the β2ADR inhibitor ICI118551 (a-c). Data are presented
as means±SEM. Significance defined by paired pre- to post-inhibition for analysis using Two-Way
Repeated Measures ANOVA with Bonferroni post hoc testing. p < 05 pre- vs. post-inhibition (*).

144

Figure 22: Contribution of the β2ADR to Dobutamine-mediated Vasodilation. Using pressure
myography, isolated coronary microvessels from YC, OC, and O+SVF animals were subjected to
βADR agonism with dobutamine with and without the β2ADR inhibitor ICI118551 (d-f). Data are
presented as means±SEM. Significance defined by paired pre- to post-inhibition for analysis using
Two-Way Repeated Measures ANOVA with Bonferroni post hoc testing. p <.05 pre- vs. postinhibition (*).
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Figure 23: Contribution of the β3 Adrenergic Receptor to Adrenergic-Dependent
Vasodilation. BRL-37344, a β3ADR agonist were added in a dose-dependent manor to isolated
coronary microvessels from YC, OC, and O+SVF animals via pressure myography. Data presented
as means±SEM. Significance determined as p <.05 when vs. YC (*) and vs. OC (#) utilizing TwoWay Repeated Measures ANOVA with Bonferroni post hoc analysis.

7.04: GRK2, Gs, and Adenylate Cyclase Function in Coronary Microvessels
To examine if age or SVF cell therapy alters functionality of GRK2 in coronary microvessels,
pressure myography studies was performed (Figure 24a-c). There was no significant difference in
the vasorelaxation of YC vessels to NE following GRK2 inhibition with Paroxetine HCl compared to
the pre-inhibition response, but both the OC and O+SVF exhibited significant increases in
vasorelaxation response to NE at lower doses when compared to pre-inhibition response curves
(Figure 24a-c).
To determine if age or SVF therapy modifies intracellular transduction and/or second messenger
proteins of the β1ADR signaling cascade, pressure myography experiments were performed. Using
pressure myography on isolated coronary microvessels and direct Gs activation with NaF, O+SVF
exhibited significantly reduced relaxation when compared to YC and OC at low doses, which
reversed at the highest dose (Figure 25a). Using Forskolin on isolated vessels via pressure
myography, there were no differences between the groups when AC was directly activated (Figure
25b). Donation of cAMP with 8-bromo-cAMP did not yield differences between groups, and did not
dilate vessels, instead leading to mild constriction (Figure 25c).
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Figure 24: Function of GRK2 in Microvessels. Pressure myography with NE-mediated
vasorelaxation before and after exogenous inhibition of GRK2 with Paroxetine HCl. NE-mediated
vasorelaxation is improved by GRK2 inhibition with Paroxetine HCl in OC (1e-8 to 1e-6 [M]) (b) and
O+SVF (1e-9 to 1e-7 [M]) (c) while vessels from YC are unaffected (a). Data are presented as
means±SEM. Significance defined by paired pre- to post-inhibition for analysis using Two-Way
Repeated Measures ANOVA with Bonferroni post hoc testing. p£.05 pre- vs. post-inhibition (*).

147

Figure 25: Intracellular G-proteins, Adenylate Cyclase, and cAMP Contribution to
Microvascular Adrenergic Signaling. Activation of Gs with sodium fluoride leads to vasorelaxation
in a dose-dependent manner which is significantly different in O+SVF treated vessels compared to
YC (1e-6 to 1e-2 [M] (*)) and OC (1e-5 to 1e-3 [M] (#)) (a). Activation of AC with forskolin leads to
concentration-dependent vasodilation that is similar between all groups (b). Direct donation of cAMP
with 8-Bromo-cAMP did not yield differences between groups (c). Data presented as means±SEM.
Significance determined as p£.05 when vs. YC (*) and vs. OC (#) utilizing Two-Way Repeated
Measures ANOVA with Bonferroni post hoc analysis.

7.05: Next-Gen RNA Sequencing
RNA sequencing was performed on isolated coronary microvessels, and transcripts
identified for adrenergic signaling and catecholamine processing; these data are represented in a
heat map (Figure 26). Catecholamine degradation enzyme monoamine oxidase A was significantly

148

increased with aging (log2FC(YC/OC) =-0.45, p<.001) but not reversed by SVF therapy
(log2FC(OC/O+SVF) =-.24, p=.16). However, there is reduced expression of catechol-omethyltransferase (responsible for catecholamine degradation) in O+SVF when compared old
(log2FC(OC/O+SVF) =.22, p=.046). There was a significant increase in transcription of the β2ADR
in O+SVF vs. OC (log2FC(OC/O+SVF)=.43, p =.03) with no significant differences between groups
for β1- and β3ADRs or a1-2 ADRs (Figure 26). Transcription of GRK2 or GRKs 4-6 was not
different between YC and OC (log2FC(YC/OC) =-0.08, p=.57) (Figure 26). Analysis revealed
inhibitory G-protein subunit ao1 (Gnao1) was increased in aging compared to youth
(log2FC(YC/OC)=-0.41, p=.024). There was no significant difference in Gnao1 between YC vs.
O+SVF. G-protein subunit ai2 (Gnai2) trended towards significance with aging relative to young
(log2FC(YC/OC)=-0.17, p=.054). In addition, positive regulation of GTPase activity due to small Gprotein signaling modulator 2 (Sgsm2) was downregulated with aging (log2FC(YC/OC)=.34,
p=.054). There was no significant difference between O+SVF vs. YC or vs. OC for Gnai2 or Sgsm2
(Figure 26). However, AC isoform 6 (AC6) was significantly downregulated in aging compared to
youth (log2FC(YC/OC) =.28, p=.016). AC6 expression was not restored to youthful levels following
SVF therapy (log2FC(YC/O+SVF) =.43 p<.001) (Figure 26). RNAseq analysis revealed a
significant increase in beta-arrestin 2 with aging compared to young (log2FC(YC/OC) =-0.47, p=.02)
but no change in beta-arrestin 1 (log2FC(YC/OC) =.119, p=.55). Beta-arrestin 2 was not
significantly different in O+SVF vs. YC or vs. OC. Related to beta-arrestin, the alpha-arrestin
arrestin domain-containing protein 3 (arrdc3) was significantly reduced by 30.3% in SVF vs. OC
(log2FC(YC/OC) =.382, p=.057). On the other hand, dynamin (responsible for endocytosis in
concert with beta-arrestin) was upregulated in O+SVF vs. old, but not young (log2FC(OC/O+SVF)
=-0.46, p=.022) (Figure 26). A summary for the results in this cohort study are illustrated in Figure
27.
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Figure 26: RNA Heat Map Relevant to Adrenergic
Signaling. Heat map representing color-coded RNA
expression levels of differentially expressed genes
involved in adrenergic signaling and receptor
recycling in isolated coronary microvessels from YC,
OC, and O+SVF samples. In total, 119 genes are
listed. Significance defined as cuffdiff and DESeq2
for cutoff p<.05. For full list of significantly
upregulated genes, please see [45]
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Figure 27: Summary of Adrenergic Signaling with Aging and SVF Therapy. In aging coronary
microvessels, there is a decrease in the β1ADR populations and vasodilation to β1ADR agonists
is reduced. Adrenergic signaling is inhibited through GRK2 and Gai proteins which are significantly
increased in the aged myocardium and marginally increased in coronary microvessels. SVF cell
therapy restores some vasodilatory capacity via rescuing β1ADR populations through posttranslational modifications of GRK2 and the receptor recycling proteins beta-arrestins, as well as
diminution in Gai proteins. Green text represents activators whereas red text represents inhibitors.
The thicker arrow pointing from NE to the βADRs indicates higher antagonism toward β1DAR
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compared to β2ADR. Solid black arrows indicate positive effects of cell signaling while dashed lines
indicate negative or inhibitory effects. A key and a summary of findings are shown below. Note,
part of the data supporting these findings (GKR2, Beta-arrestin, Ginhibitory and Gstimulatory) come from
Western blot (of cardiac tissue) and immunofluorescence (coronary microvessels) data obtained
by co-graduate student Ms. Gabrielle Rowe. These have been omitted in this dissertation since I
did not contribute to these particular experiments, but it can be found in our co-authored manuscript
[45]. Image created with BioRender.com.
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CHAPTER 8
RESULTS PART 3
STROMAL VASCULAR FRACTION REVERSES MITOCHONDRIAL DYSFUNCTION IN AGED
CORONARY MICROVESSELS

8.01: Animal and Vessel Characteristics
In this cohort of rats, there were no significant differences between groups for vessel wall
thickness, maximum diameter, or average percent tone (Table 10). Body weight was significantly
increased in OC and OSVF vs. YC (p < .001, <.001). There were also significant differences in total
ventricular weight (p < .001, < .001) and left ventricular weight (p < .001, < .001). The right ventricle
was weighed significantly more in OC vs. YC (p = .008) with no difference between YC vs. OSVF
or OC vs. OSVF.

Table 10: Animal & Vessel Characteristics. Significance as p < .05 via One-Way ANOVA with
Bonferroni post hoc analysis. * = YC vs. OC; # = OSVF vs. YC.
Animal & Vessel
Characteristics
Average Age (months)
Body Weight (g)
Total Ventricular Weight
(mg)
LV Weight (+ Septum) (mg)
RV Weight (mg)
Vessel Wall Thickness (μm)
Maximum Diameter
Average % Tone

YC (n=8)

OC (n=9)

OSVF (n=6)

5.6 +/- .26
181.63 +/- 2.34 *
444.04 +/- 33.08 *

24.8 +/- .10
252.5 +/- 7.80
658.8 +/- 15.20

24.3 +/- .20
252.7 +/- 9.50 #
670 +/- 30.0 #

373.71 +/- 13.22 *
91.2 +/- 8.23 *
12.56 +/- .90
112.25 +/- 3.78
31.01 +/- 3.31

540.2 +/- 10.10
145.56 +/- 11.70
13.15 +/- .50
134.4 +/- 5.70
30.13 +/- 3.00

491.0 +/- 35.60 #
125.2 +/- 16.0
13.72 +/- .69
143.2 +/- 18.10
27.74 +/- 4.38
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8.02: Aging Induces Hyperfission-linked Gene and Protein Expression, Reversed by SVF
There were also significant differences in pathways concerning mitochondrial fission and fusion,
but not mitophagy. Protein expression (immunofluorescence) of fission inducer DRP-1 was
significantly upregulated with aging (p = 0.007), reversed to youthful levels by SVF (p = 0.033)
(Figure 28a). There were no aging-related differences in protein expression of fusion mediators
MFN-1 or MFN-2, however, SVF lead to significantly enhanced MFN-1 protein expression (YC vs.
OSVF p = 0.003, OC vs. OSVF p < .001). Mitochondrial density marker Tom20 was nonsignificantly
reduced in aging, reversed by SVF (p = .062). Notably, gene expression of DRP-1 is reduced in
OSVF vs. old by 33.5% (p=.035) (Figure 28b). Mitochondrial fission protein 1 (Fis1) genetic
expression was nearly significantly upregulated with aging by 15% (p = .09) with no difference
between YC and OSVF or OSVF vs. OC. On the other hand, mitochondrial fission process 1 (mtfp1)
was upregulated in OSVF vs OC (p = .019) by 27.3%, with no difference between young and old.
On the contrary, MFN1 gene expression was decreased in aging by 33.5% (p = .013) and was
elevated in OSVF vs. OC by 27.3% (p=.019). There were no genetic differences between groups
for MFN2. Uncoupling protein 2 (Ucp2) was increased 20.5% with aging (p=.042), indicative of loss
of mitochondrial membrane potential and superoxide leak. Ucp2 continued to be upregulated in
OSVF vs. YC (by 25.8%, p = .008). There were no genetic differences between groups for fusion
mediator Opa1. There was 22.5% more expression of peroxisome proliferator-activated receptor
gamma, coactivator-related 1 (Pprc1) in aging vs. young (p = .043), which is involved in regulation
of mitochondrial biogenesis. There was no difference in Pprc1 in YC vs. OSVF or OSVF vs. OC.
There were additional genetic alterations with aging associated with mitochondrial function.
Mitochondrial pyruvate carrier 1 and 2 (MPC1, 2) was decreased by 29.4 and 30% in aging (p =
.019 and .044). SVF enhanced mitochondrial pyruvate carrier 1 and 2 by 18.9% and 20% vs. OC
(p = .057 and .086). Bcl2-associated athanogene 2 (antiapoptotic, mitochondrial location) was
significantly decreased by 33.2% in aging (p = .04). Along the lines of apoptosis, caspase 12 was
increased by 29.6% in aging (p = .009).
NADH:ubiquinone oxidoreductase core subunit V2 (Ndufv2), indicative of mitochondrial
complex 1 function, was reduced by 22% with aging (p = .41). In OSVF, while there was no
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difference in Ndufv2, NADH:ubiquinone oxidoreductase subunit A10 (Ndufa10), also indicative or
mitochondrial complex 1 function, was nearly significantly upregulated 15.4% vs. aging (p = .10).
Associated coenzyme 10A (CoQ10a, itself an antioxidant) was nearly significantly enhanced by
SVF therapy (20.1%, p = .077) with no difference between YC and OC. Coenzyme Q2
polyprenyltransferase (CoQ2) was increased 20.5% in OC vs. YC (p = .045). Ubiquinol-cytochrome
c reductase complex assembly factor 1 and 2 (Uqcc1 and Uqcc2, assembly factors for Complex
III), were not different in YC vs. OC, but was 19.1 and 16.6% upregulated in OSVF vs. OC (p =
.068 and .058). Cytochrome c oxidase assembly factor 20 (COX20), necessary for the assembly
of mitochondrial complex IV was reduced by 40% in aging (p = .002) but was increased by 31.6%
in YC vs. OSVF (p = .012) with no significant difference between OSVF and OC. Similarly,
cytochrome c oxidase subunit 7b (COX7b) was reduced by 25.3% in aging (p = .097). ATP
synthase membrane subunit g (ATP5mg) was downregulated by 23.6% in aging (p = .054) while
ATP synthase inhibitory factor subunit 1 (ATP5if1) was upregulated by 16.6% in OSVF vs. YC (p =
.06) with no significant difference between OC and OSVF for either.
Western blot analysis of mitophagy mediators Pink1 and Parkin in aorta and myocardium
revealed no significant differences between groups, nor was there any differences in their genetic
expression (Figure 29). However, there was a nearly significant decrease in vacuolar protein
sorting 13 homolog C (Vps13c) by 26.7% in aging (p = .054), which is a negative regulator of parkinmediated mitophagy in response to mitochondrial membrane depolarization. There was no
difference in Vps13c between YC and OSVF or OSVF and OC.

155

Figure 28: Microvascular Genetic and Protein Expression Related to Mitochondrial
Function. Protein expression for fission (DRP-1), fusion (MFN-1 and MFN-2), and mitochondrial
density (TOM20) with representative images (a).

RNA-sequencing of genetic expression

associated with mitochondrial function (b). Significance determined as p < .05 with One-Way
ANOVA and Bonferroni post-hoc analysis. RNA sequencing heatmap made using Morpheus,
https://software.broadinstitute.org/morpheus.
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Figure 29: Western Blot Analysis of Mitophagy Mediators Pink1 and Parkin. There is no
significant difference between YC, OC, or OSVF for myocardial or aortic Pink1 and Parkin (a).
Representative blot for myocardial (b) and aortic (c) Pink1/Parkin. Note: wells with bubbles/artifacts
or inadequate GAPDH were excluded from analysis. Significance defined as p < .05 via One-Way
ANOVA with Bonferroni post hoc analysis.

8.03: Mitochondrial Morphometric Analysis of Young, Old, and Old + SVF Microvessels
Young microvascular mitochondria were qualitatively characterized as rod-shaped and
networked whereas aged mitochondria were more isolated and punctate, with OSVF mitochondria
more resembling youthful mitochondria (Figure 30a-c). Quantitatively, the aspect ratio and form
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factor were significantly reduced with aging (p = .024 and < .001) and restored to youthful levels by
SVF treatment (p = < .001 and < .001) (Figure 30d). Mitochondrial fission factor (particles/pixels X
1000), also known as the mitochondrial fragmentation count, was significantly increased in aging
(p < .001), reversed by SVF (p < .001). Mitochondrial area and footprint were significantly reduced
in aging (p = .02 and < .001), whereas only the latter was restored with SVF (p = .068 and < .001).
Aging significantly attenuated both individual branch length and branches per network i.e.,
mitochondrial network density (p = < .001 and < .001) that were partially restored by SVF (p = .004
and .003 vs. YC; p = .017 and .011 vs. OC). EzColocalization analysis of these images further
reveals significantly greater logarithmic threshold overlap score (TOS(log2)) between DRP-1 and
mitochondrial TOM20 in OC vs. YC and nearly significant against OSVF (p = .043, .058) (Figure
31). Other metrics of overlap were nearly significant including TOS(linear) (p = .074 YC vs. OC)
and M1 (p = .058 OC vs. OSVF). MFN-1 exhibited overlap with TOM20 in each group without
significant difference between groups (Figure 31).

Figure 30: Morphometric Analysis of Microvascular Mitochondria in Youth, Aging, and SVF
Therapy. Qualitatively, microvascular mitochondrial morphometry is characterized as rod-like and
networked during youth (a), isolated and punctate in aging (b), and less circular and more
interconnected with SVF therapy (c). Aspect ratio and form factor are reduced in aging, reversed
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by SVF (d). Mitochondrial area (outlined areas in a-c second from bottom images) is significantly
attenuated with aging while mitochondrial fission factor is significantly elevated in aging, the latter
being reversed with SVF (e). Mitochondrial footprint (purple in a-c, bottom images) is significantly
reduced in aging, restored with SVF (f). Mean branch length and mean number of branches per
network are significantly abrogated with aging, partly restored by SVF (g). Green represents
mitochondrial TOM20, blue represents DAPI. Significance as p < .05 via One-Way ANOVA with
Bonferroni post hoc analysis.

Figure 31: Colocalization of Microvascular Mitochondria with DRP-1 and MFN-1.
Representative images of colocalization between mitochondria (TOM20) and fission mediator
DRP-1 or fusion mediator MFN-1 (a). Quantification of colocalization using various metrics for
TOM20 vs DRP-1 (b) and MFN-1 (c) with 1.0 indicating complete co-localization and -1.0 indicating
complete anti-colocalization. Significance as p < .05 as determined by One Way ANOVA with
Bonferroni post hoc analysis. Scale bar represents 2.5 μm.
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8.04: Mitochondrial Membrane Potential, Oxygen Consumption, and ATP
The MFI ratio of J-aggregates/JC-1 dye (i.e., mitochondrial membrane potential (ΔΨM)) in live
coronary microvessels is significantly abrogated with aging (p < .001), restored to youthful levels
with SVF therapy (p = .013) (Figure 32a). There was no significant difference in oxygen MFI
(BioTracker 520) at baseline (Figure 32b). Baseline ATP was not significantly altered with aging,
however, was significantly enhanced in OSVF vs. OC (p = .034) (Figure 32c).
Intraluminal flow at 10 μL/min significantly attenuated mitochondrial membrane potential during
aging only (p < .001 vs. YC and OSVF) (Figure 33a). Mitochondrial membrane potential decreased
similarly between groups at 25 μL/min. Oxygen consumption was not altered significantly between
YC and OC, however, was significantly enhanced in OSVF microvessels vs. OC (p = .015) (Figure
33b). ATP production was held constant with ATP expenditure in YC and OSVF, but not OC as
ATP MFI decreased in OC only (p = .008 vs. YC; p = .016 vs. OSVF). Controls for JC-1 (CCCP),
BioTracker 520 (CoCl2), and BioTracker ATP (oligomycin and camptothecin) enhanced or
diminished MFI as appropriate (Figure 34).
Mitochondrial membrane potential (JC-1) significantly correlated with percent relaxation to
norepinephrine [10-4 M] (r(22) = .439, p = .036) and flow (15 μL/min) (r(21) = .758, p < .001) (Figure
35 a, d). There was no significant correlation between baseline oxygen MFI and percent relaxation
to norepinephrine (r(22) = .028, p = .9) and flow (r(21) = .11, p < .625) (Figure 35 b, e). There was
nearly a correlation between baseline ATP concentration and percent relaxation to norepinephrine
(r(22) = .401, p = .058) and no significant correlation with percent relaxation to flow (r(21) = .306, p
= .166) (Figure 35c, f).

160

Figure 32: Baseline Microvascular Mitochondrial Membrane Potential, Oxygenation, and
ATP Levels. Mitochondrial membrane potential (ΔΨM) is significantly attenuated with aging,
restored with SVF therapy (a). There is no difference between groups in oxygen MFI (note:
BioTracker 520 increases MFI with decreasing oxygen) (b). ATP is nonsignificantly reduced with
aging and significantly enhanced with SVF therapy (c). Significance as p < .05 with One-Way
ANOVA and Bonferroni post-hoc analysis. Scale bar represents 100 μm.

Figure 33: Intraluminal Flow’s Effect on Mitochondrial Membrane Potential, Oxygen
Consumption, and ATP Production. Mitochondrial membrane potential is significantly diminished
upon intraluminal flow with 10 μL/min in aging alone and is reduced in each group similarly at 25

μL/min (a). Oxygen consumption is greatest in OSVF at 10 μL/min (note: BioTracker 520 increases
MFI with decreasing oxygen). ATP production matches ATP expenditure in YC and OSVF during
intraluminal flow whereas OC loses ATP bioavailability with flow (c). Significance as p < .05 with
One-Way ANOVA and Bonferroni post-hoc analysis.
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Figure 34: Positive and Negative Controls Relevant for JC-1, BioTracker 520, and BioTracker
ATP. CCCP and oligomycin negatively impacted JC-1 and BioTracker ATP MFI, respectively.
CoCl2 and camptothecin positively enhance BioTracker 520 and BioTracker ATP MFI.

Figure 35: Linear Regression Analysis of Mitochondrial Membrane Potential, Oxygen
Consumption, and ATP Bioavailability with Percent Relaxation to Norepinephrine and
Intraluminal Flow. Mitochondrial membrane potential positively and significantly correlated with
percent relaxation to norepinephrine and intraluminal flow (a,d). Oxygen consumption did not
correlate with percent relaxation to norepinephrine or intraluminal flow (b,e). Baseline ATP levels
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nearly significantly correlated norepinephrine-, but not intraluminal flow-mediated dilation (c-f).
Significance defined as p < .05 with Linear Regression analysis.

8.05: Effect of Fission and Fusion on β1ADR- and Flow-Mediated Dilation
Dilation to norepinephrine was blunted in aging compared to youth and SVF therapy at 10-7 to
10-4 M (p = < .001 for all doses vs. YC; p = < .001, < .001, < .001, .002 vs. OSVF) (Figure 36a).
For YC dilation to norepinephrine, inhibition of fusion (with MYLS22), but not fission (with MDIVI),
lead significantly attenuated dilation at 10-7 to 10-4 M (p = < .001 for all doses vs. YC; p = .039, .03,
.036, .005 vs. YC + MDIVI) (Figure 36b). In OC, neither MDIVI nor MYLS22 lead to significantly
more robust dilation to norepinephrine, albeit MDIVI did nearly significantly improved dilation at 108

to 10-7 (p = .052, .063) (Figure 36c). In OSVF response to norepinephrine, MYLS22, but not

MDIVI, lead significantly abrogated dilation at 10-7 to 10-4 M (p = .008, .001, .008, .008 vs. OSVF;
p = .05, .04, .048, .015 vs. YC + MDIVI) (Figure 36d).
In OC, flow-mediated dilation was reversed to a flow mediated constriction, significantly different
from YC at all flow rates (p = .018, <.001, < .001, <.001, < .001) and OSVF from 10-15 μL/min (p
< .001 for all rates) (Figure 37a). In YC, MYLS22, but not MDIVI, lead to significantly attenuated
dilation at flow rates of 15, 20, and 25 μL/min (p = .043, .041, .006; p = .035 vs MDIVI at 25 μL/min),
the latter two flow rates representing flow mediated constriction (Figure 37b). In OC, significantly
different dilation to flow could not be achieved with MYLS22 or MDIVI, albeit MDIVI did lead to
dilation instead of constriction at 5 and 10 μL/min (Figure 37c). In OSVF, flow mediated dilation
was reversed to flow mediated constriction by MDIVI, but not MYLS22 at flow rates of 15-25 μL/min
(p = .007, <.001, < .001) vs. OSVF and 20-25 μL/min (p = .006, .001) vs MYLS22 (Figure 37d).
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Figure 36: Inhibition of Fission or Fusion on Dilation to Norepinephrine in YC, OC, and OSVF
Microvessels. Aging attenuates dilation to norepinephrine, reversed by SVF therapy (a). MYLS22
inhibition of fusion significantly attenuates YC dilation to norepinephrine (b). Inhibition of fission
with MDIVI nearly significantly improves OC dilation to norepinephrine at early doses (c). Fusion
inhibition significantly abrogates dilation to norepinephrine in OSVF vessels (d). Significance
defined as p < .05 via Two-Way Repeated Measures ANOVA with Bonferroni post-hoc analysis.
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Figure 37: Inhibition of Fission or Fusion on Dilation to Intraluminal Flow in YC, OC, and
OSVF Microvessels. Aging induces flow-mediated constriction, reversed by SVF therapy
achieving flow-mediated dilation akin to YC (a). MYLS22 inhibition of fusion significantly attenuates
YC dilation to intraluminal flow (b) OC response to flow is not significantly altered by inhibition of
fusion or fission, albeit fission inhibition leads to brief dilation at lower flow rates (c). Fission
inhibition significantly abrogates dilation to flow in OSVF vessels (d). Significance defined as p <
.05 via Two-Way Repeated Measures ANOVA with Bonferroni post-hoc analysis.
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CHAPTER 9
RESULTS PART 4
STROMAL VASCULAR FRACTION RESTORES VASODILATORY FUNCTION BY REDUCING
OXIDATIVE STRESS IN AGEING-INDUCED CORONARY MICROVASCULAR DISEASE6

9.01: Animal Characteristics:
For this cohort study, animal groups consisted of YC, OC, and OSVF. There was a significant
increase in body weight and total ventricular weight between young control (YC) vs old control (OC)
and YC vs old treated with SVF (OSVF) (p<.001 for all) (Table 11). Left ventricular weight increased
significantly with aging (p<.001) and was reduced with SVF therapy (p=.026), albeit not to YC levels
(p<.001). There was no significant change in wall thickness, maximal diameter, or percent resting
tone.

6

Chapter represents work that in part has been submitted for publication currently under revision:
Tracy et al. Stromal Vascular Fraction Restores Vasodilatory Function by Reducing Oxidative
Stress in Aging-Induced Coronary Microvascular Disease. Antioxidants & Redox Signaling. 2022
(Under Revision).
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Table 11: Rat Body, Cardiac and Vascular Characteristics. Significance set as p < .05 (* YC
vs OC, # YC vs OSVF, ^ OC vs OSVF) via One-Way ANOVA with Bonferroni post hoc analysis.
Animal & Vessel
Characteristics
Age (Months)

YC (n=66)

OC (n=58)

OSVF (n=55)

3-6

24

24

Body Weight (g) (n)

181.25 +/- 2.5 (65) *#

249.97 +/- 3.795 (46)

246.82 +/- 2.99 (45)

Total Ventricular
Weight (mg) (n)

502.66 +/- 6.64 (66)
*#

651.47 +/- 16.31 (53)

653.89 +/- 6.74 (42)

LV Weight (mg) (n)

421.34 +/- 5.34 (66)
*#

566.55 +/- 3.74 (53)
^

530.32 +/- 14.51
(43)

Vessel Wall
Thickness (μm) (n)

12.58 +/- 0.4 (72)

16.22 +/- 1.68 (61)

15.39 +/- 1.75 (64)

Maximum Diameter
(n)

138.55 +/- 3.33 (72)

148.42 +/- 3.93 (62)

147.45 +/- 3.29 (67)

Average % Tone
(n)

30.65 +/- 1.52 (72)

29 +/- 1.62 (62)

32.71 +/- 1.81 (67)

9.02: Stromal Vascular Fraction Reduces Aging-Associated Oxidative Stress
An illustrative guide for fluorescent dyes, inhibitors/scavengers, and activators of key ROS/RNS
and their mediators used in this section are shown in Figure 13 (in the materials and methods).
There were significant increases in coronary microvascular hydrogen peroxide and peroxynitrite in
coronary arterioles from aged rats (p=.015 and p=.01, respectively), but no significant increases in
superoxide MFI at baseline (Figure 38a-c). Hydrogen peroxide, peroxynitrite, and superoxide MFI
were all significantly decreased in OSVF compared to OC (p<.001, p=.024, p=.004, respectively).
Meanwhile, there were significant decreases in nitric oxide (p=.024) and glutathione (p<.01) MFI
between youth and aging (Figure 38 d-e). SVF therapy was unable to significantly increase nitric
oxide MFI, but did significantly increase glutathione MFI compared to OC, although not fully
restored to YC levels (p=.017 vs. OC, p=.014 vs. YC). The validity of the fluorescent dyes was
confirmed with positive and negative controls for each dye (Figure 39a-e). Briefly, mytopy1,
Biotracker 515, Mitosox, 2,3-diaminonapthalene (DAN), and SEMKUR-IM MFI were appropriately
increased by exogenous hydrogen peroxide, cobalt chloride (CoCl2), SNP, and tiron + catalase,
respectively. Mytopy1, Biotracker 515, Mitosox, DAN, and SEMKUR-IM MFI were appropriately
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decreased by PEG-catalase, tiron, 2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3oxide (CPTiO), and hydrogen peroxide, respectively. Further, repeatability was confirmed via linear
regression and Bland-Altman analysis with blinded inter- and intra-observer re-analysis of 20% of
the data (Figure 40).
To elucidate the redox environments between youth, aging, and aging + SVF, we utilized RNA
sequencing to study gene expression and fluorescence staining to extrapolate protein expression
of various antioxidant and prooxidant enzymes (Figure 41a-c). Among prooxidant enzymes,
xanthine dehydrogenase was increased by 21% in OC vs. YC and 28% in SVF vs. YC (p=.042 and
p=.006, respectively). Peroxisome proliferator-activated receptor gamma (coactivator-related),
known to increase oxidative stress, was increased by 22% in OC vs. YC (p=.042). There were no
significant differences between groups for suspected prooxidant enzyme NADPH Oxidase 4
(NOX4). SHC adaptor protein 1 expression was 18.9% greater in OC vs. YC (p=.018).
Among antioxidant enzymes, there was significant increase in catalase by 19% (p=.049),
(extracellular) SOD3 by 22% (p=.007), thioredoxin reductase 1 by 23% (p=.014), and glutathioneS-transferase mu 1 by 24% (p=.019) and pi 1 by 31% (p=.025) in OC vs. YC. Antioxidant enzyme
expression increases in YC vs. OC included 26% more oxidation resistance protein 1 (p=.035),
40% more COX20 assembly factor (p=.002), and 15% and 21% more heat shock proteins 90 and
110 (p=.037 and p=.034, respectively). For OSVF vs. YC antioxidant enzymes, catalase was
increased by 19% (approaching significance, p=.057), SOD3 by 20% (p=.012), glutathione
peroxidase 3 and 4 by 24% and 18% (p=.016 and p=.024, respectively), sirtuin 5 by 20% (p=.038),
thioredoxin reductase by 20% (p=.034), and peroxiredoxin 4 by 39% (p=.015) albeit with 40%
decreased heat shock protein 110 (p=.003).
Comparing antioxidant enzyme expression between OSVF vs. OC, glutathione synthetase was
increased by 28% (p=.018), thioredoxin-like protein 1 increased by 17.2% (p=.045), heat shock
proteins 40 (member C7) and 70 increased by 21.4% and 22% (p=.01 and p=.07, respectively),
and cytochrome oxidase assembly factor 3 increased by 21% (p=.032) in OSVF. A comprehensive
listing of antioxidant and prooxidant proteins are illustrated in the heat map in Figure 41a.
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We selected gene targets of most interest and potential impact/relevance to evaluate protein
expression utilizing fluorescence imaging of isolated coronary microvessels (Figure 41b-c).
Antioxidant enzymes catalase, glutathione synthetase, and heat shock protein 70 yielded no
differences in MFI. MnSOD MFI was reduced with aging (albeit not significantly) but was
significantly increased with SVF therapy (p=.041). Prooxidant enzyme NOX4 was significantly
increased with aging (p=.032) with significant reversal to YC levels by SVF (p=.037). S-nitrosylation
of proteins was significantly reduced with aging (p=.012) but was not restored with SVF (p=.047
vs. YC).

Figure 38: Changes in Mitochondrial ROS, Nitric Oxide, and Glutathione at Baseline with
Aging and SVF Therapy. Hydrogen peroxide, peroxynitrite, and superoxide Mean Fluorescent
Intensity (MFI, arbitrary units) are increased with aging, reversed by SVF (a-c, f). Nitric oxide and
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Glutathione MFI are decreased with aging, with SVF partially restoring glutathione, but not nitric
oxide to youthful levels (d-f). Significance determined as p < 0.05 with One-Way ANOVA with
Bonferroni post-hoc analysis. Scale bar represents 100 μm. OC: Old Control, OSVF: Old + Stromal
Vascular Fraction, YC: Young Control.

Figure 39: Controls for Fluorescent Dyes Targeting ROS/NO/Glutathione. Superoxide MFI is
positively influenced by cobalt chloride and negatively affected by scavenger tiron (a). Hydrogen
peroxide MFI is positively affected by exogenous hydrogen peroxide and negatively affected by
PEG catalase (b). Nitric oxide MFI is positively affected by exogenous SNP and negatively affected
by scavenger CPTiO (c). Peroxynitrite MFI is positively affected by SNP + Menadione and
negatively affected by tiron (d). Glutathione MFI is positively affected by tiron + catalase and
negatively affected by exogenous hydrogen peroxide (e). CoCl2: Cobalt Chloride, OC: Old Control,
OSVF: Old + Stromal Vascular Fraction, YC: Young Control.
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Figure 40: Linear Regression and Bland-Altman Plots for Inter and Intra-Observer Analysis.
20% of the MFI data was re-analyzed in a blind fashion by the original analyst and an additional
analyst. Intra-observer analysis reveals significant positive trend compared with original analysis
(a) with low bias, limits of agreement (LOA), and high Interclass Correlation Coefficient (ICC) (b).
Inter-observer analysis reveals significant positive trend compared with original analysis (c) with
low bias, limits of agreement, and high Interclass Correlation Coefficient (d).
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Figure 41: Antioxidant and Prooxidant Gene and Protein Expression in Youth, Aging, and
SVF Therapy. RNA sequencing of isolated vessels with genes relevant to cellular and
mitochondrial redox balance (a). Protein MFI of isolated vessels for catalase, MnSOD, glutathione
synthetase, HSP70, NOX4, and SNO (b) with representative confocal images (c). Nuclei signified
by DAPI. Significance determined as p < 0.05 with One-Way ANOVA with Holm-Sidak post-hoc
analysis. Scale bar represents 200 μm and ROI represents 20x100 μm with blue representing
DAPI. GSH synth.: glutathione synthetase, HSP70: Heat Shock Protein 70 MnSOD: manganese
Superoxide Dismutase, NOX4: NADPH Oxidase 4, OC: Old Control, OSVF: Old + Stromal Vascular
Fraction, SNO: S-nitrosylation, YC: Young Control.

9.03: Alterations of Flow-Mediated Dilation Signaling Throughout the Lifespan and with Stromal
Vascular Fraction
Introduction of intraluminal flow into isolated coronary microvessels in pressure myography
experiments elicited different signaling responses to induce FMD between YC vs. OC vs. OSVF.
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In youth, flow elicited an increase in nitric oxide MFI (significant compared to OC at flow rate of 10
& 25 μL/min, p=.015 and p=.046, respectively) (Figure 42a). There was minimal change in nitric
oxide MFI with flow in OC and OSVF groups.
In all groups, flow induced an increase in hydrogen peroxide, but the increase was greatest in
the OC group (significant vs. YC at flow rate of 25 μL/min, p=.045) (Figure 42b). Inhibition of
superoxide dismutase with diethyldithiocarbamic acid (DETC) led to overall reduced hydrogen
peroxide production with flow in all groups, with greater reduction in OC than OSVF at 25 μL/min
(p=.041) (Figure 43). Inhibition of catalase with 3-amino-1,2,4-triazole (AMT) without flow led to
greater hydrogen peroxide MFI increases in OSVF vs. YC and OC (p=.01 and p<.01, respectively)
(Figure 42b). With AMT + flow at 10 and 25 μL/min, OSVF hydrogen peroxide MFI was significantly
greater than OC (p<.001 and p<.001, respectively) and nearly significant vs. YC (p=.051 and
p=.087, respectively). OC was non-significantly reduced compared to YC at all flow rates. These
results with AMT suggest significantly greater catalase function in OSVF vs. YC and OC.
Superoxide MFI decreased with intraluminal flow in all groups (Figure 42c). Inhibition of
superoxide dismutase with DETC led to significantly greater superoxide accumulation in YC and
OSVF groups compared to OC at baseline (p=.035 and p=.011, respectively). With flow + DETC,
OC exhibited less superoxide production at flow rates of 10 (vs. YC and OSVF, p=<.001, p=.008,
respectively) and 25 (vs. YC, p=.029) μL/min, suggesting greater SOD expression and/or function
in youth than aging, and that SOD function was restored with SVF therapy. DETC inhibition of SOD
with flow reduced hydrogen peroxide production in all groups as expected. Peroxynitrite MFI was
increased with intraluminal flow at 10 and 25 μL/min in young control and significantly so in OSVF
compared to minimal peroxynitrite production in OC (p=.027 and p=.01, respectively) (Figure 42d).
Glutathione is an essential antioxidant that reflects the redox balance of the cell, quenching
ROS such as hydrogen peroxide, superoxide, and peroxynitrite. The SEMKUR-IM dye indirectly
reports the ratio between reduced and oxidized glutathione, with increased fluorescence changes
indicating reduced glutathione, and decreased changes indicating oxidized glutathione. At
intraluminal flow rate of 10 μL/min, glutathione MFI was increased in YC but significantly decreased
in OC (p=.04) (Figure 42e). At intraluminal flow rate of 25 μL/min, there was a significant difference
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between YC (p=.01) and OSVF (p=.013) MFI vs. OC. These results are consistent with the results
that flow in OC increased hydrogen peroxide (and superoxide transiently before it was converted
to hydrogen peroxide by SOD).
These data indicate that the FMD signaling mediator is nitric oxide during youth, hydrogen
peroxide in aging, and switching to peroxynitrite with SVF therapy. To complement and strengthen
the validity of these findings, we used pressure myography with flow while recording percent
vasorelaxation in each group with or without inhibitors/scavengers/enzymes of these redox
signaling mediators. Overall, the effectiveness of FMD was significantly attenuated with aging at
flow rates of 10, 15, 20, & 25 μL/min (p<.01, p<.01, p=.024, and p<.01, respectively) but rescued
to YC levels in the SVF therapy group (p=.011, p=.006, p=.04, and p=.002, respectively) (Figure
44a). In youth, FMD was significantly attenuated by pre-incubation with N-Nitro-L-arginine
methylester (L-NAME), but not catalase or uric acid, at all flow rates (p=.005, p<.001, p<.001,
p<.001, and p<.001, respectively) (Figure 44b). This signifies that nitric oxide production is
responsible for FMD during youth, as L-NAME inhibits eNOS-mediated nitric oxide production.
During aging, FMD was not further attenuated by L-NAME, uric acid, or catalase (Figure 44c).
OSVF’s improvement in FMD was significantly abrogated by uric acid at all flow rates (p=.04, p=.04,
p=.04, p<.001, and p<.001, respectively) and L-NAME at flow rates 15-25 μL/min (p=.027, p=.014,
and p=.012, respectively) (Figure 44d). This signifies that with SVF therapy, the FMD signaling
mediator switches to peroxynitrite, at least partially dependent on nitric oxide production.
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Figure 42: Effect of Intraluminal Flow on ROS/NO/GSH MFI with and without Antioxidant
Enzyme Inhibitors. Nitric oxide signaling to flow is greatest with youth but minimal in aging and
SVF therapy (a). Hydrogen peroxide accumulation to flow is greatest in aging (b). Further, blocking
catalase with AMT yields greatest buildup of hydrogen peroxide in response to flow with SVF
therapy, indicating greatest catalase function in OSVF. There is no age- or therapy-induced
changes to superoxide response to flow at baseline, however, with DETC there is significantly less
buildup of superoxide to flow in aging, indicating greater SOD function with youth/OSVF (c). OSVF
has greater accumulation of peroxynitrite with flow than young or old control (d). Flow leads to a
significant decrease in glutathione MFI in aging alone compared to youth or OSVF (e). Significance
determined as p < 0.05 with One-Way ANOVA with Bonferroni post-hoc analysis. AMT: 3-amino1,2,4-triazole, DETC: Diethyldithiocarbamic acid, OC: Old Control, OSVF: Old + Stromal Vascular
Fraction, YC: Young Control.
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Figure 43: Hydrogen Peroxide Production with DETC Superoxide Dismutase Inhibition.
Significance defined as p < .05 via One-Way ANOVA with Bonferroni post hoc analysis. DETC:
Diethyldithiocarbamic acid. Old Control, OSVF: Old + Stromal Vascular Fraction, YC: Young
Control.

176

Figure 44: Flow-Mediated Dilation Changes in Response Inhibitors/Scavengers of ROS/RNS.
There is a significant decrease in Flow-mediated dilation (FMD) in aging, reversed by SVF therapy
(a). During youth, FMD is inhibited by L-NAME inhibition of eNOS NO production, but not uric acid
or catalase (b). During aging, there are no differences in FMD with preincubation of L-NAME, uric
acid, or catalase (c). With SVF therapy, FMD is attenuated with L-NAME and uric acid scavenging
of peroxynitrite (d). Significance determined as p < 0.05 with Two-Way Repeated Measures
ANOVA with Bonferroni (a) or Holm-Sidak (b-d) post-hoc analysis. L-NAME: N-Nitro-L-arginine
methylester, OC: Old Control, OSVF: Old + Stromal Vascular Fraction, YC: Young Control.

9.04: Baseline Oxidative and Nitrosative Stress Correlate with β1ADR-mediated Dilative Function
Consistent with our lab’s previous reporting, β1-adrenergic-mediated vasorelaxation was
reduced with aging and restored to YC levels in aging + SVF therapy. Specifically, there were
significant differences between YC vs. OC norepinephrine concentration responses at 10-8-10-4 [M]
(p=.022, p= <.001, p<.001, p<.001, and p<.001, respectively) and OSVF vs. OC at 10-8-10-4 [M]
(p<.001 for all) (Figure 45a). Similarly, there were significant differences between YC vs. OC
dobutamine dose responses at 10-9-10-5 [M] (p=.018, p<.001, p=.002, p=.001, and p<.001,
respectively) and OSVF vs. OC at 10-9-10-7 and 10-5 [M] (p=.043, p=.002, p=.004, and p=<.001,
respectively) (Figure 45b). Since aging is associated with both increased oxidative stress and
reduced β-adrenergic function, we next endeavored to determine if there was a true correlation
between them.
Using separate vessels from the same animal, we correlated percent relaxation to
norepinephrine 10-4 [M] with ROS/RNS/glutathione MFI. There were negative correlations between
percent vasorelaxation to norepinephrine and MFI of hydrogen peroxide and superoxide, but not
peroxynitrite (r(27)=-.69, p<.001; r(15)=-.505, p=.018; r(20)=-.24, p=.297, respectively) (Figures
45c-e). There was a positive correlation between increasing nitric oxide and glutathione with
percent vasorelaxation to norepinephrine (r(19)=.50, p=.021; r(18)=.50, p=.028, respectively)
(Figure 45f-g)
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Figure 45: Link Between β1ADR Dysfunction and Increased ROS and Attenuated Nitric
Oxide, and Glutathione Concentration in Aging. Aging reduces β1ADR dilative response to
norepinephrine and dobutamine, restored to young control levels by SVF therapy (a-b). β1ADR
dilation to norepinephrine (10-4 M) negatively and significantly correlates with H2O2 and superoxide,
but not peroxynitrite, while positively and significantly correlating with nitric oxide and glutathione
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MFI (c-g). Significance determined as p < 0.05 with Two-Way Repeated Measures ANOVA with
Bonferroni post-hoc analysis (a-b) and Linear Regression (c-g). OC: Old Control, OSVF: Old +
Stromal Vascular Fraction, YC: Young Control.

9.05: Effect of Adrenergic Agonism and Bradykinin on ROS/RNS MFI
For superoxide, phenylephrine led to an increase in MFI in all groups with no significance
between groups (Figure 46a). BRL led to a reduction in mitosox MFI in all groups with greater
reduction in YC and OSVF vs. OC (p = .037, .075). Salbutamol slightly increased mitosox MFI with
no difference between groups. Dobutamine led to reductions in mitosox MFI in YC and OSVF while
increasing MFI in OC (p = .005 and .001, respectively). Norepinephrine decreased YC and OSVF
superoxide MFI but increased it in OC, with near significance in OSVF vs. OC (p = .057).
There were no significant differences between groups for hydrogen peroxide MFI in response
to phenylephrine, isoproterenol, BRL, salbutamol, dobutamine, or norepinephrine (Figure 46b).
Phenylephrine led to increased mytopy1 MFI whereas the beta-adrenergic agonists led to either
slight reductions or no change in mytopy1 MFI.
Nitric oxide MFI was diminished by phenylephrine in all groups but significantly more so in YC
and OSVF vs. OC (p = .012 and .043 respectively) (Figure 46c). Isoproterenol increased DAN
MFI in YC only, with significance vs. OC and OSVF (p = .041 and .004 respectively). BRL slightly
increased DAN MFI in YC, with no change in OC, and decreased DAN MFI in OSVF with
significance between YC and OSVF (p = .024). Salbutamol slightly decreased DAN MFI in all
groups without significance between groups. There was no significant difference in DAN MFI
between groups in response to dobutamine. In response to norepinephrine, YC and OSVF
increased DAN MFI while OC DAN MFI decreased nearly significantly vs. OSVF (p = .059).
Bradykinin is known to elicit nitric oxide and prostanoid dilative signaling, as well as dilative
signaling from endothelium-dependent hyperpolarization. Bradykinin elicited minor nitric oxide
response in all groups with robust production of hydrogen peroxide, significantly greater so in YC
vs. OC and OSVF (p = .008, .026) (Figure 47). RNAseq revealed that bradykinin receptor BK2 is
significantly upregulated in OSVF by 25.5% vs. YC and 33.7% vs. OC (p = .035 and .0034)
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Figure 46: Effect of Alpha or Beta Agonism on ROS/Nitric Oxide MFI. Percent change in
superoxide (a), hydrogen peroxide (b), and nitric oxide (c) MFI was recorded after agonism with
phenylephrine (α1 agonist), norepinephrine (α1-2, β1 agonist), dobutamine (β1 agonist),
isoproterenol (β1-2 agonist), salbutamol (β2 agonist), and BRL (β3 agonist). Significance as p <
.05 via One-Way ANOVA with Bonferroni post-hoc analysis.
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Figure 47: Bradykinin Preferentially Elicits Hydrogen Peroxide Signaling in Coronary
Microvessels. Significance as p < .05 via One-Way ANOVA with Bonferroni post-hoc analysis.

9.06: Effect of GRK2 Inhibition on ROS/RNS and Inhibition of GRK2 Mitochondrial Translocation
on Beta-Adrenergic Function
GRK2 is known to inhibit vascular eNOS-mediated nitric oxide production and GRK2’s
translocation to the mitochondria via heat shock protein 90 (HSP90) enhances mitochondrial ROS
production [870]. We found a significant difference in how GRK2 inhibitor paroxetine incubation
affects superoxide MFI in YC vs. OC (p = .008) (Figure 48). Percent change in superoxide MFI
increases in YC but is decreased in OC, while nitric oxide MFI decreases in both groups nonsignificantly. During incubation with HSP90 inhibitor 17-DMAG, percent change in superoxide MFI
again is increased in YC with respect to OC with significant difference (p = .043), while there is a
decrease in nitric oxide MFI without differences between groups. Incubation with 17-DMAG does
not significantly improve OC adrenergic dilation to norepinephrine, dobutamine, salbutamol, or BRL
(Figure 49a-d).
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Figure 48: Effect of GRK2 and HSP90 Inhibition of Superoxide and Nitric Oxide MFI.
Significance as p < .05 determined by Student’s t-test.

Figure 49: Effect of HSP90 Inhibition of Beta-Adrenergic Dilative Function in Aging. 17DMAG inhibition of HSP90 did not significantly alter dilative response to norepinephrine (α1-2, β1
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agonist) (a), dobutamine (β1 agonist) (b), salbutamol (β2 agonist) (c), or BRL (β3 agonist) (d).
Significance as p < .05 determined by student’s t-test at each dose.

9.07: Exogenous ROS Eliminates while RNS Rescues β-Adrenergic Vasodilation Due to the
ROS/RNS βADR Desensitization & Internalization Axis
Immunofluorescence signal from β1ADR overlaps with fluorescence signal from plasma
membrane and RAB5 (endosomal marker) in coronary microvessels (Figure 50). Exogenous
hydrogen peroxide and superoxide donation via menadione lead to significant attenuation of YC
norepinephrine concentration response at 10-4 [M] (p = .045), BRL at response at 10-4 [M] (p = .01),
with non-significant decrease in dobutamine (p = .058 at 10-5 [M]) and salbutamol response (p =
.097, .09, .078 for 10-6-10-4 [M]) (Figure 51a-d). For isoproterenol, there were significant differences
between YC vs. OC concentration responses at 10-8-10-4 [M] (p<.001 for all doses) and OSVF vs.
OC at 10-11-10-4 [M] (p=.002, p=.002, p<.001, p<.001, p<.001, p<.001, p<.001, and p<.001,
respectively) (Figure 52a). Isoproterenol concentration response was significantly abrogated in YC
from doses 10-8-10-4 [M] (p=.003, p<.001, p<.001, p<.001, and p<.001, respectively) and OSVF at
10-8-10-4 [M] (p<.001 for all doses) when pre-incubated with exogenous ROS (Figure 52b, d). Postconcentration response, exposure to calcium-free solution + SNP still facilitated dilation, indicating
ROS-attenuated dilation is β-adrenergic specific (YC=78.39±9.76%; OSVF=88.88±6.37% dilation).
In YC, the effect from ROS on isoproterenol was nullified when co-incubating with dynasore at 108

-10-4 [M] (p=.005, p<.001, p<.001, p<.001, and p<.001, respectively), but not restored to YC levels

at 10-6-10-5 [M] (p=.037 and p=.003, respectively). Paroxetine also nullified the ROS attenuation of
dilation at doses 10-8-10-4 [M] (p=.02, <.001, p<.001, p=.001, and p=.001, respectively), albeit not
completely restored to baseline levels for doses 10-7-10-4 [M] (p=.047, p=.011, p=.01, and p=.004,
respectively). In OSVF + ROS, dynasore and paroxetine pre-incubation also rescued function from
doses 10-7-10-4 [M] (dynasore: p=.009, p=.0033, p=.005, and p=.007, respectively) and 10-5-10-4
[M] (paroxetine, p=.042 and p=.015, respectively). These reversing effects to attenuate ROSblunted adrenergic dilation were therefore the result of inhibiting GRK2-mediated desensitization
and dynamin-mediated internalization, respectively. Response to isoproterenol in old control
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vessels was significantly rescued at doses 10-7-10-6 [M] by pre-incubation with a one-minute highdose SNP preincubation followed by fifteen minutes of low-dose SNP and throughout the
experiment (p=.004 and p=.023, respectively) (Figure 52c). The response was also rescued by
pre-incubation with dynasore at 10-8-10-4 [M] (p=.015, p<.001, p<.001, p<.001, and p=.004,
respectively) and paroxetine at 10-7-10-4 [M] (p<.001, p=.022, p=.019, and p=.004, respectively).

Figure 50: Coronary Microvascular β1ADR immunofluorescence signal overlaps with
Plasma Membrane fluorescence and RAB5 (endosomal marker) immunofluorescence
signal. Images are a compiled z-stack 10 μm in depth. Scale bar represents 2.5 μm.
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Figure 51: Exogenous ROS-mediated Attenuation of Dilation to Various Beta-Adrenergic
Agonists. ROS (hydrogen peroxide + menadione) blunted the dilation of YC microvessels in
response to norepinephrine (α1-2, β1 agonist) (a), dobutamine (β1 agonist) (b), salbutamol (β2
agonist) (c), or BRL (β3 agonist) (d). Significance as p < .05 as determined by Student’s t-test at
each dose.
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Figure 52: Effect of ROS/RNS on β1-Adrenergic Receptor Desensitization & Internalization
in Youth, Aging, and SVF Therapy. With aging there is a significant decrease in dilation to
isoproterenol, reversed by SVF (* = YC vs. OC, # = SVF vs. OC, ^ = YC vs. OSVF) (a). YC vessels
exposed to exogenous ROS (hydrogen peroxide 10-4 M and menadione superoxide donor 10-5 M)
have abrogated dilation reversed by paroxetine and dynasore inhibition of desensitization &
internalization (* = baseline vs. ROS, # = dynasore vs. ROS, ^ = paroxetine vs. ROS) (b). OC
vessels exposed to SNP, dynasore, and paroxetine have significantly improved percent relaxation
(* = baseline vs. SNP, # = baseline vs. dynasore, ^ = baseline vs. paroxetine) (c). OSVF vessels
exposed to exogenous ROS have ameliorated dilation reversed by paroxetine and dynasore (* =
baseline vs. ROS, # = dynasore vs. ROS, ^ = paroxetine vs. ROS) (d). Significance defined as p <
.05 utilizing Two-Way Repeated Measures ANOVA with Bonferroni (a) or Holm-Sidak (b-d) post
hoc analysis. OC; Old Control, OSVF: Old + Stromal Vascular Fraction, ROS: Reactive Oxygen
Species, SNP: Sodium Nitroprusside. YC: Young Control.

9.08: β1ADR Recycling is Necessary in Aging, but not Youth or OSVF for Maximal Dilation to
Agonist
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To determine the contribution of β1ADR recycling (from endosome back to plasma membrane),
we inhibited recycling regulatory proteins PP2A (pro-recycling) with okadaic acid, or PI3kγ (antirecycling) with BEZ235 in a separate cohort of coronary arterioles from each group. Okadaic acid
did not significantly reduce YC dilation to isoproterenol but did significantly reduce dilation in OC at
10-5-10-4 [M] (p=.01, p<.001) and OSVF at 10-7-10-6 [M] (p=.005, p=.045) (Figure 53a-c). Inhibition
with BEZ235 did not alter aged dilation but did significantly reduce dilation in YC at 10-7-10-4 [M]
(p=.011, p=.002, p<.001, and p=.004, respectively) and OSVF at 10-6-10-4 [M] (p=.045, p=.008, and
p=.017, respectively). BEZ235 partially negated the effects of exogenous ROS incubation in YC at
10-5-10-4 [M] (p<.001, p=.004), although differences were also significant against baseline at those
doses (p<.001 for both) (Figure 53d). BEZ235 also negated the attenuation of dilation from
exogenous ROS in OSVF at 10-6-10-5 [M] (p=0.042, p=.017) (Figure 53e). There were no significant
differences between groups for MFI of PP2A, protein phosphatase 2A inhibitor 2 (I2PP2A), or PI3kγ
(Figure 54a-b).

Figure 53: Contribution of β1ADR Recycling on Dilative Function Between Groups.
Incubation with BEZ235, but not okadaic acid, attenuates dilation to isoproterenol in YC (a). In YC,
pre-incubation with ROS (hydrogen peroxide and menadione) leads to abrogation of dilation,
partially prevented by co-incubation with BEZ235 (b). OC dilation to isoproterenol is significantly
attenuated by okadaic acid, but not BEZ235 (c). In OSVF, dilation to isoproterenol is diminished
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with okadaic acid at lower respective doses and BEZ235 at higher respective doses (d). Preincubation of vessels with ROS attenuates dilation to isoproterenol in OSVF, partially prevented by
co-incubation with BEZ235 (e). Significance defined as p < .05 via Two-Way ANOVA with
Bonferroni post hoc analysis.

Figure 54: Protein Expression of βADR Recycling Mediators is Unchanged with Aging or
SVF Therapy. There is no significant change in MFI of PP2A (activates recycling) or its inhibitors
I2PP2A or PI3ky (a). Representative confocal images are shown (b). Significance determined as p
< 0.05 with One-Way ANOVA. Scale bar represents 200 μm and ROI represents 20x100 μm. OC:
Old Control, OSVF: Old + Stromal Vascular Fraction, YC: Young Control.
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CHAPTER 10
RESULTS PART 5
TELOMERASE REVERSE TRANSCRIPTASE REDUCES OXIDATIVE STRESS AND
IMPROVES VASODILATORY FUNCTION OF AGED MICROVESSELS

Considering SVF’s antioxidant effects to recover microvascular function, an alternative
therapeutic approach could be direct pharmacologic reduction of oxidative stress. Such a strategy
may be beneficial over cell therapy as there would be no need for debate about autologous vs.
allogeneic source, use of cells vs. cellular products i.e., exosome, or preconditioning requirements
(see Chapter 4), and would be easier to overcome regulatory hurdles. Another reason to study an
alternative mitochondrial antioxidative strategy is to study the isolated effects of ROS attenuation,
as SVF is also known to be immunomodulatory [871]. Indeed, one such therapeutic, TA65® or
cycloastragenol (CAG) is already marketed and sold as a supplement and is in clinical trials for
reducing oxidative stress and endothelial dysfunction in acute coronary syndrome [872]. CAG is a
telomerase reverse transcriptase (TERT) activator isolated from the Astralagous root that prevents
telomere shortening and senescence. Recently, non-canonical functions for TERT have been
described such as antioxidant capabilities to reduce ROS via its translocation to the mitochondria
during stress [873]. Loss of TERT expression in coronary artery disease leads to shift in FMD
mediation from nitric oxide to hydrogen peroxide, whereas pharmacologic TERT activation in
coronary artery disease leads to restored nitric oxide mediated FMD and enhanced NOS activity
[874]. Importantly, TERT expression is decreased with aging [874]. Therefore, in this chapter we
study the dynamics of TERT activation and inhibition (summarized in Figure 55) in aging with CAG
dietary supplementation, to determine its effect on microvascular functional regeneration.
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Figure 55: Telomerase Reverse Transcriptase (TERT) Trafficking and Attenuation of ROS to
Influence Vasodilation. AGS499 (in vitro) and Cycloastragenol (CAG, diet) pharmacologic and
therapeutic interventions activate TERT and enhance its expression. TERT in the nucleus
(nucTERT) prevents telomere shortening and biological aging. When there are acute stressors such
as hydrogen peroxide or hypoxia, TERT becomes translocated to the mitochondria (mitoTERT)
where it quenches ROS. mitoXTERT can inhibit translocation to the mitochondria (increasing
nuclear TERT) whereas nucXTERT inhibits translocation to the nucleus (leading to mitochondrial
TERT accumulation). Image created with BioRender.com.

10.01: Animal Characteristics and Echocardiography
For this cohort, female Fisher-344 were randomly divided into two groups, old control and old +
cycloastragenol chow diet (OCAG, also known as TA65®). In a separate group of experiments,
vessels from YC and OC animals were isolated and incubated with peptides known to influence
trafficking of TERT to the nucleus (mitoXTERT), to the mitochondria (mitoXTERT), to activate and

190

enhance TERT expression (AGS499), or negative control scramble peptide. There were no
differences between groups for baseline or terminal (4 weeks later) body weight, urine volume, and
heart rate (Table 12). There was a non-significant reduction in systolic blood pressure and nearly
significant reduction in diastolic blood pressure (p = .094) and mean arterial pressure (p = .079)
(Table 12 and Figure 56a). Plasma cholesterol, but not triglyceride or creatinine concentration was
nearly significantly reduced with CAG diet vs. OC (p = .095) (Figure 56b). Urine NMN and 5HIAA
were significantly increased after CAG diet (p = .012 and .016) with norepinephrine being nearly
significantly increased (p = .059) (Table 13). There were no significant differences in cardiac
parameters coronary flow reserve, cardiac output, stroke volume, ejection fraction, E/A, E/e’,
fractional shortening, or isovolumic relaxation time between OC and OCAG at two or four weeks
(Figure 57).

Table 12: Body Weight, Blood Pressure, Heart Rate, and Urine Volume for OC and OCAG
Rats. Significance as p < .05 as determined by Student’s t-test.
Group

Baseline
Body Wt
(g)

Terminal
Body Wt
(g)

Systolic
Blood
Pressure

Diastolic
Blood
Pressure

Mean
Arterial
Pressure

Heart
Rate

Baseline
Urine
Volume
(ml)

Week 4
Urine
Volume
(ml)

Old
Control

247.29 +
15.4

234.00 +
9.56

134.28 +
31.84

89.64 +
15.80

100.6 +/8.67

217.54
+ 35.71

13.79 +
2.16

16.57 +
3.21

CAG
Chow

246.89 +
22.05

233.00 +
22.50

110.05 +
13.68

72.90 +
7.43

79.09 +/3.38

212.64
+ 23.88

12.44 +
6.45

12.06 +
4.25

Figure 56: CAG Diet Influence on Blood Pressure, Total Cholesterol, Triglycerides, and
Creatinine in Advancing Age. Systolic blood pressure is non-significantly reduced while diastolic
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blood pressure is significantly reduced by CAG diet intervention (a). There is near significant
decline in cholesterol with CAG diet with no change in triglycerides or creatinine. MAP = Mean
Arterial Pressure. Significance as p < .05 as determined by Student’s t-test.

Table 13: Urine Catecholamine Levels After CAG Diet. Significance * as p < .05 via Student’s
t-test
Urine
OC (n=7)
OCAG (n=9)
Catecholamines
(per mg Creatinine)
NE
1.16 +/- 0.2
1.60 +/- 0.21
DA
3.98 +/- 1.76
7.44 +/- 1.39
5HT
6.19 +/- 1.17
9.42 +/- 1.80
NMN
1.79 +/- 0.26 *
2.65 +/- 0.42
3MT
1.28 +/- 0.39
1.87 +/- 0.35
MN
0.28 +/- 0.03
0.40 +/- 0.06
EPI
0.12 +/- 0.04
0.18 +/- 0.03
5HIAA
57.36 +/- 2.05 *
65.49 +/- 2.24
HVA
31.27 +/- 6.09
38.84 +/- 3.24
VMA
4.18 +/- 0.16
4.44 +/- 0.20
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Figure 57: Echocardiographic Assessment of CAG Diet’s Effect on Aging Cardiac Function.
Assessment of coronary flow reserve (a), cardiac output (b), stroke volume (c), percent ejection
fraction (d), E/A (e), E/e’ (f), fractional shortening (g), and isovolumic relaxation time (h).
Significance as p < .05 as determined by Student’s t-Test.

10.02: OC and OCAG Isolated Vessel Experiments
There were no differences between OCAG in terms of ventricular weight, wall thickness, or
average percent tone (Table 14). OCAG slightly but not significantly increased dilation to
dobutamine from 10-9 to 10-5 [M] while increasing dilation to NE from 10-9 to 10-4 [M], with 10-5 [M]
being significant (p = .034) (Figure 58a-b). Dilation to acetylcholine was significantly improved in
OCAG vs. OC at 10-9 [M] (p = .041) and 10-7 to 10-4 [M] (p = .005, .013, .009, .002) (Figure 58c).
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Baseline MFI of superoxide was significantly reduced (p = .036), while hydrogen peroxide was
nearly significantly reduced (p = .095) whereas nitric oxide was significantly increased (p < .001) in
OCAG vs. OC (Figure 59a-d)). Glutathione baseline MFI was non-significantly reduced by CAG
diet (p = .116) and there were no differences between groups for peroxynitrite MFI (Figure 59e).
There was a near significant association with dilation to flow and superoxide and hydrogen
peroxide MFI but not peroxynitrite, nitric oxide, or glutathione (Figure 60). Dilation to acetylcholine
nearly significantly was associated with glutathione but not superoxide, hydrogen peroxide,
peroxynitrite, or nitric oxide (Figure 61). There was no significant negative correlation between any
of the ROS/RNS/GSH MFI with dilation to norepinephrine at 10-5 [M] (Figure 62).
OC facilitated a flow-induced constriction rather than dilation, which was reversed by CAG
diet so that flow mediated dilation, albeit with no statistical difference between groups (Figure 63).
Flow elicited significantly greater hydrogen peroxide accumulation in OC than OCAG at flow rates
of 10 and 25 μL/min (p = .005 and .015) (Figure 64a). PEG-catalase non-significantly improved
dilation to flow in both groups (Figure 63b). On the contrary, flow generated enhanced superoxide
production in OCAG than OC at 25 μL/min (p = .035) and flow with DETC pre-treatment further
generated more superoxide in OCAG than OC at 0, 10, and 25 μL/min (p = < .001, < .001, .049)
(Figure 63a). Intraluminal flow reduced nitric oxide MFI in both groups, nearly significantly at a flow
rate of 10 μL/min (p = .099) (Figure 63c). L-NAME inhibition of nitric oxide production (or
superoxide production in aging) non-significantly enhanced FMD in OC with no difference in OCAG
(Figure 64b-c). There were no differences between OC and OCAG for peroxynitrite MFI at
baseline, however, with inhibition of superoxide dismutase via DETC flow induced significantly
greater peroxynitrite accumulation at 0, 10 and 25 μL/min (p = .002, .012 and .006) (Figure 64d).
Uric acid scavenging of peroxynitrite did not significantly alter FMD in either OC or OCAG (Figure
64 b-c). Flow reduced glutathione MFI in both groups, significantly more so in OCAG than OC at
flow rate of 10 ul/min (p = .045) and 25 μL/min (p = .0357) (Figure 63e).
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Table 14: OC:OCAG Cohort Cardiac and Vascular Characteristics.
Cardiac & Vessel
OC (n=11)
Characteristics
Total Ventricular Weight
678.93 +/- 12.65
(mg)
Left Ventricle (+ Septum)
570.7 +/- 9.12
(mg)
Right Ventricle Weight (mg)
109.05 +/- 5.39
Vessel Wall Thickness (μm)
15.38 +/- 1.06
Maximum Diameter (μm)
140.7 +/- 11.27
Average % Tone
28.56 +/- 1.24

OCAG (n=15)
665.05 +/- 13.81
559.76 +/- 15.84
102 +/- 3.42
14.84 +/- 1.03
142 +/- 8.47
31.71 +/- 3.14

Figure 58: Effect of CAG Diet on Dilatory Efficiency to β1ADR Agonism and Acetylcholine.
Dilation is slightly improved (albeit not significantly) to dobutamine (a), significantly enhanced with
norepinephrine (b) and acetylcholine (c). Significance as p < .05 with Student’s t-test at each dose.
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Figure 59: Mean Fluorescence Intensity (MFI) of Microvascular ROS/RNS/GSH in Aging and
CAG Diet Intervention. Representative images of microvessels infused with dyes sensitive to
superoxide, hydrogen peroxide, peroxynitrite, nitric oxide, and glutathione (a). MFI quantification
(average of each vessel wall) of each dye (b). Scale bar represents 100 μm. Significance
determined as p < .05 via Student’s t-test.
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Figure 60: Correlation Between ROS/RNS/GSH and Dilation to Intraluminal Flow. Dilation to
Intraluminal flow nearly significantly correlated negatively with superoxide (a) and hydrogen
peroxide (b). There was no association between peroxynitrite (c), nitric oxide (d) or glutathione (e)
MFI with dilation to intraluminal flow. Significance as p < .05 as determined via linear regression
analysis.
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Figure 61: Correlation Between ROS/RNS/GSH and Dilation to Norepinephrine. Dilation to
norepinephrine in OC and OCAG did not correlate with superoxide (a), hydrogen peroxide (b),
peroxynitrite (c), nitric oxide (d), or glutathione (e) MFI. Significance as p < .05 as determined via
linear regression analysis.
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Figure 62: Correlation Between ROS/RNS/GSH and Dilation to Acetylcholine. Dilation to
acetylcholine in OC and OCAG did not correlate with superoxide (a), hydrogen peroxide (b),
peroxynitrite (c), nitric oxide (d) MFI. However, there was a near significant correlation with dilation
to acetylcholine and glutathione MFI (e). Significance as p < .05 as determined via linear regression
analysis.

Figure 63: Alternations in ROS/RNS/GSH MFI in Response to Intraluminal Flow or
Superoxide Dismutase Inhibition. Accumulation or expenditure of superoxide (a), hydrogen
peroxide (b), nitric oxide (c), peroxynitrite (d), and glutathione (e) in response to flow at 10 and 25
μL/min. Flow trials were repeated with DETC inhibition of superoxide dismutase for superoxide and
peroxynitrite. Significance as p < .05 determined via Students t-test.
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Figure 64: Percent Relaxation to Intraluminal Flow in Aging and CAG Diet with
Inhibitors/Scavengers of Dilatory Mediators. Flow is slightly, but not significantly, increased with
CAG dietary intervention (a). Inhibition/scavenging of flow-mediated dilatory mediators nitric oxide
(via L-NAME), hydrogen peroxide (PEG catalase), or peroxynitrite (uric acid) did not meaningfully
alter dilation to flow in aged microvessels (b) or microvessels from CAG diet rats (c). Significance
as p <.05 determined via Student’s t-test at each dose.

10.03: TERT Peptide Experiments
Aging nearly significantly reduces isoproterenol-mediated dilation in aging at 10-6 to 10-5 [M] (p
= .071, .067). NucXTERT shunting of TERT to the mitochondria significantly improves
isoproterenol-mediated dilation in aging from 10-6 to 10-4 [M] (p = .019, .009, .017) while mitoXTERT
shunting of TERT to the nucleus non-significantly reduces isoproterenol-mediated dilation in youth
(Figure 65a). Aging reduces dobutamine-mediated dilation from 10-7 to 10-5 [M] (p = .059, .018,
.005). MitoXTERT reduces dobutamine-mediated dilation in youth from 10-7 to 10-5 [M] (p = .069,
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.022, .006) while nucXTERT nonsignificantly restores dobutamine-mediated dilation in aging
(Figure 65b). Aging blunts dilative response to acetylcholine from 10-8 to 10-6 [M] (p = .065, .002,
.026) instead leading to constriction. MitoXTERT significantly blunts dilation to acetylcholine in
youth from 10-7 to 10-4 [M] (p = .024, .026, .007, .051) while nucXTERT non-significantly improves
dilation to acetylcholine (Figure 65c). AGS499, pharmacologic activator of TERT, significantly
enhanced OC dilation to isoproterenol at doses 10-7 to 10-4 (p = .039, .021, .007, .006) while nonsignificantly enhancing dilation in OC to dobutamine and acetylcholine (Figure 66a-c). AGS499 did
not significantly affect dilation to either of the three agonists in young vessels.

Figure 65: Effect of Shunting TERT to the Mitochondria in Aging or Nucleus in Youth on
Beta Adrenergic- and Acetylcholine-mediated Dilation. Effect of mitoXTERT on YC and
nucXTERT on OC isoproterenol (a), dobutamine (b) and acetylcholine (c) dilative response.
Significance determined as p < .05 with Two Way Repeated Measures ANOVA with Holm-Sidak
post hoc testing.
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Figure 66: Effect of Pharmacologically Activating TERT on Beta Adrenergic- and
Acetylcholine-mediated Dilation in Youth and Aging. Effect of AGS499 on YC and OC
isoproterenol (a), dobutamine (b) and acetylcholine (c) dilative response. Significance determined
as p < .05 with Two Way Repeated Measures ANOVA with Holm-Sidak post hoc testing.

10.04: Mitochondrial Fission/Fusion, Nitrosative Potential, and Morphometry
Expression of fission/fusion mediators DRP-1 (pro-fission) and MFN-2 (pro-fusion) were not
significantly different between groups (Figure 67a). Albeit, DRP-1 trended towards greater
expression in aging with mild recovery in OCAG. Mitochondrial marker TOM20 was decreased in
aging and restored in OCAG, albeit non-significantly. OCAG non-significantly upregulated MnSOD
protein expression resulting in non-significantly enhanced protein nitrosylation (Figure 67b).
Mitochondrial morphology in YC was characterized as rod-like whereas in OC it was more circular
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(Figure 68). Although there was no significant difference in aspect ratio or form factor in youth vs.
aging, OCAG significantly enhanced these parameters vs. YC (p = .016, .049). There was no
significant difference in area, mitochondrial fission factor, mitochondrial footprint, branch length or
branches per network.

Figure 67: Protein Expression Contributing to Mitochondrial Dynamics and Oxidative and
Nitrosative Dynamics. Protein expression as MFI of fission mediating DRP-1, mitochondrial
marker TOM20, and fusion mediating MFN-2 (a) as well as superoxide quenching MnSOD and
protein nitrosylation marker SNO. Significance as p < .05 via Two-Way ANOVA (a) or T-test (b)
with Bonferroni post hoc analysis. DRP-1, dynamin-related protein 1; MFN-2, mitofusin 2; MnSOD,
manganese superoxide dismutase; OC, old control; OCAG, old + cycloastragenol diet, SNO Snitrosylated (protein).

203

Figure 68: Mitochondrial Morphometric Analysis After Cycloastragenol Diet. Morphology of
YC, OC, and OCAG microvascular mitochondria with area outlined and branch analysis (a). Aspect
ratio and form factor (b), area (outlined area in second to bottom row of a) and mitochondrial fission
factor (particles/pixels * 100)(c), mitochondrial footprint (purple area in bottom row of a) (d), branch
length and branches/network i.e. network density (bottom row of a). YC vs. OCAG. One Way
ANOVA with Bonferroni post hoc.
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CHAPTER 11
DISCUSSION

Current therapeutic options for coronary microvascular disease are of limited effectiveness. For
example, atenolol β1ADR blockade clinically decreases cardiac workload and oxygen demand and
causes vasorelaxation by decreasing renin release from juxtaglomerular cells. However, the
isolated effects of atenolol on isolated coronary microvessels we have shown is to cause
constriction (Figure 69). Since this dissertation shows that CMD is a hyperconstrictive pathology
in part due to blunted β1ADR function, beta blockers may potentiate microvascular
hyperconstriction and at best simply treat the symptom rather than pathologic root cause. Indeed,
atenolol has been shown to worsen coronary flow reserve, an indicator of coronary microvascular
function, in patients with essential hypertension [875]. Currently, beta blockers such as atenolol or
nebivolol are indicated as first-line pharmacotherapies for CMD [876]. Further, there are no largescale studies on pharmacotherapeutic approaches for CMD, rather mostly smaller in scale with
many non-randomized [876]. Conversely, an ideal therapy for CMD to maintain βADR contributions
to vascular tone and dilation must also not consequently enhance myocardial βADR-mediated
inotropism (i.e., using a βADR agonist). Therefore, addressing the intrinsic cause of microvascular
β1ADR dysfunction, which we suggest is oxidative stress with aging, is a justified endeavor and
may be a more appropriate therapeutic approach. We hypothesized that aging-induced CMD is
caused by a) abrogated FMD due to loss of nitric oxide signaling and b) ROS-dependent βADR
Desensitization & Internalization. We also hypothesized that these effects are reversible by
therapeutically ameliorating mitochondrial dysfunction and oxidative stress with SVF.
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11.01: Aging Causes Blunted β1ADR Density and Function, Reversed by SVF Therapy
Coronary flow reserve is significantly reduced in aging when induced by dobutamine, but not
adenosine. This indicates a β-adrenergic contribution to microvascular function that is lost with
aging. This was restored with SVF, but not BM-MSC therapy. This complements the data that
demonstrate dilation to βADR-agonism is attenuated in aging, especially with norepinephrine. The
blunted dilation with norepinephrine is especially pronounced due to its dual effect to activate
constrictive alpha-adrenergic receptors. With loss of the beta contribution in aging, the balance
shifts to favor hyperconstriction, as is seen in coronary artery disease [41]. To complement this, we
found that alpha receptor density did not change with aging or SVF therapy, however, β1ADR (but
not β2-3ADR) was significantly reduced with aging, restored by SVF. That β1ADR was the most
altered adrenergic receptor is of interest, since it has traditionally been thought that its density
diminishes as the branching order decreases (directionally towards the capillaries) [41]. β1ADR’s
contribution to microvascular dilation was confirmed, as isoproterenol’s (β1-2ADR agonist) dilative
function was more severely abrogated with CPG20712A-mediated β1ADR inhibition rather than
β2ADR inhibition with ICI118551. Measures of diastolic dysfunction were also enhanced with aging
indicating that coronary microvascular dysfunction may precede cardiac performance and perhaps
ultimately heart failure in the elderly. To that end, a future direction is to repeat a subset of the
experiments of this dissertation in trans-aortic constriction model to determine CMD’s potential
contributions towards the development of heart failure after myocardial infarction.
We next investigated the effect of aging and SVF therapy on downstream factors of β1ADR
signaling including negative regulatory factors (GRK2, Gai, and β-arrestin) as well as positive
regulatory factors (Gs). The β1ADR is associated with Gs which upon receptor activation, leads to
activation of adenylate cyclase. In the microvasculature, there was no difference in Gs density albeit
there was a decrease in Gs in the myocardium (results not shown, performed by co-graduate
student) [45]. Despite this, there was a difference in vasodilation when directly stimulating Gs with
sodium fluoride. We observed a significantly reduced relaxation in vessels from SVF-treated rats
compared to YC and OC throughout the lower doses, but significantly higher relaxation compared
to YC at the last dose. This data fits into a mixed field as Weber and colleagues reported NaF
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promoting a vasoconstriction response in mesenteric arteries from old rats [877] but is contrary to
Cushing and colleagues reporting NaF vasodilation as an endothelial-dependent mechanism in
porcine, bovine, canine, and human coronary arteries [878].
Even though the Gs protein initiates the signaling cascade for vasodilation following β1-AR
activation, crosstalk between Gs and Gai can occur [879, 880], and both govern adenylate cyclase
activity [881]. The activity and levels of Gai have been shown to increase in the myocardium with
heart failure [882, 883]; furthermore, a study conducted by Janssen and colleagues showed that
adenovirus-directed overexpression of Gai2 attenuated β-AR signaling in rabbit myocytes [884].
When we examined mRNA expression of inhibitory G-proteins in isolated coronary microvessels,
we found an increase in Gnao1 and Gnai2 with aging compared to young. This corresponded with
increase in Gai1 protein in the myocardium of OC rats that is not reversed following SVF therapy
(results not shown, performed by co-graduate student) [45]. However, there was no difference in
microvascular Gai1 between groups (results not shown, performed by co-graduate student) [45].
While many studies have examined the effect of age or HF on Gai levels in the myocardium and
the ability of Gai to cross-inhibit β1AR mediated contractile response [885], few studies have
examined the effect of age on Gai in the coronary microvasculature. Regardless, these results
suggest SVF’s ability to rejuvenate microvascular β1AR density and function is not attributable to
alleviated Gai expression.
Following ligand binding to the β1AR, signal transduction is regulated first by GRK2, which
phosphorylates the internal tail of the receptor, initiating endocytosis [886]. The role of GRK2 in
βAR desensitization has led to study of its inhibition as a potential therapeutic, both for treating
heart failure [887] and for directing favorable myocardial remodeling following MI [888]. Schutzer
et al showed increased GRK2 activity in the aorta of aged rats [23], and this was directly related to
a decline in βAR functionality in aged rat coronaries [889]. Ungerer and colleagues measured an
increase in transcription of GRK2 in myocardial samples from patients with heart failure over 50
years of age [890]. These observations do not match our own assessments of mRNA transcripts
of GRK2 in the coronary microvasculature (no difference between groups). We also found no
difference in GRK2 protein expression in coronary microvessels, albeit naturally inhibited GRK2
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(phospho-GRK2) was significantly decreased in myocardium (with non-significant increase in
OSVF) (results not shown, performed by co-graduate student) [45]. Utilizing pressure myography,
we showed an improvement in vasorelaxation to norepinephrine following GRK2 inhibition with
paroxetine in our aged groups (OC and O+SVF) but not in YC, indicating retained GRK2 function
in OSVF. Taken together these data suggest that with advancing age there is an increase in GRK2
activity in coronary microvessels that SVF does not reverse, but instead possibly alters the kinase
activity via phosphorylation status of GRK2 which needs confirmation in isolated microvessels.
GRK2 phosphorylation of the β1AR initiates receptor endocytosis through β-arrestin-mediated
binding and scaffolding and subsequent dynamin-mediated internalization. Transcription of
microvascular β-arrestin-2 is increased with aging, with no reduction with SVF therapy. This did not
translate to protein density differences of β-arrestin-2 between YC, OC, or OSVF. However,
myocardial β-arrestin-1 and β-arrestin-2 (non-specific antibody) was greater in OSVF vs. YC
(results not shown, performed by co-graduate student) [45]. Therefore, alleviation of β-arrestin
expression is not responsible for SVF’s regenerative effect on β1AR-mediated vasodilatory
function. On the other hand, alpha-arrestin arrdc3 transcription was decreased in OSVF, which
may be of importance considering arrdc3 mediates β2ADR ubiquitination (via recruitment of neural
precursor development downregulated protein 4 (NEDD4)) leading to desensitization and
internalization [891, 892], as well as delayed βADR recycling from endosomes [893]. Translational
status as well as contribution to β1ADR desensitization and internalization (or recycling delay)
represents an important future direction.
Overall, it was confirmed that age-related microvascular dysfunction occurs above the level of
adenylate cyclase, as direct stimulation of adenylate cyclase with forskolin and direct cAMP
donation led to no difference in dilation between groups. Interestingly, this observation was despite
an aging-associated decrease in adenylate cyclase isoform 6 transcription not recovered by SVF
therapy. Importantly, myocardial βADR protein density was not upregulated with SVF therapy,
which means that SVF therapy will not increase myocardial sensitivity to circulating catecholamines
to increase inotropism (results not shown, performed by co-graduate student) [45].
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Plasma catecholamines (norepinephrine) were significantly elevated in aging not reversed by
SVF, which provides an initial driving force for GRK-2-mediated desensitization and eventual βarrestin- and dynamin-mediated internalization. Consequently, SVF-mediated recovery of β1ADR
function occurs despite consistent habituating stimuli. RNA sequencing showed that the
transcription of the β1ADR was not altered in aging or upregulated with SVF (albeit β2ADR
transcription was increased with SVF). Therefore, the differences in β1ADR density and function in
aging and SVF must be due to post-translational modifications, either to the receptor itself or its
regulatory components just discussed, of which we suspected redox contributions.

11.02: SVF Rescues Vasodilatory Function Through Attenuation of ROS and Mitochondrial
Dysfunction
Aging induces a redox shift in coronary microvessels towards oxidative stress, accompanied by
a decrease in antioxidants glutathione and nitric oxide. Intravenous treatment with SVF four weeks
prior to explant reverses these trends in old rats, except for nitric oxide. Oxidative stress occurs
despite an age-related increase in gene expression of several antioxidant proteins including
catalase, superoxide dismutase 3, and thioredoxin reductase. This likely indicates attempted
compensatory regulation that cannot compete with prooxidant processes, including gene
expression of xanthine dehydrogenase, monoamine oxidase A, and SHC1 (encodes p66SHC).
These consequences with aging include abrogated vasodilation through reduced FMD and β1ADR
signaling. We show for the first time that ROS levels negatively correlate whereas nitric oxide and
glutathione positively correlates with β1ADR function. The major findings support that antioxidant
and mitochondrial regenerative effects of SVF cell therapy restores vasodilation in aging by
switching the acute mediator of FMD from hydrogen peroxide to peroxynitrite, as well as by
attenuating desensitization and internalization of the β1ADR.
To understand the mechanistic underpinnings for SVF’s ability to shift the redox landscape of
aged coronary microvessels, we must walk through each of the major sources of ROS production.
The main driver of ROS generation is leakage of 1-3% of electrons from the electron transport
chain (ETC) [43]. At the same time, the end product of oxidative phosphorylation, ATP, is becoming
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increasingly recognized as necessary for optimal dilative function [894]. Therefore, there is a
tradeoff in attempting to keep ROS production in check by modulating ETC efficiency, as is known
to be done in aging, and maintaining maximal dilative efficiency [43]. The following few paragraphs
will describe SVF’s effects on ETC function and other mitochondrial processes that ultimately
reduce oxidative stress while restoring youthful β1ADR- and flow-mediated dilative efficiency as
per Figure 69.

Figure 69: Effects of Aging and SVF Therapy on Mitochondrial Function, Vasodilation, and
Potential Mechanisms of SVF-mediated Amelioration of ROS and Mitochondrial
Dysfunction. Note genes were included with significance as p < 0.1. Image created with
BioRender.com.

The preceding step of oxidative phosphorylation is the generation of NADH, which is produced
in the TCA cycle, which itself requires the transport of pyruvate across the inner mitochondrial
membrane. The mitochondrial pyruvate carriers 1 and 2 were both genetically downregulated in
aging and restored with SVF. Therefore, high pyruvate and NADH drive oxidative phosphorylation
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according to Le Chatelier’s principle, which is likely the case in YC and OSVF vs. OC. At the same
time, high NADH/NAD+ ratio drives matrix superoxide production from complex I. Aging reduced
genetic expression of Ndufv2, a core subunit of complex 1, while SVF upregulated genetic
expression of Ndufa10, another core subunit. This could indicate a downregulation of complex 1
function in aging in attempt to blunt superoxide production, whereas SVF therapy restores complex
1 function since superoxide levels are in check. From complex I or II, electrons are shunted to
coenzyme Q. CoQ10a, itself a major antioxidant, was upregulated in SVF vs. OC, as were complex
III assembly factors Uqcc1 and Uqcc2, again suggesting a facilitation of electron transport.
Complex III is another generator of superoxide, both in the mitochondrial matrix and inner
mitochondrial space, so downregulation again could be an attempt by OC to halt superoxide
production. Complex IV subunit COX7b and assembly factor COX20 were downregulated in aging
with COX20 being restored by SVF. ATP synthase subunit ATP5mg was downregulated in aging,
albeit ATP synthase inhibitory factor ATP5if1 (encodes ATP synthase inhibitory factor (IF)) was
significantly upregulated in OSVF vs. YC. Finally, uncoupling protein 2 (UCP2), also responsible
for decoupling oxidative phosphorylation by reducing the membrane potential that drives proton
flow through ATP synthase, was genetically upregulated with aging and remained so in SVF.
The culmination of these observations was that baseline ATP production was blunted in aging
and significantly reinvigorated with SVF therapy. Furthermore, generation of endothelial shear
stress by introducing intraluminal flow facilitated greater oxygen consumption in OSVF vs. OC as
well as ATP production to match demand in YC and OSVF, but not in OC. JC-1 reported membrane
potential, as expected by enhanced UCP2 expression, was diminished in aging as a likely
compensatory mechanism to slow the respiratory rate and lower superoxide generation. On the
contrary, SVF returned mitochondrial membrane potential to levels seen in YC, despite maintained
UCP2 genetic expression. It is possible that protein expression of UCP2 in SVF does not match
the genetic trends. Additionally, it is known that ROS activate whereas glutathionylation of UCP2
results in inhibition [895], and we showed significantly increased reduced:oxidized glutathione ratio
in OSVF vs. OC. The mitochondrial permeability transition pore (mPTP) is also regulated by post-
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translational modifications, namely, oxidized glutathione (GSSG) and peroxynitrite opens the pores
[896, 897], both of which are reduced in OSVF vs. OC at baseline (without induced flow).
It is paradoxical that OSVF had upregulation of ATP5if1, since OSVF had preserved capability
to generate ATP. No differences between groups were found for translation inhibitor leucine-rich
pentatricopeptide motif-containing protein or immediate early response X-1, which causes
degradation of IF [898]. IF is also post-transcriptionally controlled (negatively) by cAMP dependent
PKA, which may be active in OSVF to explain maintained ATP production in OSVF. Indeed, IF
becomes inhibited by βADR agonism and subsequent cAMP-PKA signaling [898]. Since the mPTP,
contributing to proton leak, is composed in part of ATP synthase, IF may also inhibit mPTP
assembly in OSVF to prevent uncoupling and execution of regulated cell death [898, 899]. IF
inhibition of ATP synthase in OSVF would explain increased membrane potential and could allow
for mitohormesis to induce antioxidant regulatory response, which could be reversed during times
of need for ATP production such as βADR agonism [898]. Nevertheless, ATPif1 and UCP2
inhibition of oxidative phosphorylation were outweighed in OSVF by restoration of Mcp1, Mcp2,
Ndufa10, CoQ10a, Uqcc1, Uqcc2, COX20, lower ROS and higher GSH:GSSG ratio.
The alleviation of oxidative stress in OSVF allows for ETC to function again to make ATP without
major

consequence

since

antioxidant

capacity

can

match

new

ROS

generation.

Immunofluorescence staining found greater NOX4 protein MFI with aging albeit no increase in gene
expression. NOX4-derived hydrogen peroxide can lead to ROS-induced ROS release in part
through activation of p66SHC [900]. p66SHC diverts electrons from cytochrome C (part of the electron
transport chain) in the inner mitochondrial space to produce superoxide [188]. The MFI of MnSOD
was reduced with aging and reversed by SVF, despite no genetic expression changes.
Interestingly, p66SHC (increased gene expression in OC) can inactivate FOXO3, causing MnSOD
downregulation [258]. p66SHC overexpression is also known to reduce dilation to acetylcholine and
nitric oxide bioavailability, while the opposite is true in knockout models [265-267]. Therefore,
greater NOX4 and p66SHC could be a major driver of ROS production in aging coronary
microvasculature aside from the ETC. One mechanistic explanation for SVF’s antioxidant effects
could be to reduce signaling from NOX4/p66SHC axis. NOX4 MFI was reduced to YC levels by SVF
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and there was no expressional difference in p66SHC between YC and OSVF. Moreover, SVF
upregulated gene expression of additional antioxidant proteins such as glutathione synthetase,
Sirt5, thioredoxin-like 1, glutaredoxin-like protein, selenophosphate synthetase 1, and several heat
shock protein subunits compared to OC. Although there was no increase in glutathione synthetase
protein MFI, glutathione itself was increased with SVF to YC levels.
Mitochondrial health and proclivity for ROS generation are also determined by the fission and/or
fusion of dysfunctional mitochondria. Morphologically, we showed mitochondria were more isolated
and punctate in aging, associated with increased ROS production, compared to OSVF which
showcased greater network density and less circular shape, associated with less ROS production
[43]. In OC, this fragmented morphology was associated with greater Fis1 and DRP-1 gene and
greater DRP-1 protein expression. Additionally, DRP-1 localized to the mitochondria (where it is
activated) to a greater degree in aging. DRP-1 gene and protein expression were reduced by SVF
therapy and localization to the mitochondria was nearly significantly reduced. Additionally, SVF
therapy conferred upregulation of fusion-mediator MFN-1, but not MFN-2 genetic and protein
expression, matching a less fragmented morphology. Inducing fusion pharmacologically by others
has been associated with protection against ROS-induced mitochondrial fragmentation and
protects against cell death [901]. It is unclear if greater fusion in OSVF is a consequence of a lower
ROS environment, or if activating fusion itself aids in lowering ROS levels, or both.
Fission/fusion balance also affects dilative response to flow and β1ADR agonism. In YC and
OVSF, both of which had fused mitochondria, inhibition of Opa1 with MYL22 lead to significant
attenuation in dilation to norepinephrine. This was not replicated with DRP-1 inhibition with MDIVI.
Together, this indicates fusion confers a protective dilative effect and that blockade of fusion
(leading to non-counterbalanced fission) instigates blunted dilative effect. Thus, adding MYLS22,
we were able to make vessels from YC and OSVF behave like OC vessels exhibiting hyperfission.
OC vessels inhibited with MDIVI nonsignificantly improved dilation to norepinephrine at each dose
while MYLS22 had no effect. Therefore, inhibiting fusion alone was not sufficient to regenerate
β1ADR dilative function.
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Intraluminal flow + MYLS22 significantly attenuated YC dilation instead leading to flow mediated
constriction (with no MDIVI effect). Surprisingly, MDIVI (but not MYLS22) lead to OSVF exhibiting
flow-mediated constriction. The reason blocking fission may cause flow-mediated constriction may
be due to the fact that OSVF utilizes peroxynitrite (and hydrogen peroxide to a lesser extent) as
the mediators of FMD. Therefore, inhibiting fission and causing hyperfusion may attenuate ROS
production to the point of losing their signaling potential for dilation. This would not be the case in
YC as its FMD mediator is nitric oxide. Neither MDIVI nor MYLS22 had significant effect on OC
FMD.
If mitochondrial dysfunction is severe enough, mitophagy can be instigated by Pink1 and Parkin,
of which we found no genetic or protein expression difference between groups in myocardium or
aortic tissue. However, microvascular vps13c, the negative regulator of parkin, was decreased in
aging. Therefore, the upregulation of vps13c could reflect dysfunctional ROS generating
mitochondria and a compensatory response in OC to induce mitophagy. Interestingly, loss of
vps13c has been associated with reduced mitochondrial membrane potential, enhanced respiration
rates (as compensation for reduced membrane potential) and fragmented mitochondrial
morphology [902].
Optimal mitochondrial function could be linked to β1ADR through the production of ATP. Indeed,
we found a correlative link between ATP levels (and ΔΨM) and dilation to β1ADR agonism. After
activation of the β1ADR, adenylate cyclase converts ATP into cAMP to activate PKA to inhibit
smooth muscle myosin light chain kinase and block contraction. At older age, bioavailability of ATP
may be limited enough to impact this pathway (Figure 68). Although there was no correlation in
our data between ATP levels and FMD, recent innovations by others support an essential role for
ATP in FMD. Wilson et al found that blocking ATP production with oligomycin significantly blunted
acetylcholine and flow-mediated dilation through reduced IP3 mediated calcium signaling that would
otherwise activate eNOS and nitric oxide production [894, 903]. This effect could be replicated by
blocking mitochondrial pyruvate carriers. As nitric oxide is a necessary component of peroxynitrite,
this could also potentially contribute to loss peroxynitrite-mediated dilation as well as nitric oxide
mediated dilation.
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It has previously been reported that the mediator of coronary FMD shifts throughout the lifespan
from prostaglandin during juvenile phase, to nitric oxide during young adulthood, to hydrogen
peroxide in coronary artery disease [20]. Our data confirms this trend, as youth produced significant
nitric oxide MFI and FMD was inhibited by L-NAME, whereas in aging hydrogen peroxide MFI was
most significantly increased with flow. Catalase did not inhibit FMD in aged vessels because dilation
was minimal to begin with. With flow plus DETC inhibition of superoxide dismutase, superoxide
MFI was greater in YC and OSVF compared to OC. This suggests that there is reduced MnSOD
expression or function in aging, reversed by SVF therapy. Although RNAseq showed no difference
in MnSOD transcription, immunofluorescence showed increased MnSOD availability in OSVF
compared to OC. Other than expression changes in MnSOD described above, function of MnSOD
in aging can be inhibited by peroxynitrite-mediated tyrosine nitration (and chronic baseline
peroxynitrite MFI was increased in OC) [904]. Inhibiting catalase with AMT led to greater hydrogen
peroxide in YC and OSVF compared to OC, indicating a reduction in catalase expression/function
with aging that is restored by SVF. Interestingly, RNAseq showed increased catalase gene
expression in the aged groups, OC and OSVF, when compared to YC, while immunofluorescence
showed no difference between groups. Catalase function can be activated by phosphorylation of
catalase at tyrosine 231 and 386, and can be ubiquitin degraded, which may explain these findings
[905].
With SVF there was increased peroxynitrite MFI in response to flow, and FMD was inhibited by
uric acid scavenging of peroxynitrite as well as L-NAME. This goes against our initial hypothesis,
as we believed nitric oxide would be restored to YC levels and would mediate FMD in OSVF vessels
[874]. However, as nitric oxide is required to produce peroxynitrite (in combination with superoxide),
and L-NAME inhibited FMD, it stands to reason that peroxynitrite FMD response is dependent on
enough nitric oxide production to combine with superoxide resulting in significantly increased
peroxynitrite. Although peroxynitrite is a ROS, it has been speculated to have functional
significance in geriatric populations as a “new healthy vascular endothelium redox status”. This is
because peroxynitrite can donate nitric oxide, thereby acting as a reservoir and eliciting FMD,
possibly without the pro-atherogenic effects of hydrogen peroxide [268]. To emphasize, the
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increase in OSVF peroxynitrite is acute, and limited to periods of enhanced FMD. During baseline
(chronic status), aged vessels had greater peroxynitrite MFI than YC or OSVF. These acute vs.
chronic redox signaling changes are likely of significance to cellular health and function.
As an aside, it is interesting that bradykinin was found to increase hydrogen peroxide instead of
nitric oxide signaling, even in youth (and to a greater extent than OC and OSVF). Lacza et al. found
that there is a significant contribution of hydrogen peroxide towards bradykinin-mediated dilation
through the BK2 receptor and activation of KATP channels (i.e., endothelium-dependent
hyperpolarization) in youth (piglets) [906]. Therefore, it should be noted that ROS signaling
(especially when acute) is not detrimental in every circumstance. Interestingly, there was greater
expression of the BK2 receptor in OSVF than YC or OC (in fact, it was the 22nd highest expressional
difference in OC vs OSVF). Therefore, the contributions of bradykinin to enhanced OSVF
microvascular tone represents another thread worthy of future investigation.
β1ADR-mediated dilation with dobutamine, norepinephrine, and isoproterenol were reduced
with aging, restored by SVF therapy. Using two vessels per animal, we determined there is negative
correlation between oxidative stress and β1ADR dilative function (albeit not for peroxynitrite) and a
significant positive correlation between glutathione and nitric oxide with β1ADR function. Thus,
oxidative stress reduces functional dilation with aging while nitric oxide/glutathione preserve
functional vasodilation.
This correlative relationship also works in reverse, as activation of β1ADR lead to decreased
ROS MFI while increasing nitric oxide MFI. Activation of αADRs on the other hand led to increases
in ROS and decreases in nitric oxide MFI. Interestingly, norepinephrine (both α and β agonist) led
to greater ROS accumulation in OC than YC or OSVF, which instead decreased superoxide MFI.
This could be reflective of shifts in the αADR and βADR ratio with aging and SVF therapy. It has
been previously reported in the myocardium that sustained agonism of the β1ADR contributes to
oxidative stress [907]. Our finding that β1ADR agonism instead lead to a minor alleviation of ROS
is likely due to the different tissue source (vascular). In the myocardium, β1ADR leads to inotropism
and increased oxygen consumption and workload to increase ROS whereas in the vessels β1ADR
is leading to smooth muscle relaxation, which utilizes less ATP than constriction.
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Of note, stimulation with isoproterenol led to a robust nitric oxide response in YC only. It is
known that β1ADR-mediated dilation is achieved mostly through cAMP activation of PKA and
subsequent phosphorylation of myosin light chain kinase lowering its affinity for calmodulin leading
to vasorelaxation. However, a minor contribution of β1ADR-mediated dilation is from PKA
phosphorylation and activation of NOS 3 producing nitric oxide (as well as the Gs-MEK1/2-ERK12-NOS3 axis) [908]. Therefore, consistent with our other findings regarding nitric oxide, SVF was
unable to recover the nitric oxide contribution to β1ADR-mediated dilation.
Incubating vessels with exogenous hydrogen peroxide and superoxide (mimicking aging
conditions) completely attenuated YC and OSVF β1ADR dilation to isoproterenol. This effect was
diminished if co-incubating the ROS with dynasore (inhibiting dynamin i.e internalization) or
paroxetine (inhibiting GRK2 i.e. desensitization). OC vessels pre-incubated with SNP (mimicking
YC nitrosylation status), dynasore and paroxetine significantly improved β1ADR dilation to
isoproterenol. Dilation was restored approximately halfway to youthful levels with SNP and nearly
fully with dynasore and paroxetine. These results indicate a role for ROS and RNS in β1ADR
trafficking.
It has been speculated that the β1ADR can be influenced to internalize upon thiol oxidation,
and receptor recycling from the endosome is known to be inhibited by ROS [24, 527]. We found
that inhibition of PI3kγ (which activates I2PP2A to inhibit PP2A-mediated β1ADR recycling) with
BEZ235 countered the poor dilatory effects produced by exogenous ROS YC and OSVF vessels.
This is consistent with what others have found, specifically that ROS can influence β1ADR recycling
[24, 527]. This did not translate to BEZ235 improving OC vessel dilation. Interestingly, inhibiting
β1ADR recycling with okadaic acid led to significant reduction in isoproterenol-mediated dilation in
OC but not in youth. This signifies that recycling is not necessary in youth for successful maximal
response to agonist, likely due to plentiful receptor density at the plasma membrane. This is not
the case in aging, indicating that greater density of receptor has been desensitized and internalized,
and maximal dilative response to agonist depends in part on recycling. OSVF vessels exhibit
partially attenuated dilation with okadaic acid, but at high doses of isoproterenol this is not
significant. Interestingly, OSVF exhibited a decrease in arrdc3 transcription, which is known to act
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on the β2ADR and β3ADR localized to the endosome, where one of its effects is to delay recycling
by negatively regulating the receptor’s ability to enter SNX27-endosomal tubules [893]. Alleviation
of delays in recycling may account for OSVF functional perseverance to okadaic acid. Overall, this
indicates OC vessels are most reliant on recycling, followed by OSVF, then YC. Supporting these
observations, we found that protein levels (evaluated by MFI) of PP2A, I2PP2A, and PI3kγ were
unchanged with aging or SVF therapy, indicating the mechanisms of recycling themselves are
unchanged.
SNP-mediated improvement in β1ADR function has been attributed to nitrosylation and
inhibition of GRK2 [28]. We analyzed general protein nitrosative status using a fluorescent Snitrosocysteine antibody, believing SVF may restore β1ADR function by reducing ROS which would
alleviate nitric oxide bioavailability to nitrosylate/inhibit GRK2. Instead, we found that S-nitrosylation
status is significantly reduced in aging and OSVF compared to youth. This complements our
findings that SVF does not restore nitric oxide bioavailability. Thus, SVF’s recovery of vascular
dilative function is likely not due to GRK2 nitrosative inhibition. Interestingly, GRK2 also contributes
to catecholamine overload via its desensitization of the adrenal chromaffin α2ADR [870]. Since
plasma norepinephrine concentrations were similar between OC and OSVF, this is another piece
of evidence suggesting against SVF-mediated GRK2 nitrosative inhibition. Therefore, we conclude
that in the ROS/RNS β1ADR Desensitization and Internalization Axis, young vessels experience
limited ROS and plentiful nitric oxide bioavailability, resulting in functional β1ADR at the plasma
membrane potentially via greater GRK2 nitrosylation, less β1ADR thiol oxidation, and less ROSmediated blockade of receptor recycling. In aging, this axis shifts such that there is reduced nitric
oxide bioavailability, allowing functional GRK2 to influence desensitization and internalization, and
there is greater accumulation of ROS to oxidize β1ADR-thiols and inhibit recycling. With SVF
therapy, although nitric oxide bioavailability is not restored, ROS are reduced to alleviate β1ADR
thiol oxidation-mediated desensitization/internalization and restored receptor recycling.

11.03: Feasibility of TERT Pharmacologic Therapy for Coronary Microvascular Disease

218

Considering cellular therapeutic strategies in general still largely exist in the clinical trial realm,
with unanswered questions such as the autologous vs. allogeneic debate, what preconditioning
steps, if any, are necessary, and whether whole cells or their products should be used, it may be
simpler to use an alternative pharmacologic approach that directly attenuates oxidative stress. To
address this, a subset of experiments were replicated with aging rats fed a CAG supplemented
diet. To put it simply, the results obtained with SVF could not be exactly replicated with the CAG
diet alone. Baseline levels of superoxide were decreased with CAG diet. However, hydrogen
peroxide and peroxynitrite were non-significantly lower and glutathione nonsignificantly higher than
OC. Antioxidant modulation by TERT has been attributed (by others) in part due to activation of
NF-κB and subsequent antioxidant expression such as MnSOD [909].
Dilation to β1ADR agonists or flow in OCAG was not recovered significantly (albeit for one dose
in norepinephrine) as was the case for OSVF. For FMD, no inhibitors or scavengers (L-NAME,
catalase, uric acid) significantly impacted percent relaxation, so it is difficult to say precisely what
the mediator of FMD is. Differences between OCAG and OSVF were that at baseline, CAG
significantly increased nitric oxide bioavailability, there was a significant difference in nitric oxide
MFI with intraluminal flow in OC vs. OCAG, and OCAG significantly enhanced dilation to
acetylcholine. SVF could not restore nitric oxide bioavailability, its production during intraluminal
flow, nor improve dilation to acetylcholine vs OC [910]. These CAG findings are in agreement with
what others have shown in other settings (coronary artery disease), that TERT activation increases
NOS activity and FMD is attenuated by L-NAME [874].
In contrast to what others have found, intraluminal flow led to an increase in superoxide
production in OCAG vs. OC [911]. This was not seen in OSVF, and is an interesting contrary finding,
considering the mechanism for TERT reduction of ROS supposedly involves in part its association
with complex 1 and its ability to improve cytochrome C oxidase activity and overall respiratory chain
efficiency (and theoretically reduce electron leak) [909, 912]. Santos et al also found that ectopic
mitochondrial TERT expression can instead induce free-radical mediated mitochondrial DNA
damage and apoptosis and suggested that varied levels of mitochondrial TERT could lead to
differing effects, which could explain why we saw increased superoxide with flow. This may indicate

219

that alterations of CAG supplemental dosage may be needed for optimal therapeutic effect [913,
914]. On the other hand, DETC inhibition led to greater superoxide accumulation in OCAG,
suggesting greater SOD in OCAG rats, which is supported by (nonsignificantly) greater MnSOD
MFI in OCAG vs. OC. Therefore, it is possible that nitric oxide and/or superoxide could contribute
to FMD in OCAG rats.
One possible discrepancy between our OCAG and OSVF results, as well as our OCAG results
with other TERT studies in the literature, may be due to administration. CAG is a weakly soluble
compound not appropriate for systemic injection. Therefore, CAG was supplemented in the rat
chow to be absorbed through the gut. The pharmacologic bioavailability and biodistribution/tissue
distribution are unknown, especially as it relates to coronary microvasculature and surrounding
cardiomyocyte niche and therefore future studies need to determine these parameters while also
determining optimal dose. The vast majority of studies in the literature study TERT in in vitro cellular
systems with overexpressed TERT, so it makes sense that its translation to an animal model as a
pharmacologic requires such fine tuning. Indeed, our own studies involving ex vivo microvessels
incubated with peptides influencing TERT trafficking found enhancement of dilative function in OC
to β1ADR agonism and acetylcholine when TERT was shunted to the mitochondria (and vice versa
when TERT shunted to nucleus in YC). Therefore, optimization may be required to replicate these
ex vivo and in vitro effects in vivo through dietary supplementation.
Overall, SVF yielded more significant, potent, and efficacious effects on vascular dilative
function as well as stronger attenuation of oxidative stress compared to OC than OCAG did
compared to OC. The exception being that CAG supplementation was able to restore nitric oxide
bioavailability whereas SVF did not. Enhanced eNOS function and nitric oxide production is
theoretically the gold standard for vascular functional recovery. Indeed, nitric oxide and its
nitrosylation (of GRK2) could lead to attenuated β1ADR desensitization and internalization similar
what we theorize happens in YC (and that SVF cannot achieve). Then again, the “gold standard”
nature of nitric oxide recovery has been challenged, especially in the elderly. It has been speculated
that peroxynitrite accumulation in the elderly may preserve nitric oxide bioavailability through nitric
oxide donation and is utilized in OSVF FMD [268]. Indeed the focus on optimizing peroxynitrite in
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elderly has been termed the “new healthy vascular endothelium” [268]. Whether fine tuning of CAG
dosage to optimize attenuation of ROS and enhancement of dilative function similar to SVF while
maintaining its nitric oxide restoration would make it a worthy competitor for SVF remains to be
seen.

11.04: Conclusions:
Future investigations should aim to confirm the findings of this dissertation by studying β1ADR
trafficking through qualitative and quantification studies. For example, in vessels or in live
microvascular endothelial cells, fluorescently tracking the trafficking of the β1ADR in response to
ROS, SNP, paroxetine, and dynasore in YC, OC, OSVF would qualitatively confirm and support
our findings [28, 915]. β1ADR trafficking can also be quantified by western blotting of plasma
membrane and endosomal β1ADR [916]. It would also be of interest to examine mitochondrial
structure in terms of cristae morphology with electron microscopy. Emerging studies are showing
a critical role for Opa-1 mediated optimal cristae structure in forming respiratory supercomplexes
that maximize respiratory efficiency and minimize electron leak and ROS formation [917-919].
Therefore, insight into supercomplex formation and cristae structure between YC, OC, and OSVF
would be of interest. Utilization of Seahorse Assay on aortic tissue would provide more detailed
insight and confirm our findings on vascular mitochondrial respiratory function (we were unable to
get readings using microvascular tissue). Finally, the constituents of SVF that are responsible for
restoration of redox balance, FMD, and adrenergic homeostasis should be determined. We have
already ruled out CD11b+ macrophages as the constituent of SVF causing therapeutic effect,
despite promising preliminary study [910]. Ongoing work to that end is utilizing adipose-derived
stem cells (ADSCs) and replicating a subset of these experiments. Determining the mechanism
for SVF-mediated antioxidation is also of importance. In Figure 67 we show three possible
mechanisms: paracrine factors (exosomal or exocytosed proteins, miRNA, etc.), direct donation of
cellular products, or ADSC differentiation into healthy endothelial cells. Determining which
mechanism(s) are the cause of SVF-mediated therapeutic effect would be of benefit for its
therapeutic development. To that end, ongoing work is utilizing mass spectrometry on conditioned
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media of SVF and ADSC to determine possible paracrine contributions including antioxidant
contents. It would be of interest if SVF-derived exosomes could be used in lieu of cells [920].
Indeed, adipose SVF-derived mesenchymal stem cell exosomes have antioxidant effects and
protect against ischemia and apoptosis, encourage angiogenesis, and restore mitochondrial health
[13, 14, 671, 921].
We hypothesized that flow- and β1ADR-mediated dilation are reduced with aging and reversed
via SVF therapy by attenuating oxidative stress and restoring protective nitrosative signaling. FMD
and β1ADR were significantly reduced in aging with reversal by SVF therapy. However, nitric oxide
bioavailability was not restored by SVF cell therapy to YC levels; instead, peroxynitrite was the
mediator of improved FMD. β1-adrenergic dilative function was restored in SVF correlating with
reduced ROS, enhanced mitochondrial function, and increased antioxidant glutathione. Our
conceptual ROS/RNS β1ADR Desensitization and Internalization Axis is supported since
exogenous SNP or blockade of desensitization/internalization restored β1ADR function in aging,
and exogenous ROS attenuated β1ADR function in youth/OSVF unless simultaneously blocking
desensitization/internalization. In conclusion, aging-mediated microvascular dysfunction and
hyperconstriction can be ameliorated by targeting oxidative stress. SVF therefore has significant
translational potential for patients with CMD and is theoretically superior over current clinical
standards (e.g. beta blockers) that treat symptoms but do not address the pathologic cause of
microvascular dysfunction and hyperconstriction.

Summary:
Hypothesis: Aging-induced CMD is caused by a) abrogated FMD due to loss of nitric oxide
signaling and b) ROS-dependent βADR Desensitization & Internalization (Aim 1), reversible by
therapeutically ameliorating mitochondrial dysfunction with SVF (Aim 2).

Aim 1: Determine the Mitochondrial & ROS/RNS-dependent Contributions to FMD and βADR
Desensitization & Internalization Status in Young vs. Aged Coronary Microvessels.
•

Aging is associated with ↓ FMD and β1ADR dilation, ↑ ROS and ↓ NO/GSH
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•

Aging is associated with ↑ prooxidant/antioxidant gene expression and ↓ antioxidant protein
expression and ↑ prooxidant protein.

•

Aging switches the FMD signaling mediator from nitric oxide in youth to hydrogen peroxide.

•

β1ADR Function Correlates negatively with ROS and positively with NO/GSH

•

Exogenous ROS incubation attenuates β1ADR function, prevented with inhibition of
desensitization/internalization via paroxetine/dynasore

•

Exogenous NO restores β1ADR function, likely through GRK2 inhibition

•

Aging leads to β1ADR internalization in endosomes. Blocking Recycling leads to further
exacerbated blunted dilation.

•

Aging leads to hyperfission including ↑DRP-1, ↓MFN-1, ↓ ΔΨM, ↓ ATP production, and
isolated punctate mitochondria

Aim 2: Determine that SVF Reverses CMD by Restoring Mitochondrial Function to Restore FMD
and Alter the ROS/RNS-β1ADR Desensitization & Internalization Axis to Preserve Plasma
Membrane βADR.
•

SVF therapy is associated with ↑ FMD and β1ADR dilation, ↓ ROS and ↑ glutathione, but
no change in nitric oxide

•

SVF leads to ↑ antioxidant genetic and protein expression and ↓ prooxidant genetic and
protein expression

•

SVF switches the acute mediator of FMD from hydrogen peroxide to peroxynitrite.

•

Exogenous ROS incubation attenuates β1ADR function, prevented with inhibition of
desensitization/internalization via paroxetine/dynasore

•

SVF reduces hyperfission including ↓ DRP-1 and ↑ MFN-1 (gene and protein expression),
↑ ΔΨM, ↑ oxygen consumption, ↑ ATP production, and ↑ mitochondrial network density
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(hADMSCs) to form Purkinje cells and to use the reprogrammed Purkinje cells to bioprint Purkinje
networks. Methods: hADMSCs were reprogrammed to form Purkinje cells using a multi-step
process using transcription factors ETS2 and MESP1 to first form cardiac progenitor stem cells
followed by SHOX2 and TBX3 to form Purkinje cells. A novel bioprinting method was developed
based on Pluronic acid as the sacrificial material and type I collagen as the structural material. The
reprogrammed Purkinje cells were used in conjunction with the novel bioprinting method to bioprint
Purkinje networks. Printed constructs were evaluated for retention of functional protein connexin
40 (Cx40) and ability to undergo membrane potential changes in response to physiologic stimulus.
Results: hADMSCs were successfully reprogrammed to form Purkinje cells based on the
expression pattern of IRX3, IRX5, SEMA and SCN10. Reprogrammed purkinje cells were
incorporated into a collagen type-1 bioink and the left ventricular Purkinje network was printed using
anatomical images of the bovine Purkinje system as reference. Optimization studies demonstrated
that 1.8 mg/ml type-I collagen at a seeding density of 300,000 cells per 200 µl resulted in the most
functional bioprinted Purkinje networks. Furthermore, bioprinted Purkinje networks formed
continuous syncytium, retained expression of vital functional gap junction protein Cx40 post-print,
and exhibited membrane potential changes in response to electric stimulation and acetylcholine
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evaluated by DiBAC4(5), an electrically responsive dye. Conclusion: Based on the results of this
study, hADMSCs were successfully reprogrammed to form Purkinje cells and bioprinted to form
Purkinje networks.

A2.10: Introduction
There remains an unprecedented need to develop innovative strategies to treat patients
with cardiac pathologies. Cardiac tissue engineering strategies aim to tackle this by fabricating 3D
cardiac patches that can be used to augment or replace lost myocardial function. A penultimate
goal is the fabrication of a complete biologic heart – the Total Bioficial Heart. On average, 5,000
hearts are transplanted each year out of 50,000 transplant candidates [922]. This disparity
highlights the need for moonshot innovations in the field of tissue engineering to accomplish this
goal. Fabrication of partial or total heart tissue will first require the ability to generate the major
components of the heart, namely, the vasculature (both macrovascular and microvascular
circulations), contractile components comprised of cardiomyocytes and the conductive system
comprised of Purkinje and pacemaker cells.
In the recent literature, there has been a lot of attention to bioengineering 3D cardiac
patches to replace and restore the contractile function of the heart [12, 923-929]. There are now
many different platforms to bioengineer 3D heart muscle, using primary neonatal cardiac myocytes
or induced pluripotent stem cells (iPS) derived cardiac myocytes and many different biomaterials
have now been evaluated, including fibrin, type I collagen, polylactic-co-glycolic acid (PLGA) and
acellular scaffolds [930-933]. In addition, recent studies have shown a positive correlation between
bioengineered patch function and chemical conditioning and conditioning using coupled
electromechanical stimulation [934-939]. While the field of cardiac tissue engineering has
progressed relatively rapidly with a significant expansion in the number of available models of
contractile tissue, the same cannot be stated about the Purkinje network.
The cardiac Purkinje fiber network is comprised of highly specialized cardiomyocytes
(CMs) responsible for the synchronous excitation and contraction of the ventricles. Purkinje fibers
are distributed throughout the myocardium and are responsible for distribution and propagation of
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electrical impulses. Individual strands are 30-50 μm in diameter and contain specialized myocytes
surrounded by a thick layer of collagen [940], serving as an insulator during electrical impulse
propagation. Obtaining sufficient human conduction cells for replacement therapy in humans is
extremely rare. Native cardiac Purkinje cells are anatomically confined in the sinoatrial (SA) node,
a small structure comprising just a few thousand genuine Purkinje cells, and throughout the innerventricular wall. During embryonic development, cardiac Purkinje cells originate from a subset of
progenitors distinct from the first cells marked by NKX2.5 [941]. SHOX2 inhibits NKX2.5 expression
and activates a Purkinje cell genetic pathway that results in the up-regulation of TBX3 expression.
TBX3 and TBX2, maintain the SHOX2 cells in a state characteristic of Purkinje cells-nodal CMs
[941].
In an earlier study, we developed a 3-stage process. During stage 1, hADMSCs are
reprogrammed to cardiac progenitor cells (CPCs) using the transcription factors EST2 and MESP1
[942]. During stage 2, the CPCs are converted to CMs via beta 2 adrenergic receptor (β2AR)
activation using activin and BMP4. During stage 3, stage 2 cells are cultured in rotating bioreactors
to form 3D spheroid culture, resulting in the maturation of CMs. In a second study, CMs that were
engineered using this 3-stage process were used to bioengineer highly functional cardiac patches
[927]. This vision was developed with a clear translational strategy in place; sourcing patient
adipose tissue is relatively easy and straight forward and provides a pathway for autologous
therapy.
With this vision in mind, the purpose of the current study was twofold. First to develop
methodology to reprogram hADMSCs to form Purkinje cells and second to use the reprogrammed
Purkinje cells to 3D bioprint a rudimentary Purkinje network. In our second goal, our aim is to
provide a framework for the eventual 3D bioprinting of a fully functional Purkinje system. A fully
functional bioprinted Purkinje system made from hADMSC derived Purkinje cells should be able to
form a continuous syncytium from one end of the construct to the other, identifiable visually as no
gaps between cells and for the retention of gap junction proteins such as Cx40, that are paramount
for successful action potential propagation from one end of the construct to the other. A functional
Purkinje system should be able to respond to physiologic stimulus such as changes in membrane
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potential to initiate and propagate action potentials and should exhibit typical nodal cell action
potential waveforms. This action should be modifiable to regulatory stimuli such as acetylcholine
and norepinephrine from the parasympathetic and sympathetic system, respectively. These action
potentials should act as signals to neighboring cardiomyocytes for the eventual goal of synchronous
contraction. Finally, a fully functional 3D bioprinted Purkinje construct with surrounding
cardiomyocytes should be able to exhibit enough thickness to warrant vascularization with
adequate nutrient distribution and waste product removal. The scope of this study is not to fully
achieve the parameters outlined above, but rather this study should be viewed as a starting point
for eventually doing so. We seek to outline plausible methodology with the goal of further refinement
by our group and others. Here we hypothesize that hADMSCs will differentiate into cardiac Purkinje
cells through the protocol outlined in this study, and that these cells will remain viable, form
continuous syncytium, retain cellular identity via Cx40 expression, and will show responsiveness
to membrane potential changes via acetylcholine or electric pacing post 3D bioprinting into
experimental Purkinje rods. Furthermore, a LV Purkinje network inspired by bovine Purkinje
anatomic imagery was 3D bioprinted to show fidelity of current bioprinting technology to achieve
appropriate contours and geometry.

A2.20: Materials & Methods
All chemicals, reagents, and solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA)
unless otherwise speciﬁed. hADMSCs were obtained from ATCC (USA). A simplified flow-diagram
depiction of study methods is shown in Figure 70.
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Figure 70: Simplified Flow Diagram Depiction of Study Methods. hADMSCs differentiated into
cardiac Purkinje cells were made into a bioink by mixing with type 1 collagen. An anatomical image
of a bovine LV Purkinje network was used as reference for CAD software design of a negative
mold, printed with pluronic sacrificial material. Purkinje bioink was 3D bioprinted into the mold and
the mold was degraded. Simple Purkinje bioprinted rods were used for testing ideal cell/collagen
density to promote syncytium formation, retention of cellular identity post-print and with pacing, and
for response to electrochemical stimulation.

A2.21: Conversion of hADMSCS to form Cardiac Progenitor Cells (CPCs)
The conversion of hADMSCs (purchased from Lonza), to cardiac progenitor cells (CPCs) was
accomplished using protein transduction using TAT-MESP1 and TAT-ETS2, as described before
(22). Briefly, full-length human ETS2 and human MESP1 cDNA were cloned into pTAT-HA vector.
Proteins were expressed in BL21pLysS Escherichia coli cells, purified by 6xHis affinity
chromatography on Clontech ® Talon columns and frozen. Protein solutions were thawed, diluted
with culture medium, and sterilized by filtration. hADMSCs were treated with proteins at 50 nM daily
for 4 days and grown in alpha minimal essential media (Invitrogen) over collagen-coated Petri
dishes. Further treatment with Activin A (5ng/mL) / BMP-2 (10nug/mL) (Tocris, R&D systems) was
done for 2 days and media changed. A pWPI-based lentiviral vector NKX2.5-tdTomato has a
tandem dimer Tomato red fluorescent protein cDNA and puromycin-resistance gene, both under
the control of cardiac-specific composite NKX2.5 enhancer/HSP68 promoter.
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A2.22: Conversion of Cardiac Progenitor Cells to Purkinje Cells
In stage 2 of the protocol, once the MESP1-ETS2 converted hADMSCs reached a nodal point
for NKX2.5-puromycin selection, they were converted into Purkinje cells by transient treatment with
doxy-induction of SHOX2, TBX3, TBX5, TBX18 and HCN2 expression from inducible lentiviruses
in the NKX2.5 marked cardiac progenitors, with a GAPDH control (Figure 71A).
RNA was isolated from cells following the manufacturer’s instructions (R1054, Zymo
Research) and quantified using Nanodrop. cDNA synthesis was performed using a high-capacity
RT-PCR kit (#4368814, Life Technologies) according to the manufacturer’s instructions. cDNA was
subjected to qRT-PCR using Power SYBR Green PCR Master Mix (#4367659, Life Technologies)
in a StepOnePlus Real-Time PCR System (v. 2.0, Applied Biosystems). All the real-time PCR
reactions were carried out as 15 µL reactions in 96-well plates. Each reaction mixture contained 1
µL diluted cDNA, 2 µl each of forward and reverse primers (10 µM), 7.5 µL 2X SYBR Green PCR
Master Mix, and 2.5 µL water. Normalization was performed using GAPDH mRNA levels. All
samples were performed in triplicate. Changes in the expression of the following genes were tested:
IRX3, IRX5, SEMA, SCN10 (Figure 71B). List of primers are provided in Table 15.
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A. Protocol: Conversion of hADMSCs to Purkinje Cells

(A) Protocol: Conversion of hADMSCs to Purkinje Cells
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Figure 71: Conversion of hADMSCs to Purkinje Cells. hADMSCs are pre-infected with NKX2.5
td-tomato puromycin reporter and then are treated with TAT-fused proteins ETS2 and MESP1 for
the next 3 days, at a concentration of 50 μM each (A). Following this, these cells are force
aggregated (600 cells per aggregate) and kept in hanging drops for 2 days. The cells are then
plated and treated with Activin and BMP (2 days); during this time, the NKX2.5 td-tomato reporter
becomes active and cells are drug selected (via puromycin). Once the MESP1-ETS2 converted
hAdMSCs reaches a nodal point for NKX2.5-puromycin selection, they are converted to Purkinje
cells by transient treatment with doxy-induction of SHOX2, TBX5 and HCN2 expression from
inducible lentiviruses in the NKX2.5 marked cardiac progenitors. Gene Expression of Purkinje Cells
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Reprogrammed from hADMSCs – Changes in the expression of IRX3, IRX5, SEMA and SCN10
were used as markers for the conversion of hADMSCs to Purkinje cells (B). EM-ETS2 and MESP1
converted cells, T3-TBX3, T5-TBX5, T18-TBX18, SHOX refers to SHOX, HCN refers to HCN, SH
– SHOX and HCN, SHT3 – SHOX, HCN and TBX3, SHT5 – SHOX, HCN and TBX5, SHT18 –
SHOX, HCN and TBX5. CX45-mCHERRY Tag to Selectively Screen for Purkinje Cells – CX45, a
known marker for Purkinje cells, was tagged with mCHERRY (red) and used a marker for the
reprogramming of Purkinje cells from hADMSCs (C).

A2.23: Bioprinting the Mammalian Purkinje Network
A recent publication by Dr. Vilhena very elegantly described the bovine Purkinje network of the
left ventricle [943]. India ink was used to visualize the Purkinje network and furthermore, the
staining protocol was optimized to provide a detailed image of the Purkinje network (Figure 72A);
in this model, the left bundle branch feeds into the left ventricle and forms a very complex branching
network of Purkinje fibers which allows synchronized contractions of the heart. Using the
anatomical structure in this manuscript, a 3D model of the Purkinje network (Figure 72B) and
negative mold support structure, required to provide support during the printing process, (Figure
72C) were created using SolidWorks Computer Aided Design (CAD) software. The next stage in
the development platform was to bioprint the Purkinje network using materials only, with 28%
Pluronic acid, F-127 as the support structure (blue) and type I collagen as the Purkinje network
(red), (Figure 72D). A commercially available bioprinter, BioBot, was used to bioprint the support
(Figure 72E) and a second commercially available bioprinter, Bio Assembly Tool (BAT) was used
to bioprint the Purkinje network (Figure 72F). The negative pluronic mold was printed with a 25gauge needle, 50 psi, 5 layers thick, with a total print time of 22 minutes. The purkinje-collagen
bioprinting to fill the mold was accomplished using the Bio Assembly Tool with 25-guage needle,
1.5 psi, 5 layers thick, temperature of 4°C, with a total print time of 5 minutes. Once the collagen-
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Purkinje cell bioink was printed into the pluronic negative mold, it was incubated at 37°C for 45
minutes to allow polymerization. Dulbecco's Phosphate-Buffered Saline (DBPS) was added outside
the mold and then placed into a 4°C refrigerator for 2-4 minutes to dissolve the pluronic mold. DPBS
with dissolved pluronic was removed. Type-1 collagen was poured over the printed construct to
replace the somewhat toxic pluronic mold in order to stabilize the construct and incubated for an
additional 45 minutes at 37°C, after which culture media was added.

a)

b)

c)

d)

e)

f)

Figure 72: Left ventricular Purkinje network and 3D Printing Method. Anatomical image of an
India-Ink injected bovine left ventricular Purkinje network reproduced with permission from Almeida
et al. (Almeida et al., 2015) (a). The anatomical image was imported into SolidWorks software, and
the Purkinje network was traced using the sketch function and made 3-dimensional with the extrude
function (b). A mold of b was designed and imported into Repetier Host printing software (c). The
pluronic mold (blue) was printed and the negative space was filled with collagen and cells via pipette
or 3D printer (d). BioBots 3D printer used to print pluronic molds (e). Bio Assembly Tool (BAT) 3D
printer used to fill pluronic molds with Purkinje cells/collagen (f).
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A2.24: Optimizing of Bioprinting Variables for the Purkinje Network
Optimization studies were conducted and included collagen concentration in the range of 1.8 to
3.0 mg/ml and the cell density from 150,000 to 450,000 cells per 200 µl in bioprinted rods with
dimensions 2.5 and 39 mm in the x and y plane, respectively with 5 layers to the print. Furthermore,
the time course of syncytium formation was followed over a 10-day culture period. All optimization
variables are presented in Table 16. Syncytium formation was the priority variable, without which
other variables were not tested.
Syncytium formation was monitored with phase contrast microscopy. Viability, cellular identity,
and conductive ability were evaluated using a live/dead assay with fluorescence imaging, connexin
40 staining with fluorescence imaging, and simultaneous electrical stimulation or acetylcholine
application with fluorescence imaging of printed rods with the membrane potential dye DiBAC4(5).
Live-Dead analysis was done utilizing Hoechst (DNA of live and dead cells), Green Fluorescent
Protein (GFP), and Ethidium Homodimer III (EthD-III)(dead cell DNA). After culture for seven days,
percentage of dead cells was estimated by dividing mean fluorescence intensity (MFI) of EthD-III
by Hoeschst and/or GFP MFI, and viability or percentage of live cells was equated as 1 –
percentage of dead cells.
Cx40 fluorescence was analyzed in order to assure that Purkinje cells remained differentiated
post 3D bioprint and to assess response to pacing. Rods were fixed in 4% paraformaldehyde for
30 minutes and permeabilized with Triton X-100 .1% in PBS for 20 minutes. Rods were then placed
in 5% Fetal Bovine Serum in PBS for one hour. Primary rabbit antibody to human Cx40 (1:250
dilution) was applied and incubated overnight with rotation at 4°C. DyLight 594 (1:1000 dilution)
was used as the secondary antibody. PBS washes were included in-between each step for 15
minutes. Fluorescence images of 3D bioprinted rods and hand pipetted positive controls were
captured and the ratio of DyLight 594 to DAPI MFI was recorded to standardize differences in cell
density between images within and between various rods. Pacing was accomplished using a
custom circuit and Grass SD9 Stimulator (Grass Telefactor, West Warwick, Rhode Island). The
circuit consisted of 100 mV of pacing with a 1 kW resistor and 10 µF capacitor, with the purkinje rod
itself measuring 150 kW, all in series, with a frequency of 3 Hz and duration of .2 ms.
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To explore whether this printed network could respond to relevant physiological stimuli i.e.
electric or biochemical stimulus, rods were connected to a custom circuit as described above.
DiBAC4(5) (2 µM in DMSO) was used as an indicator of membrane potential. Changes in
fluorescence over time to voltage (35 volts), acetylcholine (10-5 M), or both were observed over a
time period of one-two minutes. Purkinje cells expressed Green Fluorescent Protein (GFP) and its
fluorescence was evaluated simultaneously with voltage as the DiBAC4(5) as a negative control
(MFI of GFP should not change). All widefield fluorescence images in this study were captured on
a Nikon Ti-E inverted microscope and analyzed in Nikon Elements software (Nikon Instruments,
Melville, NY, USA).

A2.25: Statistical Analysis
All statistical analyses were performed using two-way repeated measures ANOVA followed by
post-hoc Bonferonni test with significance determined as p < .05. SigmaPlot software (Systat) was
used for statistical analysis.

A2.30: Results
A2.31: Reprogramming hADMSCs to form Functional Purkinje Cells
The expression pattern of proteins associated with Purkinje phenotype were used to evaluate
the success of the reprogramming technology. Changes in the expression of IRX3, IRX5, SEMA
and SCN10 were selected as markers for Purkinje phenotype (Figure 71B). It was determined that
CPC’s that were reprogrammed with SHOX2 and TBX3 generated the most functional Purkinje
cells based on the expression pattern of all markers tested. Based on the results of this study,
SHOX2 and TBX3 were retained as the key regulators of Purkinje phenotype based on the
expression pattern of all four genes tested.

A2.32: Histology of Reprogrammed Purkinje Cells
An mCHERRY tag conjugated to CX45, a marker of Purkinje cells, was used to select for
Purkinje lineage and also to visualize the reprogrammed Purkinje cells (Figure 71C). hADMSCs
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that were converted using ETS2 and MESP1 to CPC and then to Purkinje cells using SHOX2 and
TBX3 were positive for CX45, further validating Purkinje lineage. In addition, the morphology of the
reprogrammed Purkinje cells were consistent with mammalian Purkinje cells, exhibiting a thin and
elongated phenotype (Figure 71C).

A2.33: Optimization of Bioprinting Variables
The key role of the bioprinted Purkinje network is to conduct electrical impulses during heart
muscle contraction and syncytium formation is critical to accomplish this goal. Purkinje cells were
first cultured on standard culture plates to assess normal morphology (Figure 73A). Cells form
interconnected networks with aggregates growing thick or thin connections we refer to as syncytium
(red circles). In 2D culture, networks branch out in sporadic directions. Before performing
optimization studies assessing capacity for syncytium formation in 3D bioprinted cultured
constructs, Purkinje cell viability post-print needed to be assessed. Rods were bioprinted using
Purkinje cells in type 1 collagen as a bioink and their viability was assessed using Hoeschst and
EthD-III. Under optimal printing conditions viability was acceptable at 59%.
Optimization studies were conducted to identify a single set of variables for bioprinting Purkinje
networks (Table 16). For these optimization studies, Purkinje rods were bioprinted for evaluation.
Test variables were the concentration of type I collagen (1.8 mg/ml, 2.4 mg/ml and 3.0 mg/ml) and
cell density (150,000, 300,000 and 450,000 cells per 200 µl media). End-point metrics included
syncytium formation, cell viability, Cx40 expression and electrical conductivity measured using
DiBAC4(5). Syncytium formation was a requirement for subsequent evaluation of end-point metrics,
as it is the most important variable and necessary for the function of the Purkinje system. Based
on these optimization studies, it was determined that a type I collagen concentration of 1.8 mg/ml
and a cell density of 150,000 cells per 200 µl media were optimal. At first, syncytium formation is
not seen in the 3D bioprinted rods, rather, spherical cell aggregates (outlined in red) are numerous
and a likely consequence of attractive forces during disruption of the cells from 2D culture for
incorporation into the collagen bioink and the printing process itself (Figure 73C). At 1.8 mg/ml and
a cell density of 150,000 cells per 200 µl, syncytium is initially formed by day 3 and can be seen as
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one continuous unit throughout the entire construct by day 5 (albeit with one break at the beginning
of the rod) culminating into a Purkinje fiber (Figure 73D-G). In contrast to the sporadic nature of
the 2D Purkinje network, the 3D Purkinje network exhibited linear directionality along the printed
construct, with uniform alignment outlined in red, consist with the physiological requirements of
conducting Purkinje network (Figure 73H). As this was the earliest observation of syncytium
formation and only set of variables to produce a continuous syncytium and fiber formation
throughout the entirety of the rod, these variables were considered optimum. Data for optimization
experiments of other cell densities and collagen concentrations are summarized in Table 16.

Hoechst (DNA from All Cells) EthD-III (Dead Cell DNA)
a)
2D Culture
c)
3D Culture Day 2

d)

3D Culture Day 5

e)

500 µm

250 µm

b)

*

#

3D Bioprinted

500 µm

500 µm

500 µm

500 µm

3D Culture Day 5: Continuous Syncytium Throughout Construct

g)

2 mm
h)

*

#

2 mm

Figure 73: Syncytium formation and Live/Dead Analysis. 2D Purkinje culture forms a
sporadic syncytium (red circles) (10x magnification) (a). BAT 3D printed cells in the LV Purkinje
network in 1.8 mg/mL collagen with 300,000 cells per 200 µL have a 59% viability (4x
magnification) (b). Purkinje cells in 3D collagen culture day 2 with cell aggregate clumps (red
arrow) (c) and syncytium formation on day 5 (d) The 3D bioprinted purkinje rod only exhibited
one break in the syncytium at the beginning of the rod (e), and forming branches are seen (red
arrows) in an attempt to bridge aggregates of purkinje cells to complete syncytium formation
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throughout the construct, success of which can be in the middle of the rod (#) (f). With the
exception of one break in the beginning of the rod, purkinje cells are interconnected connected
throughout the 3D bioprinted construct (g) outlined in red (h). Images were spliced together
from 9 phase contrast images at 4x magnification in order to exhibit the entire 3D bioprinted
Purkinje rod.

A2.34: Establishing Methodology to 3D Bioprint Mammalian Purkinje Networks
As shown in Figure 3A, the anatomical details of the bovine Purkinje network were used as the
basis for these studies. The anatomical image was imported into SolidWorks software, where the
bovine Purkinje network was successfully designed and bioprinted using reprogrammed purkinje
cells (Figure 74). Based on visual inspection of the printed Purkinje network, there was a close
match between the stl file, which represented the model for the Purkinje network and the actual
bioprinted Purkinje network. During visual inspection, the overall 3D structure of the bioprinted
Purkinje was noted, as well as the details of the branching pattern and the smaller internal
segments, all of which were aligned with the 3D model created in the stl file, confirming fidelity of
the print. Furthermore, several regions of the bioprinted Purkinje network were microscopically
evaluated to confirm syncytium formation based on GFP staining and phase contrast microscopy
(Figure 74), which served to confirm the formation of bioprinted purkinje networks. The bioprinted
Purkinje networks were maintained in culture for a period of up to 7 days, without any notable
degradation or change in the 3D structure of the bioprinted networks, based on visual inspection
and physical manipulation. Even after seven days the printed network retained physical integrity as
they could be lightly stretched or lifted out of the culture plate without tearing.
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Figure 74: Left Ventricular Purkinje Network 3D Bioprinted with the Bio Assembly Tool 3D
Bioprinter with Representative GFP and Phase Contrast Images.

A2.35: Effect of 3D Culture After Hand Pipetting, 3D Bioprinting or Pacing on Retention of Purkinje
Cell Identity
Purkinje cells were cultured in the form of rods, fabricated by manual hand-pipetting or via 3D
bioprinting. The Purkinje rods were cultured under static conditions or in the presence of controlled
electrical stimulation and Cx40 was used to assess retention of cell functional identity. When
Purkinje rods were fabricated using hand-pipetting or 3D bioprinting and cultured under static
conditions, Cx40 staining was evident with Cx40 most concentrated in cell aggregates and cellular
connections between aggregates to a lesser extent (Figure 75A-B). The application of pacing did
not significantly alter Cx40 expression (Figure 75C-F, I).
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3D Bioprinted

Paced

Figure 75: Retention of Purkinje Cellular Identity upon Culturing in Hand Pipetted Collagen
Rods, 3D Bioprinted Collagen Rods, or 3D Bioprinted Rods Subjected to Pacing. Purkinje
cells cultured in a collagen rod express the Purkinje specific gap junction protein Cx40 (red) (10x
magnification) (a). Purkinje cells 3D Bioprinted into a rod mold express Cx40 (4x magnification) (b).
Without electrical pacing, Cx40 is most prevalent in cellular aggregates (yellow arrow) but also
present in cellular connections between aggregates (white arrow)(40x magnification) (c-d). Cx40
expression is retained after pacing for one hour both in aggregates (yellow arrow) and cellular
connections between aggregates with pacing (white arrow)(40x magnification) (e-f). Custom circuit
design for Electrical pacing of Purkinje Cells (g). Representative circuit flow diagram for Electrical
Pacing of Purkinje Cells (h). Quantitative expression of Cx40 expression in response to hand
pipetting, 3D bioprinting, and pacing of purkinje cells (i). Ratio of Cx40/DAPI MFI shown for the
hand pipetted (n = 1), 3D bioprinted (n = 2), and paced (n = 2) groups.

2.36: Time-Course of Electrical Conductance Through Purkinje Rods
To measure the electrical conductance through Purkinje rods, DiBAC4(5) was used, a
membrane potential dye that enters conducting cells upon depolarization and binds to intracellular
proteins and exhibits enhanced fluorescence. Electrical stimulation or acetylcholine were used as
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modulators of electrical activity and the time course of DiBAC4(5) followed over 120 seconds. In
the case of electrical stimulation (Figure 76A), DiBAC4(5) activation is noted at baseline with a
mean fluorescence intensity (MFI) of 2714.3 arbitrary units (AU). In specific Purkinje rods (collagen
1.8, 3 and 3 mg/mL with cell density 300,000, 150,000, 300,000 cells/µL, respectively), MFI is
reduced by 29.1% and 36.6% at 60- and 120-seconds exposure, respectively and reduction was
significant between 0 and 60 seconds (p = < .001). To assure reductions in MFI were voltage
dependent, GFP fluorescence response to electric stimulation was simultaneously assessed
(Figure 76B). GFP MFI at baseline was 2276.1 AU and was reduced by 6% and 8.4% at 60- and
120-seconds exposure, respectively and reductions were not significant (p = .489 for 0 vs. 60
seconds, p = 1.0 for 0 vs. 120 seconds). To assess Purkinje rod ability to hyperpolarize, the rods
were subjected to acetylcholine for 120 seconds (Figure 76C). In the acetylcholine trial, baseline
DiBAC4(5) MFI was 1794.43 AU and was reduced by 37% and 64.2% at 60- and 120-seconds
exposure, respectively and reduction was significant (p = < .001 for 0 vs. 60 seconds, p = .016 for
60 vs 120 seconds). There were no significant differences between voltage and acetylcholine (p =
< .001 at 60 seconds, p = .052 at 120 seconds) but both treatments were significantly different than
GFP (p = > .001 for both treatments at both timepoints). MFI changes over time for all groups are
summarized in Figure 7D. Electric stimulation lead to increased DiBAC4(5) MFI in one instance,
after an acetylcholine pre-treatment (Figure 77A-B). When voltage is applied to a rod with
concomitant acetylcholine treatment, the DiBAC4(5) MFI response is blunted (Figure 77C). After
removal of the acetylcholine, electric stimulation lead to further enhanced MFI indicative of
depolarization (Figure 77D). Interestingly, there was a delay in MFI increases further from the
electrode. In one instance, acetylcholine was noted to have a local effect; when applied to the top
of the rod, there was hyperpolarization (reduced DiBAC4(5) MFI) that was not observed at the
bottom of the rod, with a clear distinction in fluorescence changes noted in Figure 77E.
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Figure 76: Hyperpolarization of Purkinje Rods in Response to Electrical or Chemical
Stimulation. Time-lapse of a Purkinje rod showing the effect of electrical stimulation on membrane
potential via altered DiBAC4(5) fluorescence (a), effect of electrical stimulation on changes in GFP
fluorescence (b), and effect of acetylcholine (10-5 M) on membrane potential via altered DiBAC4(5)
fluorescence (c). Plot showing negative percent changes in mean fluorescence intensity of the
DiBAC4(5) dye or GFP in response to electric stimulation or acetylcholine (d). Acetylcholine
dropped near the top of the rod (off screen) showed local reductions in fluorescence not observed
throughout the entirety of the rod (e). All images taken at 4x magnification. p < .05 for 60 vs 0 and
120 seconds vs. 60 seconds (*), p < .05 for DiBAC4(5) and Acetylcholine vs. GFP; data are
presented as mean ± SEM and analyzed with two-way repeated measures ANOVA followed by
post-hoc Bonferroni test.
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Figure 77: Depolarization of a Purkinje Rod in Response to Electric Stimulation, Attenuated
by Acetylcholine. Time-lapse images of electric stimulation of a Purkinje rod with collagen
concentration of 3 mg/mL and cell density of 150,000 cells per 200 µL (not included in Figure 7)
(a). MFI measurements were made in two regions; one including the electrode (white arrow) (white
box) and another distant to the electrode (orange box) (b). Time-lapse images of electric stimulation
with acetylcholine (c). In the same region, a time-lapse images were taken with electric stimulation
while the rod was subjected to acetylcholine. MFI during a 60 second time-lapse showing response
to electric stimulation at ROI including and distant to the electrode, with or without acetylcholine.
All images taken at 4x magnification.

2.40: Discussion
There have been many published reports describing the fabrication of contractile heart muscle
tissue [944-955]. These studies have primarily been focused on replacing the contractile function
of heart muscle tissue. The primary method to fabricate contractile 3D heart muscle tissue has
been to couple contractile cardiac myocytes with a scaffold and then use bioreactors for
electromechanical conditioning. There have been variations to this strategy, however, the primary
elements of this strategy have been retained. The resultant bioengineered 3D heart muscle has
shown a partial subset of functional performance metrics and the challenge in the field of cardiac
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tissue engineering is to bridge the gap between the functional performance of bioengineered and
mammalian heart muscle tissue.
There remain many challenges in the field of cardiac tissue engineering. Generating large
number of iPS derived cardiac myocytes with phenotype that resembles mature CMs, generating
a functional vasculature and fabricating advanced bioreactors for coupled electromechanical
stimulation and perfusion are a few examples of problems that need to be solved in the field of
cardiac tissue engineering. In addition to these problems, there also needs to be a conducting
network of Purkinje fibers within the bioengineered 3D heart muscle tissue. In the mammalian heart,
the Purkinje fibers represent a network of electrically conductive cells that function to distribute
electric current throughout the heart to support synchronized contraction of the heart. Furthermore,
functional interaction of the Purkinje cells with the cardiac myocytes is important in maintaining the
functional output of the heart.
The importance of the Purkinje network in cardiac physiology is well-established. However, the
importance of the Purkinje network has not been well-studied by bioengineers as there are no
reports describing the fabrication of Purkinje networks or the generation of bioengineered heart
muscle tissue with embedded Purkinje networks. This is likely due to the challenges associated
with the generation of a functional Purkinje network, rather than the recognition of the importance
of the Purkinje network in mammalian heart muscle form and function.
This study was responsive to the needs of the field of cardiac tissue engineering and targeted
to satisfy an unmet need in the field, to bioengineer a rudimentary Purkinje network and establish
methodology that can be used as a groundwork to for further refinement and potential inspiration
for other applications of this construct. To the best of our knowledge at the time of writing this
manuscript, there are no published reports describing the fabrication of Purkinje networks and that
this is the first report describing the fabrication of a Purkinje network.
hADMSCs were selected as the cell source with a clear translational pathway in mind. The ability
to safely and effective obtain adipose tissue from patients is well established in the literature and
routinely practiced in the clinic. In addition, we have previously shown the conversion of hADMSCs
to form functional CMs (22) and the utilization of the reprogrammed cardiac myocytes to
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bioengineer 3D heart muscle tissue [956]. The proposed bioengineering strategy is to start with
hADMSCs and develop the technology in place to replace all components of heart muscle tissue,
thereby providing the platform in place to fabricate anatomically and functionally matched 3D
cardiac patches and eventually the printing of the Total Bioficial Heart. This study is designed to
build upon with existing strategy and develop the technology to reprogram hADMSCs to form
Purkinje cells and also to bioprint functional Purkinje networks.
The first challenge was to develop a protocol to reprogram hADMSCs to Purkinje cells. As this
has not been described in the literature before, there was limited background information to use as
a starting point. Due to the limitations of the current literature, inspiration was drawn from nature
and cardiogenesis to understand the signals that direct the formation of Purkinje cells during heart
development in utero. During heart development, TBX3 [957], TBX5 [957] and TBX18 [958],
SHOX2 [941] and HCN1 [959], HCN2 [960], HCN4 [961] are known to modulate the development
of Purkinje cells. Furthermore, during cardiogenesis, conducting cells are derived from early
NKX2.5 positive progenitor cells, equivalent to our MLC2v-GFP positive cells at the CPC stage
[941]. Based in this information, we selected TBX factors, SHOX2 and the HCN family of factors to
reprogram hADMSCs to Purkinje cells. Since the exact stoichiometry and the combination of factors
that are required to form Purkinje cells remains an unknown variable, different combinations of
these factors were tested and changes in the gene expression profile of IRX3, IRX5, SEMA, SCN10
used as indicators of Purkinje cell phenotype. Based on the results of the screening assay, it was
determined that the combination of SHOX2 and TBX3 were the most potent in reprogramming
hADMSCs to form Purkinje cells.
Once successful in reprogramming hADMSCs to Purkinje cells, the next challenge was to
bioprint the mammalian Purkinje network. The first studies were designed to optimize bioprinting
variables. The initial seeding density of Purkinje cells and type I collagen concentration were
selected as test variables (Table 2). Optimization studies were screened based on cell viability,
syncytium formation, Cx40 expression and conductance measured by DiBAC4(5). Based on our
optimization studies, optimal bioprinting parameters as 1.8 mg/ml of type I collagen and an initial
seeding density of Purkinje cells as 300,000 cells per 200 µL of media. The formation of a
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continuous syncytium forming a Purkinje fiber with these parameters was of significance. The
ultimate goal of bioprinting a Total Bioficial Heart will require the ability to develop a continuous
conducting network from SA node to the inner ventricular walls without any disruption in cell
communication throughout this length. This is necessary for continuous propagation of action
potential from SA node to ventricular muscle. With optimal conditions, we were able to produce a
continuous Purkinje unit with a length of 25 mm, 29 mm including one break and maximal width of
2 mm. The left ventricular Purkinje main branches of calf and lamb hearts have a mean length of
3.601 mm with the largest single branch measuring 10 mm according to an anatomical and
biophysical model study by Sebastian et al. [962]. From our calculations based off their published
data, the entire length of the left ventricular conducting system is approximately 359 mm for main
branches. The continuous syncytium from our printed Purkinje rod construct certainly exceeds the
average and longest single branch length, which is a good starting point for the eventual goal of
bioprinting the entire Purkinje network. However, further optimization will be necessary to achieve
growth of a full-length continuous syncytium with complete branching pattern and angle specificity
elegantly described [962]. In our entire 3D bioprinted LV purkinje network, syncytium formation with
local areas of continuous syncytium were seen but was not continuous throughout the entirety of
the construct, likely due to the large size and intricate branching of the construct. Future studies
will explore other parameters that may encourage complete continuous network formation such as
pacing with a microelectrode array, and other physiologic and biochemical stimuli that may
encourage cell alignment.
The final step in the development platform was to assess the retention of Purkinje cell identity
post print and assess functional performance of the Purkinje cells, designed to conduct electrical
currents. Cx40 is a gap junction protein specific to Purkinje cells that aids in the electronic coupling
of neighboring cells and allows propagation of action potentials [963]. Cx40 is specifically
expressed in the atrial conducting cells and His-purkinje system. Cx40 expression is vital to the
functionality of conducting functional Purkinje cells, targeted disruption of which leads to
atrioventricular conduction defects, its expression is altered in cases of chronic atrial fibrillation,
and genetic polymorphisms of Cx40 predispose to atrial fibrillation [963, 964]. Considering we have
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previously differentiated hADMSCs to form contractile ventricular cardiomyocytes, it was important
that we confirm retention of Purkinje cell identity throughout the printing, 3D culture, and pacing
process. To assure culture in a three-dimensional environment or 3D bioprinting itself did not affect
cell differentiation, Purkinje rods were formed via manual pipetting or BAT 3D bioprinting,
respectively (Figure 6A-B). Cx40 fluorescence was identified in both cases at roughly equal levels,
supporting retention of Purkinje identity. Fluorescence was most dense within cell aggregates but
was also present in branches between aggregates, suggesting a true functional syncytium.
Considering Cx40’s necessary role for Purkinje function, we subjected 3D bioprinted Purkinje rods
to pacing for one-hour. We compared Cx40/DAPI MFI with and without pacing to assess Purkinje
network identity retention. After pacing, Cx40 fluorescence was still evident at similar levels preprint thereby supporting retention of cell identity with physiologic pacing stimulus. Interestingly,
pacing studies have found that Cx40 expression may be downregulated upon pacing and it is
suggested that this is a method for adaptation to increased conduction velocity to heart rate [965967]. A future direction of ours is to pace the Purkinje constructs for longer periods of time (up to a
week or more) with varied pacing parameters and delivery (such as microelectrode array) to assess
the capacity for adaptation within our construct. Furthermore, we suspect that subtle pacing will
encourage more efficient syncytium formation.
An additional aim of this study was to explore how our printed Purkinje construct responded to
the milieu of physiologic stimulus encountered by these cells naturally. Under normal physiological
conditions, Purkinje cells function to distribute ionic current through the heart and thereby ensure
a synchronized contraction of the entire heart in unison. Using the membrane potential dye
DiBAC4(5) we evaluated response of the construct to an electric field and to acetylcholine. During
depolarization the dye is able to cross the cell membrane where it binds specifically to intracellular
proteins wherein it can exhibit fluorescence. During hyperpolarization, the florescence is
attenuated. Acetylcholine is the biochemical signaling molecule released from the Vagus nerve
synapse on the SA and atrioventricular (AV) node for parasympathetic modulation of heart rate.
Acetylcholine activates muscarinic receptors to activate inhibitory G protein to inhibit Adenylate
Cyclase, reducing conversion of ATP to cAMP. Acetylcholine also activates acetylcholine
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dependent potassium channels to cause hyperpolarization [968, 969]. When Purkinje rods were
subjected to 10-5 M acetylcholine for two minutes, DiBAC4(5) fluorescence decreased consistent
with hyperpolarization. When voltage was applied to certain purkinje rods (collagen 1.8, 3 and 3
mg/mL and cell density 300,000, 150,000, 300,000 cells/µL, respectively) DiBAC4(5) MFI also
decreased over time, indicating hyperpolarization. Under physiologic circumstances in nodal cells,
at increased membrane potentials, voltage-gated ion channels open allowing for influx of sodium
and calcium depolarization and initiation of action potential propagation if threshold is met. In an
exploratory experiment, we used a GRASS SD9 stimulator and electrodes inserted into both ends
of the Purkinje rod to form a circuit. Our initial expectation was that depolarization (increase in
fluorescence) would occur due to activation of voltage-gated ion channels. In one Purkinje rod with
collagen concentration of 3 mg/mL and cell density of 150,000 cells/200 µL, DiBAC4(5) MFI
increased with voltage over time the effect of which was attenuated with acetylcholine (Figure 8AD). Furthermore, there was a delay in increased MFI further from the electrode, suggesting
propagation of signal downstream. It is unclear why this particular rod depolarized when the others
hyperpolarized. It is possible that treating rods first with a hyperpolarizing agent (acetylcholine) is
necessary for the depolarizing effects of pacing with the DiBAC4(5) dye to be seen. Nevertheless,
our findings with acetylcholine and pacing indicate the ability of the bioprinted Purkinje rod to
undergo membrane potential changes that should be investigated further using more specific and
accurate methods, such as analysis utilizing a microelectrode array or patch-clamp analysis.
Furthermore, future studies involving pacing delivered by microelectrode array may be beneficial
for facilitating improved growth and alignment of the Purkinje cells.
Longevity and thickness of 3D bioprinted constructs are limited by the ability of the culture media
to diffuse throughout the entirety of the construct. In the current study, the thickness of the entire
LV Purkinje construct had only five layers to the print (approximately 1 mm) and maintained
physical integrity for at least 7 days. This thickness allowed for media to easily diffuse. Our
construct, although three-dimensional in the sense that the network exhibited thickness, had no
overlapping branches or branches that ascend or descend in the z plane. Such a construct would
more accurately represent the LV purkinje network but would also require a supporting environment
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to hold up vertical plane branches. Such a supporting environment could be a 3D bioprinted
“cardiomyocyte mold”, and co-culture studies of hADMSC derived Purkinje and cardiomyocytes
would be informational in-it-of-itself. However, increased the thickness of the construct requires the
addition of vascular networks to allow even distribution of nutrients and removal of waste products.
Although we have previously constructed cardiomyocyte tissue and incorporated vascular networks
within 3D constructs [810, 970-974], addition of these to the current Purkinje construct is outside
the scope of the current validation study, but represents a future direction, that if achieved would
truly mark a significant advance towards the construction of the Total Bioficial Heart.
The bioprinting of a Total Bioficial Heart is a long-term goal which will take significant time before
becoming a translational reality. In the meantime, knowledge gained from studies advancing this
goal may be useful for utilization of other translational applications. In past studies, we have
constructed three-dimensional patches seeded with regenerative cells such as adipose SVF,
microvascular networks, or human dermal fibroblasts applied to infarcted regions of the heart with
the goal of improving functional cardiac parameters and angiogenesis post-myocardial infarction
[12, 807, 926, 928, 929]. Recently, we have engineered a 3D patch seeded with hADMSC derived
cardiomyocytes that show significant conductive function evaluated by EKG, designed as a
possible translational application for conductive pathologies following myocardial infarction [927].
It is not yet readily apparent if a 3D cardiac patch seeded with hADMSC derived Purkinje cells
would be beneficial to patients with such pathologies, considering the intraventricular location of
the Purkinje system. Such a patch while aimed at correcting problems with ventricular contraction
or synchrony as a result of conduction abnormalities, could also lead abhorrent and
dyssynchronous contractions and arrhythmias. Therefore, the potential of the Purkinje system
described in this study to be applied as a therapeutic via a patch, although also outside the scope
of the current study, warrants future deliberation.
Perhaps more applicable in the near term is the potential for 3D bioprinted Purkinje networks to
be utilized in research settings as a research model. With further development, 3D bioprinted
Purkinje rods have the potential for use as a model system for studies of pharmacology, toxicology,
and physiology of the conduction system.
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A2.50: Limitations
This study aimed to lay a foundation for the eventual 3D bioprinting of a fully functional Purkinje
network. For this initial exploratory study, our main goals were to a) successfully reprogram ADSCs
to cardiac Purkinje cells b) optimize bioink properties in order to reproduce a Purkinje network and
cell morphology close to that of native tissue and c) explore methods that can be used to validate
bioprinted adipose ADSC derived Purkinje cell/network function. Our focus for the initial bioprinting
aspects of this study were to establish these goals qualitatively, not quantitatively. Therefore, a
limitation of this study is that our assessment of syncytium formation, long-term 3D bioprinted
purkinje construct durability, gap junction expression response to pacing, and membrane potential
response to pacing/acetylcholine were mostly qualitatively assessed or quantitatively assessed
with limited replicates. Future studies will seek to quantify this data through further repetition and
addition of additional experiments with more specific and accurate methodology such as
incorporation of microelectrode studies.

A2.70: Conclusions
The objective in this study was to explore the feasibility and establish initial methodology for
bioprinting a fully functional Purkinje system. A novel protocol was developed to first reprogram
hADMSCs to Purkinje cells and also develop a novel bioprinting platform to bioprint Purkinje
networks. The functional performance of the Purkinje networks was assessed by continuous
syncytium formation and response to electrical and biochemical stimulation. It is our hope that this
groundwork study sparks future innovation for refinement of our initial methodology for bioprinting
the Purkinje network, potential establishment of its use as a research model for pharmacologic,
toxicology, and physiologic studies of the cardiac conduction system, or incorporation into
translational applications such as a cardiac patch. Based on the results of our study, it can be
stated that hADMSCs were reprogrammed to form Purkinje cells and the reprogrammed Purkinje
cells were successfully bioprinted to form a Purkinje network, an objective that has been
accomplished for the first time.
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Appendix Section 3:
Abbreviations List
3D - three-dimensional
5-HIAA- metabolite of serotonin
5HT- serotonin
a-AR- alpha-adrenergic receptor
AC- adenylyl cyclase
AC6- adenylyl cyclase isoform 6
ACE-1 - angiotensin-converting enzyme-1
ACh - acetylcholine
ADSCs - adipose derived stem cells
AGEs - advanced glycosylated end products
Akt - protein kinase B
AMSCs - adipose-derived mesenchymal stem cell
AMT - 3-amino-1,2,4-triazole
Ang II - angiotensin II
Arrdc3 - arrestin domain-containing protein 3
ASC – adipose stem cell
AT1 - angiotensin 1 receptor
ATCC - American Type Culture Collection
ATP5mg - ATP synthase membrane subunit g
ATP5if1 - ATP synthase inhibitory factor subunit 1
AU - Arbitrary Units
AV - Atrioventricular
BAT - Bio Assembly Tool

298

BF- blood flow
BM - bone marrow
BM-MSC – bone marrow-mesenchymal stem cell
BMFs – brain cortex microvascular fragments
BMI - body mass index
BMP-2 - Bone morphogenetic protein-2
BMP4 - Bone morphogenetic protein 4
BW- body weight (grams)
CAD - computer aided design (Appendix A2)
CAD - coronary artery disease
cAMP - cyclin adenosine monophosphate
cDNA - Complementary deoxyribonucleic acid
CFR - coronary flow reserve
CM - Cardiomyocyte
CMD - coronary microvascular disease
CO – cardiac output
CoCl2 - Cobalt Chloride
CoQ2 - Coenzyme Q2 polyprenyltransferase
CoQ10a - coenzyme 10A
COX7b - cytochrome c oxidase subunit 7b
COX20 - Cytochrome c oxidase assembly factor 20
CPCs Cardiac progenitor cells
CPG- CPG20712A
CPTiO - 2-4-carboxyphenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide
CRP - C-reactive protein
CVD- cardiovascular disease
Cx40 - Connexin 40
CXCR - C-X-C chemokine recptor
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DA- dopamine
DAD - delayed after depolarization
DAN - 2,3-diaminonapthalene
DETC - Diethyldithiocarbamic acid
DiBAC4(5) - Bis-(1,3-dibutylbarbituric acid)pentamethine oxonol
Dmax- maximum diameter (mm)
DMSO - Dimethyl sulfoxide
Dob- Dobutamine
DPBS - Dulbecco's Phosphate-Buffered Saline
DRP-1 - Dynamin-Related Protein 1
E’ - early mitral annular velocity
EAD - early after depolarization
ECM - extracellular matrix
EDD - endothelium dependent dilation
EDH - endothelial dependent hyperpolarization
EDV - early diastolic velocity
eEV - endothelium derived extracellular vesicles
EF - ejection fraction
eNOS - endothelial nitric oxide synthase
EPC - endothelial progenitor cell
Epi- epinephrine
ER - endoplasmic reticulum
ESCs - embryonic stem cells
ETC - electron transport chain
EthD-III - Ethidium Homodimer 3
ETS2 - ETS Proto-Oncogene 2
EVs - extracellular vesicles
FGF - fibroblast growth factor
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Fis-1 – mitochondrial fission protein 1
FMD - flow mediated dilation
FMFs - fat microvascular fragments
FS – fractional shortening
Gai- alpha subunit of inhibitory G-protein
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase
Gas – stimulatory G protein
GFP+ - green fluorescent protein
GFP+- transgenic green fluorescent protein positive
Gnai2- G-protein subunit alpha-i2
Gnao1- G-protein subunit alpha-o1
GPx - glutathione peroxidase
GRK- G-protein receptor kinase
GRK2 - G-protein receptor kinase 2
Gs- stimulatory G-protein
GSH - glutathione
GSH - glutathione
H2O2 - hydrogen peroxide
hADMSCs - Human adipogenic mesenchymal stem cells
HCN2 - Hyperpolarization Activated Cyclic Nucleotide Gated Potassium And Sodium Channel 2
HF - heart failure
HFpEF - hear failure with preserved ejection fraction
HGF - hepatocyte growth factor
HIF - hypoxia inducing factor
HSP 70 – Heat Shock Protein 70
HSP68 - Heat Shock Protein 68
HUVECs - human umbilical vein endothelial cells
i.v.- intravenous
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I2PP2A – Protein Phosphatase 2A Inhibitor 2
ICI- ICI118551
IDM - injectable decellularized matrix
IL - interleukin
iPS - Induced Pluripotent Stem Cells
iPSC-CM - induced pluripotent stem cell cardiomyocyte like
iPSC-EC - induced pluripotent stem cell endothelial cell like
iPSCs - induced pluripotent stem cell
IR - ischemia reperfusion
IRX3 - Iroquois Homeobox 3
IRX5 - Iroquois Homeobox 5
Isus - sustained potassium channel
Ito - transient outward potassium channel
IVC – inferior vena cava
iVPC - induced vascular progenitor cell
IVRT – isovolumic relaxation time
L-NAME - N-Nitro-L-arginine methylester
LAD- left anterior descending coronary artery
LDV - late diastolic velocity
LV - left ventricle
LVDP – left ventricular diastolic pressure
LVDs/d – left ventricular dimensions systolic/diastolic
MACE - Major Adverse Cardiac Events
MEM - Minimal Essential Media
MESP1 - Mesoderm Posterior BHLH Transcription Factor 1
MFI – Mean Fluorescence Intensity
Mfn-1 – mitofusin 1
Mfn-2 – mitofusin 2
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MI - myocardial infarction
miRNA - microRNA
MitoQ - Mitoquinone Mesylate
MMP - matrix metalloproteinase
MPC1 – mitochondrial pyruvate carrier 1
MPC2 - mitochondrial pyruvate carrier 2
MPTP - mitochondrial permeability transition pores
mRNA - messenger RNA
MS - multiple sclerosis
MSC- mesenchymal stem cell
MSCs - mesenchymal stem cells
mnSOD – Manganese Superoxide Dismutase
mtDNA - mitochondrial DNA
mtROS - mitochondrial ROS
NaF- sodium fluoride
Ndufa10 - NADH:ubiquinone oxidoreductase subunit A10
Ndufv2 - NADH:ubiquinone oxidoreductase core subunit V2
NE- norepinephrine
NEDD- neural precursor development downregulated protein 4
NKX2.5 - NK2 homeobox 5
NO - nitric oxide
NOX - NADPH oxidase
NOX4 - NADPH Oxidase 4
O+BM – old injected with GFP+ bone marrow-mesenchymal stem cells
O+SVF- old treated with adipose-derived stromal vascular fractions
O2●- - superoxide
OC- old control
OH● - hydroxyl group
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ONOO- - peroxynitrite
Opa-1 – optic atrophy 1
OSVF – Old + Stromal Vascular Fraction
P-GRK2- phosphorylated G-protein receptor kinase 2
Parox- Paroxetine HCl
PBS - Phosphate-Buffered Saline
PCR - Polymerase Chain Reaction
PDGF - platelet-derived growth factor
PDIA1 - protein disulfide isomerase A1
PGC-1a- proliferator-activated receptor gamma coactivator 1
Phospho-GRK2 - Phosphorylated GRK2
PI3kγ – Phosphatidylinositol 3-kinase gamma
PLGA - Polylactic-co-glycolic acid
PP2A – Protein Phosphatase 2A
PRSW – preload recruitable stroke work
PSS- physiological salt solution
pTAT-HA - Plasmid transactivator of transcription hemaglutinin
PV – pressure-volume
Uqcc1 - Ubiquinol-cytochrome c reductase complex assembly factor
Uqcc2 - Ubiquinol-cytochrome c reductase complex assembly factor
RAAS - renin-angiotensin-aldosterone system
RBC-NOS - red blood cell nitric oxide synthase
RNA - Ribonucleic Acid
RNS - reactive nitrogen species
ROI – Region of Interest
ROS - reactive oxygen species
RT- room temperature
RT-PCR - Reverse Transcriptase-Polymerase Chain Reaction
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SA - sinoatrial
SASP - senescence associated secretory phenotype
SCN10 - Sodium Voltage-Gated Channel Subunit 10
SDF-1 - stromal cell derived factor-1
SEMA - Semaphorin
Sgsm2- small G-protein signaling modulator-2
SHOX2 - Short Stature Homeobox 2
siRNA - small interfering RNA
Sirt - sirtuin deacetylase
SNO - S-nitrosylation
SNP- sodium nitroprusside
SOD - superoxide dismutase
SOD1 - copper/zinc superoxide dismutase
SOD2 - manganese superoxide dismutase
SPIONs - superparamagnetic nanoparticles
Stl - Stereolithography
SV – stroke volume
SVF - adipose-derived stromal vascular fractions
T2DM - type 2 diabetes mellitus
TAT-ETS2 - Transactivator of transcription ETS Proto-Oncogene 2
TAT-MESP1 - Transactivator of transcription Mesoderm Posterior BHLH
Tb4 - thymosin b4
TBX18 - T-Box Transcription Factor 18
TBX3 - T-Box Transcription Factor 3
TBX5 - T-Box Transcription Factor 5
TERT - telomerase reverse transcriptase
TGFb - transforming growth factor bets
TIMP - tissue inhibitor of metalloproteinase
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TNFa - tumor necrosis factor alpha
UCB-MSCs - umbilical cord blood derived mesenchymal stem cell
UCP2 - Uncoupling protein 2
UTMD - ultrasound targeted microbubble destruction
VEGF - vascular endothelial growth factor
VGCCs - voltage gated Ca2+ channels
VSM - vascular smooth muscle
VSMC – vascular smooth muscle cell
vps13c - vacuolar protein sorting 13 homolog C
YC- young control
α-MyHC - alpha myosin heavy chain
α1ADR – Alpha 1 adrenergic receptor
α2ADR - Alpha 2 adrenergic receptor
αADR - α-adrenergic receptor
β-MyHC - beta myosin heavy chain
β1ADR – Beta 1 adrenergic receptor
β2ADR – Beta 2 adrenergic receptor
β3ADR – Beta 3 adrenergic receptor
βADR - β-adrenergic receptor
ΔΨM – Mitochondrial Membrane Potential
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CURRICULUM VITAE
Evan Paul Tracy
(as of 4-19-2022)
_____________________________________________________________________________

Education
University of Louisville School of Medicine, Louisville, KY
MD/PhD Program
Department: Physiology and Biophysics

Graduate GPA: 4.00

Linfield College, McMinnville, OR
Bachelor of Science in Biology, Magna Cum Laude, May 2015

GPA: 3.866/4.00

Minors: Chemistry, Music and Philosophy
Undergraduate Thesis: 3D Echocardiography Based Evaluation of the Area of a Modeled
Ventricular Septal Defect Advisor: Dr. David Sahn, M.D. Division of Pediatric Cardiology, Cardiac
Fluid Dynamics and Imaging Laboratory, Oregon Health & Science University, Portland OR

Research Experience
Mentor: Amanda Jo LeBlanc, Ph.D. University of Louisville, Louisville, KY
Ph.D. Graduate Training

Summer 2018 & Fall 2019-Spring 2022

The purpose of this project was to explore the mechanism behind the ability of injected adiposederived Stromal Vascular Fraction (SVF) to improve cardiac and coronary artery function in
advanced age, particularly as it relates to female microvascular dysfunction. The effects of SVF on
beta adrenergic function and expression, as well as SVF’s effects on reactive oxygen species are
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studied in young, old, and old + SVF injected rat models. I am particularly interested in establishing
whether SVFs effects are direct cell mediated or act via a paracrine mechanism. Additional projects
I am working on include telomerase reverse transcriptase effect to restore microvascular function
in aged rats. I also assist as a donor surgeon in a project studying the role of CD3+ cells during
rejection during hindlimb transplantation in rat.

Mentor: Stuart K. Williams, Ph.D. University of Louisville, Louisville, KY
Ph.D. Summer Rotation

Summer 2017

The purpose of this project was to investigate the feasibility of 3D bioprinting the left ventricular
purkinje system using human adipogenic mesenchymal stem cell derived purkinje cells. The
network was successfully printed using a BioAssembly Tool 3D printer programed with anatomic
images of an India-Ink injected bovine purkinje system and human adipogenic stem cell derived
purkinje cells in type-1 collagen 3D biomatrix as a “bioink”. The purkinje network maintained
physical integrity for one month following print, retained purkinje cellular identity, and responded to
voltage stimulation with changes in localization and density of purkinje specific gap junction protein
connexin-43 as well as changes with membrane potential as evident by responses via the
membrane potential dye DiBAC4(5).

Mentor: Antonio Frias, M.D. Oregon National Primate Research Center, Beaverton OR
Research Assistant

June 2016-January 2017

The purpose of this position was to support ongoing projects investigating placental dysfunction in
nonhuman primates. Projects include investigations of the effect of high fat diet, protein restriction,
reduced perfusion via placental ligation, fetal alcohol syndrome, and Zika virus infection on
placental health. Responsibilities include assisting with image acquisition, analysis of placental MRI
and ultrasound images, stereology, H&E staining and immunohistochemistry.

Mentor: David Sahn, M.D. Oregon Health & Science University, Portland OR
Murdock Undergraduate Research Scholar

May 2014-January 2016
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Used porcine heart models to evaluate the feasibility of Real-Time 3D Color Doppler
Echocardiography to evaluate ventricular septal defect (VSD) shunt volume and compared 2D/3D
Echocardiography for quantifying VSD cross-sectional area. Additionally, I was involved in live
open-chest piglet studies operating ultrasound machinery taking cardiac images and mentoring
interns from STEM/equity programs.

Mentor: Professor John Syring, Ph.D. Linfield College, McMinnville, OR
Research Assistant

Fall 2012-Spring 2015

Developed microsatellite markers for the threatened whitebark pine tree (Pinus albicaulis) in order
to map population structure and more effectively screen for resistant populations to the devastating
blister rust (Cronartium ribicola).

Grant Applications and Awards:
1) F30 Predoctoral Fellowship (Not Funded): Impact Score 26. “Establishing a Therapeutically
Modifiable ROS/RNS-Beta 1 Adrenergic Receptor Desensitization & Internalization Axis in
Aging- mediated Coronary Microvascular Disease”. Award Number: 1 F30 HL158146-01. 3
years requested ($203,458.00). NIH NHLBI.
2) UofL Arts and Sciences Mentored Undergraduate Research and Creative Activities Grant
($1500). Mentored Ms. Michaela Dukes.

Manuscript Publications
1) Tracy et al. Adipose Stromal Vascular Fraction Restores β1-Adrenergic and Flow-Mediated
Dilation Alongside Reduced Oxidative Stress in Aging Female Coronary Microvessels.
Antioxidants & Redox Signaling (Submitted November 2021, Currently Under Revision).
2) Tracy et al. State of the Field: Cellular and Exosomal Therapy Approaches in Vascular
Regeneration. AJP Heart & Circulatory Physiology. (2022) 322 (5), H702-H724.

309

3) Rowe G, Tracy E, Beare J, LeBlanc A. Cell Therapy Rescues Aging-Induced Beta-1
Adrenergic Receptor and GRK2 Dysfunction in the Coronary Microcirculation. Geroscience.
https://doi.org/10.1007/s11357-021-00455-6
4) Tracy et al. Aging Induced Impairment of Vascular Function – Mitochondrial Contributions
and Physiological/Clinical Implications. Antioxidants & Redox Signaling (2021) 35 (12), 9741015. https://doi.org/10.1089/ars.2021.0031
5) Tracy et al. 3D Bioprinting the Cardiac Purkinje System Using Human Adipogenic
Mesenchymal Stem Cell Derived Purkinje Cells. Cardiovascular Engineering & Technology
(2020). 11, 587–604. https://doi.org/10.1007/s13239-020-00478-8
6) Tracy et al. Cardiac Tissue Remodeling in Healthy Aging: The Road to Pathology. Am J
Physiol Cell Physiol, 2020. https://doi.org/10.1152/ajpcell.00021.2020.
7) Rowe G; Kelm N; Beare J; Tracy E; Yaun F; LeBlanc A. Enhanced Beta-1 Adrenergic
Receptor Responsiveness in Coronary Arterioles following Intravenous Stromal Vascular
Fraction Therapy in Aged Rats. Aging. 2019 11(13) 4561-4578. doi: 10.18632/aging.102069
8) Tracy et al. Quantification of the area and shunt volume of multiple, circular, and noncircular
ventricular septal defects: A 2D/3D echocardiography comparison and real time 3D color
Doppler feasibility determination study. Echocardiography 2017 35(1) 9099. https://doi.org/10.1111/echo.13742
9) Lea, M.V., et al., Development of nuclear microsatellite loci for Pinus albicaulis Engelm.
(Pinaceae), a conifer of conservation concern. PLoS One, 2018. 13(10): p. e0205423.
(Acknowledgement)

Abstract Publications
1) Tracy et al. Adipose Stromal Vascular Fraction Reverses Mitochondrial Hyperfission in
Coronary Microvessels in Aging FASEB (2022) In-press

2) Huerta C, Hader S, Beare J, Tracy E, Astbury K, Jacobs E, LeBlanc A, Gutterman, D, Beyer
A. Examining the role of Drp1 in age-related microvascular dysfunction FASEB (2022) Inpress
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3) Tracy et al. Adipose Stromal Vascular Fraction Restores Coronary Microvascular FlowMediated Dilation in Aging Female Rats via Enhanced Peroxynitrite Signaling. FASEB
(2021). 35(S1) https://doi.org/10.1096/fasebj.2021.35.S1.02371
4) Dukes, M; LeBlanc, A; Tracy, E, "Inhibition of GRK2, but not HSP90 Reduces Mitochondrial
Superoxide and Improves Vasodilation Capacity of Coronary Arterioles from Aged Female
Rats" (2020). University of Louisville Undergraduate Arts and Research Showcase.
https://ir.library.louisville.edu/uars/15
*Mentored Ms. Dukes through Undergraduate Mentorship Award Grant
5) Tracy E; Gabrielle Rowe, Laura Norwood Toro, Andreas Beyer, Amanda Jo LeBlanc.
Telomerase Reverse Transcriptase Mediates Restoration of Functional Vasodilation in Isolated
Coronary

Microvessels

of

Aged

Female

Rats.

FASEB

(2020).

34

(1).

https://doi.org/10.1096/fasebj.2020.34.s1.07603
6) Tracy E; Zhu M; Dang K; Tran J; Ashraf M; Sahn D. Quantification of Shunt Volume Through
Ventricular Septal Defects of Varied Area, Shape and Number Using Real-Time 3D Color
Doppler Echocardiography: an in vitro Study. Journal of the American College of Cardiology.
2016;67(13_S):1797-1797. doi:10.1016/S0735-1097(16)31798-3
7) Tracy E; Streiff C; Zhang J; Anderson J; Monfared A; Gadd K; Ashraf M; Zhu M; Sahn D. 3D
Echocardiography Based Evaluation of the Area of a Modeled Ventricular Septal Defect.
Journal of the American Society of Echocardiography. 2016;28 (6): B110
8) Mathur P; Amacher K; Tracy E; Ashraf M; Sahn D. 3D Echocardiography Enhanced Area
Measurements of the Left Ventricular Outflow Tract Improves Assessment of Stroke Volume:
Comparison

with

2D

Echo.

Journal

of

the

American

College

of

Cardiology.

2016;67(13_S):1653-1653. doi:10.1016/S0735-1097(16)31654-0
9) Pidwerbecki A; Fuentes K; Amacher K; Zhu M; Tran J; Dang K; Tracy E; Ajjarapu R; Ashraf M;
Sahn D. Image Based Evaluation of Right Ventricular Myocardial Strain Mechanics Using 4D
and

2D

Echocardiography.

Journal

of

the

American

2016;67(13_S):1775-1775. doi:10.1016/S0735-1097(16)31776-4
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College

of

Cardiology.

10) Scelfo-Dalbey C; Nomi K; Tracy E; McCormick C; Syring J. Developing Genetic Resources in
the Threatened Whitebark Pine. 2014. Linfield College Student Symposium.

Conference Presentations
1) American Physician Scientist Association, April 8, 2022, Chicago IL
Poster: Stromal vascular fraction reverses aging-induced coronary microvascular disease
through reversal of oxidative stress-mediated beta-1 adrenergic receptor desensitization &
internalization
2) Experimental Biology, April 5 2022, Philadelphia PA
Oral & Poster: Adipose Stromal Vascular Fraction Reverses Mitochondrial Hyperfission in
Coronary Microvessels in Aging.
Oral Session - APS Novel Mitochondrial Mechanisms Underlying Vascular Dysfunction
3) American Heart Association, November 2021 (Virtual)
Poster: Establishing a Therapeutically Modifiable ROS/RNS-Beta 1 Adrenergic Receptor
Desensitization and Internalization Axis in Aging Coronary Microvessels
4) Experimental Biology, April 2021 (Virtual)
Poster: Adipose Stromal Vascular Fraction Restores Coronary Microvascular Flow-Mediated
Dilation in Aging Female Rats via Enhanced Peroxynitrite Signaling. Zweifach Award Winner
5) National MD/PhD Student Conference (Virtual), September 2020.
Poster: Coronary Microvascular B1 Adrenergic Receptor Dysfunction is Associated with
Oxidative Stress, Reversible by Adipose Stromal Vascular Fraction Injection in Aged Female
Rats
6) Experimental Biology, April 2020 (Virtual).
Poster: Telomerase Reverse Transcriptase Mediates Restoration of Functional Vasodilation in
Isolated Coronary Microvessels of Aged Female Rats.
7) International Federation of Adipose Therapeutics Science, Las Vegas, NV, December 2018.
Poster: 3D Bioprinting the Cardiac Purkinje System Using Human Adipogenic Mesenchymal
Derived Purkinje Cells. Best Poster Award
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8) Southeastern Medical Scientist Conference, Birmingham AL, October 2019.
Poster: Injection of Adipogenic Stromal Vascular Fraction Improves Adrenergic Function and
Alters Reactive Oxygen Species Composition in Response to Flow in Aged Female Coronary
Arteries.
9) Research!Louisville, Louisville, Kentucky October 2019.
Poster: Injection of Adipose-derived Stromal Vascular Fraction Alters Reactive Oxygen
Species Signaling in Coronary Arterioles from Aged Females
10) Southeastern Medical Scientist Conference, Nashville, TN, November 2018.
Poster: Injection of Adipose-derived Stromal Vascular Fraction Alters Reactive Oxygen
Species Signaling in Coronary Arterioles from Aged Females
11) Research!Louisville, Louisville, Kentucky October 2018.
Poster: Injection of Adipogenic Stromal Vascular Fraction Improves Adrenergic Function and
Alters Reactive Oxygen Species Composition in Response to Flow in Aged Female Coronary
Arteries.
12) Southeastern Medical Scientist Conference, Atlanta, GA, November 2017.
Poster: 3D Bioprinting the Cardiac Purkinje System Using Human Adipogenic Mesenchymal
Derived Purkinje Cells.
13) Research!Louisville September 2017, Louisville, Kentucky.
Poster Competition: 3D Bioprinting the Cardiac Purkinje System Using Human Adipogenic
Mesenchymal Derived Purkinje Cells. Second Place Winner.
14) American College of Physicians Kentucky Chapter September, 2017, Shelbyville, Ky.
Poster Competition. 3D Bioprinting the Cardiac Purkinje System Using Human Adipogenic
Mesenchymal Derived Purkinje Cells. Third Place Winner.
15) American College of Cardiology Scientific Sessions, Chicago, Illinois April 4, 2016
Poster. Quantification of Shunt Volume Through Ventricular Septal Defects of Varied Area,
Shape and Number Using Real-Time 3D Color Doppler Echocardiography: an in vitro Study.
16) American Society of Echocardiography Scientific Sessions, Boston, MA June 12-16, 2015
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Poster. 3D Echocardiography Based Evaluation of the Area of a Modeled Ventricular Septal
Defect
17) Oregon Academy of Science Annual Meeting, Portland, OR February 28, 2015.
Oral Presentation. 3D Echocardiography Based Evaluation of Ventricular Septal Defect
18) Murdock College Science Research Conference, Vancouver, WA November 14-15,2014
Poster. 3D Echocardiography Based Evaluation of Ventricular Septal Defect
19) Murdock College Science Research Conference, Vancouver, WA, November 8-9, 2013
Poster. Development of Microsatellite Markers for the Threatened Whitebark Pine (Pinus
albicaulis).
C. Scelfo-Dalbey, E. Tracy, K. Nomi, D. Bartholomew, T. Jennings, R. Cronn, J. Syring
20) Evolution Conference, Snowbird, Utah June 21-25, 2013
Poster (Co-presenter). Development of Microsatellite Markers for the Threatened Whitebark Pine
(Pinus albicaulis).
21) Linfield Program for Liberal Arts and Civic Engagement (PLACE), McMinnville, OR, April 8,
2015
Discussion Panel. Philosophy of the Philosophy of Science
Dr. Massimo Pigliucci, Dr. Jonathon Kaplan, Dr. Leonard Finkelman, Evan Tracy

Articles Peer Reviewed:
1) Wang et al. Melatonin engineered adipose stromal derived biomimic nanovesicles regulate
mitochondrial functions and promote myocardial repair in myocardial infarction. Frontiers in
Cardiovascular Medicine (2022) In-Press.
2) Speer et al. Aging under Pressure: The Roles of Reactive Oxygen and Nitrogen Species
(RONS) Production and Aging Skeletal Muscle in Endothelial Function and Hypertension—
From Biological Processes to Potential Interventions. Antioxidants (2021) 10, 1247
https://doi.org/10.3390/antiox10081247

Seminar Sessions Chaired/Moderated:
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1) Kim Dora, Matthew Nystoriak, Calum Wilson, Brant Isakson. “Heterocellular Communication in
the Vasculature”. Microcirculatory Society Fall Seminar Series. November 12, 2021 (Virtual).
2) Social Hour Breakout Room for APS-CV Section. Experimental Biology Conference April 2021
3) Dr. Lori Earnshaw, MD and Hosparus Health Care Team. Conveying Compassion During End
of Life Care. University of Louisville School of Medicine October 31st, 2018. Discussion Panel
Member & Moderator

Teaching Experience
1) Medical Student Tutor through U of L Office of Medical Student Affairs

2019

2) Tutoring medical students weekly on second year content/USMLE STEP1 preparation 20192021
3) Teaching Assistant for Bio 210 and 211 Principles of Biology

Fall 2013-Spring 2014

Supervised students in a laboratory setting, graded lab reports and other assignments, gave
directions in class, and supported students in and out of the lab.

4) Biology Tutor/Learning Support Services Linfield College

Fall 2012-Spring 2013

Instructed students to further their knowledge of biological principles and encouraged scientific
curiosity.

Invited Guest Lectures
1) Linfield College, Department of Philosophy, Philosophy of Science 285 Class Lecture, “Zika
Virus and the Precautionary Principle”, McMinnville, OR, November 16, 2016

Laboratory and Surgical Techniques and Equipment Knowledge
§ BioAssembly Tool and BioBot 3D Printer use
§ Pressure Myography
§ Microvessel Isolation (coronary)
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§ Vascularized Composite Allotransplantation for Modified Heterotopic Hindlimb Osteomyocutameous
Flap Model Translational Research in Rat (Donor Surgeon)
§ Adipose Stromal Vascular Fraction Isolation
§ DNA/RNA

extraction,

RNAseq

analysis,

PCR,

gel-electrophoresis,

cell

culture,

immunohistochemistry, immunofluorescence and Western blotting
§ Olympus Slide Scanner Use and Visiopharm Stereology Image Analysis.
§ Pipetting, suturing, centrifugation, spectroscopy, cell culture and other basic skills
§ Fiji Image J Image Analysis inc. mitochondrial morphometry, protein co-localization, etc.
§ Ultrasound Siemens SC 2000, GE E9, and GE Vivid 7
§ GE EchoPac image analysis software, iMCE ultrasound image analysis software and Siemens
hemispheric 3D flow analysis package
§ Cardiac defect modeling using phantom porcine hearts
§ Rat, Fruit Fly, and Zebrafish handling and maintenance
§ MATLAB (BOLD MRI image analysis)
§ MEGA (Molecular Evolutionary Genetics Analysis), Geneious software, and BLAST searching

Leadership/Volunteerism
President: Medical Humanities & Social Justice in Healthcare Student Organization

2018-2019

President: Bioengineering (Innovations) in Medicine Student Organization

2018-2019

Hosparus (Hospice) Volunteer

January 2018-March 2020

Medical Student Music Initiative

2017-2019

Providence Hospice (vigil, respite, and comfort care volunteer, 160 hours)

2015-2016

McMinnville Free Clinic Provider Assistant (94 hours)

2014-2016

President, Philosophy Club, Linfield College
2014-2015
Providence Newberg Medical Center (Short-Stay Surgery and ER, 224 hours)

Memberships/Honors/Awards
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2008-2012

Trainee Committee Member: American Physiological Society-Cardiovascular Section

2020-2023

University of Louisville Undergraduate Mentorship Award ($1500)

2020

American Physiological Society Student Member

2020-Present

Microcirculatory Student Member

2019-Present

American Heart Association Student Member

2019-Present

Kentucky Medical Association Medical Student Outreach Leadership Program Graduate

2018

UofL SOM Courses Honored: Clinical Anatomy Development and Exam (CADE)

2017

Nomination: National Young Leaders Award (National Hospice & Palliative Care Org.)

May 2016

Murdock Undergraduate Collaborative Research Scholar (Second Year)

2015-2016

Murdock Undergraduate Collaborative Research Scholar

2014-2015

Phi Sigma Tau (International Philosophy Honor Society, alpha chapter)

2014-2015

Providence Hospital Longest Serving Student Volunteer Award

2012

Linfield College Music Achievement Scholarship Award ($32,000)

2011

Students Mentored
Sahn Lab (2014-2015):
Jason Anderson (Harvard University)
Amelia Monfared (Portland State University)
Kayla Gadd (Northeastern University)
Alexandra Pidwerbecki (Oregon State University)
Priyanka Mathur (Northwestern University)
Jordan Lei (University of Pennsylvania)
Karla Fuentes

LeBlanc Lab (2018-2022):
Rajeev Nair (University of Louisville)
Samuel Oyeleye (University of Louisville)
Pallavi Katragadda (University of Cincinnati)
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Michaela Dukes (University of Louisville)

Linfield University Pre-Med Mentorship Program (2021-2022)
Morgan Johnson (Linfield University)

Published Music:
“You Are Mine” (Feat. Hisham Alshalal, Evan Tracy, Matthew DeVore, Emily Allen, Alex Moore,
Stephanie Murphy & Blake)- Artist: Sipan, Album: “Delight”. Records DK. Saxophone and
Compositional Input.
https://www.youtube.com/watch?v=t9YVYDyRhVE

318

